Simplified protein IDs	Gene name	MitoCoP disease association	Functional MitoCoP classification	MitoCoP	MitoCoP identified/ validated	MitoCoP identified	MitoCoP validated	MitoCoP disease gene	References	UniProt: involvement in disease	DisGeNET disease ID (curated associations)	OMIM	Phenotype MIM number	Half-live (HeLa) [h]	Half-life (Hu7) h	tomm40 Importomics	Mean Log2 Ratio tomm40KD/mock	p-Value	Mean mito-copies per cell (≥2/3 Reps)	Mean copy numbers per cell (≥2/3 Reps)	Category	Integral [%]	Membrane-associated [%]
P35270	SPR	Central nervous system;Metabolism	Cofactor metabolism	1	1		1	1		"DISEASE: Dystonia, DOPA-responsive, due to sepiapterin reductase deficiency (DRDSPRD) [MIM:612716]: A form of DOPA-responsive dystonia. In the majority of cases, patients manifest progressive psychomotor retardation, dystonia and spasticity. Cognitive anomalies are also often present. The disease is due to severe dopamine and serotonin deficiencies in the central nervous system caused by a defect in BH4 synthesis. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. {ECO:0000269|PubMed:11443547, ECO:0000269|PubMed:16650784, ECO:0000269|PubMed:17159114}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0005586;C0268468;C0525045	182125	612716	231.6693774	6007.447358	Class 1	-2.45515517	0.001493112	64821.28261	212577.3333	Peripheral	19.71307811	92.51709546
Q9NXH9	TRMT1	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Ears;Others"	tRNA related processes	1	1		1	1	"Blaesius K, Abbasi AA, Tahir TH, Tietze A, Picker-Minh S, Ali G, Farooq S, Hu H, Latif Z, Khan MN, Kaindl A. Mutations in the tRNA methyltransferase 1 gene TRMT1 cause congenital microcephaly, isolated inferior vermian hypoplasia and cystic leukomalacia in addition to intellectual disability. Am J Med Genet A. 2018 Nov;176(11):2517-2521. Davarniya B, Hu H, Kahrizi K, Musante L, Fattahi Z, Hosseini M, Maqsoud F, Farajollahi R, Wienker TF, Ropers HH, Najmabadi H. The Role of a Novel TRMT1 Gene Mutation and Rare GRM1 Gene Defect in Intellectual Disability in Two Azeri Families. PLoS One. 2015 Aug 26;10(8):e0129631. Zhang K, Lentini JM, Prevost CT, Hashem MO, Alkuraya FS, Fu D. An intellectual disability-associated missense variant in TRMT1 impairs tRNA modification and reconstitution of enzymatic activity. Hum Mutat. 2020 Mar;41(3):600-607. doi: 10.1002/humu.23976. Epub 2020 Jan 16. "			611669	618302	660.1499238	NaN	Class 1	-2.463735116	0.00025131	11697.391	237981.3333	Peripheral	14.84055705	82.84191012
P55265	ADAR	Central nervous system;Integumentary system	RNA-related processes	1	1	1		1		"DISEASE: Aicardi-Goutieres syndrome 6 (AGS6) [MIM:615010]: A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood. {ECO:0000269|PubMed:23001123}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Dyschromatosis symmetrica hereditaria (DSH) [MIM:127400]: An autosomal dominant pigmentary genodermatosis characterized by a mixture of hyperpigmented and hypopigmented macules distributed on the face and the dorsal parts of the hands and feet, that appear in infancy or early childhood. {ECO:0000269|PubMed:12916015, ECO:0000269|PubMed:15146470, ECO:0000269|PubMed:15659327}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006142;C0023520;C0037773;C0393591;C0406775;C0543888;C0678222;C0795996;C0796126;C1257931;C1458155;C3489724;C3489725;C3539013;C3714756	146920	615010-127400	NaN	NaN	Class 1	-1.236371614	0.000809425	NaN	NaN	0	NaN	NaN
Q02241	KIF23	Gastrointestinal system;Hematologic system;Others	Other known processes	1	1	1		1	"Méndez M, Moreno-Carralero MI, Peri VL, Camacho-Galán R, Bosch-Benítez JM, Huerta-Aragonés J, Sánchez-Calero-Guilarte J, Moreno-Risco MB, Alonso-Domínguez JM, Morán-Jiménez MJ. Congenital dyserythropoietic anemia types Ib, II, and III: novel variants in the CDIN1 gene and functional study of a novel variant in the KIF23 gene. Ann Hematol. 2021 Feb;100(2):353-364. Liljeholm M, Irvine AF, Vikberg AL, Norberg A, Month S, Sandström H, Wahlin A, Mishima M, Golovleva I. Congenital dyserythropoietic anemia type III (CDA III) is caused by a mutation in kinesin family member, KIF23. Blood. 2013 Jun 6;121(23):4791-9. "			605064		NaN	NaN	Class 4	-0.796624025	0.093629679	74473.4292	166219.6667	Integral	65.45342317	91.28517196
Q13015	MLLT11	Tumors	Cell death/ apoptosis	1	1	1		1	"Tiberio P, Lozneanu L, Angeloni V, Cavadini E, Pinciroli P, Callari M, Carcangiu ML, Lorusso D, Raspagliesi F, Pala V, Daidone MG, Appierto V. Oncotarget. 2017 Apr 4;8(14):23246-23264. "	11)(q21;DISEASE: Note=A chromosomal aberration involving MLLT11 is found in acute leukemias. Translocation t(1;q23) with KMT2A/MLL1.	C0349639	604684		NaN	NaN	NaN	NaN	NaN	3084.907067	66078.26667	0	11.30593319	NaN
Q08J23	NSUN2	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Skeletal system;Integumentary system"	tRNA related processes	1	1	1		1		"DISEASE: Mental retardation, autosomal recessive 5 (MRT5) [MIM:611091]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. {ECO:0000269|PubMed:22541559, ECO:0000269|PubMed:22541562}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0175691;C1970199;C3714756	610916	611091	NaN	89.03320098	NaN	NaN	NaN	NaN	1055444.5	0	NaN	NaN
Q9H0P0	NT5C3A	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Liver;Skeletal system;Hematologic system"	Nucleotide/ nucleoside metabolism	1	1	1		1		"DISEASE: P5N deficiency (P5ND) [MIM:266120]: Autosomal recessive condition causing hemolytic anemia characterized by marked basophilic stippling and the accumulation of high concentrations of pyrimidine nucleotides within the erythrocyte. It is implicated in the anemia of lead poisoning and is possibly associated with learning difficulties. {ECO:0000269|PubMed:11369620, ECO:0000269|PubMed:12930399, ECO:0000269|PubMed:15238149, ECO:0000269|PubMed:15604219, ECO:0000269|PubMed:15968458, ECO:0000269|PubMed:16461318, ECO:0000269|PubMed:18499901, ECO:0000269|PubMed:25153905}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002882;C0010828;C0158995;C0263454;C1849507;C3714756	606224	266120	30.1336027	NaN	Class 3	-0.785470679	0.001078933	189346.016	190137	Peripheral	43.89216703	96.3432374
Q6GMV3	PTRHD1	Central nervous system;Peripheral nervous system	Unknown	1	1	1		1	"Kuipers DJS, Carr J, Bardien S, Thomas P, Sebate B, Breedveld GJ, van Minkelen R, Brouwer RWW, van Ijcken WFJ, van Slegtenhorst MA, Bonifati V, Quadri M. PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability. Mov Disord. 2018 Nov;33(11):1814-1819. Khodadadi H, Azcona LJ, Aghamollaii V, Omrani MD, Garshasbi M, Taghavi S, Tafakhori A, Shahidi GA, Jamshidi J, Darvish H, Paisán-Ruiz C. PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism. Mov Disord. 2017 Feb;32(2):287-291."			617342		303.000599	152.7042356	Class 1	-1.435862401	0.000487342	102171.5256	753008.3333	Peripheral	5.728249955	52.97879297
A0A087X0K9;H0YLT6	TJP1	Cardiovascular system	Unknown	1	1	1		1	"De Bortoli M, Postma AV, Poloni G, Calore M, Minervini G, Mazzotti E, Rigato I, Ebert M, Lorenzon A, Vazza G, Cipriani A, Bariani R, Perazzolo Marra M, Husser D, Thiene G, Daliento L, Corrado D, Basso C, Tosatto SCE, Bauce B, van Tintelen JP, Rampazzo A. Whole-Exome Sequencing Identifies Pathogenic Variants in TJP1 Gene Associated With Arrhythmogenic Cardiomyopathy. Circ Genom Precis Med. 2018 Oct;11(10):e002123."			601009		NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P06753	TPM3	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system ;Muscular system;Skeletal system"	Other known processes	1	1	1		1		"DISEASE: Cap myopathy 1 (CAPM1) [MIM:609284]: A rare congenital skeletal muscle disorder characterized by the presence of cap-like structures which are well demarcated and peripherally located under the sarcolemma and show abnormal accumulation of sarcomeric proteins. Clinical features are early onset of hypotonia and slowly progressive muscle weakness. Respiratory problems are common. {ECO:0000269|PubMed:18300303, ECO:0000269|PubMed:19487656, ECO:0000269|PubMed:19553118, ECO:0000269|PubMed:24239060, ECO:0000269|PubMed:24692096}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Myopathy, congenital, with fiber-type disproportion (CFTD) [MIM:255310]: A genetically heterogeneous disorder in which there is relative hypotrophy of type 1 muscle fibers compared to type 2 fibers on skeletal muscle biopsy. However, these findings are not specific and can be found in many different myopathic and neuropathic conditions. {ECO:0000269|PubMed:18300303, ECO:0000269|PubMed:19953533, ECO:0000269|PubMed:20951040, ECO:0000269|PubMed:24692096}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Nemaline myopathy 1 (NEM1) [MIM:609284]: A form of nemaline myopathy with autosomal dominant or recessive inheritance. Nemaline myopathies are disorders characterized by muscle weakness of varying onset and severity, and abnormal thread-like or rod-shaped structures in muscle fibers on histologic examination. Autosomal dominant NEM1 is characterized by a moderate phenotype with onset between birth and early second decade of life. Weakness is diffuse and symmetric with slow progression often with need for a wheelchair in adulthood. The autosomal recessive form has onset at birth with moderate to severe hypotonia and diffuse weakness. In the most severe cases, death can occur before 2 years. Less severe cases have delayed major motor milestones, and these patients may walk, but often need a wheelchair before 10 years. {ECO:0000269|PubMed:10587521, ECO:0000269|PubMed:17376686, ECO:0000269|PubMed:24692096, ECO:0000269|PubMed:7704029}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Note=A chromosomal aberration involving TPM3 is found in papillary thyroid carcinomas (PTCs). A rearrangement with NTRK1 generates the TRK fusion transcript by fusing the amino end of isoform 2 of TPM3 to the 3'-end of NTRK1. {ECO:0000269|PubMed:2869410}."	C0001418;C0003886;C0007097;C0007102;C0009375;C0023893;C0024623;C0024667;C0024668;C0038356;C0040136;C0151468;C0175709;C0205641;C0205642;C0205643;C0205644;C0205645;C0205696;C0205697;C0205698;C0205699;C0206157;C0270960;C0334121;C0410203;C0410207;C0546125;C0546264;C0549473;C0752282;C1257925;C1708349;C1834558;C1836448;C2750414;C3645536;C3661489;C3710589;C3714994	191030	609284	NaN	133.9560015	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q8TAM2	TTC8	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Ears;Hematologic system;Kidney and urinary tract;Endocrine system;Reproductive system"	Other known processes	1	1	1		1		"DISEASE: Bardet-Biedl syndrome 8 (BBS8) [MIM:615985]: A syndrome characterized by usually severe pigmentary retinopathy, early-onset obesity, polydactyly, hypogenitalism, renal malformation and mental retardation. Secondary features include diabetes mellitus, hypertension and congenital heart disease. Bardet-Biedl syndrome inheritance is autosomal recessive, but three mutated alleles (two at one locus, and a third at a second locus) may be required for clinical manifestation of some forms of the disease. {ECO:0000269|PubMed:14520415, ECO:0000269|PubMed:16308660}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Retinitis pigmentosa 51 (RP51) [MIM:613464]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:14520415, ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005, ECO:0000269|PubMed:20451172, ECO:0000269|Ref.2, ECO:0000269|Ref.3, ECO:0000269|Ref.7}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0035334;C0152427;C0752166;C1691228;C1859566;C3150715;C3714756;C4277690	608132	613464-615985	NaN	NaN	Class 4	-1.647878671	0.137659378	402.4330109	3013.555	0	NaN	NaN
Q5JTZ9	AARS2	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Muscular system	tRNA related processes	1				1	"Gotz, A., Tyynismaa, H., Euro, L., Ellonen, P., Hyotylainen, T., Ojala, T., Hamalainen, R. H., Tommiska, J., Raivio, T., Oresic, M., Karikoski, R., Tammela, O., Simola, K. O., Paetau, A., Tyni, T., and Suomalainen, A. (2011) Exome sequencing identifies mitochondrial alanyl-tRNA synthetase mutations in infantile mitochondrial cardiomyopathy. Am. J. Hum. Genet. 88, 635-642"	"DISEASE: Combined oxidative phosphorylation deficiency 8 (COXPD8) [MIM:614096]: A mitochondrial disease characterized by a lethal infantile hypertrophic cardiomyopathy, generalized muscle dysfunction and some neurologic involvement. The liver is not affected. {ECO:0000269|PubMed:21549344}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leukoencephalopathy, progressive, with ovarian failure (LKENP) [MIM:615889]: An autosomal recessive neurodegenerative disorder characterized by childhood- to adulthood-onset of signs of neurologic deterioration consisting of ataxia, spasticity, and cognitive decline with features of frontal lobe dysfunction. Brain MRI shows leukoencephalopathy with striking involvement of deep white matter, and cerebellar atrophy. All female patients develop premature ovarian failure. {ECO:0000269|PubMed:24808023}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C0543888;C0751651;C1847967;C3279793;C3711381;C4014588	612035	614096-615889	104.9213847	105.763074	Class 1	-2.041302957	0.000119006	233781.1115	180952	Peripheral	36.45669895	85.7896804
Q9UDR5	AASS	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive	Amino acid metabolism	1				1		"DISEASE: 2,4-dienoyl-CoA reductase deficiency (DECRD) [MIM:616034]: A rare, autosomal recessive, inborn error of polyunsaturated fatty acids and lysine metabolism, resulting in mitochondrial dysfunction. Affected individuals have a severe encephalopathy with neurologic and metabolic abnormalities beginning in early infancy. Laboratory studies show increased C10:2 carnitine levels and hyperlysinemia. {ECO:0000269|PubMed:24847004}. Note=The protein represented in this entry is involved in disease pathogenesis. A selective decrease in mitochondrial NADP(H) levels due to NADK2 mutations causes a deficiency of NADPH-dependent mitochondrial enzymes, such as DECR1 and AASS. {ECO:0000269|PubMed:24847004}.;DISEASE: Hyperlysinemia, 1 (HYPLYS1) [MIM:238700]: An autosomal recessive metabolic condition with variable clinical features. Some patients present with non-specific seizures, hypotonia, or mildly delayed psychomotor development, and increased serum lysine and pipecolic acid on laboratory analysis. However, about half of the probands are reported to be asymptomatic, and hyperlysinemia is generally considered to be a benign metabolic variant. {ECO:0000269|PubMed:10775527}. Note=The disease is caused by mutations affecting the gene represented in this entry. In hyperlysinemia 1, both enzymatic functions of AASS are defective and patients have increased serum lysine and possibly increased saccharopine. Some individuals, however, retain significant amounts of lysine-ketoglutarate reductase and present with saccharopinuria, a metabolic condition with few, if any, clinical manifestations. {ECO:0000305|PubMed:463877}."	C0268553;C0268555;C0268556;C0936256;C1527317;C2936921;C3714756	605113	238700	NaN	NaN	Class 1	-1.051172798	0.000487896	291360.0074	273067	Ambiguous	32.09083465	41.53702128
P80404	ABAT	Central nervous system;Metabolism	Other known processes	1				1	"Besse, A., Wu, P., Bruni, F., Donti, T., Graham, B. H., Craigen, W. J., McFarland, R., Moretti, P., Lalani, S., Scott, K. L., Taylor, R. W., and Bonnen, P. E. (2015) The GABA transaminase, ABAT, is essential for mitochondrial nucleoside metabolism. Cell Metab 21, 417-427"	"DISEASE: GABA transaminase deficiency (GABATD) [MIM:613163]: An enzymatic deficiency resulting in psychomotor retardation, hypotonia, hyperreflexia, lethargy, refractory seizures, and EEG abnormalities. {ECO:0000269|PubMed:10407778}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004352;C0017168;C0022333;C0023380;C0023893;C0026825;C0026827;C0033922;C0034933;C0036572;C0149958;C0151572;C0151888;C0151889;C0234146;C0234533;C0234535;C0234784;C0241772;C0270824;C0270844;C0270846;C0277839;C0277850;C0278211;C0342708;C0422850;C0422852;C0422853;C0422854;C0422855;C0427201;C0427202;C0494475;C0522345;C0543888;C0558845;C0558846;C0558847;C0576612;C0679465;C0743002;C0751056;C0751110;C0751123;C0751330;C0751456;C0751468;C0751469;C0751470;C0751471;C0751472;C0751473;C0751474;C0751475;C0751476;C0751477;C0751478;C0751479;C0751480;C0751481;C0751494;C0751495;C0751496;C0751651;C2267233;C3495874;C3714756;C4048158;C4316903;C4317109;C4317123;C4505436	137150	613163	NaN	NaN	NaN	NaN	NaN	18611.14993	13444.33333	Soluble	13.05247967	19.28114109
Q9NP58	ABCB6	Ophthalmic system;Hematologic system;Integumentary system	"Carriers, channels & transporters"	1				1		"DISEASE: Dyschromatosis universalis hereditaria 3 (DUH3) [MIM:615402]: An autosomal dominant pigmentary genodermatosis characterized by a mixture of hyperpigmented and hypopigmented macules distributed randomly over the body, that appear in infancy or early childhood. The trunk and extremities are the dominant sites of abnormal pigmentation. Facial lesions can be seen in 50% of affected individuals, but involvement of palms and soles is unusual. Abnormalities of hair and nails have also been reported. Dyschromatosis universalis hereditaria may be associated with abnormalities of dermal connective tissue, nerve tissue, or other systemic complications. {ECO:0000269|PubMed:23519333, ECO:0000269|PubMed:24224009, ECO:0000269|PubMed:24498303, ECO:0000269|PubMed:25288164}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Microphthalmia, isolated, with coloboma, 7 (MCOPCB7) [MIM:614497]: A disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues. Ocular abnormalities like opacities of the cornea and lens, scaring of the retina and choroid, and other abnormalities may also be present. Ocular colobomas are a set of malformations resulting from abnormal morphogenesis of the optic cup and stalk, and the fusion of the fetal fissure (optic fissure). {ECO:0000269|PubMed:22226084}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Pseudohyperkalemia, familial, 2, due to red cell leak (PSHK2) [MIM:609153]: A dominantly inherited condition characterized by increased serum potassium levels, measured in whole-blood specimens stored at or below room temperature. This condition is not accompanied by clinical symptoms or biological signs except for borderline abnormalities of red cell shape. {ECO:0000269|PubMed:23180570, ECO:0000269|PubMed:24947683}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006142;C0009363;C0009402;C0009404;C0032460;C0155299;C0266551;C0344516;C0521573;C1136382;C1306229;C1527249;C1836705;C1852767;C1861453;C2931501;C3281027;C3809394	605452	615402-614497-111600	94.62825944	294.731146	Class 4	-0.658542282	0.052862017	2184.599143	23679.36667	0	44.89827757	NaN
O75027	ABCB7	Central nervous system;Failure to thrive;Hematologic system	Fe-S protein biogenesis	1				1	"Allikmets, R., Raskind, W. H., Hutchinson, A., Schueck, N. D., Dean, M., and Koeller, D. M. (1999) Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 8, 743-749"	"DISEASE: Anemia, sideroblastic, spinocerebellar ataxia (ASAT) [MIM:301310]: A X-linked recessive disorder characterized by an infantile to early childhood onset of non-progressive cerebellar ataxia and mild anemia, with hypochromia and microcytosis. {ECO:0000269|PubMed:10196363, ECO:0000269|PubMed:11050011, ECO:0000269|PubMed:11843825, ECO:0000269|PubMed:22398176}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002896;C0004134;C0004138;C0010828;C0158995;C0240991;C0278161;C0427190;C0520966;C0750937;C0750940;C0751651;C1845028;C3714756	300135	301310	97.81842396	NaN	Class 3	-0.566148098	0.002571775	162317.6144	139268.3333	Integral	95.63506696	96.72930014
Q9UKU7	ACAD8	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system	Amino acid metabolism	1				1		"DISEASE: Isobutyryl-CoA dehydrogenase deficiency (IBDD) [MIM:611283]: The symptoms of IBDD generally appear until late in infancy or in childhood and can include poor feeding and growth (failure to thrive), a weakened and enlarged heart (dilated cardiomyopathy), seizures, and low numbers of red blood cells (anemia). {ECO:0000269|PubMed:12359132, ECO:0000269|PubMed:15505379, ECO:0000269|PubMed:16857760}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0024623;C0038356;C0235874;C1708349;C1969809	604773	611283	209.8944117	63.8261583	Class 1	-2.110310707	8.672E-05	38062.33413	21000.76667	Peripheral	10.39876268	57.78864077
Q9H845	ACAD9	Central nervous system;Metabolism;Cardiovascular system;Pulmonary system ;Muscular system;Liver	OXPHOS assembly & stability	1				1	"Nouws, J., Nijtmans, L., Houten, S. M., van den Brand, M., Huynen, M., Venselaar, H., Hoefs, S., Gloerich, J., Kronick, J., Hutchin, T., Willems, P., Rodenburg, R., Wanders, R., van den Heuvel, L., Smeitink, J., and Vogel, R. O. (2010) Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I. Cell Metab 12, 283-294"	"DISEASE: Acyl-CoA dehydrogenase family, member 9, deficiency (ACAD9 deficiency) [MIM:611126]: An autosomal recessive metabolic disorder associated with mitochondrial complex I deficiency, resulting in multisystemic and variable manifestations. Clinical features include infantile onset of acute metabolic acidosis, Reye-like episodes (brain edema and vomiting that may rapidly progress to seizures, coma and death), exercise intolerance, hypertrophic cardiomyopathy, liver failure, muscle weakness, and neurologic dysfunction. {ECO:0000269|PubMed:17564966, ECO:0000269|PubMed:20816094, ECO:0000269|PubMed:20929961, ECO:0000269|PubMed:21057504, ECO:0000269|PubMed:22499348, ECO:0000269|PubMed:23836383, ECO:0000269|PubMed:23996478, ECO:0000269|PubMed:26741492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0035410;C0220994;C0751651;C1970173;C3714756	611103	611126	190.3921181	NaN	Class 1	-1.635168189	5.77762E-05	328608.2319	309409.6667	Peripheral	41.98119319	93.37465664
P11310	ACADM	Central nervous system;Metabolism;Liver;Gastrointestinal system	Fatty acid _-oxidation 	1				1		"DISEASE: Acyl-CoA dehydrogenase medium-chain deficiency (ACADMD) [MIM:201450]: An inborn error of mitochondrial fatty acid beta-oxidation which causes fasting hypoglycemia, hepatic dysfunction and encephalopathy, often resulting in death in infancy. {ECO:0000269|PubMed:10767181, ECO:0000269|PubMed:11349232, ECO:0000269|PubMed:11409868, ECO:0000269|PubMed:11486912, ECO:0000269|PubMed:1363805, ECO:0000269|PubMed:1671131, ECO:0000269|PubMed:1684086, ECO:0000269|PubMed:1902818, ECO:0000269|PubMed:2251268, ECO:0000269|PubMed:2393404, ECO:0000269|PubMed:2394825, ECO:0000269|PubMed:7603790, ECO:0000269|PubMed:7929823, ECO:0000269|PubMed:8198141, ECO:0000269|PubMed:9158144, ECO:0000269|PubMed:9882619}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0006142;C0028754;C0035410;C0043094;C0085605;C0220710;C0220994;C0520459;C3714756	607008	201450	113.2263861	NaN	Class 1	-0.981571373	0.000715373	758394.4618	671457	Soluble	5.635873256	24.03375551
P16219	ACADS	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Liver"	Fatty acid _-oxidation 	1				1		"DISEASE: Acyl-CoA dehydrogenase short-chain deficiency (ACADSD) [MIM:201470]: An inborn error of mitochondrial fatty acid beta-oxidation resulting in acute acidosis and muscle weakness in infants, and a form of lipid-storage myopathy in adults. {ECO:0000269|PubMed:11134486, ECO:0000269|PubMed:1692038, ECO:0000269|PubMed:9499414}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0005586;C0220994;C0342783;C3714756	606885	201470	161.3028986	NaN	Class 4	-0.6388396	0.014921057	93014.9414	85546.8	Soluble	13.31808744	22.09036697
P45954	ACADSB	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Pulmonary system ;Others	Lipid metabolism	1				1		"DISEASE: Short/branched-chain acyl-CoA dehydrogenase deficiency (SBCADD) [MIM:610006]: Autosomal recessive disorder and consists of a defect in catabolism of L-isoleucine which is characterized by an increase of 2-methylbutyrylglycine and 2-methylbutyrylcarnitine in blood and urine. Affected individuals have seizures and psychomotor delay as the main clinical features. {ECO:0000269|PubMed:10832746, ECO:0000269|PubMed:16317551}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004352;C1864912;C3714756	600301	610006	130.5347827	167.0237769	Class 1	-1.246057129	0.000518817	433987.6966	388896.3333	Peripheral	6.536358014	83.42178625
J3QKU9;K7EQP4;P49748	ACADVL	Metabolism;Cardiovascular system;Muscular system	Lipid metabolism	1				1		"a milder childhood form with later onset, characterized by hypoketotic hypoglycemia, low mortality and rare cardiomyopathy;an adult form, with isolated skeletal muscle involvement, rhabdomyolysis and myoglobinuria, usually triggered by exercise or fasting. {ECO:0000269|PubMed:10077518, ECO:0000269|PubMed:8554073, ECO:0000269|PubMed:9546340}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Acyl-CoA dehydrogenase very long-chain deficiency (ACADVLD) [MIM:201475]: An inborn error of mitochondrial fatty acid beta-oxidation which leads to impaired long-chain fatty acid beta-oxidation. It is clinically heterogeneous, with three major phenotypes: a severe childhood form characterized by early onset, high mortality and high incidence of cardiomyopathy"	C0003129;C0003130;C0003886;C0007194;C0035410;C0220994;C0242184;C0700292;C3714756;C3887523	609575	201475	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
E9PKF3;P24752	ACAT1	Central nervous system;Metabolism;Gastrointestinal system	Fatty acid _-oxidation 	1				1		"DISEASE: 3-ketothiolase deficiency (3KTD) [MIM:203750]: An autosomal recessive inborn error of isoleucine catabolism characterized by intermittent ketoacidotic attacks associated with unconsciousness. Some patients die during an attack or are mentally retarded. Urinary excretion of 2-methyl-3-hydroxybutyric acid, 2-methylacetoacetic acid, triglylglycine, butanone is increased. It seems likely that the severity of this disease correlates better with the environmental or acquired factors than with the ACAT1 genotype. {ECO:0000269|PubMed:1346617, ECO:0000269|PubMed:1715688, ECO:0000269|PubMed:7728148, ECO:0000269|PubMed:9744475}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0022333;C0022661;C0023893;C0036572;C0149958;C0234533;C0234535;C0270824;C0270844;C0270846;C0271713;C0422850;C0422852;C0422853;C0422854;C0422855;C0494475;C0751056;C0751110;C0751123;C0751494;C0751495;C0751496;C1536500;C3495874;C3714756;C4048158;C4316903;C4317109;C4317123;C4505436	607809	203750	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q99798	ACO2	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Cardiovascular system;Ears;Peripheral nervous system	TCA cycle	1				1	"Metodiev, M. D., Gerber, S., Hubert, L., Delahodde, A., Chretien, D., Gerard, X., Amati-Bonneau, P., Giacomotto, M. C., Boddaert, N., Kaminska, A., Desguerre, I., Amiel, J., Rio, M., Kaplan, J., Munnich, A., Rotig, A., Rozet, J. M., and Besmond, C. (2014) Mutations in the tricarboxylic acid cycle enzyme, aconitase 2, cause either isolated or syndromic optic neuropathy with encephalopathy and cerebellar atrophy. J Med Genet 51, 834-838;Spiegel, R., Pines, O., Ta-Shma, A., Burak, E., Shaag, A., Halvardson, J., Edvardson, S., Mahajna, M., Zenvirt, S., Saada, A., Shalev, S., Feuk, L., and Elpeleg, O. (2012) Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2. Am. J. Hum. Genet.  90, 518-523"	"DISEASE: Infantile cerebellar-retinal degeneration (ICRD) [MIM:614559]: A severe autosomal recessive neurodegenerative disorder characterized by onset between ages 2 and 6 months of truncal hypotonia, athetosis, seizures, and ophthalmologic abnormalities, particularly optic atrophy and retinal degeneration. Affected individuals show profound psychomotor retardation, with only some achieving rolling, sitting, or recognition of family. Brain MRI shows progressive cerebral and cerebellar degeneration. {ECO:0000269|PubMed:22405087, ECO:0000269|PubMed:25351951}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Optic atrophy 9 (OPA9) [MIM:616289]: A condition that features progressive visual loss in association with optic atrophy. Atrophy of the optic disk indicates a deficiency in the number of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts. {ECO:0000269|PubMed:25351951}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006142;C0035222;C0751651;C2239176;C3281192;C3714756;C4225384	100850	616289-614559	109.3033353	NaN	Class 1	-1.836912167	0.000164092	895284.1956	968916.3333	Soluble	11.09067612	34.26581767
Q4G176	ACSF3	Central nervous system;Metabolism	Lipid metabolism	1				1		"DISEASE: Combined malonic and methylmalonic aciduria (CMAMMA) [MIM:614265]: A metabolic disease characterized by malonic and methylmalonic aciduria, with urinary excretion of much larger amounts of methylmalonic acid than malonic acid, in the presence of normal malonyl-CoA decarboxylase activity. Clinical features include coma, ketoacidosis, hypoglycemia, failure to thrive, microcephaly, dystonia, axial hypotonia and/or developmental delay, and neurologic manifestations including seizures, psychiatric disease and/or cognitive decline. {ECO:0000269|PubMed:21841779}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0268583;C0342793;C1855119;C3280314;C3714756	614245	614265	75.52873387	NaN	Class 1	-1.790201884	9.82281E-05	150799.3571	86325.33333	Peripheral	8.674433409	86.74926651
O60488	ACSL4	Central nervous system	Lipid metabolism	1				1		"DISEASE: Alport syndrome with mental retardation, midface hypoplasia and elliptocytosis (ATS-MR) [MIM:300194]: A X-linked contiguous gene deletion syndrome characterized by glomerulonephritis, sensorineural hearing loss, mental retardation, midface hypoplasia and elliptocytosis. {ECO:0000269|PubMed:9480748}. Note=The gene represented in this entry may be involved in disease pathogenesis.;DISEASE: Mental retardation, X-linked 63 (MRX63) [MIM:300387]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non-syndromic X-linked mental retardation, while syndromic mental retardation presents with associated physical, neurological and/or psychiatric manifestations. {ECO:0000269|PubMed:11889465}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003865;C0011573;C0011581;C0025193;C0033578;C0036341;C0041696;C0041834;C0086133;C0152013;C0282126;C0376358;C0971858;C0993582;C1527249;C1845672;C1846242;C2239176;C2931498;C3714756	300157	300387	25.18861042	37.84076614	Class 1	-1.016827621	0.001157933	178066.5663	246606.3333	Peripheral	5.298998057	96.92799636
Q96PN6	ADCY10	Metabolism;Skeletal system;Kidney and urinary tract	Other known processes	1				1		"DISEASE: Hypercalciuria absorptive 2 (HCA2) [MIM:143870]: A common type of hypercalciuria, a condition characterized by excessive urinary calcium excretion. Absorptive hypercalciuria is due to gastrointestinal hyperabsorption of calcium and is a frequent cause of calcium oxalate nephrolithiasis. {ECO:0000269|PubMed:11932268}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry."	C0342639;C0543800	605205	143870	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9NX46	ADPRHL2	Central nervous system;Ophthalmic system;Pulmonary system ;Ears;Peripheral nervous system	DNA-related processes	1				1		"DISEASE: Neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures (CONDSIAS) [MIM:618170]: An autosomal recessive neurodegenerative disorder characterized by pediatric onset of progressive brain atrophy, developmental regression, and seizures in association with periods of stress, such as infections. {ECO:0000269|PubMed:30100084, ECO:0000269|PubMed:30401461}. Note=The disease is caused by mutations affecting the gene represented in this entry."		610624	618170	379.1161278	NaN	Class 1	-1.98513931	0.006300722	27337.93958	235079.3333	Peripheral	7.100605087	93.10112019
Q9Y4W6	AFG3L2	Central nervous system;Ophthalmic system;Peripheral nervous system	Protein maturation & folding	1				1	"Di Bella, D., Lazzaro, F., Brusco, A., Plumari, M., Battaglia, G., Pastore, A., Finardi, A., Cagnoli, C., Tempia, F., Frontali, M., Veneziano, L., Sacco, T., Boda, E., Brussino, A., Bonn, F., Castellotti, B., Baratta, S., Mariotti, C., Gellera, C., Fracasso, V., Magri, S., Langer, T., Plevani, P., Di Donato, S., Muzi-Falconi, M., and Taroni, F. (2010) Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet 42, 313-321"	"DISEASE: Spastic ataxia 5, autosomal recessive (SPAX5) [MIM:614487]: A neurodegenerative disorder characterized by early onset spasticity, peripheral neuropathy, ptosis, oculomotor apraxia, dystonia, cerebellar atrophy, and progressive myoclonic epilepsy. {ECO:0000269|PubMed:22022284}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spinocerebellar ataxia 28 (SCA28) [MIM:610246]: Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA28 is an autosomal dominant cerebellar ataxia (ADCA) with a slow progressive course and no evidence of sensory involvement or cognitive impairment. {ECO:0000269|PubMed:20208537, ECO:0000269|PubMed:20354562, ECO:0000269|PubMed:20725928, ECO:0000269|PubMed:24293060, ECO:0000269|PubMed:26677414, ECO:0000269|PubMed:29053796}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0037773;C0087012;C0751651;C0751776;C0751777;C0751778;C0751779;C0751780;C0751781;C0751782;C0752120;C0752121;C0752122;C0752123;C0752124;C0752125;C1853249;C3280977;C3714756	604581	614487-610246	165.849039	135.1975967	Class 1	-2.495194207	2.05027E-05	335174.3017	240640.6667	Integral	89.67208785	97.3577391
Q53H12	AGK	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Pulmonary system ;Muscular system;Skeletal system;Hematologic system;Reproductive system	Protein import & biogenesis	1				1	"Calvo, S. E., Compton, A. G., Hershman, S. G., Lim, S. C., Lieber, D. S., Tucker, E. J., Laskowski, A., Garone, C., Liu, S., Jaffe, D. B., Christodoulou, J., Fletcher, J. M., Bruno, D. L., Goldblatt, J., Dimauro, S., Thorburn, D. R., and Mootha, V. K. (2012) Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med 4, 118ra110;Mayr, J. A., Haack, T. B., Graf, E., Zimmermann, F. A., Wieland, T., Haberberger, B., Superti-Furga, A., Kirschner, J., Steinmann, B., Baumgartner, M. R., Moroni, I., Lamantea, E., Zeviani, M., Rodenburg, R. J., Smeitink, J., Strom, T. M., Meitinger, T., Sperl, W., and Prokisch, H. (2012) Lack of the mitochondrial protein acylglycerol kinase causes Sengers syndrome. Am. J. Hum. Genet.  90, 314-320"	"DISEASE: Cataract 38 (CTRCT38) [MIM:614691]: An opacification of the crystalline lens of the eye becoming evident at birth. It frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. {ECO:0000269|PubMed:22415731}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial DNA depletion syndrome 10 (MTDPS10) [MIM:212350]: An autosomal recessive mitochondrial disorder characterized by congenital cataracts, hypertrophic cardiomyopathy, skeletal myopathy, exercise intolerance, and lactic acidosis. Mental development is normal, but affected individuals may die early from cardiomyopathy. {ECO:0000269|PubMed:22277967, ECO:0000269|PubMed:22284826, ECO:0000269|PubMed:23266196, ECO:0000269|PubMed:25208612, ECO:0000269|PubMed:28712726}. Note=The disease is caused by mutations affecting the gene represented in this entry. The TIM22 complex and import of proteins into mitochondrion are affected in patients suffering of MTDPS10 (PubMed:28712726). {ECO:0000269|PubMed:28712726}."	C0086543;C0266539;C0282528;C0751651;C1859317;C3553494;C3714756	610345	614691-212350	214.7486962	NaN	Class 1	-1.586570473	9.30978E-05	780931.1988	788975.6667	Integral	96.78570487	97.38690111
O95831	AIFM1	Central nervous system;Metabolism;Muscular system;Peripheral nervous system	Protein import & biogenesis	1				1	"Ghezzi, D., Sevrioukova, I., Invernizzi, F., Lamperti, C., Mora, M., D'Adamo, P., Novara, F., Zuffardi, O., Uziel, G., and Zeviani, M. (2010) Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor. Am. J. Hum. Genet. 86, 639-649"	"DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6) [MIM:300816]: A mitochondrial disease resulting in a neurodegenerative disorder characterized by psychomotor delay, hypotonia, areflexia, muscle weakness and wasting. Some patients manifest prenatal ventriculomegaly and severe postnatal encephalomyopathy. {ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:22019070}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linked recessive neuromuscular disorder characterized by early childhood onset of a slowly progressive axonal sensorimotor neuropathy associated in some patients with sensorineural deafness and cognitive impairment. {ECO:0000269|PubMed:23217327}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form of hearing loss characterized by absent or severely abnormal auditory brainstem response, abnormal middle ear reflexes, abnormal speech discrimination, loss of outer hair cell function, and cochlear nerve hypoplasia. DFNX5 patients manifest auditory neuropathy with childhood onset, associated with distal sensory impairment affecting the peripheral nervous system. {ECO:0000269|PubMed:25986071}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002152;C0007959;C0011853;C0011854;C0019193;C0020179;C0023520;C0027540;C0035305;C0038433;C0205734;C0339546;C0342302;C0393574;C0751207;C0751208;C0751651;C0795910;C0860207;C1262760;C1845095;C1846148;C3151753;C3658290;C3714756;C3837958;C4277682;C4279912	300169	300816-310490-300614	115.2374664	234.2093459	Class 1	-1.035124618	0.000787843	1214670.649	1558916.667	Peripheral	14.66133584	69.32317748
P54819;P54819;P54819	AK2	Ears;Liver;Gastrointestinal system;Hematologic system	Nucleotide/ nucleoside metabolism	1				1		"DISEASE: Reticular dysgenesis (RDYS) [MIM:267500]: A fatal form of severe combined immunodeficiency, characterized by absence of granulocytes, almost complete deficiency of lymphocytes in peripheral blood, hypoplasia of the thymus and secondary lymphoid organs, and lack of innate and adaptive humoral and cellular immunity, leading to fatal septicemia within days after birth. In bone marrow of individuals with reticular dysgenesis, myeloid differentiation is blocked at the promyelocytic stage, whereas erythro- and megakaryocytic maturation is generally normal. Inheritance is autosomal recessive. {ECO:0000269|PubMed:19043416, ECO:0000269|PubMed:19043417}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0011052;C0011053;C0085110;C0086395;C0242583;C0272167;C0581883;C0751068;C1282908;C2700553;C3665473;C3714756;C4082305	103020	267500	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P22557	ALAS2	Metabolism;Gastrointestinal system;Hematologic system;Integumentary system	Cofactor metabolism	1				1		"DISEASE: Anemia, sideroblastic, 1 (SIDBA1) [MIM:300751]: A form of sideroblastic anemia that shows a variable hematologic response to pharmacologic doses of pyridoxine. Sideroblastic anemia is characterized by anemia of varying severity, hypochromic peripheral erythrocytes, systemic iron overload secondary to chronic ineffective erythropoiesis, and the presence of bone marrow ringed sideroblasts. Sideroblasts are characterized by iron-loaded mitochondria clustered around the nucleus. {ECO:0000269|PubMed:10029606, ECO:0000269|PubMed:10577279, ECO:0000269|PubMed:12031592, ECO:0000269|PubMed:12393718, ECO:0000269|PubMed:1570328, ECO:0000269|PubMed:19731322, ECO:0000269|PubMed:21252495, ECO:0000269|PubMed:21309041, ECO:0000269|PubMed:8107717, ECO:0000269|PubMed:9858242}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Erythropoietic protoporphyria, X-linked dominant (XLDPT) [MIM:300752]: A form of porphyria. Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. XLDPT is characterized biochemically by a high proportion of zinc-protoporphyrin in erythrocytes, in which a mismatch between protoporphyrin production and the heme requirement of differentiating erythroid cells leads to overproduction of protoporphyrin in amounts sufficient to cause photosensitivity and liver disease. {ECO:0000269|PubMed:18760763}. Note=The disease is caused by mutations affecting the gene represented in this entry. Gain of function mutations in ALS2 are responsible for XLDPT, but they can also be a possible aggravating factor in congenital erythropoietic porphyria and other erythropoietic disorders caused by mutations in other genes (PubMed:21309041). {ECO:0000269|PubMed:21309041}."	C0002896;C0004138;C0010828;C0019207;C0019208;C0023904;C0086404;C0158995;C0221018;C2677889	301300	300751-300752	NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
P54886;P54886	ALDH18A1	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Skeletal system;Kidney and urinary tract;Integumentary system"	Amino acid metabolism	1				1	"Kremer, L. S., Bader, D. M., Mertes, C., Kopajtich, R., Pichler, G., Iuso, A., Haack, T. B., Graf, E., Schwarzmayr, T., Terrile, C., Konarikova, E., Repp, B., Kastenmuller, G., Adamski, J., Lichtner, P., Leonhardt, C., Funalot, B., Donati, A., Tiranti, V., Lombes, A., Jardel, C., Glaser, D., Taylor, R. W., Ghezzi, D., Mayr, J. A., Rotig, A., Freisinger, P., Distelmaier, F., Strom, T. M., Meitinger, T., Gagneur, J., and Prokisch, H. (2017) Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun 8, 15824"	"DISEASE: Cutis laxa, autosomal dominant, 3 (ADCL3) [MIM:616603]: A form of cutis laxa, a connective tissue disorder characterized by loose, hyperextensible skin with decreased resilience and elasticity leading to a premature aged appearance. Face, hands, feet, joints, and torso may be differentially affected. Additional variable clinical features are gastrointestinal diverticula, hernia, and genital prolapse. Rare manifestations are pulmonary artery stenosis, aortic aneurysm, bronchiectasis, and emphysema. ADCL3 patients manifest thin skin with visible veins and wrinkles, cataract or corneal clouding, moderate intellectual disability, muscular hypotonia with brisk muscle reflexes, clenched fingers, and pre- and postnatal growth retardation. {ECO:0000269|PubMed:26320891}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Cutis laxa, autosomal recessive, 3A (ARCL3A) [MIM:219150]: A syndrome characterized by facial dysmorphism with a progeroid appearance, large and late-closing fontanel, cutis laxa, joint hyperlaxity, athetoid movements and hyperreflexia, pre- and postnatal growth retardation, intellectual deficit, developmental delay, and ophthalmologic abnormalities. {ECO:0000269|PubMed:11092761, ECO:0000269|PubMed:18478038, ECO:0000269|PubMed:22170564, ECO:0000269|PubMed:24767728}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spastic paraplegia 9A, autosomal dominant (SPG9A) [MIM:601162]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG9A patients have gait difficulties, motor neuropathy, and dysarthria. Additional variable features include cerebellar signs, cataract, pes cavus, and urinary urgency. {ECO:0000269|PubMed:26026163, ECO:0000269|PubMed:26297558}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spastic paraplegia 9B, autosomal recessive (SPG9B) [MIM:616586]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG9B is a complex form characterized by delayed psychomotor development, intellectual disability, and severe motor impairment. Dysmorphic facial features, tremor, and urinary incontinence are variably observed in SPG9B patients. {ECO:0000269|PubMed:26026163}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0013720;C0037773;C0086543;C0152013;C0220994;C0268350;C0268354;C0345050;C1832669;C1855670;C3714756;C4225268;C4225272	138250	616603-219150-601162-616586	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q3SY69	ALDH1L2	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Integumentary system"	Cofactor metabolism	1				1	"Sarret C, Ashkavand Z, Paules E, Dorboz I, Pediaditakis P, Sumner S, Eymard-Pierre E, Francannet C, Krupenko NI, Boespflug-Tanguy O, Krupenko SA. Deleterious mutations in ALDH1L2 suggest a novel cause for neuro-ichthyotic syndrome. NPJ Genom Med. 2019 Jul 23;4:17."			613584		317.254438	44.53152346	Class 4	0.911861595	0.039404695	24335.15027	27505.63333	Peripheral	19.90808944	88.62671343
P30038	ALDH4A1	Central nervous system;Metabolism	Amino acid metabolism	1				1		"DISEASE: Hyperprolinemia 2 (HYRPRO2) [MIM:239510]: An inborn error of proline metabolism resulting in elevated plasma levels of proline and delta-1-pyrroline-5-carboxylate (P5C). The condition is considered to be benign, but affected individuals can exhibit neurological manifestations that vary in severity. Clinical signs include seizures, intellectual deficit and mild developmental delay. {ECO:0000269|PubMed:22516612, ECO:0000269|PubMed:9700195}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0032927;C0282313;C2931835;C3714756	606811	239510	317.3907564	392.7055493	Class 3	-0.742181018	0.002077161	189850.5022	191096.6667	Soluble	5.159751143	19.48043883
P51649	ALDH5A1	Central nervous system;Metabolism	Amino acid metabolism	1				1		"DISEASE: Succinic semialdehyde dehydrogenase deficiency (SSADHD) [MIM:271980]: A rare inborn error of 4-aminobutyric acid (GABA) metabolism, which leads to accumulation of 4-hydroxybutyric acid in physiologic fluids of patients. The disease is clinically characterized by developmental delay, hypotonia, mental retardation, ataxia, seizures, hyperkinetic behavior, aggression, and sleep disturbances. {ECO:0000269|PubMed:11243727, ECO:0000269|PubMed:11901270, ECO:0000269|PubMed:14635103}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006112;C0020796;C0025363;C0027854;C0235031;C0268631;C0393593;C0393598;C0422837;C0521654;C0543888;C0743332;C0746857;C0750968;C0751377;C0751378;C0751743;C0751744;C0752197;C0752198;C0752199;C0752200;C0752201;C0752202;C0752203;C0752205;C0752206;C0752207;C0752208;C0917816;C1135773;C3714756;C4316810	610045	271980	99.02381917	NaN	Class 4	1.140119172	0.403261483	386607.144	468506	Peripheral	10.3845725	68.09505503
Q02252	ALDH6A1	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Liver"	Amino acid metabolism	1				1		"DISEASE: Methylmalonate semialdehyde dehydrogenase deficiency (MMSDHD) [MIM:614105]: A metabolic disorder characterized by elevated beta-alanine, 3-hydroxypropionic acid, and both isomers of 3-amino and 3-hydroxyisobutyric acids in urine organic acids. {ECO:0000269|PubMed:10947204}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002514;C0028754;C0151744;C0750905;C3279840	603178	614105	73.41108603	NaN	Class 4	-0.206344641	0.070268012	224883.9071	230290.3333	Peripheral	7.905500984	74.29833423
P49419	ALDH7A1	Central nervous system;Metabolism;Pulmonary system ;Gastrointestinal system	Amino acid metabolism	1				1		"DISEASE: Pyridoxine-dependent epilepsy (PDE) [MIM:266100]: Characterized by a combination of various seizure types. It usually occurs in the first hours of life and is unresponsive to standard anticonvulsants, responding only to immediate administration of pyridoxine hydrochloride. {ECO:0000269|PubMed:16491085, ECO:0000269|PubMed:17068770}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0005940;C0009363;C0024623;C0038356;C0235874;C0543888;C1291560;C1708349;C1849508;C3714756	107323	266100	163.8135908	NaN	Class 1	-1.138920142	0.0003545	716064.6179	1576720	Soluble	9.668240103	15.84371486
Q9UHK6	AMACR	Central nervous system;Metabolism;Ophthalmic system;Muscular system;Endocrine system	Fatty acid _-oxidation 	1				1		"DISEASE: Alpha-methylacyl-CoA racemase deficiency (AMACRD) [MIM:614307]: A rare autosomal recessive peroxisomal disorder characterized by elevated plasma concentrations of pristanic acid C27-bile-acid intermediates, and adult onset of variable neurodegenerative symptoms affecting the central and peripheral nervous systems. Features may include seizures, visual failure, sensorimotor neuropathy, spasticity, migraine, and white matter hyperintensities on brain imaging. {ECO:0000269|PubMed:10655068}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Congenital bile acid synthesis defect 4 (CBAS4) [MIM:214950]: A disorder characterized by the presence of trihydroxycoprostanic acid in the bile and absence of cholic acid. Patients manifest neonatal jaundice, intrahepatic cholestasis and bile duct deficiency. {ECO:0000269|PubMed:10655068, ECO:0000269|PubMed:12512044}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0001430;C0008370;C0009402;C0009404;C0011195;C0019816;C0023893;C0023895;C0027888;C0033578;C0036341;C0086565;C0205646;C0205647;C0205648;C0205649;C0205650;C0205651;C0282528;C0376358;C1112213;C1527249;C1858328;C3280428	604489	614307-214950	114.931287	NaN	Class 4	-0.311429304	0.067258675	8079.651284	15641.865	0	NaN	72.66528781
P48728	AMT	Central nervous system;Metabolism	Amino acid metabolism	1				1		"DISEASE: Non-ketotic hyperglycinemia (NKH) [MIM:605899]: Autosomal recessive disease characterized by accumulation of a large amount of glycine in body fluid and by severe neurological symptoms. {ECO:0000269|PubMed:10873393, ECO:0000269|PubMed:11286506, ECO:0000269|PubMed:16051266, ECO:0000269|PubMed:26371980, ECO:0000269|PubMed:28244183, ECO:0000269|PubMed:8005589, ECO:0000269|PubMed:9600239, ECO:0000269|PubMed:9621520}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0268560;C0268561;C0268562;C0751747;C0751748	238310	605899	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q96IL0	APOPT1	Central nervous system;Metabolism;Failure to thrive;Gastrointestinal system;Peripheral nervous system;Others	Cell death/ apoptosis	1				1	"Melchionda, L., Haack, T. B., Hardy, S., Abbink, T. E., Fernandez-Vizarra, E., Lamantea, E., Marchet, S., Morandi, L., Moggio, M., Carrozzo, R., Torraco, A., Diodato, D., Strom, T. M., Meitinger, T., Tekturk, P., Yapici, Z., Al-Murshedi, F., Stevens, R., Rodenburg, R. J., Lamperti, C., Ardissone, A., Moroni, I., Uziel, G., Prokisch, H., Taylor, R. W., Bertini, E., van der Knaap, M. S., Ghezzi, D., and Zeviani, M. (2014) Mutations in APOPT1, Encoding a Mitochondrial Protein, Cause Cavitating Leukoencephalopathy with Cytochrome c Oxidase Deficiency. Am. J. Hum. Genet. 95, 315-325"		C0268237;C0751651;C3714756	616003	220110	NaN	NaN	Class 4	-1.846859658	0.076830266	3979.727401	NaN	0	NaN	NaN
P36404	ARL2	Ophthalmic system	Regulation & signaling	1				1	"Cai XB, Wu KC, Zhang X, Lv JN, Jin GH, Xiang L, Chen J, Huang XF, Pan D, Lu B, Lu F, Qu J, Jin ZB. Whole-exome sequencing identified ARL2 as a novel candidate gene for MRCS (microcornea, rod-cone dystrophy, cataract, and posterior staphyloma) syndrome. Clin Genet. 2019 Jul;96(1):61-71."			601175	619082	303.6056032	90.17879515	Class 1	-1.368923026	0.002908915	100138.3009	727506	Peripheral	22.37327901	95.93415413
Q8NBU5	ATAD1	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Skeletal system"	Regulation & signaling	1				1		"DISEASE: Hyperekplexia 4 (HKPX4) [MIM:618011]: An autosomal recessive severe neurologic disorder apparent from birth. HKPX4 is characterized by little if any development, hypertonia, early-onset refractory seizures in some patients, and respiratory failure resulting in early death, mostly in the first months of life. {ECO:0000269|PubMed:28180185, ECO:0000269|PubMed:29390050, ECO:0000269|PubMed:29659736}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C1527249	614452	618011	48.25814923	89.49053834	Class 3	-0.53313372	0.0039892	525146.2783	516455.6667	Integral	82.18618305	96.25951143
Q5SV16;Q9NVI7;Q9NVI7	ATAD3A	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Peripheral nervous system;Skeletal system"	"Morphology, dynamics & organization"	1				1	"Harel, T., Yoon, W. H., Garone, C., Gu, S., Coban-Akdemir, Z., Eldomery, M. K., Posey, J. E., Jhangiani, S. N., Rosenfeld, J. A., Cho, M. T., Fox, S., Withers, M., Brooks, S. M., Chiang, T., Duraine, L., Erdin, S., Yuan, B., Shao, Y., Moussallem, E., Lamperti, C., Donati, M. A., Smith, J. D., McLaughlin, H. M., Eng, C. M., Walkiewicz, M., Xia, F., Pippucci, T., Magini, P., Seri, M., Zeviani, M., Hirano, M., Hunter, J. V., Srour, M., Zanigni, S., Lewis, R. A., Muzny, D. M., Lotze, T. E., Boerwinkle, E., Baylor-Hopkins Center for Mendelian, G., University of Washington Center for Mendelian, G., Gibbs, R. A., Hickey, S. E., Graham, B. H., Yang, Y., Buhas, D., Martin, D. M., Potocki, L., Graziano, C., Bellen, H. J., and Lupski, J. R. (2016) Recurrent De Novo and Biallelic Variation of ATAD3A, Encoding a Mitochondrial Membrane Protein, Results in Distinct Neurological Syndromes. Am. J. Hum. Genet. 99, 831-845"	"DISEASE: Harel-Yoon syndrome (HAYOS) [MIM:617183]: A syndrome characterized by global developmental delay, hypotonia, intellectual disability, and axonal neuropathy. Some patients have optic atrophy and hypertrophic cardiomyopathy. HAYOS inheritance can be autosomal dominant or autosomal recessive. {ECO:0000269|PubMed:27640307}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0033578;C0376358;C0751651;C3714756;C4310677	612316	617183	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
K7EK77;K7ERX7;P25705	ATP5F1A	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system "	OXPHOS complex subunits	1				1	"Lieber, D. S., Calvo, S. E., Shanahan, K., Slate, N. G., Liu, S., Hershman, S. G., Gold, N. B., Chapman, B. A., Thorburn, D. R., Berry, G. T., Schmahmann, J. D., Borowsky, M. L., Mueller, D. M., Sims, K. B., and Mootha, V. K. (2013) Targeted exome sequencing of suspected mitochondrial disorders. Neurology 80, 1762-1770"	"DISEASE: Combined oxidative phosphorylation deficiency 22 (COXPD22) [MIM:616045]: A mitochondrial disorder characterized by intrauterine growth retardation, microcephaly, hypotonia, pulmonary hypertension, failure to thrive, encephalopathy, and heart failure. {ECO:0000269|PubMed:23596069}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex V deficiency, nuclear type 4 (MC5DN4) [MIM:615228]: A mitochondrial disorder with heterogeneous clinical manifestations including dysmorphic features, psychomotor retardation, hypotonia, growth retardation, cardiomyopathy, enlarged liver, hypoplastic kidneys and elevated lactate levels in urine, plasma and cerebrospinal fluid. {ECO:0000269|PubMed:23599390}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002395;C0011265;C0276496;C0342779;C0376618;C0494463;C0546126;C0750900;C0750901;C3808899;C4015062	164360	616045-615228	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P30049	ATP5F1D	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Muscular system;Gastrointestinal system;Skeletal system;Others	OXPHOS complex subunits	1				1	"Oláhová M, Yoon WH, Thompson K, Jangam S, Fernandez L, Davidson JM, Kyle JE, Grove ME, Fisk DG, Kohler JN, Holmes M, Dries AM, Huang Y, Zhao C, Contrepois K, Zappala Z, Frésard L, Waggott D, Zink EM, Kim YM, Heyman HM, Stratton KG, Webb-Robertson BM; Undiagnosed Diseases Network, Snyder M, Merker JD, Montgomery SB, Fisher PG, Feichtinger RG, Mayr JA, Hall J, Barbosa IA, Simpson MA, Deshpande C, Waters KM, Koeller DM, Metz TO, Morris AA, Schelley S, Cowan T, Friederich MW, McFarland R, Van Hove JLK, Enns GM, Yamamoto S, Ashley EA, Wangler MF, Taylor RW, Bellen HJ, Bernstein JA, Wheeler MT. Biallelic Mutations in ATP5F1D, which Encodes a Subunit of ATP Synthase, Cause a Metabolic Disorder. Am J Hum Genet. 2018 Mar 1;102(3):494-504."			603150	618120	51.41824502	761.5946142	Class 1	-1.370922157	0.000120988	1432465.826	2731850	Peripheral	11.66920846	63.50558736
P56381	ATP5F1E	Central nervous system;Metabolism;Cardiovascular system;Peripheral nervous system	OXPHOS complex subunits	1				1	"Mayr, J. A., Havlickova, V., Zimmermann, F., Magler, I., Kaplanova, V., Jesina, P., Pecinova, A., Nuskova, H., Koch, J., Sperl, W., and Houstek, J. (2010) Mitochondrial ATP synthase deficiency due to a mutation in the ATP5E gene for the F1 epsilon subunit. Hum Mol Genet 19, 3430-3439"	"DISEASE: Mitochondrial complex V deficiency, nuclear type 3 (MC5DN3) [MIM:614053]: A mitochondrial disorder with heterogeneous clinical manifestations including dysmorphic features, psychomotor retardation, hypotonia, growth retardation, cardiomyopathy, enlarged liver, hypoplastic kidneys and elevated lactate levels in urine, plasma and cerebrospinal fluid. {ECO:0000269|PubMed:20566710}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0342779;C3279708	606153	614053	33.94554633	134.879687	Class 1	-1.347494208	0.000141204	971058.0975	1915960	Peripheral	4.672504062	55.23201644
Q96IX5	ATP5MD	Central nervous system;Ophthalmic system;Others	OXPHOS complex subunits	1				1	"Barca E, Ganetzky RD, Potluri P, Juanola-Falgarona M, Gai X, Li D, Jalas C, Hirsch Y, Emmanuele V, Tadesse S, Ziosi M, Akman HO, Chung WK, Tanji K, McCormick EM, Place E, Consugar M, Pierce EA, Hakonarson H, Wallace DC, Hirano M, Falk MJ. USMG5 Ashkenazi Jewish founder mutation impairs mitochondrial complex V dimerization and ATP synthesis. Hum Mol Genet. 2018 Oct 1;27(19):3305-3312. d"			615204	618683	13.36279282	32.37857793	Class 1	-2.533145356	5.21833E-05	1416362.03	3319700	Integral	96.76203926	89.37931494
P35670	ATP7B	Central nervous system;Liver	"Carriers, channels & transporters"	1				1		"DISEASE: Wilson disease (WD) [MIM:277900]: An autosomal recessive disorder of copper metabolism in which copper cannot be incorporated into ceruloplasmin in liver, and cannot be excreted from the liver into the bile. Copper accumulates in the liver and subsequently in the brain and kidney. The disease is characterized by neurologic manifestations and signs of cirrhosis. {ECO:0000269|PubMed:10051024, ECO:0000269|PubMed:10194254, ECO:0000269|PubMed:10447265, ECO:0000269|PubMed:10453196, ECO:0000269|PubMed:10502776, ECO:0000269|PubMed:10502777, ECO:0000269|PubMed:10544227, ECO:0000269|PubMed:10721669, ECO:0000269|PubMed:10790207, ECO:0000269|PubMed:10942420, ECO:0000269|PubMed:11043508, ECO:0000269|PubMed:11093740, ECO:0000269|PubMed:11180609, ECO:0000269|PubMed:11216666, ECO:0000269|PubMed:11231950, ECO:0000269|PubMed:11243728, ECO:0000269|PubMed:11405812, ECO:0000269|PubMed:11690702, ECO:0000269|PubMed:11954751, ECO:0000269|PubMed:12325021, ECO:0000269|PubMed:12376745, ECO:0000269|PubMed:12544487, ECO:0000269|PubMed:14639035, ECO:0000269|PubMed:14966923, ECO:0000269|PubMed:14986826, ECO:0000269|PubMed:15024742, ECO:0000269|PubMed:15557537, ECO:0000269|PubMed:15811015, ECO:0000269|PubMed:15845031, ECO:0000269|PubMed:15952988, ECO:0000269|PubMed:15967699, ECO:0000269|PubMed:16088907, ECO:0000269|PubMed:16207219, ECO:0000269|PubMed:16283883, ECO:0000269|PubMed:16649058, ECO:0000269|PubMed:17718866, ECO:0000269|PubMed:17823867, ECO:0000269|PubMed:17919502, ECO:0000269|PubMed:17949296, ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:18373411, ECO:0000269|PubMed:19033537, ECO:0000269|PubMed:20333758, ECO:0000269|PubMed:21398519, ECO:0000269|PubMed:21454443, ECO:0000269|PubMed:21645214, ECO:0000269|PubMed:21682854, ECO:0000269|PubMed:22075048, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:22484412, ECO:0000269|PubMed:22763723, ECO:0000269|PubMed:23159873, ECO:0000269|PubMed:23235335, ECO:0000269|PubMed:23275100, ECO:0000269|PubMed:23333878, ECO:0000269|PubMed:23518715, ECO:0000269|PubMed:23962630, ECO:0000269|PubMed:24476933, ECO:0000269|PubMed:24555712, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:25704634, ECO:0000269|PubMed:25982861, ECO:0000269|PubMed:26004889, ECO:0000269|PubMed:28856630, ECO:0000269|PubMed:7626145, ECO:0000269|PubMed:8298641, ECO:0000269|PubMed:8533760, ECO:0000269|PubMed:8782057, ECO:0000269|PubMed:8931691, ECO:0000269|PubMed:8938442, ECO:0000269|PubMed:8980283, ECO:0000269|PubMed:9222767, ECO:0000269|PubMed:9311736, ECO:0000269|PubMed:9452121, ECO:0000269|PubMed:9482578, ECO:0000269|PubMed:9554743, ECO:0000269|PubMed:9671269, ECO:0000269|PubMed:9772425, ECO:0000269|PubMed:9829905, ECO:0000269|PubMed:9837819, ECO:0000269|PubMed:9887381}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006142;C0007097;C0008370;C0009402;C0009404;C0015695;C0019158;C0019202;C0019207;C0019208;C0021368;C0022665;C0023520;C0023890;C0023895;C0023903;C0023904;C0026640;C0033578;C0041696;C0086404;C0086565;C0153381;C0162557;C0205696;C0205697;C0205698;C0205699;C0235874;C0239946;C0242339;C0345904;C0376358;C0598784;C0678222;C0740457;C0919267;C1112213;C1140680;C1168401;C1257931;C1269683;C1458155;C1527249;C1527352;C2711227;C3714756	606882	277900	NaN	NaN	Class 4	-0.428370291	0.577922816	502.5409014	6143.886667	0	NaN	NaN
Q8N5M1	ATPAF2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Liver;Skeletal system;Kidney and urinary tract"	OXPHOS assembly & stability	1				1	"De Meirleir, L., Seneca, S., Lissens, W., De Clercq, I., Eyskens, F., Gerlo, E., Smet, J., and Van Coster, R. (2004) Respiratory chain complex V deficiency due to a mutation in the assembly gene ATP12. J Med Genet 41, 120-124"	"DISEASE: Mitochondrial complex V deficiency, nuclear type 1 (MC5DN1) [MIM:604273]: A mitochondrial disorder with heterogeneous clinical manifestations including dysmorphic features, psychomotor retardation, hypotonia, growth retardation, cardiomyopathy, enlarged liver, hypoplastic kidneys and elevated lactate levels in urine, plasma and cerebrospinal fluid. {ECO:0000269|PubMed:14757859}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C0220994;C0342779;C0751651;C2700431;C3276276	608918	604273	609.8802178	NaN	Class 1	-1.726980399	0.000153045	89143.94815	75215	Peripheral	4.27974359	95.19622277
Q13825	AUH	Central nervous system;Metabolism;Liver;Gastrointestinal system	Fatty acid _-oxidation 	1				1		"DISEASE: 3-methylglutaconic aciduria 1 (MGA1) [MIM:250950]: An inborn error of leucine metabolism. It leads to an autosomal recessive syndrome with variable clinical phenotype, ranging from delayed speech development to severe psychomotor retardation, coma, failure to thrive, metabolic acidosis and dystonia. MGA1 can be distinguished from other forms of MGA by the pattern of metabolite excretion: 3-methylglutaconic acid levels are higher than those detected in other forms, whereas methylglutaric acid levels are usually only slightly elevated and there is a high level of 3-hydroxyisovaleric acid excretion (not present in other MGA forms). {ECO:0000269|PubMed:12655555}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0342727;C0342728;C3714756	600529	250950	119.3136842	322.7045007	Class 1	-1.532460806	0.000162427	52726.12692	40376.93333	Peripheral	3.21838154	84.90423074
O15382	BCAT2	Central nervous system;Metabolism;Liver	Amino acid metabolism	1				1	"Wang XL, Li CJ, Xing Y, Yang YH, Jia JP. Hypervalinemia and hyperleucine-isoleucinemia caused by mutations in the branched-chain-amino-acid aminotransferase gene. J Inherit Metab Dis. 2015 Sep;38(5):855-61."			113530	618850	94.6897417	NaN	Class 3	-0.862959715	0.001999009	582688.5767	569520.6667	Soluble	2.509894387	29.96854751
P12694	BCKDHA	Central nervous system;Metabolism	Amino acid metabolism	1				1		"DISEASE: Maple syrup urine disease 1A (MSUD1A) [MIM:248600]: A metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated. {ECO:0000269|PubMed:1867199, ECO:0000269|PubMed:1885764, ECO:0000269|PubMed:2060625, ECO:0000269|PubMed:21844576, ECO:0000269|PubMed:2241958, ECO:0000269|PubMed:2703538, ECO:0000269|PubMed:7883996, ECO:0000269|PubMed:8037208, ECO:0000269|PubMed:8161368}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0024776;C0220994;C0268568;C0268569;C0543888;C0751285;C1621920;C1855369;C1855371;C2930990;C3714756	608348	248600	67.30265099	NaN	Class 1	-1.266728502	0.000145573	211329.7567	183473.6667	Peripheral	5.027596358	51.53159883
P21953	BCKDHB	Central nervous system;Metabolism;Failure to thrive	Amino acid metabolism	1				1		"DISEASE: Maple syrup urine disease 1B (MSUD1B) [MIM:248600]: A metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated. {ECO:0000269|PubMed:11509994, ECO:0000269|PubMed:22326532, ECO:0000269|PubMed:8161368}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0024776;C0220994;C0268568;C0268569;C0543888;C0751285;C1621920;C1855369;C1855371;C2930990;C3714756	248611	248600	120.6944306	92.79317059	Class 1	-1.349210029	0.000303377	190443.3279	187444.4333	Soluble	8.736393968	47.12300125
H3BUV3;O14874;O14874	BCKDK	Central nervous system;Metabolism	Amino acid metabolism	1				1		"DISEASE: Branched-chain ketoacid dehydrogenase kinase deficiency (BCKDKD) [MIM:614923]: A metabolic disorder characterized by autism, epilepsy, intellectual disability, and reduced branched-chain amino acids. {ECO:0000269|PubMed:22956686, ECO:0000269|PubMed:24449431}. Note=The disease is caused by mutations affecting the gene represented in this entry. A diet enriched in branched amino acids (BCAAs) allows to normalize plasma BCAA levels. This suggests that it may be possible to treat patients with mutations in BCKDK with BCAA supplementation."	C3554078;C3714756	614901	614923	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9Y276	BCS1L	"Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system ;Ears;Liver;Peripheral nervous system;Kidney and urinary tract;Others;Integumentary system"	OXPHOS assembly & stability	1				1	"de Lonlay, P., Valnot, I., Barrientos, A., Gorbatyuk, M., Tzagoloff, A., Taanman, J. W., Benayoun, E., Chretien, D., Kadhom, N., Lombes, A., de Baulny, H. O., Niaudet, P., Munnich, A., Rustin, P., and Rotig, A. (2001) A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure. Nat Genet 29, 57-60"	"DISEASE: Bjoernstad syndrome (BJS) [MIM:262000]: An autosomal recessive disease characterized by congenital sensorineural hearing loss and twisted hairs (pili torti). Pili torti is a condition in which the hair shafts are flattened at irregular intervals and twisted 180 degrees from the normal axis, making the hair extremely brittle. {ECO:0000269|PubMed:17314340, ECO:0000269|PubMed:24172246}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: GRACILE syndrome (GRACILE) [MIM:603358]: GRACILE stands for 'growth retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis, and early death'. It is a recessively inherited lethal disease characterized by fetal growth retardation, lactic acidosis, aminoaciduria, cholestasis, and abnormalities in iron metabolism. {ECO:0000269|PubMed:12215968, ECO:0000269|PubMed:17314340}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex III deficiency, nuclear 1 (MC3DN1) [MIM:124000]: A disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. Clinical features include mitochondrial encephalopathy, psychomotor retardation, ataxia, severe failure to thrive, liver dysfunction, renal tubulopathy, muscle weakness and exercise intolerance. {ECO:0000269|PubMed:11528392, ECO:0000269|PubMed:12910490, ECO:0000269|PubMed:17314340, ECO:0000269|PubMed:17403714, ECO:0000269|PubMed:18628306, ECO:0000269|PubMed:19162478, ECO:0000269|PubMed:22991165}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0023520;C0266006;C0342778;C0543888;C0751267;C0751268;C0751651;C1112213;C1864002;C3541471;C3714756	603647	262000-603358-256000-124000	587.4852682	432.5093076	Class 1	-2.11860288	3.09516E-05	123122.5472	94567.4	Integral	96.82213531	97.00238507
Q53S33	BOLA3	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Cardiovascular system;Pulmonary system ;Gastrointestinal system	Fe-S protein biogenesis	1				1	"Cameron, J. M., Janer, A., Levandovskiy, V., Mackay, N., Rouault, T. A., Tong, W. H., Ogilvie, I., Shoubridge, E. A., and Robinson, B. H. (2011) Mutations in iron-sulfur cluster scaffold genes NFU1 and BOLA3 cause a fatal deficiency of multiple respiratory chain and 2-oxoacid dehydrogenase enzymes. Am. J. Hum. Genet. 89, 486-495"	"DISEASE: Multiple mitochondrial dysfunctions syndrome 2 with hyperglycinemia (MMDS2) [MIM:614299]: A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death. Some patients show failure to thrive, pulmonary hypertension, hypotonia and irritability. Biochemical features include severe combined deficiency of the 2-oxoacid dehydrogenases, defective lipoic acid synthesis and reduction in activity of mitochondrial respiratory chain complexes. {ECO:0000269|PubMed:21944046, ECO:0000269|PubMed:22562699, ECO:0000269|PubMed:24334290, ECO:0000269|PubMed:26741492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C0543888;C0751651;C3280378;C3714756	613183	614299	180.116807	224.0583727	Class 1	-2.915774859	3.20964E-05	98497.19985	95630.16667	Peripheral	4.623522994	74.58712955
Q9H3J6	C12orf65	Central nervous system;Ophthalmic system;Failure to thrive;Pulmonary system ;Gastrointestinal system;Peripheral nervous system	Unknown	1				1	"Antonicka, H., Ostergaard, E., Sasarman, F., Weraarpachai, W., Wibrand, F., Pedersen, A. M., Rodenburg, R. J., van der Knaap, M. S., Smeitink, J. A., Chrzanowska-Lightowlers, Z. M., and Shoubridge, E. A. (2010) Mutations in C12orf65 in patients with encephalomyopathy and a mitochondrial translation defect. Am. J. Hum. Genet. 87, 115-122"	"DISEASE: Combined oxidative phosphorylation deficiency 7 (COXPD7) [MIM:613559]: A mitochondrial disease resulting in encephalomyopathy. Clinical manifestations include psychomotor delay and regression, ataxia, optic atrophy, nystagmus and muscle atrophy and weakness. {ECO:0000269|PubMed:20598281}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spastic paraplegia 55, autosomal recessive (SPG55) [MIM:615035]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. Complicated forms are recognized by additional variable features including spastic quadriparesis, seizures, dementia, amyotrophy, extrapyramidal disturbance, cerebral or cerebellar atrophy, optic atrophy, and peripheral neuropathy, as well as by extra neurological manifestations. {ECO:0000269|PubMed:23188110}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007959;C0037773;C0162666;C0751651;C3150801;C3539506;C3714756	613541	613559-615035	40.18872957	NaN	Class 1	-3.725714372	0.000140586	26270.39521	15785.83	Peripheral	6.955128866	80.7168243
Q9NSK7	C19orf12	Central nervous system;Ophthalmic system;Peripheral nervous system;Skeletal system	Unknown	1				1	"Hartig, M. B., Iuso, A., Haack, T., Kmiec, T., Jurkiewicz, E., Heim, K., Roeber, S., Tarabin, V., Dusi, S., Krajewska-Walasek, M., Jozwiak, S., Hempel, M., Winkelmann, J., Elstner, M., Oexle, K., Klopstock, T., Mueller-Felber, W., Gasser, T., Trenkwalder, C., Tiranti, V., Kretzschmar, H., Schmitz, G., Strom, T. M., Meitinger, T., and Prokisch, H. (2011) Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 89, 543-550"	"DISEASE: Neurodegeneration with brain iron accumulation 4 (NBIA4) [MIM:614298]: A neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. NBIA4 results in speech difficulty, extrapyramidal signs, oromandibular and generalized dystonia, and parkinsonism. Most patients have progressive involvement of the corticospinal tract, with spasticity, hyperreflexia, and extensor plantar responses. {ECO:0000269|PubMed:21981780, ECO:0000269|PubMed:22508347, ECO:0000269|PubMed:22584950, ECO:0000269|PubMed:22704260, ECO:0000269|PubMed:23269600, ECO:0000269|PubMed:23278385, ECO:0000269|PubMed:23521069, ECO:0000269|PubMed:23857908, ECO:0000269|PubMed:25592411, ECO:0000269|PubMed:26136767, ECO:0000269|PubMed:26187298}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spastic paraplegia 43, autosomal recessive (SPG43) [MIM:615043]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SP43 is characterized by childhood onset of progressive spasticity affecting the lower and upper limbs. {ECO:0000269|PubMed:23857908}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0030567;C0037773;C0751651;C0919267;C1140680;C2680446;C3280371;C3714756	614297	615043-614298	NaN	NaN	NaN	NaN	NaN	2110.21348	NaN	0	NaN	NaN
I3L3B0;I3L3Q7;Q07021	C1QBP	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Muscular system;Ears;Liver;Peripheral nervous system;Kidney and urinary tract;Endocrine system	Cell death/ apoptosis	1				1	"Feichtinger, R. G., Olahova, M., Kishita, Y., Garone, C., Kremer, L. S., Yagi, M., Uchiumi, T., Jourdain, A. A., Thompson, K., D'Souza, A. R., Kopajtich, R., Alston, C. L., Koch, J., Sperl, W., Mastantuono, E., Strom, T. M., Wortmann, S. B., Meitinger, T., Pierre, G., Chinnery, P. F., Chrzanowska-Lightowlers, Z. M., Lightowlers, R. N., DiMauro, S., Calvo, S. E., Mootha, V. K., Moggio, M., Sciacco, M., Comi, G. P., Ronchi, D., Murayama, K., Ohtake, A., Rebelo-Guiomar, P., Kohda, M., Kang, D., Mayr, J. A., Taylor, R. W., Okazaki, Y., Minczuk, M., and Prokisch, H. (2017) Biallelic C1QBP Mutations Cause Severe Neonatal-, Childhood-, or Later-Onset Cardiomyopathy Associated with Combined Respiratory-Chain Deficiencies. Am. J. Hum. Genet. 101, 525-538"	"DISEASE: Combined oxidative phosphorylation deficiency 33 (COXPD33) [MIM:617713]: An autosomal recessive disorder caused by multiple mitochondrial respiratory chain defects and impaired mitochondrial energy metabolism. Clinical manifestations are highly variable. Affected infants present with cardiomyopathy accompanied by multisystemic features involving liver, kidney, and brain. Death in infancy is observed in some patients. Children and adults present with myopathy and progressive external ophthalmoplegia. {ECO:0000269|PubMed:28942965}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006142;C0678222;C0751651;C1257931;C1458155;C4540209	601269	617713	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q8N8R5	C2orf69	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Cardiovascular system;Muscular system;Liver;Hematologic system;Others	Unknown	1				1	"Lausberg E, Gießelmann S, Dewulf JP, Wiame E, Holz A, Salvarinova R, van Karnebeek CD, Klemm P, Ohl K, Mull M, Braunschweig T, Weis J, Sommer CJ, Demuth S, Haase C, Stollbrink-Peschgens C, Debray FG, Libioulle C, Choukair D, Oommen PT, Borkhardt A, Surowy H, Wieczorek D, Wagner N, Meyer R, Eggermann T, Begemann M, Van Schaftingen E, Häusler M, Tenbrock K, van den Heuvel L, Elbracht M, Kurth I, Kraft F. C2orf69 mutations disrupt mitochondrial function and cause a multisystem human disorder with recurring autoinflammation. J Clin Invest. 2021 Jun 15;131(12):e143078. Wong HH, Seet SH, Maier M, Gurel A, Traspas RM, Lee C, Zhang S, Talim B, Loh AYT, Chia CY, Teoh TS, Sng D, Rensvold J, Unal S, Shishkova E, Cepni E, Nathan FM, Sirota FL, Liang C, Yarali N, Simsek-Kiper PO, Mitani T, Ceylaner S, Arman-Bilir O, Mbarek H, Gumruk F, Efthymiou S, U_urlu Çi Men D, Georgiadou D, Sotiropoulou K, Houlden H, Paul F, Pehlivan D, Lainé C, Chai G, Ali NA, Choo SC, Keng SS, Boisson B, Yılmaz E, Xue S, Coon JJ, Ly TTN, Gilani N, Hasbini D, Kayserili H, Zaki M, Isfort RJ, Ordonez N, Tripolszki K, Bauer P, Rezaei N, Seyedpour S, Khotaei GT, Bascom CC, Maroofian R, Chaabouni M, Alsubhi A, Eyaid W, I_ıkay S, Gleeson JG, Lupski JR, Casanova JL, Pagliarini DJ, Akarsu NA, Maurer-Stroh S, Cetinkaya A, Bertoli-Avella A, Mathuru AS, Ho L, Bard FA, Reversade B. Loss of C2orf69 defines a fatal autoinflammatory syndrome in humans and zebrafish that evokes a glycogen storage-associated mitochondriopathy. Am J Hum Genet. 2021 May 21:S0002-9297(21)00187-7."			619219		NaN	72.90777771	Class 1	-1.526677271	0.00042292	4509.657125	73639.86667	Peripheral	25.11295622	90.72619539
P35218	CA5A	Central nervous system;Metabolism;Pulmonary system 	Other known processes	1				1		"DISEASE: Hyperammonemia due to carbonic anhydrase VA deficiency (CA5AD) [MIM:615751]: An autosomal recessive inborn error of metabolism, clinically characterized by infantile hyperammonemic encephalopathy. Metabolic abnormalities include hypoglycemia, hyperlactatemia, metabolic acidosis and respiratory alkalosis. {ECO:0000269|PubMed:24530203}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C3714756;C3810404	114761	615751	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9HA77	CARS2	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Ears;Liver	tRNA related processes	1				1	"Coughlin, C. R., 2nd, Scharer, G. H., Friederich, M. W., Yu, H. C., Geiger, E. A., Creadon-Swindell, G., Collins, A. E., Vanlander, A. V., Coster, R. V., Powell, C. A., Swanson, M. A., Minczuk, M., Van Hove, J. L., and Shaikh, T. H. (2015) Mutations in the mitochondrial cysteinyl-tRNA synthase gene, CARS2, lead to a severe epileptic encephalopathy and complex movement disorder. J Med Genet 52, 532-540;Hallmann, K., Zsurka, G., Moskau-Hartmann, S., Kirschner, J., Korinthenberg, R., Ruppert, A. K., Ozdemir, O., Weber, Y., Becker, F., Lerche, H., Elger, C. E., Thiele, H., Nurnberg, P., Sander, T., and Kunz, W. S. (2014) A homozygous splice-site mutation in CARS2 is associated with progressive myoclonic epilepsy. Neurology 83, 2183-2187"	"DISEASE: Combined oxidative phosphorylation deficiency 27 (COXPD27) [MIM:616672]: An autosomal recessive mitochondrial disorder characterized by multiple mitochondrial respiratory-chain-complex deficiencies causing neurological regression, progressive cognitive decline, complex movement disorder, epileptic encephalopathy, progressive spastic tetraparesis, and progressive impairment of vision and hearing. {ECO:0000269|PubMed:25361775, ECO:0000269|PubMed:25787132}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3714756;C4225251	612800	616672	112.4701917	135.2129504	Class 1	-1.375666636	0.000200695	404846.992	317144.6667	Peripheral	19.45060076	81.16631938
Q8WYQ3	CHCHD10	Central nervous system;Metabolism;Pulmonary system ;Muscular system;Ears;Gastrointestinal system;Peripheral nervous system;Others	"Morphology, dynamics & organization"	1				1	"Ajroud-Driss, S., Fecto, F., Ajroud, K., Lalani, I., Calvo, S. E., Mootha, V. K., Deng, H. X., Siddique, N., Tahmoush, A. J., Heiman-Patterson, T. D., and Siddique, T. (2015) Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy. Neurogenetics 16, 1-9"	"DISEASE: Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 (FTDALS2) [MIM:615911]: A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. {ECO:0000269|PubMed:24934289, ECO:0000269|PubMed:25155093}. Note=The disease is caused by mutations affecting the gene represented in this entry. The pathological events leading to disease involve fragmentation of the mitochondrial network, mitochondrial ultrastructural abnormalities including loss, disorganization and dilatation of cristae, and mitochondrial dysfunction associated with respiratory chain deficiency (PubMed:24934289). {ECO:0000269|PubMed:24934289}.;DISEASE: Myopathy, isolated mitochondrial, autosomal dominant (IMMD) [MIM:616209]: A mitochondrial myopathy presenting with severe exercise intolerance, progressive proximal weakness, and lactic acidemia. The disorder is slowly progressive, with later involvement of facial muscles, muscles of the upper limbs, and distal muscles. {ECO:0000269|PubMed:25193783}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spinal muscular atrophy, Jokela type (SMAJ) [MIM:615048]: An autosomal dominant, slowly progressive, lower motor neuron disease. SMAJ is characterized by adult-onset of muscle cramps and fasciculations affecting the proximal and distal muscles of the upper and lower limbs. The disorder results in weakness and mild muscle atrophy later in life. {ECO:0000269|PubMed:25428574}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002736;C0003886;C0007959;C0270960;C0751651;C3554398;C3888102;C4014648;C4015513	615903	615903-615911-615048	7.013582295	NaN	Class 1	-1.314872796	0.000596485	68812.32017	NaN	Ambiguous	30.49500063	26.73445776
Q9Y6H1	CHCHD2	Central nervous system	DNA-related processes	1				1		"DISEASE: Parkinson disease 22 (PARK22) [MIM:616710]: An autosomal dominant form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. {ECO:0000269|PubMed:25662902}. Note=The gene represented in this entry may be involved in disease pathogenesis."	C0030567;C4225238	616244	616710	NaN	2.622992578	Class 4	-0.415314821	0.015506507	760035.5811	1437253.333	Ambiguous	19.26438676	32.25292496
Q9H078	CLPB	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Gastrointestinal system;Hematologic system;Endocrine system;Tumors"	Other known processes	1				1	"Saunders, C., Smith, L., Wibrand, F., Ravn, K., Bross, P., Thiffault, I., Christensen, M., Atherton, A., Farrow, E., Miller, N., Kingsmore, S. F., and Ostergaard, E. (2015) CLPB variants associated with autosomal-recessive mitochondrial disorder with cataract, neutropenia, epilepsy, and methylglutaconic aciduria. Am. J. Hum. Genet. 96, 258-265;Wortmann, S. B., Zietkiewicz, S., Kousi, M., Szklarczyk, R., Haack, T. B., Gersting, S. W., Muntau, A. C., Rakovic, A., Renkema, G. H., Rodenburg, R. J., Strom, T. M., Meitinger, T., Rubio-Gozalbo, M. E., Chrusciel, E., Distelmaier, F., Golzio, C., Jansen, J. H., van Karnebeek, C., Lillquist, Y., Lucke, T., Ounap, K., Zordania, R., Yaplito-Lee, J., van Bokhoven, H., Spelbrink, J. N., Vaz, F. M., Pras-Raves, M., Ploski, R., Pronicka, E., Klein, C., Willemsen, M. A., de Brouwer, A. P., Prokisch, H., Katsanis, N., and Wevers, R. A. (2015) CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder. Am. J. Hum. Genet. 96, 245-257"	"DISEASE: 3-methylglutaconic aciduria with cataracts, neurologic involvement and neutropenia (MEGCANN) [MIM:616271]: An autosomal recessive inborn error of metabolism with a highly variable phenotype. Primary disease symptoms are increased levels of 3-methylglutaconic acid, neurologic deterioration and neutropenia. Other common features include progressive encephalopathy, movement abnormalities, delayed psychomotor development, cataracts, seizures, and recurrent infections. {ECO:0000269|PubMed:25597510, ECO:0000269|PubMed:25597511}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3714756;C4225393	616254	616271	96.43619936	NaN	Class 1	-1.112135984	0.000510068	227913.9087	223755.6667	Peripheral	9.675463031	90.59467716
Q16740	CLPP	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Ears;Endocrine system;Reproductive system"	Protein maturation & folding	1				1	"Ahmed, S., Jelani, M., Alrayes, N., Mohamoud, H. S., Almramhi, M. M., Anshasi, W., Ahmed, N. A., Wang, J., Nasir, J., and Al-Aama, J. Y. (2015) Exome analysis identified a novel missense mutation in the CLPP gene in a consanguineous Saudi family expanding the clinical spectrum of Perrault Syndrome type-3. J Neurol Sci 353, 149-154"	"DISEASE: Perrault syndrome 3 (PRLTS3) [MIM:614129]: A sex-influenced disorder characterized by sensorineural deafness in both males and females, and ovarian dysgenesis in females. Affected females have primary amenorrhea, streak gonads, and infertility, whereas affected males show normal pubertal development and are fertile. A spectrum of additional clinical features, including cerebellar ataxia, learning disability, and peripheral neuropathy, have been described in some PRLTS3 affected individuals. {ECO:0000269|PubMed:23541340, ECO:0000269|PubMed:25956234}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0685838;C0751651;C3714756;C3808414	601119	614129	192.6716195	NaN	Class 1	-2.052981889	0.000129085	657773.6278	824653.3333	Peripheral	7.798733521	82.34227192
O76031	CLPX	Metabolism;Hematologic system;Integumentary system	Protein maturation & folding	1				1		"DISEASE: Protoporphyria, erythropoietic, 2 (EPP2) [MIM:618015]: An autosomal dominant form of porphyria with onset in infancy. Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. Erythropoietic protoporphyria is marked by excessive protoporphyrin in erythrocytes, plasma, liver and feces, and by widely varying photosensitive skin changes ranging from a burning or pruritic sensation to erythema, edema and wheals. {ECO:0000269|PubMed:28874591}. Note=The disease may be caused by mutations affecting the gene represented in this entry."		615611	618015	50.71941062	74.27576615	Class 1	-2.312378516	5.01267E-05	313890.2653	301918.3333	Peripheral	7.826025639	92.86406822
Q9Y2R0	COA3	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Peripheral nervous system;Skeletal system;Others"	OXPHOS assembly & stability	1				1	"Ostergaard, E., Weraarpachai, W., Ravn, K., Born, A. P., Jonson, L., Duno, M., Wibrand, F., Shoubridge, E. A., and Vissing, J. (2015) Mutations in COA3 cause isolated complex IV deficiency associated with neuropathy, exercise intolerance, obesity, and short stature. J Med Genet 52, 203-207"		C0268237;C0751651;C3714756	614775		54.7797608	NaN	Class 1	-2.813286095	8.37107E-05	1117642.108	1189298.667	Integral	92.6714864	92.20261067
Q86WW8	COA5	Cardiovascular system	OXPHOS assembly & stability	1				1	"Huigsloot, M., Nijtmans, L. G., Szklarczyk, R., Baars, M. J., van den Brand, M. A., Hendriksfranssen, M. G., van den Heuvel, L. P., Smeitink, J. A., Huynen, M. A., and Rodenburg, R. J. (2011) A mutation in C2orf64 causes impaired cytochrome c oxidase assembly and mitochondrial cardiomyopathy. Am. J. Hum. Genet. 88, 488-493"	"DISEASE: Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 3 (CEMCOX3) [MIM:616500]: An infantile disorder with a fatal course in the first weeks of life, characterized by hypertrophic cardiomyopathy and mitochondrial complex IV deficiency. Postmortem microscopic investigations show accumulation of lipid droplets in cardiomyocytes and mitochondrial proliferation. {ECO:0000269|PubMed:21457908}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007194;C0268237;C0751651;C1858424;C3714756;C4225154	613920	616500	7.339780303	NaN	NaN	NaN	NaN	52796.21244	52235.7	0	NaN	55.32826435
Q5JTJ3	COA6	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system ;Muscular system"	OXPHOS assembly & stability	1				1	"Baertling, F., M, A. M. v. d. B., Hertecant, J. L., Al-Shamsi, A., L, P. v. d. H., Distelmaier, F., Mayatepek, E., Smeitink, J. A., Nijtmans, L. G., and Rodenburg, R. J. (2015) Mutations in COA6 cause cytochrome c oxidase deficiency and neonatal hypertrophic cardiomyopathy. Hum Mutat 36, 34-38;Calvo, S. E., Compton, A. G., Hershman, S. G., Lim, S. C., Lieber, D. S., Tucker, E. J., Laskowski, A., Garone, C., Liu, S., Jaffe, D. B., Christodoulou, J., Fletcher, J. M., Bruno, D. L., Goldblatt, J., Dimauro, S., Thorburn, D. R., and Mootha, V. K. (2012) Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med 4, 118ra110;Ghosh, A., Trivedi, P. P., Timbalia, S. A., Griffin, A. T., Rahn, J. J., Chan, S. S., and Gohil, V. M. (2014) Copper supplementation restores cytochrome c oxidase assembly defect in a mitochondrial disease model of COA6 deficiency. Hum Mol Genet 23, 3596-3606"	"DISEASE: Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4 (CEMCOX4) [MIM:616501]: An infantile disorder with a fatal course in the first weeks of life, characterized by hypertrophic cardiomyopathy, left ventricular non-compaction, lactic acidosis, metabolic hypotonia, and mitochondrial complex IV deficiency. {ECO:0000269|PubMed:24549041, ECO:0000269|PubMed:25339201, ECO:0000269|PubMed:25959673}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C1858424;C4225304	614772	616501	NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q96BR5	COA7	Central nervous system;Metabolism;Muscular system;Peripheral nervous system;Skeletal system	OXPHOS assembly & stability	1				1	"Martinez Lyons, A., Ardissone, A., Reyes, A., Robinson, A. J., Moroni, I., Ghezzi, D., Fernandez-Vizarra, E., and Zeviani, M. (2016) COA7 (C1orf163/RESA1) mutations associated with mitochondrial leukoencephalopathy and cytochrome c oxidase deficiency. J Med Genet 53, 846-849"		C0268237	615623	618387	63.83292893	103.8962604	Class 1	-2.056563449	0.000940783	264627.0758	405952.3333	Soluble	4.697606328	19.87940091
Q13057	COASY	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Peripheral nervous system;Skeletal system"	Cofactor metabolism	1				1	"Dusi, S., Valletta, L., Haack, T. B., Tsuchiya, Y., Venco, P., Pasqualato, S., Goffrini, P., Tigano, M., Demchenko, N., Wieland, T., Schwarzmayr, T., Strom, T. M., Invernizzi, F., Garavaglia, B., Gregory, A., Sanford, L., Hamada, J., Bettencourt, C., Houlden, H., Chiapparini, L., Zorzi, G., Kurian, M. A., Nardocci, N., Prokisch, H., Hayflick, S., Gout, I., and Tiranti, V. (2014) Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 94, 11-22"	"DISEASE: Neurodegeneration with brain iron accumulation 6 (NBIA6) [MIM:615643]: A neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. It is characterized by progressive motor and cognitive dysfunction beginning in childhood or young adulthood. Patients show extrapyramidal motor signs, such as spasticity, dystonia, and parkinsonism. {ECO:0000269|PubMed:24360804}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C3714756;C3810230	609855	615643-618266	113.8896875	178.2199569	Class 2	-1.347025567	0.013122917	27059.86332	176238.3333	Peripheral	19.96955488	94.21003154
Q96H96	COQ2	Central nervous system;Metabolism;Ophthalmic system;Muscular system;Liver;Hematologic system;Kidney and urinary tract	Cofactor metabolism	1				1	"Quinzii, C., Naini, A., Salviati, L., Trevisson, E., Navas, P., Dimauro, S., and Hirano, M. (2006) A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am. J. Hum. Genet.  78, 345-349"	"a multisystem infantile form with encephalopathy, cardiomyopathy and renal failure;a predominantly cerebellar form with ataxia and cerebellar atrophy;and an isolated myopathic form. {ECO:0000269|PubMed:16400613, ECO:0000269|PubMed:17374725, ECO:0000269|PubMed:17855635, ECO:0000269|PubMed:23343605, ECO:0000269|PubMed:25564041, ECO:0000269|PubMed:27493029, ECO:0000269|PubMed:28044327}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Coenzyme Q10 deficiency, primary, 1 (COQ10D1) [MIM:607426]: An autosomal recessive disorder with variable manifestations consistent with 5 major phenotypes. The phenotypes include an encephalomyopathic form with seizures and ataxia;DISEASE: Multiple system atrophy 1 (MSA1) [MIM:146500]: A progressive neurodegenerative disorder clinically characterized by parkinsonism, cerebellar ataxia, and autonomic, urogenital, and pyramidal dysfunction in various combinations. Pathologically, it is characterized by degeneration of striatonigral and olivopontocerebellar structures, and glial cytoplasmic inclusions that consist of abnormally phosphorylated alpha-synuclein or tau. {ECO:0000269|PubMed:23758206}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;Leigh syndrome with growth retardation"		609825	607426-146500	57.18841173	NaN	Class 2	-1.473259403	0.017122062	2722.355623	7823.836667	0	NaN	NaN
Q9Y3A0	COQ4	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system ;Peripheral nervous system"	Cofactor metabolism	1				1	"Brea-Calvo, G., Haack, T. B., Karall, D., Ohtake, A., Invernizzi, F., Carrozzo, R., Kremer, L., Dusi, S., Fauth, C., Scholl-Burgi, S., Graf, E., Ahting, U., Resta, N., Laforgia, N., Verrigni, D., Okazaki, Y., Kohda, M., Martinelli, D., Freisinger, P., Strom, T. M., Meitinger, T., Lamperti, C., Lacson, A., Navas, P., Mayr, J. A., Bertini, E., Murayama, K., Zeviani, M., Prokisch, H., and Ghezzi, D. (2015) COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency. Am. J. Hum. Genet.  96, 309-317;Chung, W. K., Martin, K., Jalas, C., Braddock, S. R., Juusola, J., Monaghan, K. G., Warner, B., Franks, S., Yudkoff, M., Lulis, L., Rhodes, R. H., Prasad, V., Torti, E., Cho, M. T., and Shinawi, M. (2015) Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy. J Med Genet 52, 627-635"	"DISEASE: Coenzyme Q10 deficiency, primary, 7 (COQ10D7) [MIM:616276]: An autosomal recessive disorder resulting from mitochondrial dysfunction and characterized by decreased levels of coenzyme Q10, and severe cardiac or neurologic symptoms soon after birth, usually resulting in death. Rarely, symptoms may have later onset. {ECO:0000269|PubMed:25658047, ECO:0000269|PubMed:26741492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C3714756;C4225392	612898	616276	NaN	NaN	Class 4	0.216323227	0.330305985	23474.05347	13077.36667	Peripheral	48.74370485	89.03186729
Q5HYK3	COQ5	Central nervous system;Others	Cofactor metabolism	1				1	"Malicdan, M. C. V., Vilboux, T., Ben-Zeev, B., Guo, J., Eliyahu, A., Pode-Shakked, B., Dori, A., Kakani, S., Chandrasekharappa, S. C., Ferreira, C. R., Shelestovich, N., Marek-Yagel, D., Pri-Chen, H., Blatt, I., Niederhuber, J. E., He, L., Toro, C., Taylor, R. W., Deeken, J., Yardeni, T., Wallace, D. C., Gahl, W. A., and Anikster, Y. (Oct 16 2017) A novel inborn error of the coenzyme Q10 biosynthesis pathway: cerebellar ataxia and static encephalomyopathy due to COQ5 C-methyltransferase deficiency. Hum. Mutat. 10.1002/humu.23345"		C0020796;C0025363;C0917816;C3714756	616359		15.24102516	NaN	Class 1	-1.525271309	0.000302057	157613.1434	143610.6667	Peripheral	10.36093943	92.93242869
Q9Y2Z9	COQ6	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Ears;Kidney and urinary tract"	Cofactor metabolism	1				1	"Heeringa, S. F., Chernin, G., Chaki, M., Zhou, W., Sloan, A. J., Ji, Z., Xie, L. X., Salviati, L., Hurd, T. W., Vega-Warner, V., Killen, P. D., Raphael, Y., Ashraf, S., Ovunc, B., Schoeb, D. S., McLaughlin, H. M., Airik, R., Vlangos, C. N., Gbadegesin, R., Hinkes, B., Saisawat, P., Trevisson, E., Doimo, M., Casarin, A., Pertegato, V., Giorgi, G., Prokisch, H., Rotig, A., Nurnberg, G., Becker, C., Wang, S., Ozaltin, F., Topaloglu, R., Bakkaloglu, A., Bakkaloglu, S. A., Muller, D., Beissert, A., Mir, S., Berdeli, A., Varpizen, S., Zenker, M., Matejas, V., Santos-Ocana, C., Navas, P., Kusakabe, T., Kispert, A., Akman, S., Soliman, N. A., Krick, S., Mundel, P., Reiser, J., Nurnberg, P., Clarke, C. F., Wiggins, R. C., Faul, C., and Hildebrandt, F. (2011) COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest 121, 2013-2024"	"DISEASE: Coenzyme Q10 deficiency, primary, 6 (COQ10D6) [MIM:614650]: An autosomal recessive disorder characterized by onset in infancy of severe progressive nephrotic syndrome resulting in end-stage renal failure and sensorineural deafness. Renal biopsy usually shows focal segmental glomerulosclerosis. {ECO:0000269|PubMed:21540551, ECO:0000269|PubMed:28044327}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Note=Mutations in COQ6 may play a role in susceptibility to Schwannomatosis, a cancer predisposition syndrome in which patients develop multiple non-vestibular schwannomas, benign neoplasms that arise from Schwann cells of the cranial, peripheral, and autonomic nerves. {ECO:0000269|PubMed:24763291}."	C0543888;C0751651;C0917817;C1335929;C2931480;C3553349	614647	614650	70.86412985	NaN	Class 1	-1.280277877	0.000373279	132090.5484	9775100	Peripheral	15.64193098	93.66486772
Q99807	COQ7	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Ears;Peripheral nervous system;Skeletal system;Kidney and urinary tract"	Cofactor metabolism	1				1	"Freyer, C., Stranneheim, H., Naess, K., Mourier, A., Felser, A., Maffezzini, C., Lesko, N., Bruhn, H., Engvall, M., Wibom, R., Barbaro, M., Hinze, Y., Magnusson, M., Andeer, R., Zetterstrom, R. H., von Dobeln, U., Wredenberg, A., and Wedell, A. (2015) Rescue of primary ubiquinone deficiency due to a novel COQ7 defect using 2,4-dihydroxybensoic acid. J Med Genet 52, 779-783"	"DISEASE: Coenzyme Q10 deficiency, primary, 8 (COQ10D8) [MIM:616733]: An autosomal recessive disorder resulting from mitochondrial dysfunction and characterized by decreased levels of coenzyme Q10. Patients manifest neonatal lung hypoplasia, contractures, early infantile hypertension and cardiac hypertrophy, secondary to prenatal kidney dysplasia, with neonatal and infantile renal dysfunction. Clinical features also include progressive peripheral neuropathy, muscular hypotonia and atrophy, and mild psychomotor delay with hearing and visual impairment. {ECO:0000269|PubMed:26084283}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C4225226	601683	616733	30.76462464	NaN	Class 1	-2.404256008	4.91909E-06	114879.8002	88568.56667	Peripheral	18.70348259	94.26381953
Q8NI60	COQ8A	Central nervous system;Metabolism;Ophthalmic system;Muscular system	Cofactor metabolism	1				1	"Mollet, J., Delahodde, A., Serre, V., Chretien, D., Schlemmer, D., Lombes, A., Boddaert, N., Desguerre, I., de Lonlay, P., de Baulny, H. O., Munnich, A., and Rotig, A. (2008) CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am. J. Hum. Genet. 82, 623-630"	"DISEASE: Coenzyme Q10 deficiency, primary, 4 (COQ10D4) [MIM:612016]: An autosomal recessive disorder characterized by childhood-onset of cerebellar ataxia and exercise intolerance. Patient manifest gait ataxia and cerebellar atrophy with slow progression. Additional features include brisk tendon reflexes and Hoffmann sign, variable psychomotor retardation and variable seizures. {ECO:0000269|PubMed:18319072, ECO:0000269|PubMed:18319074, ECO:0000269|PubMed:20580948, ECO:0000269|PubMed:22036850, ECO:0000269|PubMed:24048965, ECO:0000269|PubMed:24218524, ECO:0000269|PubMed:25498144, ECO:0000269|PubMed:26818466, ECO:0000269|PubMed:27106809}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0007959;C0023520;C0751651;C2677589;C3551954;C3714756	606980	612016	10.27056121	13.69051153	Class 1	-1.127596539	0.000796641	346325.041	277223.6667	Ambiguous	36.21963717	97.43987495
Q96D53	COQ8B	Kidney and urinary tract	Cofactor metabolism	1				1	"Ashraf, S., Gee, H. Y., Woerner, S., Xie, L. X., Vega-Warner, V., Lovric, S., Fang, H., Song, X., Cattran, D. C., Avila-Casado, C., Paterson, A. D., Nitschke, P., Bole-Feysot, C., Cochat, P., Esteve-Rudd, J., Haberberger, B., Allen, S. J., Zhou, W., Airik, R., Otto, E. A., Barua, M., Al-Hamed, M. H., Kari, J. A., Evans, J., Bierzynska, A., Saleem, M. A., Bockenhauer, D., Kleta, R., El Desoky, S., Hacihamdioglu, D. O., Gok, F., Washburn, J., Wiggins, R. C., Choi, M., Lifton, R. P., Levy, S., Han, Z., Salviati, L., Prokisch, H., Williams, D. S., Pollak, M., Clarke, C. F., Pei, Y., Antignac, C., and Hildebrandt, F. (2013) ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest 123, 5179-5189"	"DISEASE: Nephrotic syndrome 9 (NPHS9) [MIM:615573]: A form of nephrotic syndrome, a renal disease clinically characterized by progressive renal failure, severe proteinuria, hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show focal segmental glomerulosclerosis. {ECO:0000269|PubMed:24270420, ECO:0000269|PubMed:25967120}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3809965	615567	615573	28.50882926	NaN	Class 1	-0.992894995	0.000879306	85051.86814	64453.13333	Peripheral	46.85371229	91.71872711
O75208	COQ9	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Pulmonary system ;Kidney and urinary tract;Others	Cofactor metabolism	1				1	"Duncan, A. J., Bitner-Glindzicz, M., Meunier, B., Costello, H., Hargreaves, I. P., Lopez, L. C., Hirano, M., Quinzii, C. M., Sadowski, M. I., Hardy, J., Singleton, A., Clayton, P. T., and Rahman, S. (2009) A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am. J. Hum. Genet.  84, 558-566"	"a multisystem infantile form with encephalopathy, cardiomyopathy and renal failure;a predominantly cerebellar form with ataxia and cerebellar atrophy;and an isolated myopathic form. {ECO:0000269|PubMed:19375058}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Coenzyme Q10 deficiency, primary, 5 (COQ10D5) [MIM:614654]: A form of coenzyme Q10 deficiency, an autosomal recessive disorder with variable manifestations consistent with 5 major phenotypes. The phenotypes include an encephalomyopathic form with seizures and ataxia;Leigh syndrome with growth retardation"	C0023520;C0543888;C0751651;C3553374;C3714756	612837	614654	24.44318615	NaN	Class 1	-2.580029589	5.82417E-05	101538.9976	94847.46667	Peripheral	21.17632126	88.66372073
Q12887	COX10	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Ears;Peripheral nervous system;Hematologic system;Kidney and urinary tract;Others;Reproductive system	OXPHOS assembly & stability	1				1	"Valnot, I., von Kleist-Retzow, J. C., Barrientos, A., Gorbatyuk, M., Taanman, J. W., Mehaye, B., Rustin, P., Tzagoloff, A., Munnich, A., and Rotig, A. (2000) A mutation in the human heme A:farnesyltransferase gene (COX10) causes cytochrome c oxidase deficiency. Hum Mol Genet 9, 1245-1249"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex IV deficiency (MT-C4D) [MIM:220110]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations, ranging from isolated myopathy to severe multisystem disease affecting several tissues and organs. Features include hypertrophic cardiomyopathy, hepatomegaly and liver dysfunction, hypotonia, muscle weakness, exercise intolerance, developmental delay, delayed motor development and mental retardation. Some affected individuals manifest a fatal hypertrophic cardiomyopathy resulting in neonatal death. A subset of patients manifest Leigh syndrome. {ECO:0000269|PubMed:10767350, ECO:0000269|PubMed:12928484, ECO:0000269|PubMed:26741492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0023520;C0268237;C0543888;C0751267;C0751268;C0751651;C1968949;C3714756	602125	256000-220110	47.70376876	NaN	Class 1	-1.807159451	1.75433E-05	2049.292889	8374.966667	0	NaN	NaN
Q96I36	COX14	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system "	OXPHOS assembly & stability	1				1	"Weraarpachai, W., Sasarman, F., Nishimura, T., Antonicka, H., Aure, K., Rotig, A., Lombes, A., and Shoubridge, E. A. (2012) Mutations in C12orf62, a factor that couples COX I synthesis with cytochrome c oxidase assembly, cause fatal neonatal lactic acidosis. Am. J. Hum. Genet. 90, 142-151"	"DISEASE: Note=Defects in COX14 may be a cause of a mitochondrial disorder presenting with severe congenital lactic acidosis and dysmorphic features associated with a COX assembly defect. Other features include brain hypertrophy, diffuse alteration of the white-matter myelination, and numerous cavities in the parieto-occipital region, brainstem, and cerebellum, as well as hepatomegaly, hypertrophic cardiomyopathy, renal hypoplasia, and adrenal-gland hyperplasia. {ECO:0000269|PubMed:22243966}."	C0268237;C0751651;C3714756	614478	220110	8.530795259	29.68300613	Class 1	-1.944610801	0.000246565	24303.8421	147928.4667	0	NaN	85.15838555
Q7KZN9	COX15	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Gastrointestinal system"	OXPHOS assembly & stability	1				1	"Antonicka, H., Mattman, A., Carlson, C. G., Glerum, D. M., Hoffbuhr, K. C., Leary, S. C., Kennaway, N. G., and Shoubridge, E. A. (2003) Mutations in COX15 produce a defect in the mitochondrial heme biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy. Am. J. Hum. Genet.  72, 101-114"	"DISEASE: Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2 (CEMCOX2) [MIM:615119]: An infantile disorder, with a rapidly progressive fatal course, characterized by cytochrome c oxidase deficiency. Clinical features include microcephaly, encephalopathy, hypertrophic cardiomyopathy, persistent lactic acidosis, respiratory distress, hypotonia and seizures. Postmortem cardiac muscle studies show marked complex IV deficiency. Complex IV activity is only slightly decreased in the skeletal muscle. {ECO:0000269|PubMed:12474143, ECO:0000269|PubMed:21412973}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:15235026, ECO:0000269|PubMed:15863660}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0023520;C0543888;C0751267;C0751268;C0751651;C1838951;C1850597;C1850598;C1850599;C1850600;C1858424;C2931891;C3554534;C3714756	603646	615119-256000	54.09236032	65.71792963	Class 1	-1.01623992	0.000676975	85819.71675	118926.4667	Integral	98.64681829	95.61697431
Q9P0S2	COX16	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Ears;Liver;Gastrointestinal system;Hematologic system"	OXPHOS assembly & stability	1				1	"Wintjes LTM, Kava M, van den Brandt FA, van den Brand MAM, Lapina O, Bliksrud YT, Kulseth MA, Amundsen SS, Selberg TR, Ybema-Antoine M, Tutakhel OAZ, Greed L, Thorburn DR, Tangeraas T, Balasubramaniam S, Rodenburg RJT. A novel variant in COX16 causes cytochrome c oxidase deficiency, severe fatal neonatal lactic acidosis, encephalopathy, cardiomyopathy, and liver dysfunction. Hum Mutat. 2021 Feb;42(2):135-141."			618064		NaN	NaN	Class 2	-2.361349691	0.039883375	27126.68183	NaN	0	NaN	NaN
Q5RI15	COX20	Central nervous system;Metabolism;Others	OXPHOS assembly & stability	1				1	"Szklarczyk, R., Wanschers, B. F., Nijtmans, L. G., Rodenburg, R. J., Zschocke, J., Dikow, N., van den Brand, M. A., Hendriks-Franssen, M. G., Gilissen, C., Veltman, J. A., Nooteboom, M., Koopman, W. J., Willems, P. H., Smeitink, J. A., Huynen, M. A., and van den Heuvel, L. P. (2013) A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia. Hum Mol Genet 22, 656-667"	"DISEASE: Mitochondrial complex IV deficiency (MT-C4D) [MIM:220110]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations, ranging from isolated myopathy to severe multisystem disease affecting several tissues and organs. Features include hypertrophic cardiomyopathy, hepatomegaly and liver dysfunction, hypotonia, muscle weakness, exercise intolerance, developmental delay, delayed motor development and mental retardation. Some affected individuals manifest a fatal hypertrophic cardiomyopathy resulting in neonatal death. A subset of patients manifest Leigh syndrome. {ECO:0000269|PubMed:23125284, ECO:0000269|PubMed:24202787, ECO:0000269|PubMed:29154948}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0268237;C0751651	614698	220110	135.4049006	231.5790306	Class 1	-1.676247391	0.00016513	135488.4403	103696.8	Integral	95.62274969	88.7147294
P13073	COX4I1	"Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Hematologic system"	OXPHOS complex subunits	1				1	"Abu-Libdeh, B., Douiev, L., Amro, S., Shahrour, M., Ta-Shma, A., Miller, C., Elpeleg, O., and Saada, A. (2017) Mutation in the COX4I1 gene is associated with short stature, poor weight gain and increased chromosomal breaks, simulating Fanconi anemia. Eur. J. Hum. Genet. 25, 1142-1146"		C0751651	123864		27.79306675	NaN	Class 1	-1.417838136	0.000209396	2310323.103	3615496.667	Integral	90.05415238	92.70223677
Q96KJ9	COX4I2	Central nervous system;Failure to thrive;Pulmonary system ;Liver;Gastrointestinal system;Skeletal system;Hematologic system;Integumentary system	OXPHOS complex subunits	1				1	"Shteyer, E., Saada, A., Shaag, A., Al-Hijawi, F. A., Kidess, R., Revel-Vilk, S., and Elpeleg, O. (2009) Exocrine pancreatic insufficiency, dyserythropoeitic anemia, and calvarial hyperostosis are caused by a mutation in the COX4I2 gene. Am. J. Hum. Genet. 84, 412-417"	"DISEASE: Exocrine pancreatic insufficiency dyserythropoietic anemia and calvarial hyperostosis (EPIDACH) [MIM:612714]: Patients present with pancreatic insufficiency, intestinal malabsorption, failure to thrive, and anemia soon after birth. {ECO:0000269|PubMed:19268275}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0010828;C0158995;C0751651;C2675184	607976	612714	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P20674	COX5A	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Liver;Gastrointestinal system"	OXPHOS complex subunits	1				1	"Baertling, F., Al-Murshedi, F., Sanchez-Caballero, L., Al-Senaidi, K., Joshi, N. P., Venselaar, H., van den Brand, M. A., Nijtmans, L. G., and Rodenburg, R. J. (2017) Mutation in mitochondrial complex IV subunit COX5A causes pulmonary arterial hypertension, lactic acidemia, and failure to thrive. Hum Mutat 38, 692-703"	"DISEASE: Note=Mitochondrial complex IV deficiency is a rare condition caused by mutation in COX5A that lead to pulmonary arterial hypertension (PAH), failure to thrive and lactic acidemia. {ECO:0000269|PubMed:28247525}."	C0268237;C0751651	603773		85.65062646	NaN	Class 1	-1.456128258	0.000479155	1702329.155	3112153.333	Ambiguous	74.01543932	69.82616695
P12074	COX6A1	Central nervous system;Ears;Peripheral nervous system;Skeletal system	OXPHOS complex subunits	1				1	"Tamiya, G., Makino, S., Hayashi, M., Abe, A., Numakura, C., Ueki, M., Tanaka, A., Ito, C., Toshimori, K., Ogawa, N., Terashima, T., Maegawa, H., Yanagisawa, D., Tooyama, I., Tada, M., Onodera, O., and Hayasaka, K. (2014) A Mutation of COX6A1 Causes a Recessive Axonal or Mixed Form of Charcot-Marie-Tooth Disease. Am. J. Hum. Genet. 95, 294-300"	"DISEASE: Charcot-Marie-Tooth disease, recessive, intermediate type, D (CMTRID) [MIM:616039]: A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Recessive intermediate forms of Charcot-Marie-Tooth disease are characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. {ECO:0000269|PubMed:25152455}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007959;C0751651;C4015029	602072	616039	NaN	61.09961331	Class 1	-2.410096482	0.000674857	37792.96297	NaN	Integral	89.13492242	87.51691517
Q02221	COX6A2	"Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system ;Muscular system"	OXPHOS complex subunits	1				1	"Inoue M, Uchino S, Iida A, Noguchi S, Hayashi S, Takahashi T, Fujii K, Komaki H, Takeshita E, Nonaka I, Okada Y, Yoshizawa T, Van Lommel L, Schuit F, Goto YI, Mimaki M, Nishino I. COX6A2 variants cause a muscle-specific cytochrome c oxidase deficiency. Ann Neurol. 2019 Aug;86(2):193-202."			602009	619062	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P14854	COX6B1	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Muscular system	OXPHOS complex subunits	1				1	"Massa, V., Fernandez-Vizarra, E., Alshahwan, S., Bakhsh, E., Goffrini, P., Ferrero, I., Mereghetti, P., D'Adamo, P., Gasparini, P., and Zeviani, M. (2008) Severe infantile encephalomyopathy caused by a mutation in COX6B1, a nucleus-encoded subunit of cytochrome c oxidase. Am. J. Hum. Genet. 82, 1281-1289"	"DISEASE: Mitochondrial complex IV deficiency (MT-C4D) [MIM:220110]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations, ranging from isolated myopathy to severe multisystem disease affecting several tissues and organs. Features include hypertrophic cardiomyopathy, hepatomegaly and liver dysfunction, hypotonia, muscle weakness, exercise intolerance, developmental delay, delayed motor development and mental retardation. Some affected individuals manifest a fatal hypertrophic cardiomyopathy resulting in neonatal death. A subset of patients manifest Leigh syndrome. {ECO:0000269|PubMed:18499082}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0268237;C0751651;C3714756	124089	220110	33.45765405	68.33696895	Class 1	-2.337518998	0.000174227	1745157.774	2577393.333	Ambiguous	68.418962	55.50604219
P24311	COX7B	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Kidney and urinary tract;Integumentary system"	OXPHOS complex subunits	1				1	"Indrieri, A., van Rahden, V. A., Tiranti, V., Morleo, M., Iaconis, D., Tammaro, R., D'Amato, I., Conte, I., Maystadt, I., Demuth, S., Zvulunov, A., Kutsche, K., Zeviani, M., and Franco, B. (2012) Mutations in COX7B Cause Microphthalmia with Linear Skin Lesions, an Unconventional Mitochondrial Disease. Am. J. Hum. Genet. 91, 942-949"	"DISEASE: Linear skin defects with multiple congenital anomalies 2 (LSDMCA2) [MIM:300887]: A distinct form of aplasia cutis congenita presenting as multiple linear skin defects on the face and neck associated with poor growth, microcephaly, and facial dysmorphism. Additional features include intellectual disability, nail dystrophy, short stature and cardiac abnormalities. {ECO:0000269|PubMed:23122588}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0013720;C0751651;C0796070;C3550921;C3714756	300885	300887	18.5945366	NaN	Class 1	-1.338128041	0.001901795	13881.72986	NaN	0	NaN	NaN
P10176	COX8A	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Skeletal system;Others"	OXPHOS complex subunits	1				1	"Hallmann, K., Kudin, A. P., Zsurka, G., Kornblum, C., Reimann, J., Stuve, B., Waltz, S., Hattingen, E., Thiele, H., Nurnberg, P., Rub, C., Voos, W., Kopatz, J., Neumann, H., and Kunz, W. S. (2016) Loss of the smallest subunit of cytochrome c oxidase, COX8A, causes Leigh-like syndrome and epilepsy. Brain 139, 338-345"		C0001969;C0268237;C0751651	123870	220110	Infinite	NaN	Class 1	-2.483316655	0.000102133	361196.2884	221859	0	NaN	95.40452795
P36551	CPOX	Metabolism;Liver;Hematologic system;Integumentary system	Cofactor metabolism	1				1		"DISEASE: Hereditary coproporphyria (HCP) [MIM:121300]: A form of porphyria. Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. Hereditary coproporphyria is an acute hepatic porphyria characterized by skin photosensitivity, attacks of abdominal pain, neurological disturbances, and psychiatric symptoms. Most attacks are precipitated by drugs, alcohol, caloric deprivation, infections, or endocrine factors. Hereditary coproporphyria is biochemically characterized by overexcretion of coproporphyrin III in the urine and in the feces. {ECO:0000269|PubMed:12181641, ECO:0000269|PubMed:15896662, ECO:0000269|PubMed:16398658, ECO:0000269|PubMed:7757079, ECO:0000269|PubMed:7849704, ECO:0000269|PubMed:8012360, ECO:0000269|PubMed:8990017, ECO:0000269|PubMed:9048920, ECO:0000269|PubMed:9298818, ECO:0000269|PubMed:9888388}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0162531;C0162566;C0342859	612732	121300	79.08512798	170.6178277	Class 1	-1.061206594	0.000924582	411974.8596	476395.3333	Soluble	4.840229554	30.17346253
P31327	CPS1	Central nervous system;Metabolism;Liver	Amino acid metabolism	1				1		"DISEASE: Carbamoyl phosphate synthetase 1 deficiency (CPS1D) [MIM:237300]: An autosomal recessive disorder of the urea cycle causing hyperammonemia. It can present as a devastating metabolic disease dominated by severe hyperammonemia in neonates or as a more insidious late-onset condition, generally manifesting as life-threatening hyperammonemic crises under catabolic situations. Clinical features include protein intolerance, intermittent ataxia, seizures, lethargy, developmental delay and mental retardation. {ECO:0000269|PubMed:11388595, ECO:0000269|PubMed:11474210, ECO:0000269|PubMed:12655559, ECO:0000269|PubMed:12955727, ECO:0000269|PubMed:15164414, ECO:0000269|PubMed:15617192, ECO:0000269|PubMed:16737834, ECO:0000269|PubMed:17310273, ECO:0000269|PubMed:20578160, ECO:0000269|PubMed:21120950, ECO:0000269|PubMed:22173106, ECO:0000269|PubMed:23649895, ECO:0000269|PubMed:24813853, ECO:0000269|PubMed:26440671, ECO:0000269|PubMed:9711878}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Pulmonary hypertension, neonatal (PHN) [MIM:615371]: A disease characterized by elevated pulmonary artery pressure. Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration syndrome, congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or congenital heart disease. {ECO:0000269|PubMed:11407344}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. CPS1 variants influence the availability of precursors for nitric oxide (NO) synthesis and play a role in clinical situations where endogenous NO production is critically important, such as neonatal pulmonary hypertension, increased pulmonary artery pressure following surgical repair of congenital heart defects or hepatovenocclusive disease following bone marrow transplantation. Infants with neonatal pulmonary hypertension homozygous for Thr-1406 have lower L-arginine concentrations than neonates homozygous for Asn-1406 (PubMed:11407344). {ECO:0000269|PubMed:11407344}."	C0009421;C0023893;C0031190;C0032927;C0220994;C0282313;C0376618;C0751753;C0860634;C3714756;C3714958;C4082171;C4085580	608307	237300-615371	95.70490867	169.1065337	Class 1	-1.000747024	0.001597713	11244.80194	9633.263333	Peripheral	35.35355207	84.11898678
P50416	CPT1A	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Muscular system;Liver;Gastrointestinal system;Kidney and urinary tract	Fatty acid _-oxidation 	1				1		"DISEASE: Carnitine palmitoyltransferase 1A deficiency (CPT1AD) [MIM:255120]: Rare autosomal recessive metabolic disorder of long-chain fatty acid oxidation characterized by severe episodes of hypoketotic hypoglycemia usually occurring after fasting or illness. Onset is in infancy or early childhood. {ECO:0000269|PubMed:11350182, ECO:0000269|PubMed:11441142, ECO:0000269|PubMed:12111367, ECO:0000269|PubMed:12189492, ECO:0000269|PubMed:14517221, ECO:0000269|PubMed:15110323, ECO:0000269|PubMed:15669684, ECO:0000269|PubMed:9691089}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002152;C0006142;C0011849;C0011853;C0011860;C0022661;C0038433;C0220994;C0678222;C1257931;C1458155;C1829703	600528	255120	86.96177941	182.6608197	Class 4	-0.311544598	0.02582457	4714.056873	3796.666667	0	NaN	90.91525109
P23786	CPT2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Liver;Gastrointestinal system;Kidney and urinary tract"	Fatty acid _-oxidation 	1				1		"DISEASE: Carnitine palmitoyltransferase 2 deficiency, infantile (CPT2DI) [MIM:600649]: An autosomal recessive disorder of mitochondrial long-chain fatty acid oxidation, characterized by hepatic or hepato-cardio-muscular manifestations with onset in infancy. Clinical features include hypoketotic hypoglycemia, lethargy, seizures, hepatomegaly, liver dysfunction, cardiomegaly and dilated cardiomyopathy. {ECO:0000269|PubMed:1528846, ECO:0000269|PubMed:8651281}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Carnitine palmitoyltransferase 2 deficiency, lethal neonatal (CPT2DLN) [MIM:608836]: An autosomal recessive disorder of mitochondrial long-chain fatty acid oxidation with fatal outcome, presenting shortly after birth. It is characterized by respiratory distress, seizures, altered mental status, hepatomegaly, cardiomegaly, cardiac arrhythmia, and, in many cases, dysmorphic features, renal dysgenesis, and migration defects. recessive. {ECO:0000269|PubMed:11477613}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Carnitine palmitoyltransferase 2 deficiency, myopathic, stress-induced (CPT2D) [MIM:255110]: An autosomal recessive disorder of mitochondrial long-chain fatty acid oxidation, characterized by recurrent myoglobinuria, episodes of muscle pain, stiffness, and rhabdomyolysis. These symptoms are exacerbated by prolonged exercise, fasting, cold, or viral infection. CPT2DM affects most frequently children or young adults, and severity of attacks is highly variable. Myoglobinuria can cause kidney failure and death. {ECO:0000269|PubMed:10090476, ECO:0000269|PubMed:11477613, ECO:0000269|PubMed:14605500, ECO:0000269|PubMed:14615409, ECO:0000269|PubMed:1528846, ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:15622536, ECO:0000269|PubMed:7711730, ECO:0000269|PubMed:8358442, ECO:0000269|PubMed:8651281, ECO:0000269|PubMed:9600456, ECO:0000269|PubMed:9758712, ECO:0000269|Ref.13, ECO:0000269|Ref.17}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Encephalopathy, acute, infection-induced, 4 (IIAE4) [MIM:614212]: A severe neurologic complication of an infection. It manifests within days in otherwise healthy children after common viral infections, without evidence of viral infection of the brain or inflammatory cell infiltration. In affected children, high-grade fever is accompanied within 12 to 48 hours by febrile convulsions, often leading to coma, multiple-organ failure, brain edema, and high morbidity and mortality. The infections are usually viral, particularly influenza, although other viruses and even mycoplasma have been found to cause the disorder. {ECO:0000269|PubMed:15811315, ECO:0000269|PubMed:21697855}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. CPT2 polymorphic variants do not cause classical carnitine palmitoyltransferase 2 deficiency, and patients harboring any of them are asymptomatic most of the time. However, they are prone to viral infection (high fever)-related encephalopathy (PubMed:21697855). {ECO:0000269|PubMed:21697855}."	C0003886;C0006112;C0026848;C0035410;C0220994;C0270960;C0750968;C0751743;C0751744;C1135773;C1833508;C1833511;C1833518;C3280160	600650	600649-608836-255110-614212	109.960502	NaN	Class 1	-1.247006971	0.000161185	251821.6039	180992.3333	Peripheral	6.556376963	94.27113756
P43155	CRAT	Central nervous system;Metabolism;Peripheral nervous system	Fatty acid _-oxidation 	1				1		"DISEASE: Neurodegeneration with brain iron accumulation 8 (NBIA8) [MIM:617917]: A neurodegenerative disorder associated with iron accumulation, primarily in the basal ganglia. Disease onset is in early childhood. Clinical features include speech delay, progressive cerebellar ataxia, unbalanced gait, and loss of ambulation. NBIA8 transmission pattern is consistent with autosomal recessive inheritance. {ECO:0000269|PubMed:29395073}. Note=The disease is caused by mutations affecting the gene represented in this entry."		600184	617917	183.6013536	108.9676888	Class 4	-0.713115039	0.01322613	36052.64444	21462.1	Peripheral	3.205466221	68.32793002
P00387	CYB5R3	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Skeletal system;Hematologic system"	Lipid metabolism	1				1		"DISEASE: Methemoglobinemia CYB5R3-related (METHB-CYB5R3) [MIM:250800]: A form of methemoglobinemia, a hematologic disease characterized by the presence of excessive amounts of methemoglobin in blood cells, resulting in decreased oxygen carrying capacity of the blood, cyanosis and hypoxia. There are two types of methemoglobinemia CYB5R3-related. In type 1, the defect affects the soluble form of the enzyme, is restricted to red blood cells, and causes well-tolerated methemoglobinemia. In type 2, the defect affects both the soluble and microsomal forms of the enzyme and is thus generalized, affecting red cells, leukocytes and all body tissues. Type 2 methemoglobinemia is associated with mental deficiency and other neurologic symptoms. {ECO:0000269|PubMed:10807796, ECO:0000269|PubMed:12393396, ECO:0000269|PubMed:1400360, ECO:0000269|PubMed:15622768, ECO:0000269|PubMed:15953014, ECO:0000269|PubMed:1707593, ECO:0000269|PubMed:1898726, ECO:0000269|PubMed:7718898, ECO:0000269|PubMed:8119939, ECO:0000269|PubMed:9695975, ECO:0000269|PubMed:9886302}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0010520;C0025637;C0268193;C0272087;C2749559;C2749560;C2749561;C2749562;C3714756	613213	250800-250800	98.92047384	NaN	Class 4	-0.379121371	0.052382248	608419.5291	1831411	Integral	93.8184034	88.37119437
P08574	CYC1	Metabolism;Liver	OXPHOS complex subunits	1				1	"Gaignard, P., Menezes, M., Schiff, M., Bayot, A., Rak, M., Ogier de Baulny, H., Su, C. H., Gilleron, M., Lombes, A., Abida, H., Tzagoloff, A., Riley, L., Cooper, S. T., Mina, K., Sivadorai, P., Davis, M. R., Allcock, R. J., Kresoje, N., Laing, N. G., Thorburn, D. R., Slama, A., Christodoulou, J., and Rustin, P. (2013) Mutations in CYC1, Encoding Cytochrome c Subunit of Respiratory Chain Complex III, Cause Insulin-Responsive Hyperglycemia. Am. J. Hum. Genet. 93, 384-389"	"DISEASE: Mitochondrial complex III deficiency, nuclear 6 (MC3DN6) [MIM:615453]: An autosomal recessive disorder caused by mitochondrial dysfunction. It is characterized by onset in early childhood of episodic acute lactic acidosis, ketoacidosis, and insulin-responsive hyperglycemia, usually associated with infection. Laboratory studies show decreased activity of mitochondrial complex III. Psychomotor development is normal. {ECO:0000269|PubMed:23910460}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0342778;C0751651;C1852372;C3714756;C3809553	123980	615453	138.2087864	167.7320499	Class 1	-1.828419053	7.13259E-05	613151.7371	587999	Integral	80.72131803	94.61995032
P99999	CYCS	Hematologic system	Other known processes	1				1	"Morison, I. M., Cramer Borde, E. M., Cheesman, E. J., Cheong, P. L., Holyoake, A. J., Fichelson, S., Weeks, R. J., Lo, A., Davies, S. M., Wilbanks, S. M., Fagerlund, R. D., Ludgate, M. W., da Silva Tatley, F. M., Coker, M. S., Bockett, N. A., Hughes, G., Pippig, D. A., Smith, M. P., Capron, C., and Ledgerwood, E. C. (2008) A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet 40, 387-389"	"DISEASE: Thrombocytopenia 4 (THC4) [MIM:612004]: Thrombocytopenia is defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. {ECO:0000269|PubMed:18345000}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007786;C0007787;C0010828;C0015695;C0022116;C0028754;C0040034;C0158995;C0263454;C0268583;C0472381;C0751019;C0751020;C0751021;C0751022;C0751651;C0917798;C0917805;C1527335;C1855119;C2677608;C2711227	123970	612004	NaN	48.90938154	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
P05108	CYP11A1	Pulmonary system ;Endocrine system;Reproductive system;Integumentary system	Lipid metabolism	1				1		"DISEASE: Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR) [MIM:613743]: A rare disorder that can present as acute adrenal insufficiency in infancy or childhood. ACTH and plasma renin activity are elevated and adrenal steroids are inappropriately low or absent;the 46,XY patients have female external genitalia, sometimes with clitoromegaly. The phenotypic spectrum ranges from prematurity, complete underandrogenization, and severe early-onset adrenal failure to term birth with clitoromegaly and later-onset adrenal failure. Patients with congenital adrenal insufficiency do not manifest the massive adrenal enlargement typical of congenital lipoid adrenal hyperplasia. {ECO:0000269|PubMed:11502818, ECO:0000269|PubMed:12161514, ECO:0000269|PubMed:16705068, ECO:0000269|PubMed:18182448, ECO:0000269|PubMed:19116240}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0001623;C0014170;C0022333;C0036572;C0036875;C0149958;C0234533;C0234535;C0238395;C0270824;C0270844;C0270846;C0342474;C0342482;C0422850;C0422852;C0422853;C0422854;C0422855;C0476089;C0494475;C0751056;C0751110;C0751123;C0751494;C0751495;C0751496;C2751824;C3151055;C3489793;C3495874;C3496069;C3502132;C4048158;C4316903;C4317109;C4317123;C4505436	118485	613743	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P15538	CYP11B1	Cardiovascular system;Endocrine system;Reproductive system	Lipid metabolism	1				1		"DISEASE: Adrenal hyperplasia 4 (AH4) [MIM:202010]: A form of congenital adrenal hyperplasia, a common recessive disease due to defective synthesis of cortisol. Congenital adrenal hyperplasia is characterized by androgen excess leading to ambiguous genitalia in affected females, rapid somatic growth during childhood in both sexes with premature closure of the epiphyses and short adult stature. Four clinical types: 'salt wasting' (SW, the most severe type), 'simple virilizing' (SV, less severely affected patients), with normal aldosterone biosynthesis, 'non-classic form' or late-onset (NC or LOAH) and 'cryptic' (asymptomatic). {ECO:0000269|PubMed:16046588, ECO:0000269|PubMed:20089618, ECO:0000269|PubMed:2022736, ECO:0000269|PubMed:20331679, ECO:0000269|PubMed:20947076, ECO:0000269|PubMed:23940125, ECO:0000269|PubMed:24022297, ECO:0000269|PubMed:24536089, ECO:0000269|PubMed:24987415, ECO:0000269|PubMed:26053152, ECO:0000269|PubMed:26476331, ECO:0000269|PubMed:9302260}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Hyperaldosteronism, familial, 1 (HALD1) [MIM:103900]: A disorder characterized by hypertension, variable hyperaldosteronism, and abnormal adrenal steroid production, including 18-oxocortisol and 18-hydroxycortisol. There is significant phenotypic heterogeneity, and some individuals never develop hypertension. Note=The disease is caused by mutations affecting the gene represented in this entry. The molecular defect causing hyperaldosteronism familial 1 is an anti-Lepore-type fusion of the CYP11B1 and CYP11B2 genes. The hybrid gene has the promoting part of CYP11B1, ACTH-sensitive, and the coding part of CYP11B2."	C0020428;C0036875;C0268292;C1260386;C1384514;C3669121	610613	202010-103900	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P19099	CYP11B2	Metabolism;Failure to thrive;Endocrine system	Lipid metabolism	1				1		"DISEASE: Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency) [MIM:203400]: Autosomal recessive disorder of aldosterone biosynthesis. There are two biochemically different forms of selective aldosterone deficiency be termed corticosterone methyloxidase (CMO) deficiency type 1 and type 2. In CMO-1 deficiency, aldosterone is undetectable in plasma, while its immediate precursor, 18-hydroxycorticosterone, is low or normal. {ECO:0000269|PubMed:11238478, ECO:0000269|PubMed:9177280}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Corticosterone methyloxidase 2 deficiency (CMO-2 deficiency) [MIM:610600]: Autosomal recessive disorder of aldosterone biosynthesis. In CMO-2 deficiency, aldosterone can be low or normal, but at the expense of increased secretion of 18-hydroxycorticosterone. Consequently, patients have a greatly increased ratio of 18-hydroxycorticosterone to aldosterone and a low ratio of corticosterone to 18-hydroxycorticosterone in serum. {ECO:0000269|PubMed:12788848, ECO:0000269|PubMed:1346492, ECO:0000269|PubMed:1594605, ECO:0000269|PubMed:9625333, ECO:0000269|PubMed:9814506}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Hyperaldosteronism, familial, 1 (HALD1) [MIM:103900]: A disorder characterized by hypertension, variable hyperaldosteronism, and abnormal adrenal steroid production, including 18-oxocortisol and 18-hydroxycortisol. There is significant phenotypic heterogeneity, and some individuals never develop hypertension. Note=The disease is caused by mutations affecting the gene represented in this entry. The molecular defect causing hyperaldosteronism familial 1 is an anti-Lepore-type fusion of the CYP11B1 and CYP11B2 genes. The hybrid gene has the promoting part of CYP11B1, ACTH-sensitive, and the coding part of CYP11B2."	C0020428;C0020595;C0033578;C0268293;C0376185;C0376358;C1260386;C1384514;C3463917	124080	203400-610600	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q07973	CYP24A1	Central nervous system;Metabolism;Failure to thrive;Kidney and urinary tract	Lipid metabolism	1				1		"DISEASE: Hypercalcemia, infantile, 1 (HCINF1) [MIM:143880]: A disorder characterized by abnormally high level of calcium in the blood, failure to thrive, vomiting, dehydration, and nephrocalcinosis. {ECO:0000269|PubMed:21675912}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0000786;C0000822;C0001787;C0006142;C0020437;C0020438;C0024121;C0026141;C0029456;C0029459;C0035078;C0242379;C0268080;C0392525;C0475732;C0678222;C0751406;C1257931;C1458155;C1565489;C4310232;C4310473	126065	143880	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q02318	CYP27A1	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Liver;Skeletal system	Lipid metabolism	1				1		"DISEASE: Cerebrotendinous xanthomatosis (CTX) [MIM:213700]: Rare sterol storage disorder characterized clinically by progressive neurologic dysfunction, premature atherosclerosis, and cataracts. {ECO:0000269|PubMed:12000359, ECO:0000269|PubMed:2019602, ECO:0000269|PubMed:7915755, ECO:0000269|PubMed:9186905, ECO:0000269|PubMed:9790667}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0004153;C0005944;C0008370;C0020445;C0023520;C0023890;C0029453;C0086543;C0220994;C0238052;C0239946;C1112213;C1563937;C3714756	606530	213700	NaN	51.76344444	NaN	NaN	NaN	0	0	0	0	0
O15528	CYP27B1	Central nervous system;Metabolism;Failure to thrive;Skeletal system;Endocrine system	Lipid metabolism	1				1		"DISEASE: Rickets vitamin D-dependent 1A (VDDR1A) [MIM:264700]: A disorder caused by a selective deficiency of the active form of vitamin D (1,25-dihydroxyvitamin D3) and resulting in defective bone mineralization and clinical features of rickets. {ECO:0000269|PubMed:10320521, ECO:0000269|PubMed:10566658, ECO:0000269|PubMed:12050193, ECO:0000269|PubMed:9486994, ECO:0000269|PubMed:9837822}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0020437;C0026141;C0033975;C0035579;C0085655;C0263984;C0268689;C0349204;C0554591	609506	264700	NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q8N465	D2HGDH	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system "	Other known processes	1				1	"Struys, E. A., Salomons, G. S., Achouri, Y., Van Schaftingen, E., Grosso, S., Craigen, W. J., Verhoeven, N. M., and Jakobs, C. (2005) Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am. J. Hum. Genet. 76, 358-360"	"DISEASE: D-2-hydroxyglutaric aciduria 1 (D2HGA1) [MIM:600721]: A rare recessive neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine. {ECO:0000269|PubMed:15609246, ECO:0000269|PubMed:16037974, ECO:0000269|PubMed:16081310}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002514;C0023520;C0543888;C0750905;C2746066;C3152055;C3714756	609186	600721	NaN	NaN	Class 1	-0.913593943	0.00666123	36120.41201	24061.73333	Peripheral	13.83072424	65.80154064
Q6PI48	DARS2	Central nervous system;Metabolism	tRNA related processes	1				1	"Scheper, G. C., van der Klok, T., van Andel, R. J., van Berkel, C. G., Sissler, M., Smet, J., Muravina, T. I., Serkov, S. V., Uziel, G., Bugiani, M., Schiffmann, R., Krageloh-Mann, I., Smeitink, J. A., Florentz, C., Van Coster, R., Pronk, J. C., and van der Knaap, M. S. (2007) Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet 39, 534-539"	"DISEASE: Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) [MIM:611105]: Autosomal recessive disease and is defined on the basis of a highly characteristic constellation of abnormalities observed by magnetic resonance imaging and spectroscopy. Affected individuals develop slowly progressive cerebellar ataxia, spasticity, and dorsal column dysfunction, sometimes with a mild cognitive deficit or decline. {ECO:0000269|PubMed:17384640}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0023520;C0751651;C1970180;C3714756	610956	611105	201.6153437	148.0699783	Class 1	-2.263610054	4.87515E-05	753192.7074	753048.3333	Peripheral	9.386302202	84.41524916
P11182	DBT	Central nervous system;Metabolism;Failure to thrive	Amino acid metabolism	1				1		"DISEASE: Maple syrup urine disease 2 (MSUD2) [MIM:248600]: A metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated. {ECO:0000269|PubMed:1847055, ECO:0000269|PubMed:9621512}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Note=Patients with primary biliary cirrhosis (PBC) show autoantibodies against the E2 component of branched-chain alpha-keto acid dehydrogenase complex. PBC is a chronic, progressive cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies in patients serum. It manifests with inflammatory obliteration of intra-hepatic bile duct, leading to liver cell damage and cirrhosis. {ECO:0000269|PubMed:2908870, ECO:0000269|PubMed:7543435, ECO:0000269|PubMed:9141421}."	C0024776;C0220994;C0268568;C0268569;C0543888;C0751285;C1621920;C1855369;C1855371;C2930990;C3714756	248610	248600	102.8769709	NaN	Class 1	-2.314090397	1.58875E-05	244246.5966	260022.6667	Peripheral	3.676012352	72.87073333
Q7Z4W1	DCXR	Metabolism	Carbohydrate & energy metabolism	1				1		"DISEASE: Pentosuria (PNTSU) [MIM:260800]: An inborn error of metabolism characterized by excessive urinary excretion of L-xylulose. {ECO:0000269|PubMed:11882650, ECO:0000269|PubMed:22042873, ECO:0000269|PubMed:4392213}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023893;C0028754;C0033578;C0268162;C0376358	608347	260800	237.8179969	NaN	Class 1	-4.059141	5.62573E-05	436945.5808	1306888.333	Soluble	3.681575711	43.45746478
Q16854	DGUOK	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Muscular system;Ears;Liver;Gastrointestinal system;Peripheral nervous system;Hematologic system;Others;Endocrine system"	Nucleotide/ nucleoside metabolism	1				1	"Mandel, H., Szargel, R., Labay, V., Elpeleg, O., Saada, A., Shalata, A., Anbinder, Y., Berkowitz, D., Hartman, C., Barak, M., Eriksson, S., and Cohen, N. (2001) The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 29, 337-341"	"DISEASE: Mitochondrial DNA depletion syndrome 3 (MTDPS3) [MIM:251880]: A disorder due to mitochondrial dysfunction characterized by onset in infancy of progressive liver failure, hypoglycemia, increased lactate in body fluids, and neurologic abnormalities including hypotonia, encephalopathy, peripheral neuropathy. Affected tissues show both decreased activity of the mtDNA-encoded respiratory chain complexes and mtDNA depletion. {ECO:0000269|PubMed:12205643, ECO:0000269|PubMed:15639197}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Portal hypertension, non-cirrhotic (NCPH) [MIM:617068]: An autosomal recessive disorder characterized by portal hypertension associated with hepatosplenomegaly, in absence of cirrhosis, extrahepatic diseases, and splanchnic venous thrombosis. Portal hypertension is defined by a portal venous system pressure that is at least 5 mm Hg higher than the pressure in the inferior vena cava. High pressure in the portal venous system leads to shunting of blood through vessels that are poorly suited to carrying large blood volumes, resulting in collateral circulation and splenomegaly. NCPH patients show normal liver function. {ECO:0000269|PubMed:17073823, ECO:0000269|PubMed:26874653}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4 (PEOB4) [MIM:617070]: A form of progressive external ophthalmoplegia, a mitochondrial myopathy characterized by progressive paralysis of the levator palpebrae, orbicularis oculi, and extraocular muscles. PEOB4 patients manifest clinically variable features including mitochondrial myopathy with or without progressive external ophthalmoplegia, recurrent rhabdomyolysis, and adult-onset lower motor neuron syndrome with mild cognitive impairment. {ECO:0000269|PubMed:23043144}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0008370;C0010398;C0020541;C0023520;C0751651;C1112213;C2673809;C3151513;C3711385;C4310733;C4310735	601465	251880-617068-617070	Infinite	NaN	Class 4	-0.472433757	0.049240834	19448.68815	27072.20333	Peripheral	11.18307914	90.64039422
P00374	DHFR	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Liver;Hematologic system"	Cofactor metabolism	1				1		"DISEASE: Megaloblastic anemia due to dihydrofolate reductase deficiency (DHFRD) [MIM:613839]: An inborn error of metabolism, characterized by megaloblastic anemia and/or pancytopenia, severe cerebral folate deficiency, and cerebral tetrahydrobiopterin deficiency. Clinical features include variable neurologic symptoms, ranging from severe developmental delay and generalized seizures in infancy, to childhood absence epilepsy with learning difficulties, to lack of symptoms. {ECO:0000269|PubMed:21310276, ECO:0000269|PubMed:21310277}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0000786;C0000822;C0002888;C0003873;C0004352;C0006142;C0009402;C0009404;C0010828;C0013221;C0016412;C0019193;C0021361;C0025521;C0027627;C0027765;C0029463;C0030312;C0038279;C0041755;C0158995;C0341869;C0678222;C0860207;C0917730;C1257931;C1262760;C1458155;C1527249;C2751584;C3151205;C3658290;C3714756;C4277682;C4279912	126060	613839	20.33508109	NaN	Class 1	-1.15084035	0.005054393	11091.67295	1716418.667	0	14.41272415	NaN
Q02127	DHODH	"Congenital anomalies and dysmorphisms, intrauterine abnormalities"	Nucleotide/ nucleoside metabolism	1				1		"DISEASE: Postaxial acrofacial dysostosis (POADS) [MIM:263750]: POADS is characterized by severe micrognathia, cleft lip and/or palate, hypoplasia or aplasia of the posterior elements of the limbs, coloboma of the eyelids and supernumerary nipples. POADS is a very rare disorder: only 2 multiplex families, each consisting of 2 affected siblings born to unaffected, nonconsanguineous parents, have been described among a total of around 30 reported cases. {ECO:0000269|PubMed:19915526}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002875;C0002895;C0005283;C0019025;C0023440;C0037889;C0085578;C0265257;C0271979;C3714756	126064	263750	279.1165222	NaN	Class 1	-2.499403673	2.84518E-05	79964.27293	80335.76667	Integral	91.21567639	93.55566283
Q96HY7	DHTKD1	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Peripheral nervous system;Skeletal system"	Unknown	1				1		"DISEASE: 2-aminoadipic 2-oxoadipic aciduria (AMOXAD) [MIM:204750]: A metabolic disorder characterized by increased levels of 2-oxoadipate and 2-hydroxyadipate in the urine, and elevated 2-aminoadipate in the plasma. Patients can have mild to severe intellectual disability, muscular hypotonia, developmental delay, ataxia, and epilepsy. Most cases are asymptomatic. {ECO:0000269|PubMed:23141293}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Charcot-Marie-Tooth disease 2Q (CMT2Q) [MIM:615025]: An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. {ECO:0000269|PubMed:23141294}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007959;C0023893;C0751651;C1859817;C3554366;C3714756	614984	204750-615025	138.3870304	78.40453512	Class 1	-1.059458277	0.001499264	89825.38274	67612.06667	Ambiguous	22.34679936	64.76562046
Q7L2E3;Q7L2E3	DHX30	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Ears;Skeletal system"	Ribosome assembly & translation	1				1		"DISEASE: Neurodevelopmental disorder with severe motor impairment and absent language (NEDMIAL) [MIM:617804]: An autosomal dominant neurodevelopmental disorder characterized by global developmental delay, intellectual disability, severe speech impairment and gait abnormalities. {ECO:0000269|PubMed:28327206, ECO:0000269|PubMed:29100085}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0033578;C0376358;C3714756	616423	617804	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9NR28	DIABLO	Ears	Cell death/ apoptosis	1				1		"DISEASE: Deafness, autosomal dominant, 64 (DFNA64) [MIM:614152]: A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:21722859}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007786;C0020179;C0027055;C0033578;C0376358;C0393574;C0751207;C0751208;C0917798;C3279948	605219	614152	NaN	NaN	NaN	NaN	NaN	362686.4174	NaN	0	NaN	NaN
P10515	DLAT	Central nervous system;Metabolism;Ophthalmic system	PDH complex & PDH regulation	1				1	"Head, R. A., Brown, R. M., Zolkipli, Z., Shahdadpuri, R., King, M. D., Clayton, P. T., and Brown, G. K. (2005) Clinical and genetic spectrum of pyruvate dehydrogenase deficiency: dihydrolipoamide acetyltransferase (E2) deficiency. Ann Neurol 58, 234-241"	"DISEASE: Note=Primary biliary cirrhosis is a chronic, progressive cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies in patients' serum. It manifests with inflammatory obliteration of intra-hepatic bile duct, leading to liver cell damage and cirrhosis. Patients with primary biliary cirrhosis show autoantibodies against the E2 component of pyruvate dehydrogenase complex.;DISEASE: Pyruvate dehydrogenase E2 deficiency (PDHE2 deficiency) [MIM:245348]: Pyruvate dehydrogenase (PDH) deficiency is a major cause of primary lactic acidosis and neurological dysfunction in infancy and early childhood. In this form of PDH deficiency episodic dystonia is the major neurological manifestation, with other more common features of pyruvate dehydrogenase deficiency, such as hypotonia and ataxia, being less prominent. {ECO:0000269|PubMed:16049940}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0151744;C0751651;C1855565;C3714756	608770	245348	135.9193064	NaN	Class 1	-1.227325703	0.000200456	652504.0443	690112.6667	Integral	68.82889806	95.51813065
P09622	DLD	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system ;Liver;Gastrointestinal system"	Carbohydrate & energy metabolism	1				1	"Liu, T. C., Kim, H., Arizmendi, C., Kitano, A., and Patel, M. S. (1993) Identification of two missense mutations in a dihydrolipoamide dehydrogenase-deficient patient. Proc. Natl. Acad. Sci. U S A 90, 5186-5190"	"DISEASE: Dihydrolipoamide dehydrogenase deficiency (DLDD) [MIM:246900]: An autosomal recessive metabolic disorder characterized biochemically by a combined deficiency of the branched-chain alpha-keto acid dehydrogenase complex (BCKDC), pyruvate dehydrogenase complex (PDC), and alpha-ketoglutarate dehydrogenase complex (KGDC). Clinically, affected individuals have lactic acidosis and neurologic deterioration due to sensitivity of the central nervous system to defects in oxidative metabolism. {ECO:0000269|PubMed:10448086, ECO:0000269|PubMed:11687750, ECO:0000269|PubMed:12925875, ECO:0000269|PubMed:15712224, ECO:0000269|PubMed:16442803, ECO:0000269|PubMed:16770810, ECO:0000269|PubMed:17404228, ECO:0000269|PubMed:20160912, ECO:0000269|PubMed:8506365, ECO:0000269|PubMed:8968745, ECO:0000269|PubMed:9540846, ECO:0000269|PubMed:9934985}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0268193;C0751651;C3492932;C3714756	238331	246900	86.66447363	254.6807335	Class 1	-1.031432897	0.000346547	1634083.631	1805250	Peripheral	12.54784808	71.66433019
P36957	DLST	Tumors	TCA cycle	1				1	"Remacha L, Pirman D, Mahoney CE, Coloma J, Calsina B, Currás-Freixes M, Letón R, Torres-Pérez R, Richter S, Pita G, Herráez B, Cianchetta G, Honrado E, Maestre L, Urioste M, Aller J, García-Uriarte Ó, Gálvez MÁ, Luque RM, Lahera M, Moreno-Rengel C, Eisenhofer G, Montero-Conde C, Rodríguez-Antona C, Llorca Ó, Smolen GA, Robledo M, Cascón A. Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. Am J Hum Genet. 2019 Apr 4;104(4):651-664."			126063	618475	157.286632	220.4865432	Class 1	-1.402253698	0.000133033	743250.3522	786948	Ambiguous	73.2959473	83.98575943
Q9UI17	DMGDH	Muscular system;Others	Other known processes	1				1		"DISEASE: DMGDH deficiency (DMGDHD) [MIM:605850]: Disorder characterized by fish odor, muscle fatigue with increased serum creatine kinase. Biochemically it is characterized by an increase of N,N-dimethylglycine (DMG) in serum and urine. {ECO:0000269|PubMed:11231903, ECO:0000269|PubMed:27486859}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C1853892	605849	605850	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P51530	DNA2	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Muscular system;Skeletal system;Kidney and urinary tract;Others"	DNA-related processes	1				1	"Ronchi, D., Di Fonzo, A., Lin, W., Bordoni, A., Liu, C., Fassone, E., Pagliarani, S., Rizzuti, M., Zheng, L., Filosto, M., Ferro, M. T., Ranieri, M., Magri, F., Peverelli, L., Li, H., Yuan, Y. C., Corti, S., Sciacco, M., Moggio, M., Bresolin, N., Shen, B., and Comi, G. P. (2013) Mutations in DNA2 Link Progressive Myopathy to Mitochondrial DNA Instability. Am. J. Hum. Genet. 92, 293-300"	"DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 6 (PEOA6) [MIM:615156]: A disorder characterized by muscle weakness, mainly affecting the lower limbs, external ophthalmoplegia, exercise intolerance, and mitochondrial DNA deletions on muscle biopsy. Symptoms may appear in childhood or adulthood and show slow progression. {ECO:0000269|PubMed:23352259}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Seckel syndrome 8 (SCKL8) [MIM:615807]: A rare autosomal recessive disorder characterized by proportionate dwarfism of prenatal onset associated with low birth weight, growth retardation, severe microcephaly with a bird-headed like appearance, and mental retardation. {ECO:0000269|PubMed:24389050}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007820;C0025958;C0431350;C0751651;C3554599;C3714756	601810	615807-615156	NaN	NaN	Class 4	-1.304995386	0.059407069	263.8515295	37836.33333	0	NaN	NaN
Q96DA6	DNAJC19	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Liver;Hematologic system;Reproductive system"	Protein import & biogenesis	1				1	"Davey, K. M., Parboosingh, J. S., McLeod, D. R., Chan, A., Casey, R., Ferreira, P., Snyder, F. F., Bridge, P. J., and Bernier, F. P. (2006) Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition. J Med Genet 43, 385-393;Ojala, T., Polinati, P., Manninen, T., Hiippala, A., Rajantie, J., Karikoski, R., Suomalainen, A., and Tyni, T. (2012) New mutation of mitochondrial DNAJC19 causing dilated and noncompaction cardiomyopathy, anemia, ataxia, and male genital anomalies. Pediatr Res 72, 432-437"	"DISEASE: 3-methylglutaconic aciduria 5 (MGA5) [MIM:610198]: An autosomal recessive disorder characterized by early-onset dilated cardiomyopathy, growth failure, cerebellar ataxia causing significant motor delays, testicular dysgenesis, growth failure and significant increases in urine organic acids, particularly 3-methylglutaconic acid and 3-methylglutaric acid. {ECO:0000269|PubMed:16055927}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0007193;C0264886;C0751651;C1857776;C3714756;C4021133	608977	610198	164.8653049	221.3209335	Class 1	-3.625789556	5.12474E-06	352731.5574	261642.6667	0	NaN	85.67891397
Q96LL9	DNAJC30	Central nervous system;Ophthalmic system	Unknown	1				1	"Stenton SL, Sheremet NL, Catarino CB, Andreeva NA, Assouline Z, Barboni P, Barel O, Berutti R, Bychkov I, Caporali L, Capristo M, Carbonelli M, Cascavilla ML, Charbel Issa P, Freisinger P, Gerber S, Ghezzi D, Graf E, Heidler J, Hempel M, Heon E, Itkis YS, Javasky E, Kaplan J, Kopajtich R, Kornblum C, Kovacs-Nagy R, Krylova TD, Kunz WS, La Morgia C, Lamperti C, Ludwig C, Malacarne PF, Maresca A, Mayr JA, Meisterknecht J, Nevinitsyna TA, Palombo F, Pode-Shakked B, Shmelkova MS, Strom TM, Tagliavini F, Tzadok M, van der Ven AT, Vignal-Clermont C, Wagner M, Zakharova EY, Zhorzholadze NV, Rozet JM, Carelli V, Tsygankova PG, Klopstock T, Wittig I, Prokisch H. Impaired complex I repair causes recessive Leber's hereditary optic neuropathy. J Clin Invest. 2021 Mar 15;131(6):e138267."			618202		46.76578994	42.70659574	Class 1	-3.223196404	8.69301E-05	14175.1414	6046.336667	Integral	94.38294852	92.92271624
P26358	DNMT1	Central nervous system;Ophthalmic system;Ears;Peripheral nervous system	DNA-related processes	1				1		"DISEASE: Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant (ADCADN) [MIM:604121]: An autosomal dominant neurologic disorder characterized by adult onset of progressive cerebellar ataxia, narcolepsy, cataplexy, sensorineural deafness, and dementia. More variable features include optic atrophy, sensory neuropathy, psychosis, and depression. {ECO:0000269|PubMed:22328086}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Neuropathy, hereditary sensory, 1E (HSN1E) [MIM:614116]: A neurodegenerative disorder characterized by adult onset of progressive peripheral sensory loss associated with progressive hearing impairment and early-onset dementia. {ECO:0000269|PubMed:21532572}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0001418;C0003469;C0003865;C0004096;C0004138;C0005586;C0006142;C0007097;C0007102;C0007959;C0009375;C0013364;C0020071;C0020072;C0020074;C0020075;C0024623;C0025149;C0027626;C0027889;C0033578;C0036341;C0038356;C0086405;C0205641;C0205642;C0205643;C0205644;C0205645;C0205696;C0205697;C0205698;C0205699;C0205833;C0206085;C0278510;C0278876;C0282612;C0338630;C0376280;C0376358;C0497327;C0525045;C0678222;C0699739;C0751071;C0751291;C0971858;C0993582;C1257931;C1275668;C1279420;C1384666;C1458155;C1708349;C1858804;C2931852;C3279885;C3714756;C3807295	126375	604121-614116	NaN	40.74103263	Class 1	-1.180009789	0.003767196	817.7892513	383074.6667	0	NaN	NaN
O00429;O00429	DRP1	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system ;Peripheral nervous system"	"Morphology, dynamics & organization"	1				1	"Waterham, H. R., Koster, J., van Roermund, C. W., Mooyer, P. A., Wanders, R. J., and Leonard, J. V. (2007) A lethal defect of mitochondrial and peroxisomal fission. N Engl J Med 356, 1736-1741"	"DISEASE: Encephalopathy due to defective mitochondrial and peroxisomal fission 1 (EMPF1) [MIM:614388]: A rare autosomal dominant systemic disorder resulting in lack of neurologic development and death in infancy. After birth, infants present in the first week of life with poor feeding and neurologic impairment, including hypotonia, little spontaneous movement, no tendon reflexes, no response to light stimulation, and poor visual fixation. Other features include mildly elevated plasma concentration of very-long-chain fatty acids, lactic acidosis, microcephaly, deep-set eyes, optic atrophy and hypoplasia, and an abnormal gyral pattern in both frontal lobes associated with dysmyelination. {ECO:0000269|PubMed:17460227, ECO:0000269|PubMed:26604000, ECO:0000269|PubMed:26992161, ECO:0000269|PubMed:27145208, ECO:0000269|PubMed:27301544, ECO:0000269|PubMed:27328748, ECO:0000269|PubMed:29899447}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Note=May be associated with Alzheimer disease through amyloid-beta-induced increased S-nitrosylation of DNM1L, which triggers, directly or indirectly, excessive mitochondrial fission, synaptic loss and neuronal damage. {ECO:0000269|PubMed:19342591}.;DISEASE: Optic atrophy 5 (OPA5) [MIM:610708]: A form of optic atrophy, a disease characterized by progressive visual loss in association with a deficiency in the number of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts. OPA5 is an autosomal dominant non-syndromic form that manifests as slowly progressive visual loss with variable onset from the first to third decades. Additional ocular abnormalities may include central scotoma and dyschromatopsia. {ECO:0000269|PubMed:28969390}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0001125;C0025958;C0029124;C0151744;C0162666;C0282528;C0338508;C0543888;C0751651;C1853139;C1956147;C3280660;C3853041	603850	614388-610708	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P33316;P33316	DUT	Metabolism;Hematologic system;Endocrine system;Tumors	Nucleotide/ nucleoside metabolism	1				1	"Dos Santos RS, Daures M, Philippi A, Romero S, Marselli L, Marchetti P, Senée V, Bacq D, Besse C, Baz B, Marroquí L, Ivanoff S, Masliah-Planchon J, Nicolino M, Soulier J, Socié G, Eizirik DL, Gautier JF, Julier C. dUTPase (DUT) Is Mutated in a Novel Monogenic Syndrome With Diabetes and Bone Marrow Failure. Diabetes. 2017 Apr;66(4):1086-1096."			601266		NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q5JPH6	EARS2	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Muscular system;Liver"	tRNA related processes	1				1	"Steenweg, M. E., Ghezzi, D., Haack, T., Abbink, T. E., Martinelli, D., van Berkel, C. G., Bley, A., Diogo, L., Grillo, E., Te Water Naude, J., Strom, T. M., Bertini, E., Prokisch, H., van der Knaap, M. S., and Zeviani, M. (2012) Leukoencephalopathy with thalamus and brainstem involvement and high lactate 'LTBL' caused by EARS2 mutations. Brain 135, 1387-1394"	"DISEASE: Combined oxidative phosphorylation deficiency 12 (COXPD12) [MIM:614924]: An autosomal recessive, mitochondrial, neurologic disorder characterized by onset in infancy of hypotonia and delayed psychomotor development, or early developmental regression, associated with T2-weighted hyperintensities in the deep cerebral white matter, brainstem, and cerebellar white matter. Serum lactate is increased due to a defect in mitochondrial respiration. There are 2 main phenotypic groups: those with a milder disease course and some recovery of skills after age 2 years, and those with a severe disease course resulting in marked disability. {ECO:0000269|PubMed:22492562, ECO:0000269|PubMed:23008233, ECO:0000269|PubMed:26741492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C0543888;C0751651;C3554079	612799	614924	61.56027484	NaN	Class 1	-1.783258988	6.11653E-05	101465.2681	74633.73333	Peripheral	18.00802879	86.42602262
P30084	ECHS1	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Pulmonary system ;Ears	Fatty acid _-oxidation 	1				1	"Peters, H., Buck, N., Wanders, R., Ruiter, J., Waterham, H., Koster, J., Yaplito-Lee, J., Ferdinandusse, S., and Pitt, J. (2014) ECHS1 mutations in Leigh disease: a new inborn error of metabolism affecting valine metabolism. Brain 137, 2903-2908"	"DISEASE: Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency (ECHS1D) [MIM:616277]: A severe, autosomal recessive inborn error affecting valine metabolism. Disease features include brain lesions in the basal ganglia, neurodegeneration, delayed psychomotor development, hypotonia, spasticity, and increased lactic acid in serum and cerebral serum fluid. {ECO:0000269|PubMed:25125611, ECO:0000269|PubMed:25393721, ECO:0000269|PubMed:26000322, ECO:0000269|PubMed:26251176, ECO:0000269|PubMed:26741492, ECO:0000269|PubMed:27221955}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0001973;C0023264;C0024623;C0028754;C0038356;C0751267;C0751268;C0751651;C1708349;C4225391	602292	616277	127.8239056	320.9990768	Class 1	-2.030276227	6.20219E-05	1583128.069	1605710	Soluble	2.337394852	19.5974277
Q9BQ52	ELAC2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Ears"	tRNA related processes	1				1	"Haack, Tobias B., Kopajtich, R., Freisinger, P., Wieland, T., Rorbach, J., Nicholls, Thomas J., Baruffini, E., Walther, A., Danhauser, K., Zimmermann, Franz A., Husain, Ralf A., Schum, J., Mundy, H., Ferrero, I., Strom, Tim M., Meitinger, T., Taylor, Robert W., Minczuk, M., Mayr, Johannes A., and Prokisch, H. (2013) ELAC2 Mutations Cause a Mitochondrial RNA Processing Defect Associated with Hypertrophic Cardiomyopathy. Am. J. Hum. Genet.  93, 211-223"	"DISEASE: Combined oxidative phosphorylation deficiency 17 (COXPD17) [MIM:615440]: An autosomal recessive disorder of mitochondrial dysfunction characterized by onset of severe hypertrophic cardiomyopathy in the first year of life. Other features include hypotonia, poor growth, lactic acidosis, and failure to thrive. The disorder may be fatal in early childhood. {ECO:0000269|PubMed:23849775}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Prostate cancer, hereditary, 2 (HPC2) [MIM:614731]: A condition associated with familial predisposition to cancer of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:10986046, ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11507049, ECO:0000269|PubMed:11522646, ECO:0000269|PubMed:12515253, ECO:0000269|PubMed:12522685, ECO:0000269|PubMed:12711671, ECO:0000269|PubMed:12783937, ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:18987736, ECO:0000269|Ref.3}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0033578;C0376358;C0751651;C2931456;C3539120;C3714756;C3809526	605367	615440-614731	19.92317218	NaN	Class 1	-1.978596792	5.45361E-05	148156.4626	440925.3333	Peripheral	11.72013106	63.2971198
O75616	ERAL1	"Congenital anomalies and dysmorphisms, intrauterine abnormalities;Ears;Reproductive system"	Ribosome assembly & translation	1				1	"Chatzispyrou, I. A., Alders, M., Guerrero-Castillo, S., Zapata Perez, R., Haagmans, M. A., Mouchiroud, L., Koster, J., Ofman, R., Baas, F., Waterham, H. R., Spelbrink, J. N., Auwerx, J., Mannens, M. M., Houtkooper, R. H., and Plomp, A. S. (2017) A homozygous missense mutation in ERAL1, encoding a mitochondrial rRNA chaperone, causes Perrault syndrome. Hum Mol Genet 26, 2541-2550"	"DISEASE: Perrault syndrome 6 (PRLTS6) [MIM:617565]: A form of Perrault syndrome, a sex-influenced disorder characterized by sensorineural deafness in both males and females, and ovarian dysgenesis in females. Affected females have primary amenorrhea, streak gonads, and infertility, whereas affected males show normal pubertal development and are fertile. PRLTS6 inheritance is autosomal recessive. {ECO:0000269|PubMed:28449065}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0036875;C0685838;C4479656	607435	617565	41.07726559	NaN	Class 1	-1.79949636	7.95466E-05	156789.8097	177492.6667	Peripheral	13.4734464	88.07827601
H0YKF0;H0YLU7;P13804	ETFA	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Muscular system;Kidney and urinary tract"	Other known processes	1				1		"DISEASE: Glutaric aciduria 2A (GA2A) [MIM:231680]: An autosomal recessively inherited disorder of fatty acid, amino acid, and choline metabolism. It is characterized by multiple acyl-CoA dehydrogenase deficiencies resulting in large excretion not only of glutaric acid, but also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-butyric, and isovaleric acids. {ECO:0000269|PubMed:12815589, ECO:0000269|PubMed:1430199, ECO:0000269|PubMed:1882842, ECO:0000269|PubMed:9334218}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0029408;C0035410;C0086743;C0220994;C0268596;C1856401;C1856403;C1856405;C2239176;C3278154;C3278155;C3278156;C3714756	608053	231680	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P38117	ETFB	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Muscular system;Kidney and urinary tract"	Fatty acid _-oxidation 	1				1		"DISEASE: Glutaric aciduria 2B (GA2B) [MIM:231680]: An autosomal recessively inherited disorder of fatty acid, amino acid, and choline metabolism. It is characterized by multiple acyl-CoA dehydrogenase deficiencies resulting in large excretion not only of glutaric acid, but also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-butyric, and isovaleric acids. {ECO:0000269|PubMed:12815589, ECO:0000269|PubMed:7912128}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0035410;C0220994;C0268596;C1856401;C1856403;C1856405;C3278154;C3278155;C3278156;C3714756	130410	231680	109.2107686	360.8243523	Class 1	-2.052195271	4.80293E-05	2796936.909	2917953.333	Soluble	3.389929466	22.26054182
Q16134	ETFDH	Central nervous system;Metabolism;Cardiovascular system;Pulmonary system ;Muscular system;Liver;Gastrointestinal system	Fatty acid _-oxidation 	1				1		"DISEASE: Glutaric aciduria 2C (GA2C) [MIM:231680]: An autosomal recessively inherited disorder of fatty acid, amino acid, and choline metabolism. It is characterized by multiple acyl-CoA dehydrogenase deficiencies resulting in large excretion not only of glutaric acid, but also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-butyric, and isovaleric acids. {ECO:0000269|PubMed:12359134, ECO:0000269|PubMed:12815589, ECO:0000269|PubMed:16527485, ECO:0000269|PubMed:17412732, ECO:0000269|PubMed:19249206, ECO:0000269|PubMed:20370797}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0023520;C0025517;C0028754;C0035410;C0220994;C0268596;C0751651;C1527249;C1856401;C1856403;C1856405;C3278154;C3278155;C3278156;C3714756	231675	231680	210.970685	163.8506433	Class 1	-2.305522165	0.000127693	121535.3611	141852.3333	Integral	86.04657271	87.11038121
O95571	ETHE1	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Gastrointestinal system;Hematologic system"	Other known processes	1				1	"Tiranti, V., D'Adamo, P., Briem, E., Ferrari, G., Mineri, R., Lamantea, E., Mandel, H., Balestri, P., Garcia-Silva, M. T., Vollmer, B., Rinaldo, P., Hahn, S. H., Leonard, J., Rahman, S., Dionisi-Vici, C., Garavaglia, B., Gasparini, P., and Zeviani, M. (2004) Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am. J. Hum. Genet. 74, 239-252"	"DISEASE: Ethylmalonic encephalopathy (EE) [MIM:602473]: Autosomal recessive disorder characterized by neurodevelopmental delay and regression, recurrent petechiae, acrocyanosis, diarrhea, leading to death in the first decade of life. It is also associated with persistent lactic acidemia and ethylmalonic and methylsuccinic aciduria. {ECO:0000269|PubMed:14732903, ECO:0000269|PubMed:18593870, ECO:0000269|PubMed:23144459}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C1865349;C3714756	608451	602473	607.3961885	NaN	Class 1	-2.388464165	4.7338E-05	93057.78958	63257.2	Peripheral	7.49807599	91.70304176
Q96C01	FAM136A	Central nervous system;Ears	Unknown	1				1	"Requena T, Cabrera S, Martín-Sierra C, Price SD, Lysakowski A, Lopez-Escamez JA. Identification of two novel mutations in FAM136A and DTNA genes in autosomal-dominant familial Meniere's disease. Hum Mol Genet. 2015 Feb 15;24(4):1119-26."			616275		99.62643407	NaN	Class 4	-0.065169422	0.05920063	391630.2785	464735	Peripheral	4.069567945	85.9485446
O95363	FARS2	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Ears;Liver;Hematologic system"	tRNA related processes	1				1	"Elo, J. M., Yadavalli, S. S., Euro, L., Isohanni, P., Gotz, A., Carroll, C. J., Valanne, L., Alkuraya, F. S., Uusimaa, J., Paetau, A., Caruso, E. M., Pihko, H., Ibba, M., Tyynismaa, H., and Suomalainen, A. (2012) Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy. Hum Mol Genet 21, 4521-4529"	"DISEASE: Combined oxidative phosphorylation deficiency 14 (COXPD14) [MIM:614946]: A severe multisystemic autosomal recessive disorder characterized by neonatal onset of global developmental delay, refractory seizures, and lactic acidosis. Biochemical studies show deficiencies of multiple mitochondrial respiratory enzymes. {ECO:0000269|PubMed:22499341, ECO:0000269|PubMed:22833457}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spastic paraplegia 77, autosomal recessive (SPG77) [MIM:617046]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. {ECO:0000269|PubMed:26553276}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C3554168;C4310750	611592	614946-617046	71.76377714	67.95287935	Class 1	-1.697476114	0.000108514	41083.08648	52528.03333	Peripheral	10.64572427	91.98594385
Q9NYY8	FASTKD2	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Skeletal system;Others"	Ribosome assembly & translation	1				1	"Ghezzi, D., Saada, A., D'Adamo, P., Fernandez-Vizarra, E., Gasparini, P., Tiranti, V., Elpeleg, O., and Zeviani, M. (2008) FASTKD2 nonsense mutation in an infantile mitochondrial encephalomyopathy associated with cytochrome c oxidase deficiency. Am. J. Hum. Genet. 83, 415-423"		C0268237;C0543888;C0751651	612322	220110	40.91009727	29.35203384	Class 1	-2.240430442	3.22552E-05	111721.8152	88649.7	Peripheral	27.43005131	94.76395109
Q9UKA2	FBXL4	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Muscular system;Gastrointestinal system;Kidney and urinary tract"	Protein degradation & quality control	1				1	"Bonnen, P. E., Yarham, J. W., Besse, A., Wu, P., Faqeih, E. A., Al-Asmari, A. M., Saleh, M. A., Eyaid, W., Hadeel, A., He, L., Smith, F., Yau, S., Simcox, E. M., Miwa, S., Donti, T., Abu-Amero, K. K., Wong, L. J., Craigen, W. J., Graham, B. H., Scott, K. L., McFarland, R., and Taylor, R. W. (2013) Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. Am. J. Hum. Genet. 93, 471-481;Gai, X., Ghezzi, D., Johnson, M. A., Biagosch, C. A., Shamseldin, H. E., Haack, T. B., Reyes, A., Tsukikawa, M., Sheldon, C. A., Srinivasan, S., Gorza, M., Kremer, L. S., Wieland, T., Strom, T. M., Polyak, E., Place, E., Consugar, M., Ostrovsky, J., Vidoni, S., Robinson, A. J., Wong, L. J., Sondheimer, N., Salih, M. A., Al-Jishi, E., Raab, C. P., Bean, C., Furlan, F., Parini, R., Lamperti, C., Mayr, J. A., Konstantopoulou, V., Huemer, M., Pierce, E. A., Meitinger, T., Freisinger, P., Sperl, W., Prokisch, H., Alkuraya, F. S., Falk, M. J., and Zeviani, M. (2013) Mutations in FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy. Am. J. Hum. Genet. 93, 482-495"	"DISEASE: Mitochondrial DNA depletion syndrome 13 (MTDPS13) [MIM:615471]: An autosomal recessive disorder characterized by early infantile onset of encephalopathy, hypotonia, lactic acidosis, and severe global developmental delay. Cells derived from patient tissues show defects in mitochondrial oxidative phosphorylation and decreased mtDNA content. {ECO:0000269|PubMed:23993193, ECO:0000269|PubMed:23993194, ECO:0000269|PubMed:27182039}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C3714756;C3809592	605654	615471	NaN	72.91554633	Class 1	-1.071516277	0.000637533	3702.550093	10647.43667	Ambiguous	81.4775477	78.17041014
Q6P4F2	FDX2	Metabolism;Muscular system	Fe-S protein biogenesis	1				1	"Spiegel, R., Saada, A., Halvardson, J., Soiferman, D., Shaag, A., Edvardson, S., Horovitz, Y., Khayat, M., Shalev, S. A., Feuk, L., and Elpeleg, O. (2014) Deleterious mutation in FDX1L gene is associated with a novel mitochondrial muscle myopathy. Eur J Hum Genet 22, 902-906"		C0751651	614585	251900	NaN	NaN	Class 1	-2.961920677	0.00036273	70802.3223	63715	Soluble	2.656530083	28.66496907
P22570;P22570	FDXR	Ophthalmic system;Ears	Fe-S protein biogenesis	1				1	"Paul, A., Drecourt, A., Petit, F., Deguine, D. D., Vasnier, C., Oufadem, M., Masson, C., Bonnet, C., Masmoudi, S., Mosnier, I., Mahieu, L., Bouccara, D., Kaplan, J., Challe, G., Domange, C., Mochel, F., Sterkers, O., Gerber, S., Nitschke, P., Bole-Feysot, C., Jonard, L., Gherbi, S., Mercati, O., Ben Aissa, I., Lyonnet, S., Rotig, A., Delahodde, A., and Marlin, S. (2017) FDXR Mutations Cause Sensorial Neuropathies and Expand the Spectrum of Mitochondrial Fe-S-Synthesis Diseases. Am. J. Hum. Genet. 101, 630-637;Peng, Y., Shinde, D. N., Valencia, A. C., Mo, J. S., Rosenfeld, J., Truitt Cho, M., Chamberlin, A., Li, Z., Liu, J., Gui, B., Brockhage, R., Basinger, A., Alvarez-Leon, B., Heydemann, P., Magoulas, P. L., Lewis, A. M., Scaglia, F., Gril, S., Chong, S. C., Bower, M., Monaghan, K. G., Willaert, R., Plona, M. R., Dineen, R., Milan, F., Hoganson, G., Powis, Z., Helbig, K. L., Keller-Ramey, J., Harris, B., Anderson, L. C., Green, T., Sukoff Rizzo, S. J., Kaylor, J., Chen, J., Guan, M. X., Sellars, E., Sparagana, S. P., Gibson, J. B., Reinholdt, L. G., Tang, S., and Huang, T. (Oct 5, 2017) Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy. Hum Mol Genet 10.1093/hmg/ddx377"	"DISEASE: Auditory neuropathy and optic atrophy (ANOA) [MIM:617717]: An autosomal recessive disease characterized by hearing loss, visual impairment and optic atrophy, with onset in the first or second decades of life. Optic atrophy is caused by degeneration of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts. {ECO:0000269|PubMed:28965846}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0025958;C0751651;C3714756;C4521678	103270	617717	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P22830	FECH	Metabolism;Liver;Gastrointestinal system;Hematologic system;Integumentary system	Cofactor metabolism	1				1		"DISEASE: Protoporphyria, erythropoietic, 1 (EPP1) [MIM:177000]: An autosomal recessive form of porphyria with onset usually before age 10 years. Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. Erythropoietic protoporphyria is marked by excessive protoporphyrin in erythrocytes, plasma, liver and feces, and by widely varying photosensitive skin changes ranging from a burning or pruritic sensation to erythema, edema and wheals. {ECO:0000269|PubMed:10942404, ECO:0000269|PubMed:11375302, ECO:0000269|PubMed:12063482, ECO:0000269|PubMed:12601550, ECO:0000269|PubMed:1376018, ECO:0000269|PubMed:15286165, ECO:0000269|PubMed:17196862, ECO:0000269|PubMed:1755842, ECO:0000269|PubMed:7910885, ECO:0000269|PubMed:8757534, ECO:0000269|PubMed:9211198, ECO:0000269|PubMed:9585598, ECO:0000269|PubMed:9740232}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0005395;C0016059;C0162568;C0349426;C1623038	612386	177000	36.58061937	NaN	Class 1	-1.436603823	0.000318776	220559.8382	179349.3333	Peripheral	9.718497398	95.21998151
P07954	FH	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Liver;Tumors"	TCA cycle	1				1	"Bourgeron, T., Chretien, D., Poggi-Bach, J., Doonan, S., Rabier, D., Letouze, P., Munnich, A., Rotig, A., Landrieu, P., and Rustin, P. (1994) Mutation of the fumarase gene in two siblings with progressive encephalopathy and fumarase deficiency.  J Clin Invest  93, 2514-2518"	"DISEASE: Fumarase deficiency (FMRD) [MIM:606812]: A severe autosomal recessive metabolic disorder characterized by early-onset hypotonia, profound psychomotor retardation, and brain abnormalities, such as agenesis of the corpus callosum, gyral defects, and ventriculomegaly. Many patients show neonatal distress, metabolic acidosis, and/or encephalopathy. {ECO:0000269|PubMed:9635293, ECO:0000269|Ref.17}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Hereditary leiomyomatosis and renal cell cancer (HLRCC) [MIM:150800]: A disorder characterized by predisposition to cutaneous and uterine leiomyomas, and papillary type 2 renal cancer which occurs in about 20% of patients. {ECO:0000269|PubMed:11865300}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006826;C0020305;C0022665;C0154040;C0154045;C0206695;C0342770;C0344456;C0438413;C0476089;C0543888;C0740457;C0751651;C1378703;C1708350;C2936826;C3714756	136850	606812-150800	172.5247094	210.1591328	Class 1	-0.919376816	0.001269944	444937.0306	545044.3333	Soluble	6.893601608	24.5095501
Q8NFF5;Q8NFF5	FLAD1	Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system	Cofactor metabolism	1				1	"Taylor, R. W., Pyle, A., Griffin, H., Blakely, E. L., Duff, J., He, L., Smertenko, T., Alston, C. L., Neeve, V. C., Best, A., Yarham, J. W., Kirschner, J., Schara, U., Talim, B., Topaloglu, H., Baric, I., Holinski-Feder, E., Abicht, A., Czermin, B., Kleinle, S., Morris, A. A., Vassallo, G., Gorman, G. S., Ramesh, V., Turnbull, D. M., Santibanez-Koref, M., McFarland, R., Horvath, R., and Chinnery, P. F. (2014) Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. JAMA 312, 68-77"	"DISEASE: Lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency (LSMFLAD) [MIM:255100]: An autosomal recessive, inborn error of metabolism characterized by variable mitochondrial dysfunction. Clinical features range from severe cardiac and respiratory insufficiency with onset in infancy and resulting in early death, to mild muscle weakness with onset in adulthood. Some patients show significant improvement with riboflavin treatment. Analysis of skeletal muscle show multiple mitochondrial respiratory chain deficiency and a lipid storage myopathy in most patients. {ECO:0000269|PubMed:27259049}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0410214;C0751651;C3714756;C4310822	610595	255100	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q96CU9	FOXRED1	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Muscular system"	OXPHOS assembly & stability	1				1	"Calvo, S. E., Tucker, E. J., Compton, A. G., Kirby, D. M., Crawford, G., Burtt, N. P., Rivas, M., Guiducci, C., Bruno, D. L., Goldberger, O. A., Redman, M. C., Wiltshire, E., Wilson, C. J., Altshuler, D., Gabriel, S. B., Daly, M. J., Thorburn, D. R., and Mootha, V. K. (2010) High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency. Nat Genet 42, 851-858"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:20818383, ECO:0000269|PubMed:20858599, ECO:0000269|PubMed:25678554}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007194;C0023264;C0162666;C0543888;C0751267;C0751268;C0751651;C0949855;C0949856;C0949857;C1838979;C2936907;C3714756	613622	618241	95.07937193	84.27727376	Class 1	-1.889076952	4.44502E-05	60943.0412	36508.36667	Peripheral	27.46541744	93.77779862
Q16595	FXN	Central nervous system;Ophthalmic system;Cardiovascular system;Peripheral nervous system;Skeletal system	Fe-S protein biogenesis	1				1	"Rotig, A., de Lonlay, P., Chretien, D., Foury, F., Koenig, M., Sidi, D., Munnich, A., and Rustin, P. (1997) Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17, 215-217"	"DISEASE: Friedreich ataxia (FRDA) [MIM:229300]: Autosomal recessive, progressive degenerative disease characterized by neurodegeneration and cardiomyopathy it is the most common inherited ataxia. The disorder is usually manifest before adolescence and is generally characterized by incoordination of limb movements, dysarthria, nystagmus, diminished or absent tendon reflexes, Babinski sign, impairment of position and vibratory senses, scoliosis, pes cavus, and hammer toe. In most patients, FRDA is due to GAA triplet repeat expansions in the first intron of the frataxin gene. But in some cases the disease is due to mutations in the coding region. {ECO:0000269|PubMed:10732799, ECO:0000269|PubMed:10874325, ECO:0000269|PubMed:19629184, ECO:0000269|PubMed:9150176, ECO:0000269|PubMed:9779809, ECO:0000269|PubMed:9989622, ECO:0000269|Ref.36, ECO:0000269|Ref.7, ECO:0000269|Ref.8}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0007194;C0007959;C0016719;C0751651;C1847416;C1856689;C3714756	606829	229300-229300	230.5909438	NaN	Class 1	-1.234534821	0.000635644	337700.9533	261227.3333	Soluble	5.600076158	8.591049803
P41250	GARS	Peripheral nervous system;Skeletal system	tRNA related processes	1				1	"McMillan, H. J., Schwartzentruber, J., Smith, A., Lee, S., Chakraborty, P., Bulman, D. E., Beaulieu, C. L., Majewski, J., Boycott, K. M., and Geraghty, M. T. (2014) Compound heterozygous mutations in glycyl-tRNA synthetase are a proposed cause of systemic mitochondrial disease. BMC Med Genet 15, 36;Taylor, R. W., Pyle, A., Griffin, H., Blakely, E. L., Duff, J., He, L., Smertenko, T., Alston, C. L., Neeve, V. C., Best, A., Yarham, J. W., Kirschner, J., Schara, U., Talim, B., Topaloglu, H., Baric, I., Holinski-Feder, E., Abicht, A., Czermin, B., Kleinle, S., Morris, A. A., Vassallo, G., Gorman, G. S., Ramesh, V., Turnbull, D. M., Santibanez-Koref, M., McFarland, R., Horvath, R., and Chinnery, P. F. (2014) Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. JAMA 312, 68-77"	"DISEASE: Charcot-Marie-Tooth disease 2D (CMT2D) [MIM:601472]: A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. {ECO:0000269|PubMed:12690580, ECO:0000269|PubMed:17035524, ECO:0000269|PubMed:17101916, ECO:0000269|PubMed:17663003, ECO:0000269|PubMed:20169446, ECO:0000269|PubMed:24604904, ECO:0000269|PubMed:25168514, ECO:0000269|PubMed:26244500, ECO:0000269|PubMed:26503042}. Note=The disease is caused by mutations affecting the gene represented in this entry. Contrary to the wild-type protein, CMT2D variants Gly-125 and Arg-294 strongly interact with NRP1. This interaction may compete out VEGFA binding and inhibits VEGFA-NRP1 signling which is essential for motor neuron survival, as suggested by experiments done in a mouse model. {ECO:0000269|PubMed:26503042}.;DISEASE: Neuronopathy, distal hereditary motor, 5A (HMN5A) [MIM:600794]: A disorder characterized by distal muscular atrophy mainly affecting the upper extremities, in contrast to other distal motor neuronopathies. These constitute a heterogeneous group of neuromuscular diseases caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. {ECO:0000269|PubMed:12690580, ECO:0000269|PubMed:17035524, ECO:0000269|PubMed:23279345, ECO:0000269|PubMed:24627108, ECO:0000269|PubMed:26503042}. Note=The disease is caused by mutations affecting the gene represented in this entry. Contrary to the wild-type protein, HMN5A variant Pro-183 strongly interacts with NRP1. This interaction may compete out VEGFA binding and inhibits VEGFA-NRP1 signling which is essential for motor neuron survival, as suggested by experiments done in a mouse model. {ECO:0000269|PubMed:26503042}."	C0003886;C0007959;C0751651;C1832274;C1833308	600287	601472-600794	156.1942724	141.5123945	Class 1	-1.669986963	1.62645E-05	63179.57758	759401	Peripheral	14.59082515	79.3998941
O75879	GATB	"Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Hematologic system"	tRNA related processes	1				1	"Friederich MW, Timal S, Powell CA, Dallabona C, Kurolap A, Palacios-Zambrano S, Bratkovic D, Derks TGJ, Bick D, Bouman K, Chatfield KC, Damouny-Naoum N, Dishop MK, Falik-Zaccai TC, Fares F, Fedida A, Ferrero I, Gallagher RC, Garesse R, Gilberti M, González C, Gowan K, Habib C, Halligan RK, Kalfon L, Knight K, Lefeber D, Mamblona L, Mandel H, Mory A, Ottoson J, Paperna T, Pruijn GJM, Rebelo-Guiomar PF, Saada A, Sainz B Jr, Salvemini H, Schoots MH, Smeitink JA, Szukszto MJ, Ter Horst HJ, van den Brandt F, van Spronsen FJ, Veltman JA, Wartchow E, Wintjes LT, Zohar Y, Fernández-Moreno MA, Baris HN, Donnini C, Minczuk M, Rodenburg RJ, Van Hove JLK. Pathogenic variants in glutamyl-tRNAGln amidotransferase subunits cause a lethal mitochondrial cardiomyopathy disorder. Nat Commun. 2018 Oct 3;9(1):4065."			603645	618838	41.39449369	NaN	Class 1	-1.209887908	0.000363187	68236.85934	45517.93333	Peripheral	21.13549668	83.19497033
O43716	GATC	Metabolism;Cardiovascular system;Muscular system;Liver;Hematologic system	tRNA related processes	1				1	"Friederich MW, Timal S, Powell CA, Dallabona C, Kurolap A, Palacios-Zambrano S, Bratkovic D, Derks TGJ, Bick D, Bouman K, Chatfield KC, Damouny-Naoum N, Dishop MK, Falik-Zaccai TC, Fares F, Fedida A, Ferrero I, Gallagher RC, Garesse R, Gilberti M, González C, Gowan K, Habib C, Halligan RK, Kalfon L, Knight K, Lefeber D, Mamblona L, Mandel H, Mory A, Ottoson J, Paperna T, Pruijn GJM, Rebelo-Guiomar PF, Saada A, Sainz B Jr, Salvemini H, Schoots MH, Smeitink JA, Szukszto MJ, Ter Horst HJ, van den Brandt F, van Spronsen FJ, Veltman JA, Wartchow E, Wintjes LT, Zohar Y, Fernández-Moreno MA, Baris HN, Donnini C, Minczuk M, Rodenburg RJ, Van Hove JLK. Pathogenic variants in glutamyl-tRNAGln amidotransferase subunits cause a lethal mitochondrial cardiomyopathy disorder. Nat Commun. 2018 Oct 3;9(1):4065."			617210	618839	NaN	94.35653559	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
P50440	GATM	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Muscular system;Skeletal system"	Carbohydrate & energy metabolism	1				1		"DISEASE: Cerebral creatine deficiency syndrome 3 (CCDS3) [MIM:612718]: An autosomal recessive disorder characterized by developmental delay/regression, mental retardation, severe disturbance of expressive and cognitive speech, and severe depletion of creatine/phosphocreatine in the brain. Most patients develop a myopathy characterized by muscle weakness and atrophy later in life. {ECO:0000269|PubMed:11555793, ECO:0000269|PubMed:20682460, ECO:0000269|PubMed:22386973, ECO:0000269|PubMed:23660394, ECO:0000269|PubMed:23770102, ECO:0000269|PubMed:26490222, ECO:0000269|PubMed:27233232}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007097;C0018801;C0018802;C0022658;C0023212;C0024667;C0024668;C0027540;C0151744;C0205696;C0205697;C0205698;C0205699;C0235527;C0543888;C0751651;C1257925;C1959583;C1961112;C2675179;C3714756	602360	612718	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q92947	GCDH	Central nervous system;Metabolism	Fatty acid _-oxidation 	1				1		"DISEASE: Glutaric aciduria 1 (GA1) [MIM:231670]: An autosomal recessive metabolic disorder characterized by progressive dystonia and athetosis due to gliosis and neuronal loss in the basal ganglia. {ECO:0000269|PubMed:14707522, ECO:0000269|PubMed:18775954, ECO:0000269|PubMed:24973495, ECO:0000269|PubMed:8541831, ECO:0000269|PubMed:8900227, ECO:0000269|PubMed:8900228, ECO:0000269|PubMed:9600243}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0268595;C3714756	608801	231670	141.415519	168.6488529	Class 1	-1.289247042	0.000283939	175046.0633	111018.2	Soluble	12.91421872	25.99362058
Q8TB36	GDAP1	Central nervous system;Peripheral nervous system;Skeletal system	"Morphology, dynamics & organization"	1				1	"Baxter, R. V., Ben Othmane, K., Rochelle, J. M., Stajich, J. E., Hulette, C., Dew-Knight, S., Hentati, F., Ben Hamida, M., Bel, S., Stenger, J. E., Gilbert, J. R., Pericak-Vance, M. A., and Vance, J. M. (2002) Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet 30, 21-22;Cuesta, A., Pedrola, L., Sevilla, T., Garcia-Planells, J., Chumillas, M. J., Mayordomo, F., LeGuern, E., Marin, I., Vilchez, J. J., and Palau, F. (2002) The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet 30, 22-25"	"DISEASE: Charcot-Marie-Tooth disease 2K (CMT2K) [MIM:607831]: An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Charcot-Marie-Tooth disease type 2K onset is in early childhood (younger than 3 years). This phenotype is characterized by foot deformities, kyphoscoliosis, distal limb muscle weakness and atrophy, areflexia, and diminished sensation in the lower limbs. Weakness in the upper limbs is observed in the first decade, with clawing of the fingers. Inheritance can be autosomal dominant or recessive. {ECO:0000269|PubMed:15772096, ECO:0000269|PubMed:20685671, ECO:0000269|PubMed:22206013, ECO:0000269|PubMed:26525999, ECO:0000269|PubMed:28244113}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Charcot-Marie-Tooth disease 4A (CMT4A) [MIM:214400]: A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4. CMT4A is a severe form characterized by early age of onset and rapid progression leading to inability to walk in late childhood or adolescence. {ECO:0000269|PubMed:11743579, ECO:0000269|PubMed:12601710, ECO:0000269|PubMed:15772096, ECO:0000269|PubMed:16172208}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, autosomal recessive (CMT2RV) [MIM:607706]: A form of Charcot-Marie-Tooth disease characterized by the association of axonal neuropathy with vocal cord paresis. Charcot-Marie-Tooth disease is a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. {ECO:0000269|PubMed:12868504, ECO:0000269|PubMed:16172208}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Charcot-Marie-Tooth disease, recessive, intermediate type, A (CMTRIA) [MIM:608340]: A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Recessive intermediate forms of Charcot-Marie-Tooth disease are characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. {ECO:0000269|PubMed:12499475, ECO:0000269|PubMed:12566285, ECO:0000269|PubMed:15772096, ECO:0000269|PubMed:16172208}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0007959;C0751651;C1842197;C1842983;C1842984;C1843173;C1843183;C1859198;C3714756	606598	607831-607706-608340-214400	98.6023051	923.8093221	Class 1	-0.961393389	0.00181411	72741.08888	46093.73333	Integral	92.84757918	93.72631857
Q96RP9	GFM1	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Liver;Gastrointestinal system"	Ribosome assembly & translation	1				1	"Coenen, M. J., Antonicka, H., Ugalde, C., Sasarman, F., Rossi, R., Heister, J. G., Newbold, R. F., Trijbels, F. J., van den Heuvel, L. P., Shoubridge, E. A., and Smeitink, J. A. (2004) Mutant mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency. N Engl J Med 351, 2080-2086"	"DISEASE: Combined oxidative phosphorylation deficiency 1 (COXPD1) [MIM:609060]: A mitochondrial disease resulting in early rapidly progressive hepatoencephalopathy. {ECO:0000269|PubMed:15537906, ECO:0000269|PubMed:17160893, ECO:0000269|PubMed:21119709, ECO:0000269|PubMed:26741492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C0543888;C0751651;C1836797;C3714756	606639	609060	48.20402822	NaN	Class 1	-1.180722579	0.000634034	251792.3486	243951.5	Peripheral	17.37690897	95.14940547
Q969S9;Q969S9	GFM2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system "	Ribosome assembly & translation	1				1	"Fukumura, S., Ohba, C., Watanabe, T., Minagawa, K., Shimura, M., Murayama, K., Ohtake, A., Saitsu, H., Matsumoto, N., and Tsutsumi, H. (2015) Compound heterozygous GFM2 mutations with Leigh syndrome complicated by arthrogryposis multiplex congenita. J Hum Genet 60, 509-513"		C0751651	606544	618397	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
H7C2A0;P32189;P32189;Q14409	GK;GK3P	Central nervous system;Metabolism;Gastrointestinal system;Skeletal system;Endocrine system	Other known processes	1				1		"DISEASE: Glycerol kinase deficiency (GKD) [MIM:307030]: A metabolic disorder manifesting as 3 clinically distinct forms: infantile, juvenile, and adult. The infantile form is the most severe and is associated with severe developmental delay and adrenal insufficiency. Patients with the adult form have no symptoms and are often detected fortuitously. GKD results in hyperglycerolemia, a condition characterized by the accumulation of glycerol in the blood and urine. {ECO:0000269|PubMed:10736265, ECO:0000269|PubMed:8651297, ECO:0000269|PubMed:9719371}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023893;C0151744;C0268418;C3714756	300474	307030	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P23378	GLDC	Central nervous system;Metabolism	Amino acid metabolism	1				1		"DISEASE: Non-ketotic hyperglycinemia (NKH) [MIM:605899]: Autosomal recessive disease characterized by accumulation of a large amount of glycine in body fluid and by severe neurological symptoms. {ECO:0000269|PubMed:11286506, ECO:0000269|PubMed:11592811, ECO:0000269|PubMed:1634607, ECO:0000269|PubMed:1996985, ECO:0000269|PubMed:28244183, ECO:0000269|PubMed:28737873}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0268560;C0268561;C0268562;C0543888;C0751747;C0751748;C3714756	238300	605899	NaN	62.03773583	Class 1	-1.199011853	0.000438512	59429.94835	46755.56667	Ambiguous	20.91868874	33.54835753
Q86SX6	GLRX5	Central nervous system;Metabolism;Ophthalmic system;Liver;Gastrointestinal system;Hematologic system;Others;Endocrine system	Fe-S protein biogenesis	1				1	"Camaschella, C., Campanella, A., De Falco, L., Boschetto, L., Merlini, R., Silvestri, L., Levi, S., and Iolascon, A. (2007) The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 110, 1353-1358, Ye, H., Jeong, S. Y., Ghosh, M. C., Kovtunovych, G., Silvestri, L., Ortillo, D., Uchida, N., Tisdale, J., Camaschella, C., and Rouault, T. A. (2010) Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest 120, 1749-1761"	"DISEASE: Anemia, sideroblastic, 3, pyridoxine-refractory (SIDBA3) [MIM:616860]: A form of sideroblastic anemia, a bone marrow disorder defined by the presence of pathologic iron deposits in erythroblast mitochondria. Sideroblastic anemia is characterized by anemia of varying severity, hypochromic peripheral erythrocytes, systemic iron overload secondary to chronic ineffective erythropoiesis, and the presence of bone marrow ringed sideroblasts. Sideroblasts are characterized by iron-loaded mitochondria clustered around the nucleus. SIDBA3 is refractory to treatment with vitamin B6, while iron chelation therapy may result in clinical improvement. SIDBA3 inheritance is autosomal recessive. {ECO:0000269|PubMed:17485548, ECO:0000269|PubMed:20364084, ECO:0000269|PubMed:25342667, ECO:0000269|PubMed:26100117}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spasticity, childhood-onset, with hyperglycinemia (SPAHGC) [MIM:616859]: An autosomal recessive disorder characterized by childhood-onset of spasticity, spinal lesions, leukodystrophy, optic atrophy in some patients, non-ketotic hyperglycinemia, and defective enzymatic glycine cleavage. Glycine levels in the cerebrospinal fluid are mildly increased in some but not all patients. The increase is less pronounced than in patients with classic non-ketotic hyperglycinemia. {ECO:0000269|PubMed:24334290}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002896;C0010828;C0158995;C0751651;C2673914;C4225155;C4225178	609588	616860-616859	78.95113558	126.8056989	Class 1	-1.903542965	0.000120551	1012048.367	1089820.667	Soluble	3.404158947	46.47284784
P00367	GLUD1	Central nervous system;Metabolism;Endocrine system	Amino acid metabolism	1				1		"DISEASE: Familial hyperinsulinemic hypoglycemia 6 (HHF6) [MIM:606762]: Familial hyperinsulinemic hypoglycemia [MIM:256450], also referred to as congenital hyperinsulinism, nesidioblastosis, or persistent hyperinsulinemic hypoglycemia of infancy (PPHI), is the most common cause of persistent hypoglycemia in infancy and is due to defective negative feedback regulation of insulin secretion by low glucose levels. In HHF6 elevated oxidation rate of glutamate to alpha-ketoglutarate stimulates insulin secretion in the pancreatic beta cells, while they impair detoxification of ammonium in the liver. {ECO:0000269|PubMed:10636977, ECO:0000269|PubMed:11214910, ECO:0000269|PubMed:11297618, ECO:0000269|PubMed:9571255}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0015934;C0020459;C0220994;C0543888;C0751651;C1257963;C1257964;C1257965;C1847555;C3714756	138130	606762	206.0218218	1086.632702	Class 3	-0.880620209	0.001274331	1981235.609	2474940	Ambiguous	14.94346737	18.73179462
Q8IVS8	GLYCTK	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system "	Carbohydrate & energy metabolism	1				1		"DISEASE: D-glyceric aciduria (D-GA) [MIM:220120]: A rare metabolic disease characterized by chronic metabolic acidosis and a highly variable clinical phenotype. Clinical features range from an encephalopathic presentation with seizures, microcephaly, severe mental retardation and early death, to milder manifestations with only speech delay or even normal development. {ECO:0000269|PubMed:20949620}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0342765;C0543888;C1291386;C3714756;C3887877	610516	220120	NaN	NaN	Class 4	-0.804999698	0.018071789	765.2727509	11440.6	0	NaN	NaN
P00505	GOT2	Central nervous system;Metabolism;Failure to thrive;Others	Amino acid metabolism	1				1	"van Karnebeek CDM, Ramos RJ, Wen XY, Tarailo-Graovac M, Gleeson JG, Skrypnyk C, Brand-Arzamendi K, Karbassi F, Issa MY, van der Lee R, Drögemöller BI, Koster J, Rousseau J, Campeau PM, Wang Y, Cao F, Li M, Ruiter J, Ciapaite J, Kluijtmans LAJ, Willemsen MAAP, Jans JJ, Ross CJ, Wintjes LT, Rodenburg RJ, Huigen MCDG, Jia Z, Waterham HR, Wasserman WW, Wanders RJA, Verhoeven-Duif NM, Zaki MS, Wevers RA. Bi-allelic GOT2 Mutations Cause a Treatable Malate-Aspartate Shuttle-Related Encephalopathy. Am J Hum Genet. 2019 Sep 5;105(3):534-548."			138150	618721	171.0934058	544.0020437	Class 1	-1.244975632	0.000833611	2521347.922	3483973.333	Peripheral	1.996245279	86.75123384
Q8TD30	GPT2	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive"	Amino acid metabolism	1				1		"DISEASE: Mental retardation, autosomal recessive 49 (MRT49) [MIM:616281]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT49 patients show a developmental encephalopathy characterized by rapid onset of failure to thrive and microcephaly, as well as profoundly delayed development. {ECO:0000269|PubMed:25758935}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C4225388	138210	616281	16.65541665	38.51831127	Class 1	-1.344642774	0.001237316	115268.5655	83474.56667	Peripheral	9.365142395	91.00019603
P36969	GPX4	Central nervous system;Cardiovascular system;Pulmonary system ;Skeletal system;Tumors	Oxidative stress response	1				1		"DISEASE: Spondylometaphyseal dysplasia, Sedaghatian type (SMDS) [MIM:250220]: A form of spondylometaphyseal dysplasia, a group of short stature disorders distinguished by abnormalities in the vertebrae and the metaphyses of the tubular bones. SMDS is a neonatal lethal form characterized by severe metaphyseal chondrodysplasia with mild limb shortening, platyspondyly, cardiac conduction defects, and central nervous system abnormalities. {ECO:0000269|PubMed:24706940}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006142;C0006635;C0009402;C0009404;C0010417;C0012684;C0015695;C0016059;C0018801;C0018802;C0021364;C0023212;C0235527;C0271650;C0431663;C0431664;C0678222;C0752351;C0848676;C0917731;C1136082;C1257931;C1458155;C1527249;C1563730;C1563731;C1623038;C1855229;C1959583;C1961112;C2711227;C4302111	138322	250220	232.5319947	NaN	Class 4	0.39995839	0.013249136	NaN	NaN	Peripheral	8.110329065	93.72479976
Q9UBQ7	GRHPR	Metabolism;Kidney and urinary tract	Other known processes	1				1		"DISEASE: Hyperoxaluria primary 2 (HP2) [MIM:260000]: A disorder characterized by elevated urinary excretion of oxalate and L-glycerate, progressive tissue accumulation of insoluble calcium oxalate, nephrolithiasis, nephrocalcinosis, and end-stage renal disease. {ECO:0000269|PubMed:10484776}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0033578;C0268165;C0282528;C0376358	604296	260000	286.1741054	450.3967521	Class 1	-2.885032756	0.000117522	131615.3407	533274.3333	Ambiguous	20.00078082	22.6131092
O43708	GSTZ1	Metabolism	Amino acid metabolism	1				1		"DISEASE: Maleylacetoacetate isomerase deficiency (MAAID) [MIM:617596]: An autosomal recessive inborn error of metabolism characterized by mild elevations in succinylacetone in blood and urine, usually identified by newborn screening. Liver function and coagulation are normal. MAAID is a benign disorder. {ECO:0000269|PubMed:27876694}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0005586;C0005684;C0005695;C0042594;C1291607	603758	617596	224.1084595	NaN	Class 1	-3.073734527	2.71961E-05	30510.42223	96279.75	0	NaN	57.07716842
Q969Y2	GTPBP3	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system	tRNA related processes	1				1	"Kopajtich, R., Nicholls, T. J., Rorbach, J., Metodiev, M. D., Freisinger, P., Mandel, H., Vanlander, A., Ghezzi, D., Carrozzo, R., Taylor, R. W., Marquard, K., Murayama, K., Wieland, T., Schwarzmayr, T., Mayr, J. A., Pearce, S. F., Powell, C. A., Saada, A., Ohtake, A., Invernizzi, F., Lamantea, E., Sommerville, E. W., Pyle, A., Chinnery, P. F., Crushell, E., Okazaki, Y., Kohda, M., Kishita, Y., Tokuzawa, Y., Assouline, Z., Rio, M., Feillet, F., Mousson de Camaret, B., Chretien, D., Munnich, A., Menten, B., Sante, T., Smet, J., Regal, L., Lorber, A., Khoury, A., Zeviani, M., Strom, T. M., Meitinger, T., Bertini, E. S., Van Coster, R., Klopstock, T., Rotig, A., Haack, T. B., Minczuk, M., and Prokisch, H. (2014) Mutations in GTPBP3 cause a mitochondrial translation defect associated with hypertrophic cardiomyopathy, lactic acidosis, and encephalopathy. Am. J. Hum. Genet.  95, 708-720"	"DISEASE: Combined oxidative phosphorylation deficiency 23 (COXPD23) [MIM:616198]: An autosomal recessive mitochondrial disorder characterized by hypertrophic cardiomyopathy and/or neurologic symptoms with onset in early childhood. Disease features include hypertrophic cardiomyopathy, hypotonia, delayed psychomotor development, lactic acidosis, impaired activities of respiratory complexes I and IV, and defective translation of mitochondrial proteins. Disease severity is variable, ranging from death in early infancy to survival into the second decade of life. {ECO:0000269|PubMed:25434004, ECO:0000269|PubMed:26741492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C3714756;C4015447	608536	616198	482.97071	267.3508986	Class 1	-2.594461619	2.49627E-05	93946.90942	70720.6	Peripheral	11.1834868	90.03232284
Q8N442	GUF1	Central nervous system	Ribosome assembly & translation	1				1		"DISEASE: Epileptic encephalopathy, early infantile, 40 (EIEE40) [MIM:617065]: A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. EIEE40 inheritance is autosomal recessive. {ECO:0000269|PubMed:26486472}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0037769;C4310737	617064	617065	167.0677527	79.09628843	Class 1	-1.848688949	0.000105207	49398.72805	26823.03333	Peripheral	22.64683322	93.46676096
Q16836	HADH	Metabolism;Liver;Endocrine system	Fatty acid _-oxidation 	1				1		"DISEASE: 3-alpha-hydroxyacyl-CoA dehydrogenase deficiency (HADH deficiency) [MIM:231530]: An autosomal recessive, metabolic disorder with various clinical presentations including hypoglycemia, hepatoencephalopathy, myopathy or cardiomyopathy, and in some cases sudden death. {ECO:0000269|Ref.13}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Familial hyperinsulinemic hypoglycemia 4 (HHF4) [MIM:609975]: Most common cause of persistent hypoglycemia in infancy. Unless early and aggressive intervention is undertaken, brain damage from recurrent episodes of hypoglycemia may occur. HHF4 should be easily recognizable by analysis of acylcarnitine species and that this disorder responds well to treatment with diazoxide. It provides the first 'experiment of nature' that links impaired fatty acid oxidation to hyperinsulinism and that provides support for the concept that a lipid signaling pathway is implicated in the control of insulin secretion. {ECO:0000269|PubMed:11489939}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0020459;C0028754;C0032927;C0282313;C1291230;C1864948;C3714756	601609	231530-609975	NaN	NaN	Class 1	-1.698766701	0.000346844	1218293.832	1589155	0	14.71849738	NaN
P40939	HADHA	Central nervous system;Metabolism;Cardiovascular system;Muscular system;Liver;Others	Fatty acid _-oxidation 	1				1		"DISEASE: Long-chain 3-hydroxyl-CoA dehydrogenase deficiency (LCHAD deficiency) [MIM:609016]: The clinical features are very similar to TFP deficiency. Biochemically, LCHAD deficiency is characterized by reduced long-chain 3-hydroxyl-CoA dehydrogenase activity, while the other enzyme activities of the TFP complex are normal or only slightly reduced. {ECO:0000269|PubMed:7811722, ECO:0000269|PubMed:9266371}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Maternal acute fatty liver of pregnancy (AFLP) [MIM:609016]: Severe maternal illness occurring during pregnancies with affected fetuses. This disease is associated with LCHAD deficiency and characterized by sudden unexplained infant death or hypoglycemia and abnormal liver enzymes (Reye-like syndrome). {ECO:0000269|PubMed:7846063}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial trifunctional protein deficiency (MTPD) [MIM:609015]: A disease biochemically characterized by loss of all enzyme activities of the mitochondrial trifunctional protein complex. Variable clinical manifestations include hypoglycemia, cardiomyopathy, delayed psychomotor development, sensorimotor axonopathy, generalized weakness, hepatic dysfunction, respiratory failure. Sudden infant death may occur. Most patients die from heart failure. {ECO:0000269|PubMed:9739053}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0007959;C0008370;C0019193;C0020305;C0029408;C0035410;C0086743;C0151744;C0220994;C0860207;C1112213;C1262760;C1455728;C1969443;C3658290;C3711645;C3714237;C3714756;C4277682;C4279912	600890	609016-609015	41.15936236	NaN	Class 1	-0.981206537	0.000784976	690610.691	668918	Peripheral	12.86548508	90.93261668
C9JE81;P55084	HADHB	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system ;Muscular system;Liver;Gastrointestinal system;Peripheral nervous system;Kidney and urinary tract;Endocrine system"	Fatty acid _-oxidation 	1				1		"DISEASE: Mitochondrial trifunctional protein deficiency (MTPD) [MIM:609015]: A disease biochemically characterized by loss of all enzyme activities of the mitochondrial trifunctional protein complex. Variable clinical manifestations include hypoglycemia, cardiomyopathy, delayed psychomotor development, sensorimotor axonopathy, generalized weakness, hepatic dysfunction, respiratory failure. Sudden infant death may occur. Most patients die from heart failure. {ECO:0000269|PubMed:12754706, ECO:0000269|PubMed:8651282, ECO:0000269|PubMed:9259266}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0006142;C0007959;C0015695;C0018799;C0035410;C0154251;C0220994;C0678222;C1257931;C1458155;C1969443;C2711227;C3711645;C3714237	143450	609015	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P49590	HARS2	"Congenital anomalies and dysmorphisms, intrauterine abnormalities;Ears;Reproductive system"	tRNA related processes	1				1	"Pierce, S. B., Chisholm, K. M., Lynch, E. D., Lee, M. K., Walsh, T., Opitz, J. M., Li, W., Klevit, R. E., and King, M. C. (2011) Mutations in mitochondrial histidyl tRNA synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome. Proc. Natl. Acad. Sci. U S A 108, 6543-6548"	"DISEASE: Perrault syndrome 2 (PRLTS2) [MIM:614926]: A sex-influenced disorder characterized by sensorineural deafness in both males and females and ovarian dysgenesis in females. Affected females have primary amenorrhea, streak gonads, and infertility, whereas affected males show normal pubertal development and are fertile. {ECO:0000269|PubMed:21464306}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0685838;C0751651;C3554105;C3714756	600783	614926	116.8613495	NaN	Class 1	-1.773066087	2.29396E-05	167506.3368	131872.7333	Peripheral	11.88866422	69.44165407
O00165;O00165	HAX1	Central nervous system;Ears;Peripheral nervous system;Hematologic system;Tumors	Regulation & signaling	1				1		"DISEASE: Neutropenia, severe congenital 3, autosomal recessive (SCN3) [MIM:610738]: A disorder of hematopoiesis characterized by maturation arrest of granulopoiesis at the level of promyelocytes with peripheral blood absolute neutrophil counts below 0.5 x 10(9)/l and early onset of severe bacterial infections. Some patients affected by severe congenital neutropenia type 3 have neurological manifestations such as psychomotor retardation and seizures. {ECO:0000269|PubMed:17187068, ECO:0000269|PubMed:18337561, ECO:0000269|PubMed:19796188, ECO:0000269|PubMed:20220065}. Note=The disease is caused by mutations affecting the gene represented in this entry. The clinical phenotype due to HAX1 deficiency appears to depend on the localization of the mutations and their influence on the transcript variants. Mutations affecting exclusively isoform 1 are associated with isolated congenital neutropenia, whereas mutations affecting both isoform 1 and isoform 5 are associated with additional neurologic symptoms (PubMed:18337561). {ECO:0000269|PubMed:18337561}."	C0010828;C0158995;C0340970;C0376545;C0543888;C1853118;C3714756	605998	610738	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P53701	HCCS	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Integumentary system"	Other known processes	1				1	"Wimplinger, I., Morleo, M., Rosenberger, G., Iaconis, D., Orth, U., Meinecke, P., Lerer, I., Ballabio, A., Gal, A., Franco, B., and Kutsche, K. (2006) Mutations of the mitochondrial holocytochrome c-type synthase in X-linked dominant microphthalmia with linear skin defects syndrome. Am. J. Hum. Genet.  79, 878-889"	"DISEASE: Linear skin defects with multiple congenital anomalies 1 (LSDMCA1) [MIM:309801]: A disorder characterized by dermal, ocular, neurological and cardiac abnormalities. LSDMCA1 main features are unilateral or bilateral microphthalmia, linear skin defects in affected females, and in utero lethality for males. Skin defects are limited to the face and neck, consisting of areas of aplastic skin that heal with age to form hyperpigmented areas. Additional features in female patients include agenesis of the corpus callosum, sclerocornea, chorioretinal abnormalities, infantile seizures, congenital heart defect, mental retardation, and diaphragmatic hernia. Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities. {ECO:0000269|PubMed:17033964}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0009363;C0086543;C0543888;C0751651;C0796070;C3714756	300056	309801	77.61648532	95.3245584	Class 1	-1.303032451	0.000286726	126973.9618	135125.5	Integral	92.15142955	94.73106673
P55789	HERV1	Central nervous system;Ophthalmic system;Muscular system;Ears	Fe-S protein biogenesis	1				1	"Di Fonzo, A., Ronchi, D., Lodi, T., Fassone, E., Tigano, M., Lamperti, C., Corti, S., Bordoni, A., Fortunato, F., Nizzardo, M., Napoli, L., Donadoni, C., Salani, S., Saladino, F., Moggio, M., Bresolin, N., Ferrero, I., and Comi, G. P. (2009) The mitochondrial disulfide relay system protein GFER is mutated in autosomal-recessive myopathy with cataract and combined respiratory-chain deficiency. Am. J. Hum. Genet. 84, 594-604"	"DISEASE: Myopathy, mitochondrial progressive, with congenital cataract, hearing loss and developmental delay (MPMCHD) [MIM:613076]: A disease characterized by progressive myopathy and partial combined respiratory-chain deficiency, congenital cataract, sensorineural hearing loss, and developmental delay. {ECO:0000269|PubMed:19409522, ECO:0000269|PubMed:20593814}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0022660;C0086543;C0162557;C0270960;C0392622;C0751651;C1565662;C2609414;C2751320;C3714756	600924	613076	162.8491393	NaN	Class 1	-2.338909723	0.000834812	57408.59136	42140	Soluble	11.83063107	19.00433267
B9A058;Q6NVY1	HIBCH	Central nervous system;Metabolism;Ophthalmic system;Gastrointestinal system;Reproductive system	Fatty acid _-oxidation 	1				1	"Ferdinandusse, S., Waterham, H. R., Heales, S. J., Brown, G. K., Hargreaves, I. P., Taanman, J. W., Gunny, R., Abulhoul, L., Wanders, R. J., Clayton, P. T., Leonard, J. V., and Rahman, S. (2013) HIBCH mutations can cause Leigh-like disease with combined deficiency of multiple mitochondrial respiratory chain enzymes and pyruvate dehydrogenase. Orphanet J Rare Dis 8, 188"	"DISEASE: 3-hydroxyisobutryl-CoA hydrolase deficiency (HIBCHD) [MIM:250620]: An autosomal recessive inborn error of valine metabolism. It causes severely delayed psychomotor development, neurodegeneration, increased lactic acid, and brain lesions in the basal ganglia. {ECO:0000269|PubMed:17160907}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0029408;C0086743;C0342738;C0751651;C3714756	610690	250620	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
B1AR63;P19367	HK1	Metabolism;Ophthalmic system;Liver;Peripheral nervous system;Skeletal system;Hematologic system;Others	Carbohydrate & energy metabolism	1				1		"DISEASE: Hexokinase deficiency (HK deficiency) [MIM:235700]: Rare autosomal recessive disease with nonspherocytic hemolytic anemia as the predominant clinical feature. {ECO:0000269|PubMed:12393545, ECO:0000269|PubMed:7655856}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Neuropathy, hereditary motor and sensory, Russe type (HMSNR) [MIM:605285]: An autosomal recessive progressive complex peripheral neuropathy characterized by onset in the first decade of distal lower limb weakness and muscle atrophy resulting in walking difficulties. Distal impairment of the upper limbs usually occurs later, as does proximal lower limb weakness. There is distal sensory impairment, with pes cavus and areflexia. Laboratory studies suggest that it is a myelinopathy resulting in reduced nerve conduction velocities in the demyelinating range as well as a length-dependent axonopathy. {ECO:0000269|PubMed:19536174}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Retinitis pigmentosa 79 (RP79) [MIM:617460]: A form of retinitis pigmentosa, a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP79 inheritance is autosomal dominant. {ECO:0000269|PubMed:25190649, ECO:0000269|PubMed:25316723}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002152;C0007959;C0010828;C0011853;C0011860;C0036341;C0038433;C0151744;C0152013;C0158995;C1854449;C3150343;C3714756;C4479526	142600	235700-605285-617460	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P35914	HMGCL	Central nervous system;Metabolism;Liver;Gastrointestinal system	Carbohydrate & energy metabolism	1				1		"DISEASE: 3-hydroxy-3-methylglutaryl-CoA lyase deficiency (HMGCLD) [MIM:246450]: An autosomal recessive disease affecting ketogenesis and L-leucine catabolism. The disease usually appears in the first year of life after a fasting period and its clinical acute symptoms include vomiting, seizures, metabolic acidosis, hypoketotic hypoglycemia and lethargy. These symptoms sometimes progress to coma, with fatal outcome in some cases. {ECO:0000269|PubMed:11129331, ECO:0000269|PubMed:12746442, ECO:0000269|PubMed:16601870, ECO:0000269|PubMed:17173698, ECO:0000269|PubMed:17459752, ECO:0000269|PubMed:19036343, ECO:0000269|PubMed:19177531, ECO:0000269|PubMed:8798725, ECO:0000269|PubMed:9463337, ECO:0000269|PubMed:9784232}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0268601;C0543888;C0751651;C1533587;C3714756	613898	246450	136.7210051	138.472845	Class 1	-0.979767834	0.005476253	184103.2497	178019	Peripheral	5.16355211	77.65713781
P54868	HMGCS2	Central nervous system;Metabolism;Liver;Gastrointestinal system	Lipid metabolism	1				1		"DISEASE: 3-hydroxy-3-methylglutaryl-CoA synthase-2 deficiency (HMGCS2D) [MIM:605911]: A metabolic disorder characterized by severe hypoketotic hypoglycemia, encephalopathy, and hepatomegaly. {ECO:0000269|PubMed:11228257, ECO:0000269|PubMed:11479731, ECO:0000269|PubMed:12647205}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007102;C0009375;C0026640;C0027626;C0151744;C0153381;C0220994;C2751532;C3714756	600234	605911	NaN	64.37832239	NaN	NaN	NaN	0	0	0	0	0
Q86XE5	HOGA1	Metabolism;Kidney and urinary tract	Amino acid metabolism	1				1		"DISEASE: Hyperoxaluria primary 3 (HP3) [MIM:613616]: A disorder phenotypically similar to hyperoxaluria type 1 and type 2. It is characterized by increase in urinary oxalate excretion and mild glycolic aciduria. Clinical manifestations include calcium oxalate urolithiasis, hematuria, pain, and/or urinary tract infection. {ECO:0000269|PubMed:20797690}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0008370;C0282528;C3150878	613597	613616	NaN	NaN	NaN	NaN	NaN	304.049627	NaN	0	NaN	NaN
Q96IR7	HPDL	Central nervous system;Metabolism;Ophthalmic system;Pulmonary system ;Muscular system	Unknown	1				1	"Husain RA, Grimmel M, Wagner M, Hennings JC, Marx C, Feichtinger RG, Saadi A, Rostásy K, Radelfahr F, Bevot A, Döbler-Neumann M, Hartmann H, Colleaux L, Cordts I, Kobeleva X, Darvish H, Bakhtiari S, Kruer MC, Besse A, Ng AC, Chiang D, Bolduc F, Tafakhori A, Mane S, Ghasemi Firouzabadi S, Huebner AK, Buchert R, Beck-Woedl S, Müller AJ, Laugwitz L, Nägele T, Wang ZQ, Strom TM, Sturm M, Meitinger T, Klockgether T, Riess O, Klopstock T, Brandl U, Hübner CA, Deschauer M, Mayr JA, Bonnen PE, Krägeloh-Mann I, Wortmann SB, Haack TB. Bi-allelic HPDL Variants Cause a Neurodegenerative Disease Ranging from Neonatal Encephalopathy to Adolescent-Onset Spastic Paraplegia. Am J Hum Genet. 2020 Aug 6;107(2):364-373. Ghosh SG, Lee S, Fabunan R, Chai G, Zaki MS, Abdel-Salam G, Sultan T, Ben-Omran T, Alvi JR, McEvoy-Venneri J, Stanley V, Patel A, Ross D, Ding J, Jain M, Pan D, Lübbert P, Kammerer B, Wiedemann N, Verhoeven-Duif NM, Jans JJ, Murphy D, Toosi MB, Ashrafzadeh F, Imannezhad S, Karimiani EG, Ibrahim K, Waters ER, Maroofian R, Gleeson JG. Biallelic variants in HPDL, encoding 4-hydroxyphenylpyruvate dioxygenase-like protein, lead to an infantile neurodegenerative condition. Genet Med. 2021 Mar;23(3):524-533."			618994	"619026, 619027 "	70.78143114	NaN	Class 1	-1.830792555	0.000224213	NaN	NaN	0	NaN	NaN
Q8IWL3	HSCB	Hematologic system;Tumors	Fe-S protein biogenesis	1				1	"Crispin A, Guo C, Chen C, Campagna DR, Schmidt PJ, Lichtenstein D, Cao C, Sendamarai AK, Hildick-Smith GJ, Huston NC, Boudreaux J, Bottomley SS, Heeney MM, Paw BH, Fleming MD, Ducamp S. Mutations in the iron-sulfur cluster biogenesis protein HSCB cause congenital sideroblastic anemia. J Clin Invest. 2020 Oct 1;130(10):5245-5256."			608142		Infinite	225.534426	Class 1	-3.110455019	0.002181957	88330.55215	106400.6667	Peripheral	2.901060046	59.62566371
Q99714;Q99714	HSD17B10	Central nervous system;Metabolism;Ophthalmic system;Gastrointestinal system	Lipid metabolism	1				1	"Chatfield, K. C., Coughlin, C. R., 2nd, Friederich, M. W., Gallagher, R. C., Hesselberth, J. R., Lovell, M. A., Ofman, R., Swanson, M. A., Thomas, J. A., Wanders, R. J., Wartchow, E. P., and Van Hove, J. L. (2015) Mitochondrial energy failure in HSD10 disease is due to defective mtDNA transcript processing. Mitochondrion 21, 1-10;Falk, M. J., Gai, X., Shigematsu, M., Vilardo, E., Takase, R., McCormick, E., Christian, T., Place, E., Pierce, E. A., Consugar, M., Gamper, H. B., Rossmanith, W., and Hou, Y. M. (2016) A novel HSD17B10 mutation impairing the activities of the mitochondrial RNase P complex causes X-linked intractable epilepsy and neurodevelopmental regression. RNA Biol 13, 477-485"	"DISEASE: HDS10 mitochondrial disease (HSD10MD) [MIM:300438]: An X-linked multisystemic disorder with highly variable severity. Age at onset ranges from the neonatal period to early childhood. Features include progressive neurodegeneration, psychomotor retardation, loss of mental and motor skills, seizures, cardiomyopathy, and visual and hearing impairment. Some patients manifest lactic acidosis and metabolic acidosis. {ECO:0000269|PubMed:12696021, ECO:0000269|PubMed:16148061, ECO:0000269|PubMed:17236142, ECO:0000269|PubMed:18996107, ECO:0000269|PubMed:19706438, ECO:0000269|PubMed:20077426, ECO:0000269|PubMed:22132097, ECO:0000269|PubMed:24549042, ECO:0000269|PubMed:25575635, ECO:0000269|PubMed:25925575, ECO:0000269|PubMed:26950678, ECO:0000269|PubMed:28888424}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mental retardation, X-linked 17 (MRX17) [MIM:300705]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non-syndromic X-linked mental retardation, while syndromic mental retardation presents with associated physical, neurological and/or psychiatric manifestations. {ECO:0000269|PubMed:18252223}. Note=The gene represented in this entry is involved in disease pathogenesis. A chromosomal microduplication involving HSD17B10 and HUWE1 has been found in patients with mental retardation."	C0152013;C0751651;C3266731;C3714756	300256	300438	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P61604	HSP10	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities"	Protein maturation & folding	1				1	"Bie AS, Fernandez-Guerra P, Birkler RI, Nisemblat S, Pelnena D, Lu X, Deignan JL, Lee H, Dorrani N, Corydon TJ, Palmfeldt J, Bivina L, Azem A, Herman K, Bross P. Effects of a Mutation in the HSPE1 Gene Encoding the Mitochondrial Co-chaperonin HSP10 and Its Potential Association with a Neurological and Developmental Disorder. Front Mol Biosci. 2016 Oct 7;3:65."			600141		397.4906567	NaN	Class 1	-1.465936694	0.000199058	9714795.037	18334500	Soluble	2.719424356	17.35592013
C9JL19;C9JL25;P10809	HSP60	Central nervous system;Failure to thrive;Pulmonary system ;Skeletal system	Protein maturation & folding	1				1	"Hansen, J. J., Durr, A., Cournu-Rebeix, I., Georgopoulos, C., Ang, D., Nielsen, M. N., Davoine, C. S., Brice, A., Fontaine, B., Gregersen, N., and Bross, P. (2002) Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am. J. Hum. Genet. 70, 1328-1332"	"DISEASE: Leukodystrophy, hypomyelinating, 4 (HLD4) [MIM:612233]: A severe autosomal recessive hypomyelinating leukodystrophy. Clinically characterized by infantile-onset rotary nystagmus, progressive spastic paraplegia, neurologic regression, motor impairment, profound mental retardation. Death usually occurs within the first two decades of life. {ECO:0000269|PubMed:18571143}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spastic paraplegia 13, autosomal dominant (SPG13) [MIM:605280]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. {ECO:0000269|PubMed:11898127}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0001418;C0007134;C0007194;C0019693;C0023520;C0024623;C0033141;C0036529;C0037773;C0038356;C0205641;C0205642;C0205643;C0205644;C0205645;C0238281;C0279702;C0376618;C0543888;C0740376;C0740391;C0740392;C0751651;C0751845;C0751846;C0751847;C0751848;C0751849;C0878544;C0948089;C1266042;C1266043;C1266044;C1306837;C1708349;C1854467;C2677109;C3714756;C4505456	118190	612233-605280	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O43464	HTRA2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system ;Ears;Hematologic system;Others"	Protein degradation & quality control	1				1	"Mandel, H., Saita, S., Edvardson, S., Jalas, C., Shaag, A., Goldsher, D., Vlodavsky, E., Langer, T., and Elpeleg, O. (2016) Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and 3-methylglutaconic aciduria. J Med Genet 53, 690-696;Olahova, M., Thompson, K., Hardy, S. A., Barbosa, I. A., Besse, A., Anagnostou, M. E., White, K., Davey, T., Simpson, M. A., Champion, M., Enns, G., Schelley, S., Lightowlers, R. N., Chrzanowska-Lightowlers, Z. M., McFarland, R., Deshpande, C., Bonnen, P. E., and Taylor, R. W. (2017) Pathogenic variants in HTRA2 cause an early-onset mitochondrial syndrome associated with 3-methylglutaconic aciduria. J Inherit Metab Dis 40, 121-130"	"DISEASE: 3-methylglutaconic aciduria 8 (MGCA8) [MIM:617248]: An autosomal recessive inborn error of metabolism resulting in early death. Clinical features include extreme hypertonia observed at birth, alternating with hypotonia, subsequent appearance of extrapyramidal symptoms, lack of psychomotor development, microcephaly, and intractable seizures. Patients show lactic acidemia, 3-methylglutaconic aciduria, intermittent neutropenia, and progressive brain atrophy. {ECO:0000269|PubMed:27208207, ECO:0000269|PubMed:27696117}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Parkinson disease 13 (PARK13) [MIM:610297]: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. {ECO:0000269|PubMed:15961413, ECO:0000269|PubMed:18401856}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry."	C0007787;C0030567;C0086543;C0242422;C0242423;C0270960;C0472381;C0543888;C0751019;C0751020;C0751021;C0751022;C0751651;C0752097;C0752098;C0752100;C0752101;C0752104;C0752105;C0917805;C1527335;C1853202;C1868675;C3714756;C4275179;C4310650	606441	617248-610297	226.8457222	NaN	Class 1	-1.018941536	0.004722994	67597.30812	55403.86667	Peripheral	11.9153821	88.03893867
Q9NSE4	IARS2	"Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Ears;Gastrointestinal system;Peripheral nervous system;Skeletal system;Endocrine system"	tRNA related processes	1				1	"Schwartzentruber, J., Buhas, D., Majewski, J., Sasarman, F., Papillon-Cavanagh, S., Thiffaut, I., Sheldon, K. M., Massicotte, C., Patry, L., Simon, M., Zare, A. S., McKernan, K. J., Consortium, F. C., Michaud, J., Boles, R. G., Deal, C. L., Desilets, V., Shoubridge, E. A., and Samuels, M. E. (2014) Mutation in the Nuclear Encoded Mitochondrial Isoleucyl tRNA-Synthetase IARS2 in Patients with Cataracts, Growth Hormone Deficiency with Short Stature, Partial Sensorineural Deafness and Peripheral Neuropathy or with Leigh Syndrome. Hum Mutat 35, 1285-1289"	"DISEASE: Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia (CAGSSS) [MIM:616007]: An autosomal recessive disorder characterized by cataracts, short-stature secondary to growth hormone deficiency, sensorineural hearing deficit, peripheral sensory neuropathy, skeletal dysplasia, scoliosis, and facial dysmorphism. {ECO:0000269|PubMed:25130867}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0010093;C0029927;C0751651;C3714756;C4014942	612801	616007	117.8827369	278.4134085	Class 1	-1.154939372	0.00036166	567367.2632	535637.6667	Peripheral	16.83198214	88.2240121
Q5T440	IBA57	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Muscular system;Peripheral nervous system;Skeletal system"	Fe-S protein biogenesis	1				1	"Ajit Bolar, N., Vanlander, A. V., Wilbrecht, C., Van der Aa, N., Smet, J., De Paepe, B., Vandeweyer, G., Kooy, F., Eyskens, F., De Latter, E., Delanghe, G., Govaert, P., Leroy, J. G., Loeys, B., Lill, R., Van Laer, L., and Van Coster, R. (2013) Mutation of the iron-sulfur cluster assembly gene IBA57 causes severe myopathy and encephalopathy. Hum Mol Genet 22, 2590-2602"	"DISEASE: Multiple mitochondrial dysfunctions syndrome 3 (MMDS3) [MIM:615330]: A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death. Some patients show failure to thrive, pulmonary hypertension, hypotonia and irritability. Biochemical features include severe combined deficiency of the 2-oxoacid dehydrogenases, defective lipoic acid synthesis and reduction in activity of mitochondrial respiratory chain complexes. {ECO:0000269|PubMed:23462291}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spastic paraplegia 74, autosomal recessive (SPG74) [MIM:616451]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG74 is characterized by a combination of spastic paraplegia, optic atrophy, and peripheral neuropathy with childhood-onset and slow progression into late adulthood. {ECO:0000269|PubMed:25609768}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0023520;C0751651;C3502075;C3809165;C4225322	615316	616451-615330	244.4807441	268.8653409	Class 1	-2.288965308	3.40446E-05	209186.0855	185291	Peripheral	4.434531261	76.11387196
P48735	IDH2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system"	TCA cycle	1				1		"DISEASE: D-2-hydroxyglutaric aciduria 2 (D2HGA2) [MIM:613657]: A neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine. {ECO:0000269|PubMed:20847235}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. {ECO:0000269|PubMed:19228619, ECO:0000269|PubMed:25495392}. Note=The gene represented in this entry is involved in disease pathogenesis.;DISEASE: Note=enetic variations are associated with cartilaginous tumors such as enchondroma or chondrosarcoma. {ECO:0000269|PubMed:26161668}."	C0001787;C0004114;C0005426;C0007193;C0007194;C0007682;C0010828;C0013366;C0014084;C0014474;C0018273;C0018800;C0018916;C0020295;C0020981;C0022333;C0023467;C0023487;C0024454;C0026998;C0027643;C0028945;C0029408;C0029456;C0029459;C0035078;C0036572;C0079774;C0086743;C0149958;C0158995;C0205788;C0205789;C0206698;C0206725;C0234533;C0234535;C0242698;C0264886;C0270824;C0270844;C0270846;C0279070;C0280475;C0280793;C0334579;C0334580;C0334581;C0334582;C0334590;C0344461;C0345905;C0376545;C0376634;C0422850;C0422852;C0422853;C0422854;C0422855;C0431108;C0494475;C0543888;C0677608;C0751056;C0751110;C0751123;C0751395;C0751396;C0751406;C0751494;C0751495;C0751496;C0936248;C1383860;C1565489;C1621958;C1704356;C1842010;C1879321;C1959588;C2746066;C2750850;C3150909;C3152055;C3495874;C3714756;C3805278;C4048158;C4316903;C4317109;C4317123;C4505436	147650	613657	107.1883932	NaN	Class 4	-0.448468495	0.010072776	484982.2895	422900.3333	Peripheral	9.219442104	72.92687335
H0YLI6;P50213	IDH3A	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system ;Ears;Gastrointestinal system;Peripheral nervous system;Others"	TCA cycle	1				1	"Fattal-Valevski, A., Eliyahu, H., Fraenkel, N. D., Elmaliach, G., Hausman-Kedem, M., Shaag, A., Mandel, D., Pines, O., and Elpeleg, O. (2017) Homozygous mutation, p.Pro304His, in IDH3A, encoding isocitrate dehydrogenase subunit is associated with severe encephalopathy in infancy. Neurogenetics 18, 57-61"		C0029408;C0086743	601149		NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
A0A087WZN1;A0A087X2E5;O43837;O43837	IDH3B	Ophthalmic system	TCA cycle	1				1	"Hartong, D. T., Dange, M., McGee, T. L., Berson, E. L., Dryja, T. P., and Colman, R. F. (2008) Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle. Nat Genet 40, 1230-1234"	"DISEASE: Retinitis pigmentosa 46 (RP46) [MIM:612572]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:18806796}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0024623;C0035334;C0038356;C0235874;C0751651;C1708349;C2675496	604526	612572	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q96T52	IMMP2L	Central nervous system;Skeletal system	Protein maturation & folding	1				1	"Baldan F, Gnan C, Franzoni A, Ferino L, Allegri L, Passon N, Damante G. Cytogenet Genome Res. 2018;154(4):196-200"	DISEASE: Gilles de la Tourette syndrome (GTS) [MIM:137580]: Neurologic disorder manifested particularly by motor and vocal tics and associated with behavioral abnormalities. {ECO:0000269|PubMed:11254443}. Note=The disease may be caused by mutations affecting the gene represented in this entry.	C0004352	605977		33.29323387	105.7629377	Class 1	-1.564870954	0.000236965	12060.83042	18482.485	0	NaN	67.08439467
Q9BUE6	ISCA1	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive	Fe-S protein biogenesis	1				1		"DISEASE: Multiple mitochondrial dysfunctions syndrome 5 (MMDS5) [MIM:617613]: An autosomal recessive, severe disorder characterized by early onset neurological deterioration, seizures, cerebral and cerebellar leukodystrophy, dysmyelination, cortical migrational abnormalities, lactic acidosis and early demise. {ECO:0000269|PubMed:28356563}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C4539919	611006	617613	25.15840895	NaN	Class 1	-2.779245501	5.76315E-05	113408.0789	75945.13333	Peripheral	9.295566665	70.9250583
Q86U28	ISCA2	Central nervous system;Ophthalmic system;Failure to thrive;Skeletal system	Fe-S protein biogenesis	1				1	"Al-Hassnan, Z. N., Al-Dosary, M., Alfadhel, M., Faqeih, E. A., Alsagob, M., Kenana, R., Almass, R., Al-Harazi, O. S., Al-Hindi, H., Malibari, O. I., Almutari, F. B., Tulbah, S., Alhadeq, F., Al-Sheddi, T., Alamro, R., AlAsmari, A., Almuntashri, M., Alshaalan, H., Al-Mohanna, F. A., Colak, D., and Kaya, N. (2015) ISCA2 mutation causes infantile neurodegenerative mitochondrial disorder. J Med Genet 52, 186-194"	"DISEASE: Multiple mitochondrial dysfunctions syndrome 4 (MMDS4) [MIM:616370]: A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death. {ECO:0000269|PubMed:25539947}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C0751651;C3502075;C3714756;C4225348	615317	616370	393.5604765	56.69125574	Class 1	-3.380326144	0.0022813	81809.77265	132871.5667	Soluble	4.575681208	25.24794941
Q9H1K1	ISCU	Metabolism;Cardiovascular system;Muscular system	Fe-S protein biogenesis	1				1	"Mochel, F., Knight, M. A., Tong, W. H., Hernandez, D., Ayyad, K., Taivassalo, T., Andersen, P. M., Singleton, A., Rouault, T. A., Fischbeck, K. H., and Haller, R. G. (2008) Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am. J. Hum. Genet.  82, 652-660;Olsson, A., Lind, L., Thornell, L. E., and Holmberg, M. (2008) Myopathy with lactic acidosis is linked to chromosome 12q23.3-24.11 and caused by an intron mutation in the ISCU gene resulting in a splicing defect. Hum Mol Genet 17, 1666-1672"	"DISEASE: Myopathy with exercise intolerance Swedish type (MEIS) [MIM:255125]: Autosomal recessive metabolic disease characterized by lifelong severe exercise intolerance, in which minor exertion causes fatigue of active muscles, shortness of breath, and cardiac palpitations in association with lactic acidosis. The biochemical phenotype is characterized by a deficiency in mitochondrial iron-sulfur proteins and impaired muscle oxidative metabolism. {ECO:0000269|PubMed:18304497}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0035410;C0270960;C0751651;C1850718	611911	255125	17.49068783	NaN	Class 1	-2.095162639	5.53806E-05	183275.4393	106735.4667	Peripheral	4.369044084	73.5644743
Q9HD34	ISD11	Metabolism;Failure to thrive;Pulmonary system ;Muscular system;Liver;Gastrointestinal system	Fe-S protein biogenesis	1				1	"Lim, S. C., Friemel, M., Marum, J. E., Tucker, E. J., Bruno, D. L., Riley, L. G., Christodoulou, J., Kirk, E. P., Boneh, A., Degennaro, C., Springer, M., Mootha, V. K., Rouault, T. A., Leimkuhler, S., Thorburn, D. R., and Compton, A. G. (2013) Mutations in LYRM4, encoding iron-sulfur cluster biogenesis factor ISD11, cause deficiency of multiple respiratory chain complexes. Hum Mol Genet 22, 4460-4473"	"DISEASE: Combined oxidative phosphorylation deficiency 19 (COXPD19) [MIM:615595]: A mitochondrial disorder characterized by respiratory distress, hypotonia, and severe lactic acidosis in the newborn period. Other features include gastroesophageal reflux and elevated liver enzymes with normal synthetic function. {ECO:0000269|PubMed:23814038}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0036341;C0751651;C3810055	613311	615595	190.3532137	NaN	Class 1	-3.288032857	0.000144661	260620.9783	174342.3333	Peripheral	2.784766913	74.68310136
P26440;H7C4G6	IVD	Central nervous system;Metabolism;Gastrointestinal system	Fatty acid _-oxidation 	1				1		"DISEASE: Isovaleric acidemia (IVA) [MIM:243500]: A metabolic disorder characterized by retarded psychomotor development, a peculiar odor resembling sweaty feet, an aversion to dietary protein, and pernicious vomiting, leading to acidosis and coma. The acute neonatal form leads to massive metabolic acidosis from the first days of life and rapid death. {ECO:0000269|PubMed:2063866, ECO:0000269|PubMed:22004070, ECO:0000269|PubMed:22350545, ECO:0000269|PubMed:23587913, ECO:0000269|PubMed:28535199, ECO:0000269|PubMed:9665741}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023893;C0220994;C0268575;C0271713;C3714756	607036	243500	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q15046;Q15046	KARS	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Ears;Peripheral nervous system;Tumors"	tRNA related processes	1				1	"Kohda, M., Tokuzawa, Y., Kishita, Y., Nyuzuki, H., Moriyama, Y., Mizuno, Y., Hirata, T., Yatsuka, Y., Yamashita-Sugahara, Y., Nakachi, Y., Kato, H., Okuda, A., Tamaru, S., Borna, N. N., Banshoya, K., Aigaki, T., Sato-Miyata, Y., Ohnuma, K., Suzuki, T., Nagao, A., Maehata, H., Matsuda, F., Higasa, K., Nagasaki, M., Yasuda, J., Yamamoto, M., Fushimi, T., Shimura, M., Kaiho-Ichimoto, K., Harashima, H., Yamazaki, T., Mori, M., Murayama, K., Ohtake, A., and Okazaki, Y. (2016) A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies. PLoS Genet 12, e1005679"	"DISEASE: Charcot-Marie-Tooth disease, recessive, intermediate type, B (CMTRIB) [MIM:613641]: A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Recessive intermediate forms of Charcot-Marie-Tooth disease are characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. {ECO:0000269|PubMed:20920668}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Deafness, autosomal recessive, 89 (DFNB89) [MIM:613916]: A form of non-syndromic deafness characterized by bilateral, prelingual, moderate to severe hearing loss affecting all frequencies. {ECO:0000269|PubMed:23768514, ECO:0000269|PubMed:28887846}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007959;C0751651;C3150897;C3151351;C3714756	601421	613641-613916	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9H9P8	L2HGDH	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities"	Carbohydrate & energy metabolism	1				1	"Topcu, M., Jobard, F., Halliez, S., Coskun, T., Yalcinkayal, C., Gerceker, F. O., Wanders, R. J., Prud'homme, J. F., Lathrop, M., Ozguc, M., and Fischer, J. (2004) L-2-Hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22.1. Hum Mol Genet 13, 2803-2811"	"DISEASE: L-2-hydroxyglutaric aciduria (L2HGA) [MIM:236792]: A rare autosomal recessive disorder clinically characterized by mild psychomotor delay in the first years of life, followed by progressive cerebellar ataxia, dysarthria and moderate to severe mental retardation. Diagnosis is based on the presence of an excess of L-2-hydroxyglutaric acid in urine, blood and cerebrospinal fluid. {ECO:0000269|PubMed:15385440, ECO:0000269|PubMed:15548604, ECO:0000269|PubMed:16134148}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0014544;C0020796;C0023520;C0025363;C0086237;C0236018;C0265541;C0497552;C0751111;C0917816;C1855995;C2746066;C3714756;C3888081	609584	236792	153.8329928	NaN	Class 1	-1.188592606	0.000364188	77163.59108	68350.23333	Peripheral	20.3852952	89.75783997
Q15031	LARS2	Ears;Reproductive system	tRNA related processes	1				1	"Pierce, S. B., Gersak, K., Michaelson-Cohen, R., Walsh, T., Lee, M. K., Malach, D., Klevit, R. E., King, M. C., and Levy-Lahad, E. (2013) Mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase, lead to premature ovarian failure and hearing loss in Perrault syndrome. Am. J. Hum. Genet. 92, 614-620"	"DISEASE: Hydrops, lactic acidosis, and sideroblastic anemia (HLASA) [MIM:617021]: A lethal, multisystem metabolic disorder characterized by severe lactic acidosis, hydrops, and sideroblastic anemia. Additional features include impaired cardiac function, disordered coagulation, pulmonary hypertension, and progressive renal disease. {ECO:0000269|PubMed:26537577}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Perrault syndrome 4 (PRLTS4) [MIM:615300]: An autosomal recessive, sex-influenced disorder characterized by sensorineural deafness in both males and females, and ovarian dysgenesis in females. Affected females have primary amenorrhea, streak gonads, and infertility, whereas affected males show normal pubertal development and are fertile. {ECO:0000269|PubMed:23541342}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0005586;C0020305;C0036341;C0685838;C0751651;C3714756;C3809105;C4310761	604544	615300	110.234281	NaN	Class 1	-1.01421552	0.000495787	127635.8929	126449	Peripheral	12.65761791	80.41990711
O43766	LIAS	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Skeletal system"	Other known processes	1				1	"Mayr, J. A., Zimmermann, F. A., Fauth, C., Bergheim, C., Meierhofer, D., Radmayr, D., Zschocke, J., Koch, J., and Sperl, W. (2011) Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. Am. J. Hum. Genet. 89, 792-797"	"DISEASE: Hyperglycinemia, lactic acidosis, and seizures (HGCLAS) [MIM:614462]: An enzymatic defect resulting in an autosomal recessive disorder of mitochondrial metabolism. It is characterized by early-onset lactic acidosis, severe encephalomyopathy, and a pyruvate oxidation defect. Affected individuals have neonatal-onset epilepsy, poor growth, psychomotor retardation, muscular hypotonia, lactic acidosis, and elevated glycine concentration in plasma and urine. {ECO:0000269|PubMed:22152680}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C3280887	607031	614462	14.8414012	NaN	Class 1	-2.740101391	0.000434819	23904.21349	18939.35667	Peripheral	10.6775369	52.90898219
P49916	LIG3	Central nervous system;Metabolism;Ophthalmic system;Pulmonary system ;Muscular system;Ears;Gastrointestinal system;Kidney and urinary tract;Others	DNA-related processes	1				1	"Bonora E, Chakrabarty S, Kellaris G, Tsutsumi M, Bianco F, Bergamini C, Ullah F, Isidori F, Liparulo I, Diquigiovanni C, Masin L, Rizzardi N, Cratere MG, Boschetti E, Papa V, Maresca A, Cenacchi G, Casadio R, Martelli P, Matera I, Ceccherini I, Fato R, Raiola G, Arrigo S, Signa S, Sementa AR, Severino M, Striano P, Fiorillo C, Goto T, Uchino S, Oyazato Y, Nakamura H, Mishra SK, Yeh YS, Kato T, Nozu K, Tanboon J, Morioka I, Nishino I, Toda T, Goto YI, Ohtake A, Kosaki K, Yamaguchi Y, Nonaka I, Iijima K, Mimaki M, Kurahashi H, Raams A, MacInnes A, Alders M, Engelen M, Linthorst G, de Koning T, den Dunnen W, Dijkstra G, van Spaendonck K, van Gent DC, Aronica EM, Picco P, Carelli V, Seri M, Katsanis N, Duijkers FAM, Taniguchi-Ikeda M, De Giorgio R. Biallelic variants in LIG3 cause a novel mitochondrial neurogastrointestinal encephalomyopathy. Brain. 2021 Jun 22;144(5):1451-1466. Invernizzi F, Legati A, Nasca A, Lamantea E, Garavaglia B, Gusic M, Kopajtich R, Prokisch H, Zeviani M, Lamperti C, Ghezzi D. Myopathic mitochondrial DNA depletion syndrome associated with biallelic variants in LIG3. Brain. 2021 Jun 24:awab238. "			600940		180.3278165	172.9502516	Class 4	-0.926707749	0.051383881	2178.762007	359183.6667	Peripheral	16.5140373	63.63944953
Q9Y234	LIPT1	Central nervous system;Metabolism;Cardiovascular system;Pulmonary system ;Liver	Other known processes	1				1	"Soreze, Y., Boutron, A., Habarou, F., Barnerias, C., Nonnenmacher, L., Delpech, H., Mamoune, A., Chretien, D., Hubert, L., Bole-Feysot, C., Nitschke, P., Correia, I., Sardet, C., Boddaert, N., Hamel, Y., Delahodde, A., Ottolenghi, C., and de Lonlay, P. (2013) Mutations in human lipoyltransferase gene LIPT1 cause a Leigh disease with secondary deficiency for pyruvate and alpha-ketoglutarate dehydrogenase. Orphanet J Rare Dis 8, 192"	"DISEASE: Lipoyltransferase 1 deficiency (LIPT1D) [MIM:616299]: A disorder due to a defect in lipoic acid metabolism, resulting in severe lactic acidosis and metabolic decompensation. Variable clinical manifestations include delayed psychomotor development, severe hypotonia, dystonia, loss of head control, coma, bradycardia, and pulmonary hypertension. {ECO:0000269|PubMed:24256811, ECO:0000269|PubMed:24341803}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C4225379	610284	616299	NaN	NaN	Class 1	-3.568055539	0.000177175	8625.130399	6216.152333	0	NaN	79.17393747
A6NK58	LIPT2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system "	Other known processes	1				1	"Habarou, F., Hamel, Y., Haack, T. B., Feichtinger, R. G., Lebigot, E., Marquardt, I., Busiah, K., Laroche, C., Madrange, M., Grisel, C., Pontoizeau, C., Eisermann, M., Boutron, A., Chretien, D., Chadefaux-Vekemans, B., Barouki, R., Bole-Feysot, C., Nitschke, P., Goudin, N., Boddaert, N., Nemazanyy, I., Delahodde, A., Kolker, S., Rodenburg, R. J., Korenke, G. C., Meitinger, T., Strom, T. M., Prokisch, H., Rotig, A., Ottolenghi, C., Mayr, J. A., and de Lonlay, P. (2017) Biallelic Mutations in LIPT2 Cause a Mitochondrial Lipoylation Defect Associated with Severe Neonatal Encephalopathy. Am. J. Hum. Genet. 101, 283-290"	"DISEASE: Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities (NELABA) [MIM:617668]: An autosomal recessive disorder characterized by severe encephalopathy with neonatal onset, metabolic features including lactic acidosis, little or no psychomotor development, and brain abnormalities including cerebral atrophy, cysts, and white matter abnormalities. {ECO:0000269|PubMed:28757203}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C4540052	617659	617668	NaN	NaN	Class 2	-1.734052999	0.01407932	13475.40176	13412.395	Peripheral	5.151815283	53.6397945
P36776;K7ER56	LONP1	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Ears;Gastrointestinal system;Skeletal system;Reproductive system"	Protein degradation & quality control	1				1	"Dikoglu, E., Alfaiz, A., Gorna, M., Bertola, D., Chae, J. H., Cho, T. J., Derbent, M., Alanay, Y., Guran, T., Kim, O. H., Llerenar, J. C., Jr., Yamamoto, G., Superti-Furga, G., Reymond, A., Xenarios, I., Stevenson, B., Campos-Xavier, B., Bonafe, L., Superti-Furga, A., and Unger, S. (2015) Mutations in LONP1, a mitochondrial matrix protease, cause CODAS syndrome. Am J Med Genet A 167, 1501-1509;Strauss, K. A., Jinks, R. N., Puffenberger, E. G., Venkatesh, S., Singh, K., Cheng, I., Mikita, N., Thilagavathi, J., Lee, J., Sarafianos, S., Benkert, A., Koehler, A., Zhu, A., Trovillion, V., McGlincy, M., Morlet, T., Deardorff, M., Innes, A. M., Prasad, C., Chudley, A. E., Lee, I. N., and Suzuki, C. K. (2015) CODAS syndrome is associated with mutations of LONP1, encoding mitochondrial AAA+ Lon protease. Am. J. Hum. Genet. 96, 121-135"	"DISEASE: CODAS syndrome (CODASS) [MIM:600373]: A rare syndrome characterized by the combination of cerebral, ocular, dental, auricular, and skeletal features. These include developmental delay, craniofacial anomalies, cataracts, ptosis, median nasal groove, delayed tooth eruption, hearing loss, short stature, delayed epiphyseal ossification, metaphyseal hip dysplasia, and vertebral coronal clefts. {ECO:0000269|PubMed:25574826, ECO:0000269|PubMed:25808063}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C1838180;C3714756	605490	600373	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
H7C3W8;P42704	LRPPRC	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Skeletal system"	RNA-related processes	1				1	"Mootha, V. K., Lepage, P., Miller, K., Bunkenborg, J., Reich, M., Hjerrild, M., Delmonte, T., Villeneuve, A., Sladek, R., Xu, F., Mitchell, G. A., Morin, C., Mann, M., Hudson, T. J., Robinson, B., Rioux, J. D., and Lander, E. S. (2003) Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc. Natl. Acad. Sci. U S A 100, 605-610"	"DISEASE: Leigh syndrome French-Canadian type (LSFC) [MIM:220111]: Severe neurological disorder characterized by bilaterally symmetrical necrotic lesions in subcortical brain regions that is commonly associated with systemic cytochrome c oxidase (COX) deficiency. In the Saguenay-Lac Saint Jean region of Quebec province in Canada, a biochemically distinct form of Leigh syndrome with COX deficiency has been described. Patients have been observed to have a developmental delay, hypotonia, mild facial dysmorphism, chronic well-compensated metabolic acidosis, and high mortality due to episodes of severe acidosis and coma. Enzyme activity was close to normal in kidney and heart, 50% of normal in fibroblasts and skeletal muscle, and nearly absent in brain and liver. LSFC patients show reduced (<30%) levels of LRPPRC in both fibroblast and liver mitochondria and a specifically reduced translation of COX subunits MT-CO1/COXI and MT-CO3 (COXIII). {ECO:0000269|PubMed:12529507, ECO:0000269|PubMed:26510951}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C1857355;C3714756	607544	220111	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P21397	MAOA	Central nervous system;Metabolism;Failure to thrive	Other known processes	1				1		"DISEASE: Brunner syndrome (BRNRS) [MIM:300615]: A form of X-linked non-dysmorphic mild mental retardation. Male patients are affected by borderline mental retardation and exhibit abnormal behavior, including disturbed regulation of impulsive aggression. Obligate female carriers have normal intelligence and behavior. {ECO:0000269|PubMed:8211186}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0001973;C0003431;C0004352;C0004930;C0004936;C0005586;C0005587;C0006142;C0009241;C0011570;C0011581;C0013409;C0013415;C0014175;C0019147;C0019151;C0020179;C0020649;C0026848;C0030567;C0031511;C0033054;C0033975;C0036341;C0041696;C0085762;C0158850;C0269102;C0270458;C0376338;C0393574;C0525045;C0600427;C0745744;C0751197;C0751198;C0751207;C0751208;C0796275;C1136249;C1257877;C1269683;C1285261;C2063866;C2362914;C2936476;C3714756;C4046029	309850	300615	NaN	230.5349468	Class 4	-0.137404633	0.788480349	102919.5466	49062.26667	Integral	84.40763639	92.0103235
Q96GW9	MARS2	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Ears;Gastrointestinal system;Skeletal system;Kidney and urinary tract;Others;Endocrine system"	tRNA related processes	1				1	"Bayat, V., Thiffault, I., Jaiswal, M., Tetreault, M., Donti, T., Sasarman, F., Bernard, G., Demers-Lamarche, J., Dicaire, M. J., Mathieu, J., Vanasse, M., Bouchard, J. P., Rioux, M. F., Lourenco, C. M., Li, Z., Haueter, C., Shoubridge, E. A., Graham, B. H., Brais, B., and Bellen, H. J. (2012) Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans. PLoS Biol 10, e1001288"	"DISEASE: Combined oxidative phosphorylation deficiency 25 (COXPD25) [MIM:616430]: A mitochondrial disorder resulting in developmental delay, growth failure, and sensorineural hearing loss. {ECO:0000269|PubMed:25754315}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spastic ataxia 3, autosomal recessive (SPAX3) [MIM:611390]: A neurologic disorder characterized by cerebellar ataxia, ataxic gait, spasticity, and hyperreflexia. Other variable features include dysarthria, dysmetria, mild cognitive impairment, urinary urgency and dystonic positioning. {ECO:0000269|PubMed:22448145}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0037773;C0751651;C1969645;C3714756;C4225329	609728	616430-611390	519.058622	160.4913433	Class 1	-1.530447738	0.000171734	78579.48414	53276.7	Peripheral	18.15729454	78.80339759
Q8IVS2	MCAT	Central nervous system;Ophthalmic system	Fatty acid _-oxidation 	1				1	"Li H, Yuan S, Minegishi Y, Suga A, Yoshitake K, Sheng X, Ye J, Smith S, Bunkoczi G, Yamamoto M, Iwata T. Novel mutations in malonyl-CoA-acyl carrier protein transacylase provoke autosomal recessive optic neuropathy. Hum Mol Genet. 2020 Feb 1;29(3):444-458."			614479		102.1797885	183.118563	Class 1	-1.848979802	8.78213E-05	203730.9133	179781.4667	Peripheral	16.42578658	83.75405604
Q96RQ3	MCCC1	Central nervous system;Metabolism	Amino acid metabolism	1				1		"DISEASE: 3-methylcrotonoyl-CoA carboxylase 1 deficiency (MCC1D) [MIM:210200]: An autosomal recessive disorder of leucine catabolism. The phenotype is variable, ranging from neonatal onset with severe neurological involvement to asymptomatic adults. There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in combination with a severe secondary carnitine deficiency. {ECO:0000269|PubMed:11170888, ECO:0000269|PubMed:11181649, ECO:0000269|PubMed:11406611, ECO:0000269|PubMed:16010683, ECO:0000269|PubMed:17968484, ECO:0000269|PubMed:21071250, ECO:0000269|PubMed:22150417, ECO:0000269|PubMed:22264772, ECO:0000269|PubMed:22642865, ECO:0000269|PubMed:25382614, ECO:0000269|PubMed:27601257, ECO:0000269|Ref.6}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0268600;C3714756	609010	210200	139.4737789	NaN	Class 1	-1.462272532	0.00040282	59015.28	57296.96667	Peripheral	21.81474936	96.46744836
D6RD67;Q9HCC0	MCCC2	Central nervous system;Metabolism;Pulmonary system ;Muscular system;Liver	Amino acid metabolism	1				1		"DISEASE: 3-methylcrotonoyl-CoA carboxylase 2 deficiency (MCC2D) [MIM:210210]: An autosomal recessive disorder of leucine catabolism. The phenotype is variable, ranging from neonatal onset with severe neurological involvement to asymptomatic adults. There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, usually in combination with a severe secondary carnitine deficiency. {ECO:0000269|PubMed:11170888, ECO:0000269|PubMed:11181649, ECO:0000269|PubMed:11406611, ECO:0000269|PubMed:16010683, ECO:0000269|PubMed:17968484, ECO:0000269|PubMed:21071250, ECO:0000269|PubMed:22150417, ECO:0000269|PubMed:22264772, ECO:0000269|PubMed:22642865, ECO:0000269|PubMed:25382614, ECO:0000269|PubMed:27601257}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0268600;C1859499;C3714756	609014	210210	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q96PE7	MCEE	Central nervous system;Metabolism;Failure to thrive;Pulmonary system ;Gastrointestinal system	Lipid metabolism	1				1		"DISEASE: Methylmalonyl-CoA epimerase deficiency (MCEED) [MIM:251120]: Autosomal recessive inborn error of amino acid metabolism, involving valine, threonine, isoleucine and methionine. This organic aciduria may present in the neonatal period with life-threatening metabolic acidosis, hyperammonemia, feeding difficulties, pancytopenia and coma. {ECO:0000269|PubMed:16752391}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0271713;C1855100;C3714756	608419	251120	383.1403065	214.8748659	Class 1	-2.824132106	0.002220693	24946.6425	NaN	0	NaN	82.34988523
G3XAL0;P40926	MDH2	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Gastrointestinal system;Reproductive system	TCA cycle	1				1	"Ait-El-Mkadem, S., Dayem-Quere, M., Gusic, M., Chaussenot, A., Bannwarth, S., Francois, B., Genin, E. C., Fragaki, K., Volker-Touw, C. L., Vasnier, C., Serre, V., van Gassen, K. L., Lespinasse, F., Richter, S., Eisenhofer, G., Rouzier, C., Mochel, F., De Saint-Martin, A., Abi Warde, M. T., de Sain-van der Velde, M. G., Jans, J. J., Amiel, J., Avsec, Z., Mertes, C., Haack, T. B., Strom, T., Meitinger, T., Bonnen, P. E., Taylor, R. W., Gagneur, J., van Hasselt, P. M., Rotig, A., Delahodde, A., Prokisch, H., Fuchs, S. A., and Paquis-Flucklinger, V. (2017) Mutations in MDH2, Encoding a Krebs Cycle Enzyme, Cause Early-Onset Severe Encephalopathy. Am. J. Hum. Genet. 100, 151-159"	"DISEASE: Epileptic encephalopathy, early infantile, 51 (EIEE51) [MIM:617339]: A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. EIEE51 is an autosomal recessive form characterized by onset of intractable seizures and hypotonia in the first days or weeks of life, and severely delayed psychomotor development. {ECO:0000269|PubMed:27989324}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007097;C0024667;C0024668;C0154040;C0154045;C0205696;C0205697;C0205698;C0205699;C0344456;C0438413;C0543888;C0751651;C1257925;C3714756;C4479208	154100	617339	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9BV79	MECR	Central nervous system;Metabolism;Ophthalmic system;Gastrointestinal system	Fatty acid _-oxidation 	1				1	"Heimer, G., Keratar, J. M., Riley, L. G., Balasubramaniam, S., Eyal, E., Pietikainen, L. P., Hiltunen, J. K., Marek-Yagel, D., Hamada, J., Gregory, A., Rogers, C., Hogarth, P., Nance, M. A., Shalva, N., Veber, A., Tzadok, M., Nissenkorn, A., Tonduti, D., Renaldo, F., University of Washington Center for Mendelian, G., Kraoua, I., Panteghini, C., Valletta, L., Garavaglia, B., Cowley, M. J., Gayevskiy, V., Roscioli, T., Silberstein, J. M., Hoffmann, C., Raas-Rothschild, A., Tiranti, V., Anikster, Y., Christodoulou, J., Kastaniotis, A. J., Ben-Zeev, B., and Hayflick, S. J. (2016) MECR Mutations Cause Childhood-Onset Dystonia and Optic Atrophy, a Mitochondrial Fatty Acid Synthesis Disorder. Am. J. Hum. Genet. 99, 1229-1244"	"DISEASE: Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities (DYTOABG) [MIM:617282]: An autosomal recessive neurologic disorder characterized by childhood-onset dystonia, basal ganglia degeneration and optic atrophy with decreased visual acuity. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYTOABG severity is variable, and some patients lose independent ambulation. {ECO:0000269|PubMed:27817865}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3714756;C4310634	608205	617282	NaN	164.4619389	Class 1	-1.073531463	0.001020674	108570.6607	77554.03333	Peripheral	1.746608177	71.1675979
A0A0A0MS29;H7C433;Q9GZY8;Q9GZY8;Q9GZY8	MFF	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Gastrointestinal system;Peripheral nervous system"	"Morphology, dynamics & organization"	1				1	"Koch, J., Feichtinger, R. G., Freisinger, P., Pies, M., Schrodl, F., Iuso, A., Sperl, W., Mayr, J. A., Prokisch, H., and Haack, T. B. (2016) Disturbed mitochondrial and peroxisomal dynamics due to loss of MFF causes Leigh-like encephalopathy, optic atrophy and peripheral neuropathy. J Med Genet 53, 270-278;Shamseldin, H. E., Alshammari, M., Al-Sheddi, T., Salih, M. A., Alkhalidi, H., Kentab, A., Repetto, G. M., Hashem, M., and Alkuraya, F. S. (2012) Genomic analysis of mitochondrial diseases in a consanguineous population reveals novel candidate disease genes. J Med Genet 49, 234-241"	"DISEASE: Encephalopathy due to defective mitochondrial and peroxisomal fission 2 (EMPF2) [MIM:617086]: An autosomal recessive disorder characterized by delayed psychomotor development, severe hypotonia with inability to walk, microcephaly, and abnormal signals in the basal ganglia. More variable features include early-onset seizures, optic atrophy, and peripheral neuropathy. {ECO:0000269|PubMed:26783368}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C1527249;C3714756;C4310726	614785	617086	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O95140	MFN2	Ophthalmic system;Ears;Peripheral nervous system;Skeletal system	"Morphology, dynamics & organization"	1				1	"Vielhaber, S., Debska-Vielhaber, G., Peeva, V., Schoeler, S., Kudin, A. P., Minin, I., Schreiber, S., Dengler, R., Kollewe, K., Zuschratter, W., Kornblum, C., Zsurka, G., and Kunz, W. S. (2013) Mitofusin 2 mutations affect mitochondrial function by mitochondrial DNA depletion. Acta Neuropathol 125, 245-256;Zuchner, S., Mersiyanova, I. V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J., Dadali, E. L., Zappia, M., Nelis, E., Patitucci, A., Senderek, J., Parman, Y., Evgrafov, O., Jonghe, P. D., Takahashi, Y., Tsuji, S., Pericak-Vance, M. A., Quattrone, A., Battologlu, E., Polyakov, A. V., Timmerman, V., Schroder, J. M., and Vance, J. M. (2004) Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36, 449-451"	"DISEASE: Charcot-Marie-Tooth disease 2A2A (CMT2A2A) [MIM:609260]: An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. {ECO:0000269|PubMed:15064763, ECO:0000269|PubMed:15549395, ECO:0000269|PubMed:16762064, ECO:0000269|PubMed:20350294, ECO:0000269|PubMed:22206013}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Charcot-Marie-Tooth disease 2A2B (CMT2A2B) [MIM:617087]: An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2A2B is a severe form with autosomal recessive inheritance. {ECO:0000269|PubMed:18458227, ECO:0000269|PubMed:20350294, ECO:0000269|PubMed:21715711, ECO:0000269|PubMed:26085578, ECO:0000269|PubMed:26955893}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Neuropathy, hereditary motor and sensory, 6A (HMSN6A) [MIM:601152]: An autosomal dominant neurologic disorder characterized by optic atrophy and peripheral sensorimotor neuropathy manifesting as axonal Charcot-Marie-Tooth disease. Charcot-Marie-Tooth disease is a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. It is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies and primary peripheral axonal neuropathies. Peripheral axonal neuropathies are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, and normal or slightly reduced nerve conduction velocities. {ECO:0000269|PubMed:16437557, ECO:0000269|PubMed:20350294, ECO:0000269|PubMed:24604904, ECO:0000269|PubMed:26085578}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0007959;C0018800;C0023804;C0024445;C0037773;C0393807;C0751602;C0751651;C1383860;C1836485;C2931642;C4310725	608507	617087-601152	9.147394215	15.0929491	Class 3	-0.544206315	0.004531103	85243.36099	75005.06667	Integral	82.92114542	90.90557351
Q5QPE8;Q9BQP7	MGME1	Central nervous system;Ophthalmic system;Cardiovascular system;Pulmonary system ;Muscular system;Gastrointestinal system;Skeletal system;Kidney and urinary tract;Reproductive system	DNA-related processes	1				1	"Kornblum, C., Nicholls, T. J., Haack, T. B., Scholer, S., Peeva, V., Danhauser, K., Hallmann, K., Zsurka, G., Rorbach, J., Iuso, A., Wieland, T., Sciacco, M., Ronchi, D., Comi, G. P., Moggio, M., Quinzii, C. M., Dimauro, S., Calvo, S. E., Mootha, V. K., Klopstock, T., Strom, T. M., Meitinger, T., Minczuk, M., Kunz, W. S., and Prokisch, H. (2013) Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease. Nat Genet 45, 214-219"	"DISEASE: Mitochondrial DNA depletion syndrome 11 (MTDPS11) [MIM:615084]: An autosomal recessive mitochondrial disorder characterized by onset in childhood or adulthood of progressive external ophthalmoplegia, muscle weakness and atrophy, exercise intolerance, and respiratory insufficiency due to muscle weakness. More variable features include spinal deformity, emaciation, and cardiac abnormalities. Skeletal muscle biopsies show deletion and depletion of mitochondrial DNA (mtDNA) with variable defects in respiratory chain enzyme activities. {ECO:0000269|PubMed:23313956}. Note=The disease may be caused by mutations affecting the gene represented in this entry."	C0013911;C0029089;C0035229;C0162292;C0235063;C0339693;C0751401;C0751651;C0949855;C0949856;C0949857;C1145670;C3554462	615076	615084	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q5XKP0	MIC13	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Ears;Liver;Kidney and urinary tract;Others"	"Morphology, dynamics & organization"	1				1	"Guarani, V., Jardel, C., Chretien, D., Lombes, A., Benit, P., Labasse, C., Lacene, E., Bourillon, A., Imbard, A., Benoist, J. F., Dorboz, I., Gilleron, M., Goetzman, E. S., Gaignard, P., Slama, A., Elmaleh-Berges, M., Romero, N. B., Rustin, P., Ogier de Baulny, H., Paulo, J. A., Harper, J. W., and Schiff, M. (2016) QIL1 mutation causes MICOS disassembly and early onset fatal mitochondrial encephalopathy with liver disease. Elife 5, pii: e17163;Zeharia, A., Friedman, J. R., Tobar, A., Saada, A., Konen, O., Fellig, Y., Shaag, A., Nunnari, J., and Elpeleg, O. (2016) Mitochondrial hepato-encephalopathy due to deficiency of QIL1/MIC13 (C19orf70), a MICOS complex subunit. Eur J Hum Genet 24, 1778-1782"		C0574084	616658	618329	47.31486924	NaN	Class 1	-2.010436418	0.000165352	159452.2366	362692.3333	Integral	69.02027893	93.8497241
A0A0J9YXT7;Q9BUR5	MIC26	Central nervous system;Metabolism;Muscular system;Gastrointestinal system;Others	"Morphology, dynamics & organization"	1				1	"Benincá C, Zanette V, Brischigliaro M, Johnson M, Reyes A, Valle DAD, J Robinson A, Degiorgi A, Yeates A, Telles BA, Prudent J, Baruffini E, S F Santos ML, R de Souza RL, Fernandez-Vizarra E, J Whitworth A, Zeviani M. Mutation in the MICOS subunit gene APOO (MIC26) associated with an X-linked recessive mitochondrial myopathy, lactic acidosis, cognitive impairment and autistic features. J Med Genet. 2021 Mar;58(3):155-167."			300753		NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9BPX6	MICU1	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Muscular system;Peripheral nervous system"	Regulation & signaling	1				1	"Logan, C. V., Szabadkai, G., Sharpe, J. A., Parry, D. A., Torelli, S., Childs, A. M., Kriek, M., Phadke, R., Johnson, C. A., Roberts, N. Y., Bonthron, D. T., Pysden, K. A., Whyte, T., Munteanu, I., Foley, A. R., Wheway, G., Szymanska, K., Natarajan, S., Abdelhamed, Z. A., Morgan, J. E., Roper, H., Santen, G. W., Niks, E. H., van der Pol, W. L., Lindhout, D., Raffaello, A., De Stefani, D., den Dunnen, J. T., Sun, Y., Ginjaar, I., Sewry, C. A., Hurles, M., Rizzuto, R., Consortium, U. K., Duchen, M. R., Muntoni, F., and Sheridan, E. (2014) Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling. Nat Genet 46, 188-193"	"DISEASE: Myopathy with extrapyramidal signs (MPXPS) [MIM:615673]: An autosomal recessive disorder characterized by early-onset proximal muscle weakness with a static course and moderately to grossly elevated serum creatine kinase levels accompanied by learning difficulties. Most patients develop subtle extrapyramidal motor signs that progress to a debilitating disorder of involuntary movement with variable features, including chorea, tremor, dystonic posturing and orofacial dyskinesia. Additional variable features include ataxia, microcephaly, ophthalmoplegia, ptosis, optic atrophy and axonal peripheral neuropathy. {ECO:0000269|PubMed:24336167}. Note=The disease is caused by mutations affecting the gene represented in this entry. The complex phenotype is due to alterations in mitochondrial calcium signaling characterized by increased mitochondrial Ca(2+) load (PubMed:24336167). {ECO:0000269|PubMed:24336167}.;DISEASE: Note=An homozygous partial MICU1 deletion is responsible for a disorder manifesting in childhood with fatigue, lethargy and muscle weakness. The disease is caused by mutations affecting the gene represented in this entry. {ECO:0000269|PubMed:27123478}."	C0003886;C0004782;C0015371;C0023186;C0026650;C0026848;C0266487;C0270960;C0699743;C0750951;C0751262;C0751263;C0751265;C0751651;C1330966;C3714756;C3810285	605084	615673	43.98406459	NaN	Class 1	-2.791281611	8.11408E-05	86079.36531	86104.33333	Peripheral	28.62303099	96.86311793
Q8IYU8	MICU2	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities"	Regulation & signaling	1				1	"Shamseldin, H. E., Alasmari, A., Salih, M. A., Samman, M. M., Mian, S. A., Alshidi, T., Ibrahim, N., Hashem, M., Faqeih, E., Al-Mohanna, F., and Alkuraya, F. S. (2017) A null mutation in MICU2 causes abnormal mitochondrial calcium homeostasis and a severe neurodevelopmental disorder. Brain 140, 2806-2813"			610632		46.91499093	55.83843544	Class 1	-2.485729063	0.000189458	82044.66071	84352	Peripheral	20.09172694	95.40072636
Q96C03	MID49	Muscular system	"Morphology, dynamics & organization"	1				1	"Bartsakoulia M, Pyle A, Troncoso-Chandía D, Vial-Brizzi J, Paz-Fiblas MV, Duff J, Griffin H, Boczonadi V, Lochmüller H, Kleinle S, Chinnery PF, Grünert S, Kirschner J, Eisner V, Horvath R. A novel mechanism causing imbalance of mitochondrial fusion and fission in human myopathies. Hum Mol Genet. 2018 Apr 1;27(7):1186-1195. "			615498	619024	13.45824854	NaN	Class 1	-1.15556395	2.34461E-05	711.7142721	3043.314667	Ambiguous	70.91347714	85.6292753
L0R8F8;Q9NQG6	MID51;MIEF1-MP	Metabolism;Ophthalmic system;Others;Endocrine system	"Morphology, dynamics & organization"	1				1	"Charif M, Wong YC, Kim S, Guichet A, Vignal C, Zanlonghi X, Bensaid P, Procaccio V, Bonneau D, Amati-Bonneau P, Reynier P, Krainc D, Lenaers G. Dominant mutations in MIEF1 affect mitochondrial dynamics and cause a singular late onset optic neuropathy. Mol Neurodegener. 2021 Feb 25;16(1):12."			615497		NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q99797	MIPEP	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Gastrointestinal system"	Protein maturation & folding	1				1	"Eldomery, M. K., Akdemir, Z. C., Vogtle, F. N., Charng, W. L., Mulica, P., Rosenfeld, J. A., Gambin, T., Gu, S., Burrage, L. C., Al Shamsi, A., Penney, S., Jhangiani, S. N., Zimmerman, H. H., Muzny, D. M., Wang, X., Tang, J., Medikonda, R., Ramachandran, P. V., Wong, L. J., Boerwinkle, E., Gibbs, R. A., Eng, C. M., Lalani, S. R., Hertecant, J., Rodenburg, R. J., Abdul-Rahman, O. A., Yang, Y., Xia, F., Wang, M. C., Lupski, J. R., Meisinger, C., and Sutton, V. R. (2016) MIPEP recessive variants cause a syndrome of left ventricular non-compaction, hypotonia, and infantile death. Genome Med 8, 106"	"DISEASE: Combined oxidative phosphorylation deficiency 31 (COXPD31) [MIM:617228]: An autosomal recessive, severe mitochondrial disease with multisystemic manifestations appearing soon after birth or in early infancy. Clinical features include left ventricular non-compaction, global developmental delay, severe hypotonia, seizures, cataract, and abnormal movements. Death may occur in early childhood. {ECO:0000269|PubMed:27799064}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0086543;C4310661	602241	617228	72.84277091	70.48378316	Class 1	-1.741603306	0.000129859	153560.598	107945.9667	Peripheral	18.70378666	97.01858992
O95822	MLYCD	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Kidney and urinary tract;Others;Reproductive system"	Lipid metabolism	1				1		"DISEASE: Malonyl-CoA decarboxylase deficiency (MLYCD deficiency) [MIM:248360]: Autosomal recessive disease characterized by abdominal pain, chronic constipation, episodic vomiting, metabolic acidosis and malonic aciduria. {ECO:0000269|PubMed:10417274}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0342793;C3714756	606761	248360	Infinite	78.40216845	Class 1	-2.416453405	4.58596E-05	19051.95292	21297.13667	Peripheral	8.780401254	72.19538329
Q8IVH4	MMAA	Central nervous system;Failure to thrive;Gastrointestinal system	Cofactor metabolism	1				1		"DISEASE: Methylmalonic aciduria type cblA (MMAA) [MIM:251100]: A disorder of methylmalonate and cobalamin metabolism due to defective synthesis of adenosylcobalamin. {ECO:0000269|PubMed:12438653, ECO:0000269|PubMed:15308131, ECO:0000269|PubMed:15523652, ECO:0000269|PubMed:17957493, ECO:0000269|PubMed:20876572, ECO:0000269|PubMed:23026888, ECO:0000269|PubMed:28497574}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C1855109;C3714756	607481	251100	150.6628458	NaN	Class 1	-2.016428855	0.000368544	9130.621118	5555.406667	Peripheral	12.88000521	87.64925939
Q96EY8	MMAB	Central nervous system;Metabolism;Failure to thrive;Pulmonary system ;Gastrointestinal system;Hematologic system	Cofactor metabolism	1				1		"DISEASE: Methylmalonic aciduria type cblB (MMAB) [MIM:251110]: A disorder of methylmalonate and cobalamin metabolism due to defective synthesis of adenosylcobalamin. {ECO:0000269|PubMed:12471062, ECO:0000269|PubMed:15781192, ECO:0000269|PubMed:17957493}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0011581;C0220994;C1855102;C3714756	607568	251110	70.0644347	NaN	Class 1	-1.721956813	0.000157674	392683.6732	321327.3333	Peripheral	5.852004722	75.23913976
Q9H3L0	MMADHC	Central nervous system;Metabolism;Pulmonary system ;Hematologic system	Cofactor metabolism	1				1		"DISEASE: Methylmalonic aciduria and homocystinuria, cblD type (MAHCD) [MIM:277410]: An autosomal recessive disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Clinical features include developmental delay, hyotonia, mental retardation, seizures, megaloblastic anemia. Some patients manifest combined methylmalonic aciduria and homocystinuria (referred to as cblD original), some have only isolated homocystinuria (cblD variant 1), and others have only methylmalonic aciduria (cblD variant 2). {ECO:0000269|PubMed:18385497, ECO:0000269|PubMed:24722857, ECO:0000269|PubMed:26483544}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C1848552;C1848553;C1848554;C3714756	611935	277410	2.058856383	NaN	Class 4	0.344889348	0.298726613	6787.340374	24175.56667	Peripheral	15.98613593	91.43160835
Q9NZB8	MOCS1	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities"	Nucleotide/ nucleoside metabolism	1				1		"DISEASE: Molybdenum cofactor deficiency, complementation group A (MOCODA) [MIM:252150]: An autosomal recessive metabolic disorder leading to the pleiotropic loss of molybdoenzyme activities. It is clinically characterized by onset in infancy of poor feeding, intractable seizures, severe psychomotor retardation, and death in early childhood in most patients. {ECO:0000269|PubMed:12754701, ECO:0000269|PubMed:16021469, ECO:0000269|PubMed:9731530, ECO:0000269|PubMed:9921896}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0268119;C0543888;C1854988;C3714756	603707	252150	NaN	138.7250434	Class 2	-1.543428286	0.028662833	18985.55478	37394.78667	Peripheral	16.65960822	87.34027994
Q9Y5U8	MPC1	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Liver"	"Carriers, channels & transporters"	1				1	"Bricker, D. K., Taylor, E. B., Schell, J. C., Orsak, T., Boutron, A., Chen, Y. C., Cox, J. E., Cardon, C. M., Van Vranken, J. G., Dephoure, N., Redin, C., Boudina, S., Gygi, S. P., Brivet, M., Thummel, C. S., and Rutter, J. (2012) A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 337, 96-100"	"DISEASE: Mitochondrial pyruvate carrier deficiency (MPYCD) [MIM:614741]: An autosomal recessive metabolic disorder characterized by severely delayed psychomotor development, mild dysmorphic features, hepatomegaly, marked metabolic acidosis, hyperlactacidemia with normal lactate/pyruvate, and encephalopathy. Some patients have epilepsy and peripheral neuropathy. {ECO:0000269|PubMed:22628558}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0013146;C0013170;C0013222;C0029231;C0038580;C0038586;C0236969;C0740858;C0751651;C1510472;C3553607;C4316881	614738	614741	197.7634887	NaN	Class 1	-1.424356748	2.80549E-05	84012.40071	132767.3667	0	NaN	99.2035281
Q10713	MPPA	Central nervous system;Ears	Protein maturation & folding	1				1	"Jobling, R. K., Assoum, M., Gakh, O., Blaser, S., Raiman, J. A., Mignot, C., Roze, E., Durr, A., Brice, A., Levy, N., Prasad, C., Paton, T., Paterson, A. D., Roslin, N. M., Marshall, C. R., Desvignes, J. P., Roeckel-Trevisiol, N., Scherer, S. W., Rouleau, G. A., Megarbane, A., Isaya, G., Delague, V., and Yoon, G. (2015) PMPCA mutations cause abnormal mitochondrial protein processing in patients with non-progressive cerebellar ataxia. Brain 138, 1505-1517"	"DISEASE: Spinocerebellar ataxia, autosomal recessive, 2 (SCAR2) [MIM:213200]: A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR2 is characterized by onset of impaired motor development and ataxic gait in early childhood. Additional features often include loss of fine motor skills, dysarthria, nystagmus, cerebellar signs, and delayed cognitive development with intellectual disability. {ECO:0000269|PubMed:25808372, ECO:0000269|PubMed:26657514}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0266470;C0751651;C1859298	613036	213200	89.90925911	225.2458863	Class 1	-1.320281715	0.000500347	706870.7681	722745.6667	Peripheral	5.875775423	74.98158547
O75439	MPPB	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive"	Protein maturation & folding	1				1		"DISEASE: Multiple mitochondrial dysfunctions syndrome 6 (MMDS6) [MIM:617954]: An autosomal recessive, neurodegenerative disorder characterized by basal ganglia lesions, cerebellar atrophy, and neurologic regression in the first year of life. Common features include truncal hypotonia, lack of independent ambulation, poor speech, intellectual disability, and motor abnormalities, such as ataxia, dystonia, and spasticity. {ECO:0000269|PubMed:29576218}. Note=The disease is caused by mutations affecting the gene represented in this entry."		603131	617954	41.17855289	NaN	Class 1	-1.408107966	0.000162295	1025287.22	1034709.667	Peripheral	16.84728247	61.03791967
P39210	MPV17	Central nervous system;Metabolism;Muscular system;Liver;Peripheral nervous system;Skeletal system	Unknown	1				1	"Spinazzola, A., Viscomi, C., Fernandez-Vizarra, E., Carrara, F., D'Adamo, P., Calvo, S., Marsano, R. M., Donnini, C., Weiher, H., Strisciuglio, P., Parini, R., Sarzi, E., Chan, A., DiMauro, S., Rotig, A., Gasparini, P., Ferrero, I., Mootha, V. K., Tiranti, V., and Zeviani, M. (2006) MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet 38, 570-575"	"DISEASE: Mitochondrial DNA depletion syndrome 6 (MTDPS6) [MIM:256810]: A disease due to mitochondrial dysfunction. It is characterized by infantile onset of progressive liver failure, often leading to death in the first year of life, peripheral neuropathy, corneal scarring, acral ulceration and osteomyelitis leading to autoamputation, cerebral leukoencephalopathy, failure to thrive, and recurrent metabolic acidosis with intercurrent infections. {ECO:0000269|PubMed:16582907, ECO:0000269|PubMed:16582910, ECO:0000269|PubMed:16909392, ECO:0000269|PubMed:20074988, ECO:0000269|PubMed:26741492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007959;C0008370;C0009197;C0017668;C0022283;C0033687;C0036305;C0086432;C0391976;C0549567;C0751651;C0949855;C0949856;C0949857;C1112213;C1850406;C1850407;C3714756	137960	618400-256810	220.0550646	NaN	Class 1	-1.606511042	0.000503369	25542.81031	NaN	Integral	97.23248334	96.74821125
Q9UI43	MRM2	Central nervous system;Metabolism;Muscular system;Liver	RNA-related processes	1				1	"Garone, C., D'Souza, A. R., Dallabona, C., Lodi, T., Rebelo-Guiomar, P., Rorbach, J., Donati, M. A., Procopio, E., Montomoli, M., Guerrini, R., Zeviani, M., Calvo, S. E., Mootha, V. K., DiMauro, S., Ferrero, I., and Minczuk, M. (Aug 25, 2017) Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome. Hum Mol Genet 10.1093/hmg/ddx314"			606906	618567	7.844883329	NaN	Class 1	-3.30779308	8.57369E-05	59538.74941	51345	Peripheral	18.35191568	80.66857156
P52815	MRPL12	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Endocrine system"	Mitochondrial ribosomes	1				1	"Serre, V., Rozanska, A., Beinat, M., Chretien, D., Boddaert, N., Munnich, A., Rötig, A., and Chrzanowska-Lightowlers, Z. M. (2013) Mutations in mitochondrial ribosomal protein MRPL12 leads to growth retardation, neurological deterioration and mitochondrial translation deficiency. Biochim Biophys Acta 1832, 1304-1312"		C0152013;C0751651	602375		NaN	222.5088815	Class 4	-1.091209668	0.051210451	1244821.662	2041326.667	0	NaN	33.57139768
Q96A35	MRPL24	Central nervous system;Metabolism;Cardiovascular system	Mitochondrial ribosomes	1				1	"Di Nottia M, Marchese M, Verrigni D, Mutti CD, Torraco A, Oliva R, Fernandez-Vizarra E, Morani F, Trani G, Rizza T, Ghezzi D, Ardissone A, Nesti C, Vasco G, Zeviani M, Minczuk M, Bertini E, Santorelli FM, Carrozzo R. A homozygous MRPL24 mutation causes a complex movement disorder and affects the mitoribosome assembly. Neurobiol Dis. 2020 Jul;141:104880."			611836		57.7444828	NaN	Class 1	-2.827466791	5.66592E-05	350119.7681	304678.3333	Peripheral	25.78962839	74.26774666
P09001	MRPL3	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Liver	Mitochondrial ribosomes	1				1	"Galmiche, L., Serre, V., Beinat, M., Assouline, Z., Lebre, A. S., Chretien, D., Nietschke, P., Benes, V., Boddaert, N., Sidi, D., Brunelle, F., Rio, M., Munnich, A., and Rotig, A. (2011) Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy. Hum Mutat 32, 1225-1231"	"DISEASE: Combined oxidative phosphorylation deficiency 9 (COXPD9) [MIM:614582]: A mitochondrial disease characterized by failure to thrive, poor feeding, hypertrophic cardiomyopathy, hepatomegaly, and psychomotor retardation. Death in infancy has been observed in some cases. {ECO:0000269|PubMed:21786366}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007194;C0751651;C3281234	607118	614582	48.88642775	NaN	Class 1	-2.318036638	8.66714E-05	330727.821	206919.6667	Peripheral	4.878655922	86.2870859
Q9H9J2	MRPL44	Ophthalmic system;Cardiovascular system;Liver	Mitochondrial ribosomes	1				1	"Carroll, C. J., Isohanni, P., Poyhonen, R., Euro, L., Richter, U., Brilhante, V., Gotz, A., Lahtinen, T., Paetau, A., Pihko, H., Battersby, B. J., Tyynismaa, H., and Suomalainen, A. (2013) Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy. J Med Genet 50, 151-159"	"DISEASE: Combined oxidative phosphorylation deficiency 16 (COXPD16) [MIM:615395]: An autosomal recessive, mitochondrial disorder characterized by hypertrophic cardiomyopathy, liver steatosis, and decreased levels of mitochondrial complexes I and IV in heart and skeletal muscle. {ECO:0000269|PubMed:23315540}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3809339	611849	615395	68.41804135	86.28184538	Class 1	-1.666530778	0.000129083	326273.2847	299408.6667	Ambiguous	56.99010173	77.4721974
O60783	MRPS14	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Gastrointestinal system;Others"	Mitochondrial ribosomes	1				1	"Jackson CB, Huemer M, Bolognini R, Martin F, Szinnai G, Donner BC, Richter U, Battersby BJ, Nuoffer JM, Suomalainen A, Schaller A. A variant in MRPS14 (uS14m) causes perinatal hypertrophic cardiomyopathy with neonatal lactic acidosis, growth retardation, dysmorphic features and neurological involvement. Hum Mol Genet. 2019 Feb 15;28(4):639-649."			611978	618378	106.8570751	135.2063266	Class 1	-3.028211897	3.7676E-06	198728.4833	225033	Ambiguous	52.10387952	80.01405228
Q9Y3D3	MRPS16	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Integumentary system"	Mitochondrial ribosomes	1				1	"Miller, C., Saada, A., Shaul, N., Shabtai, N., Ben-Shalom, E., Shaag, A., Hershkovitz, E., and Elpeleg, O. (2004) Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation. Ann Neurol 56, 734-738"	DISEASE: Combined oxidative phosphorylation deficiency 2 (COXPD2) [MIM:610498]: A mitochondrial disease resulting in fatal neonatal metabolic acidosis with agenesis of the corpus callosum. {ECO:0000269|PubMed:15505824}. Note=The disease is caused by mutations affecting the gene represented in this entry.	C0023520;C0751651;C1864843	609204	610498	111.1871354	NaN	Class 1	-2.075034087	5.08283E-05	369447.0063	339592.3333	Peripheral	38.02048117	91.01922988
Q9Y399	MRPS2	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Muscular system;Ears"	Mitochondrial ribosomes	1				1		"DISEASE: Combined oxidative phosphorylation deficiency 36 (COXPD36) [MIM:617950]: An autosomal recessive, multisystem disease resulting from deficiencies of mitochondrial respiratory enzyme complexes and mitochondrial dysfunction. Clinical manifestations include sensorineural hearing impairment, mild developmental delay, hypoglycemia, and intellectual disability. {ECO:0000269|PubMed:29576219}. Note=The disease is caused by mutations affecting the gene represented in this entry."		611971	617950	41.57844078	NaN	Class 1	-1.844004136	8.96816E-05	338065.4332	394038	Peripheral	21.10228498	88.06703344
G5E9V5;G5E9W7;P82650	MRPS22	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Peripheral nervous system;Kidney and urinary tract;Endocrine system;Reproductive system"	Mitochondrial ribosomes	1				1	"Saada, A., Shaag, A., Arnon, S., Dolfin, T., Miller, C., Fuchs-Telem, D., Lombes, A., and Elpeleg, O. (2007) Antenatal mitochondrial disease caused by mitochondrial ribosomal protein (MRPS22) mutation. J Med Genet 44, 784-786"	"DISEASE: Combined oxidative phosphorylation deficiency 5 (COXPD5) [MIM:611719]: A mitochondrial disease resulting in severe metabolic acidosis, edema, hypertrophic cardiomyopathy, tubulopathy, and hypotonia. {ECO:0000269|PubMed:17873122}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Ovarian dysgenesis 7 (ODG7) [MIM:618117]: A form of ovarian dysgenesis, a disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads. ODG7 is an autosomal recessive condition. {ECO:0000269|PubMed:29566152}. Note=The disease may be caused by mutations affecting the gene represented in this entry."	C0006142;C0678222;C0751651;C1257931;C1458155;C2673642;C3714756	605810	611719-618117	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9Y3D9	MRPS23	Liver	Mitochondrial ribosomes	1				1	"Kohda, M., Tokuzawa, Y., Kishita, Y., Nyuzuki, H., Moriyama, Y., Mizuno, Y., Hirata, T., Yatsuka, Y., Yamashita-Sugahara, Y., Nakachi, Y., Kato, H., Okuda, A., Tamaru, S., Borna, N. N., Banshoya, K., Aigaki, T., Sato-Miyata, Y., Ohnuma, K., Suzuki, T., Nagao, A., Maehata, H., Matsuda, F., Higasa, K., Nagasaki, M., Yasuda, J., Yamamoto, M., Fushimi, T., Shimura, M., Kaiho-Ichimoto, K., Harashima, H., Yamazaki, T., Mori, M., Murayama, K., Ohtake, A., and Okazaki, Y. (2016) A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies. PLoS Genet 12, e1005679"	DISEASE: Note=Defects in MRPS23 may play a role in mitochondrial disorders characterized by combined respiratory chain complex deficiencies. {ECO:0000269|PubMed:26741492}.	C0006142;C0678222;C0751651;C1257931;C1458155	611985		37.05302591	NaN	Class 1	-2.013758636	9.01503E-05	502920.4618	478399	Peripheral	12.42905892	83.52885073
P82663	MRPS25	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Muscular system;Gastrointestinal system;Skeletal system;Others;Endocrine system"	Mitochondrial ribosomes	1				1	"Bugiardini E, Mitchell AL, Rosa ID, Horning-Do HT, Pitmann AM, Poole OV, Holton JL, Shah S, Woodward C, Hargreaves I, Quinlivan R, Amunts A, Wiesner RJ, Houlden H, Holt IJ, Hanna MG, Pitceathly RDS, Spinazzola A. MRPS25 mutations impair mitochondrial translation and cause encephalomyopathy. Hum Mol Genet. 2019 Aug 15;28(16):2711-2719."			611987	619025	172.4148738	NaN	Class 1	-2.890351435	9.17986E-06	591097.0823	501959.6667	Peripheral	24.72563985	84.70076331
Q9Y2Q9	MRPS28	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Ears;Liver;Gastrointestinal system"	Mitochondrial ribosomes	1				1	"Pulman J, Ruzzenente B, Bianchi L, Rio M, Boddaert N, Munnich A, Rötig A, Metodiev MD. Mutations in the MRPS28 gene encoding the small mitoribosomal subunit protein bS1m in a patient with intrauterine growth retardation, craniofacial dysmorphism and multisystemic involvement. Hum Mol Genet. 2019 May 1;28(9):1445-1462."			611990	618958	40.4753594	NaN	Class 1	-1.889568619	0.000144693	414458.1054	327398.3333	Peripheral	22.67651864	83.98574288
P82930	MRPS34	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system ;Skeletal system"	Mitochondrial ribosomes	1				1	"Lake, N. J., Webb, B. D., Stroud, D. A., Richman, T. R., Ruzzenente, B., Compton, A. G., Mountford, H. S., Pulman, J., Zangarelli, C., Rio, M., Bodaert, N., Assouline, Z., Sherpa, M. D., Schadt, E. E., Houten, S. M., Byrnes, J., McCormick, E. M., Zolkipli-Cunningham, Z., Haude, K., Zhang, Z., Retterer, K., Bai, R., Calvo, S. E., Mootha, V. K., Christodoulou, J., Rotig, A., Filipovska, A., Cristian, I., Falk, M. J., Metodiev, M. D., and Thorburn, D. R. (2017) Biallelic Mutations in MRPS34 Lead to Instability of the Small Mitoribosomal Subunit and Leigh Syndrome. Am. J. Hum. Genet. 101, 239-254"	"DISEASE: Combined oxidative phosphorylation deficiency 32 (COXPD32) [MIM:617664]: An autosomal recessive disorder due to deficiency of mitochondrial respiratory chain complexes, I, III and IV, and characterized by delayed psychomotor development and neurodevelopmental regression. Additional variable symptoms include poor or absent speech, inability to walk, and abnormal movements. {ECO:0000269|PubMed:28777931}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C4540029	611994	617664	NaN	76.52987927	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q96EY7	MRPS39	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system ;Ears"	Mitochondrial ribosomes	1				1	"Borna NN, Kishita Y, Kohda M, Lim SC, Shimura M, Wu Y, Mogushi K, Yatsuka Y, Harashima H, Hisatomi Y, Fushimi T, Ichimoto K, Murayama K, Ohtake A, Okazaki Y. Mitochondrial ribosomal protein PTCD3 mutations cause oxidative phosphorylation defects with Leigh syndrome. Neurogenetics. 2019 Mar;20(1):9-25."			614918	619057	94.32762899	79.20317886	Class 1	-2.394168474	3.37004E-05	357874.741	302768	Peripheral	39.14028329	88.19640061
Q9Y2R9	MRPS7	Central nervous system;Metabolism;Failure to thrive;Ears;Liver;Gastrointestinal system;Hematologic system;Kidney and urinary tract;Endocrine system	Mitochondrial ribosomes	1				1	"Menezes, M. J., Guo, Y., Zhang, J., Riley, L. G., Cooper, S. T., Thorburn, D. R., Li, J., Dong, D., Li, Z., Glessner, J., Davis, R. L., Sue, C. M., Alexander, S. I., Arbuckle, S., Kirwan, P., Keating, B. J., Xu, X., Hakonarson, H., and Christodoulou, J. (2015) Mutation in mitochondrial ribosomal protein S7 (MRPS7) causes congenital sensorineural deafness, progressive hepatic and renal failure and lactic acidemia. Hum Mol Genet 24, 2297-2307"	"DISEASE: Combined oxidative phosphorylation deficiency 34 (COXPD34) [MIM:617872]: An autosomal recessive disorder caused by mitochondrial dysfunction and combined respiratory chain deficiencies of complexes I, III and IV. Clinical manifestations are variable and include congenital sensorineural deafness, lactic acidemia, and progressive hepatic and renal failure. {ECO:0000269|PubMed:25556185}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006142;C0678222;C0751651;C1257931;C1458155	611974	617872	29.94331944	NaN	Class 1	-2.104627067	0.000205852	607187.1529	854770.3333	Peripheral	15.79743554	85.83821489
Q9BUK6	MSTO1	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Muscular system;Ears;Peripheral nervous system;Skeletal system;Endocrine system;Reproductive system"	"Morphology, dynamics & organization"	1				1	"Gal, A., Balicza, P., Weaver, D., Naghdi, S., Joseph, S. K., Varnai, P., Gyuris, T., Horvath, A., Nagy, L., Seifert, E. L., Molnar, M. J., and Hajnoczky, G. (2017) MSTO1 is a cytoplasmic pro-mitochondrial fusion protein, whose mutation induces myopathy and ataxia in humans. EMBO Mol Med 9, 967-984;Nasca, A., Scotton, C., Zaharieva, I., Neri, M., Selvatici, R., Magnusson, O. T., Gal, A., Weaver, D., Rossi, R., Armaroli, A., Pane, M., Phadke, R., Sarkozy, A., Muntoni, F., Hughes, I., Cecconi, A., Hajnoczky, G., Donati, A., Mercuri, E., Zeviani, M., Ferlini, A., and Ghezzi, D. (2017) Recessive mutations in MSTO1 cause mitochondrial dynamics impairment, leading to myopathy and ataxia. Hum Mutat 38, 970-977"	"DISEASE: Myopathy, mitochondrial, and ataxia (MMYAT) [MIM:617675]: A neuromuscular disorder characterized by muscle weakness and atrophy, ataxia, poor growth, delayed motor development, dysdiadochokinesia, dysmetria and additional neurologic features. Some patients show skeletal and endocrine anomalies, as well as behavioral psychiatric manifestations. MMYAT transmission pattern is consistent with autosomal dominant inheritance in some families, and autosomal recessive inheritance in others. {ECO:0000269|PubMed:28544275, ECO:0000269|PubMed:28554942}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C4540096	617619	617675	NaN	NaN	Class 4	-0.060894994	0.734868684	1357.575306	50166.53333	0	NaN	NaN
P00846	MT-ATP6	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Muscular system;Peripheral nervous system	OXPHOS complex subunits	1				1	"Holt, I. J., Harding, A. E., Petty, R. K., and Morgan-Hughes, J. A. (1990) A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am. J. Hum. Genet. 46, 428-433"	"DISEASE: Ataxia and polyneuropathy, adult-onset (APAO) [MIM:500010]: A mitochondrial disease characterized by ataxia, axonal sensorimotor polyneuropathy, abnormal eye movements, and dysarthria. {ECO:0000269|PubMed:16049925, ECO:0000269|PubMed:18055910}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Cardiomyopathy, infantile hypertrophic (CMHI) [MIM:500006]: An infantile form of hypertrophic cardiomyopathy, a heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:19188198}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes. {ECO:0000269|PubMed:7726182}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:17352390, ECO:0000269|PubMed:8395787, ECO:0000269|PubMed:9270604, ECO:0000269|PubMed:9501263, ECO:0000269|PubMed:9556461}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex V deficiency, mitochondrial 1 (MC5DM1) [MIM:516060]: A mitochondrial disorder with heterogeneous clinical manifestations including neuropathy, ataxia, hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy can present with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray, absent to severe left ventricular outflow tract obstruction, and distinct septal contours/morphologies with extremely varying clinical course. {ECO:0000269|PubMed:16049925, ECO:0000269|PubMed:18055910}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial infantile bilateral striatal necrosis (MIBSN) [MIM:500003]: Bilateral striatal necrosis is a neurological disorder resembling Leigh syndrome. {ECO:0000269|PubMed:7668837}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Myopathy, lactic acidosis, and sideroblastic anemia 3 (MLASA3) [MIM:500011]: A rare mitochondrial disorder characterized by sideroblastic anemia, muscle weakness, and exercise intolerance associated with persistent lactic acidemia. Additional MLASA3 features are failure to thrive, hearing loss, epilepsy, stroke-like episodes, and severe developmental delay. {ECO:0000269|PubMed:25037980}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Neuropathy, ataxia, and retinitis pigmentosa (NARP) [MIM:551500]: A syndrome characterized by variable combination of developmental delay, psychomotor retardation, hearing loss, optic atrophy and retinitis pigmentosa, dementia, seizures, ataxia, proximal neurogenic muscle weakness, and sensory neuropathy. {ECO:0000269|PubMed:2137962}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0011849;C0020564;C0023264;C0036341;C0271650;C0342779;C0795996;C0917796;C1328349;C1838916;C1838951;C1839022;C1850597;C1850598;C1850599;C1850600;C2748884;C2931092;C2931891;C3275684;C4016603;C4225415;C4225591	516060	mitomap	110.1084861	272.0267949	Class 1	-2.386546656	6.29748E-05	1498767.228	2090513.333	0	NaN	97.37650778
P03928	MT-ATP8	Central nervous system;Metabolism;Cardiovascular system;Peripheral nervous system	OXPHOS complex subunits	1				1	"Jonckheere, A. I., Hogeveen, M., Nijtmans, L. G., van den Brand, M. A., Janssen, A. J., Diepstra, J. H., van den Brandt, F. C., van den Heuvel, L. P., Hol, F. A., Hofste, T. G., Kapusta, L., Dillmann, U., Shamdeen, M. G., Smeitink, J. A., and Rodenburg, R. J. (2008) A novel mitochondrial ATP8 gene mutation in a patient with apical hypertrophic cardiomyopathy and neuropathy. J Med Genet 45, 129-133"	"DISEASE: Cardiomyopathy, infantile hypertrophic (CMHI) [MIM:500006]: An infantile form of hypertrophic cardiomyopathy, a heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:19188198}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry.;DISEASE: Mitochondrial complex V deficiency, mitochondrial 2 (MC5DM2) [MIM:516070]: A mitochondrial disorder with heterogeneous clinical manifestations including neuropathy, ataxia, hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy can present with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray, absent to severe left ventricular outflow tract obstruction, and distinct septal contours/morphologies with extremely varying clinical course. {ECO:0000269|PubMed:19188198}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0022541;C0342779;C2748884;C3275685;C3275686;C3888025	516070		242.5760621	594.5857507	Class 1	-2.309172709	4.30393E-05	1056256.901	675025.3333	Integral	71.4497906	92.79138277
P00395	MT-CO1	Central nervous system;Metabolism;Ophthalmic system;Muscular system;Ears;Hematologic system	OXPHOS complex subunits	1				1	"Reid, F. M., Vernham, G. A., and Jacobs, H. T. (1994) A novel mitochondrial point mutation in a maternal pedigree with sensorineural deafness. Hum Mutat 3, 243-247"	"DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:16407113, ECO:0000269|PubMed:19218458}. Note=The gene represented in this entry may be involved in disease pathogenesis.;DISEASE: Deafness, sensorineural, mitochondrial (DFNM) [MIM:500008]: A form of non-syndromic deafness with maternal inheritance. Affected individuals manifest progressive, postlingual, sensorineural hearing loss involving high frequencies. {ECO:0000269|PubMed:10577941}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes. {ECO:0000269|PubMed:1322638}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex IV deficiency (MT-C4D) [MIM:220110]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations, ranging from isolated myopathy to severe multisystem disease affecting several tissues and organs. Features include hypertrophic cardiomyopathy, hepatomegaly and liver dysfunction, hypotonia, muscle weakness, exercise intolerance, developmental delay, delayed motor development and mental retardation. Some affected individuals manifest a fatal hypertrophic cardiomyopathy resulting in neonatal death. A subset of patients manifest Leigh syndrome. {ECO:0000269|PubMed:12140182, ECO:0000269|PubMed:16284789}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Note=MT-CO1 may play a role in the pathogenesis of acquired idiopathic sideroblastic anemia, a disease characterized by inadequate formation of heme and excessive accumulation of iron in mitochondria. Mitochondrial iron overload may be attributable to mutations of mitochondrial DNA because these can cause respiratory chain dysfunction, thereby impairing reduction of ferric iron to ferrous iron. The reduced form of iron is essential to the last step of mitochondrial heme biosynthesis. {ECO:0000269|PubMed:9389715, ECO:0000269|PubMed:9851701}.;DISEASE: Recurrent myoglobinuria mitochondrial (RM-MT) [MIM:550500]: Recurrent myoglobinuria is characterized by recurrent attacks of rhabdomyolysis (necrosis or disintegration of skeletal muscle) associated with muscle pain and weakness, and followed by excretion of myoglobin in the urine. {ECO:0000269|PubMed:10980727}. Note=The gene represented in this entry may be involved in disease pathogenesis."	C0007097;C0020564;C0024667;C0024668;C0033141;C0036529;C0162671;C0205696;C0205697;C0205698;C0205699;C0268237;C0699790;C0878544;C0917796;C1257925;C1527249;C1838854;C1857332;C4274324	516030	mitomap	Infinite	NaN	Class 1	-2.340291664	0.000136228	49770.06193	220212.6667	0	NaN	96.02121059
P00403	MT-CO2	Central nervous system;Metabolism;Muscular system;Ears	OXPHOS complex subunits	1				1	"Clark, K. M., Taylor, R. W., Johnson, M. A., Chinnery, P. F., Chrzanowska-Lightowlers, Z. M., Andrews, R. M., Nelson, I. P., Wood, N. W., Lamont, P. J., Hanna, M. G., Lightowlers, R. N., and Turnbull, D. M. (1999) An mtDNA mutation in the initiation codon of the cytochrome C oxidase subunit II gene results in lower levels of the protein and a mitochondrial encephalomyopathy. Am. J. Hum. Genet. 64, 1330-1339"	"DISEASE: Mitochondrial complex IV deficiency (MT-C4D) [MIM:220110]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations, ranging from isolated myopathy to severe multisystem disease affecting several tissues and organs. Features include hypertrophic cardiomyopathy, hepatomegaly and liver dysfunction, hypotonia, muscle weakness, exercise intolerance, developmental delay, delayed motor development and mental retardation. Some affected individuals manifest a fatal hypertrophic cardiomyopathy resulting in neonatal death. A subset of patients manifest Leigh syndrome. {ECO:0000269|PubMed:10486321}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002152;C0011570;C0011581;C0011853;C0027819;C0038433;C0162671;C0268237;C1527249	516040	mitomap	150.7396188	187.1034882	Class 1	-2.584699815	0.00013951	1840931.851	2948416.667	Integral	97.26003203	96.66914533
P00414	MT-CO3	Central nervous system;Metabolism;Ophthalmic system;Muscular system	OXPHOS complex subunits	1				1		"DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes. {ECO:0000269|PubMed:8240356}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex IV deficiency (MT-C4D) [MIM:220110]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations, ranging from isolated myopathy to severe multisystem disease affecting several tissues and organs. Features include hypertrophic cardiomyopathy, hepatomegaly and liver dysfunction, hypotonia, muscle weakness, exercise intolerance, developmental delay, delayed motor development and mental retardation. Some affected individuals manifest a fatal hypertrophic cardiomyopathy resulting in neonatal death. A subset of patients manifest Leigh syndrome. {ECO:0000269|PubMed:8630495}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Recurrent myoglobinuria mitochondrial (RM-MT) [MIM:550500]: Recurrent myoglobinuria is characterized by recurrent attacks of rhabdomyolysis (necrosis or disintegration of skeletal muscle) associated with muscle pain and weakness, and followed by excretion of myoglobin in the urine. {ECO:0000269|PubMed:8630495}. Note=The gene represented in this entry may be involved in disease pathogenesis."	C0014556;C0014558;C0162671;C0268237;C0393672;C0393682;C0917796;C4274324	516050	mitomap	124.118962	246.3520848	Class 1	-2.577528613	0.000269863	222762.929	484661.3333	0	NaN	96.23980004
P00156	MT-CYB	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Muscular system"	OXPHOS complex subunits	1				1	"Andreu, A. L., Hanna, M. G., Reichmann, H., Bruno, C., Penn, A. S., Tanji, K., Pallotti, F., Iwata, S., Bonilla, E., Lach, B., Morgan-Hughes, J., and DiMauro, S. (1999) Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med 341, 1037-1044"	"DISEASE: Cardiomyopathy, infantile histiocytoid (CMIH) [MIM:500000]: A heart disease characterized by the presence of pale granular foamy histiocyte-like cells within the myocardium. It usually affects children younger than 2 years of age, with a clear predominance of females over males. Infants present with dysrhythmia or cardiac arrest. The clinical course is usually fulminant, sometimes simulating sudden infant death syndrome. {ECO:0000269|PubMed:10960495}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes. {ECO:0000269|PubMed:1732158}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry.;DISEASE: Note=Defects in MT-CYB are a rare cause of mitochondrial dysfunction underlying different myopathies. They include mitochondrial encephalomyopathy, hypertrophic cardiomyopathy (HCM), and sporadic mitochondrial myopathy (MM). In mitochondrial myopathy, exercise intolerance is the predominant symptom. Additional features include lactic acidosis, muscle weakness and/or myoglobinuria. Defects in MTCYB are also found in cases of exercise intolerance accompanied by deafness, mental retardation, retinitis pigmentosa, cataract, growth retardation, epilepsy (multisystem disorder). {ECO:0000269|PubMed:11047755, ECO:0000269|PubMed:11601507}."	C0162671;C0342778;C0917796;C1527249;C1708371	516020	mitomap	192.9965205	NaN	Class 1	-2.127263892	7.71899E-05	11496.74053	NaN	0	NaN	87.51763605
Q96DP5	MTFMT	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Tumors	tRNA related processes	1				1	"Tucker, E. J., Hershman, S. G., Kohrer, C., Belcher-Timme, C. A., Patel, J., Goldberger, O. A., Christodoulou, J., Silberstein, J. M., McKenzie, M., Ryan, M. T., Compton, A. G., Jaffe, J. D., Carr, S. A., Calvo, S. E., RajBhandary, U. L., Thorburn, D. R., and Mootha, V. K. (2011) Mutations in MTFMT underlie a human disorder of formylation causing impaired mitochondrial translation. Cell Metab 14, 428-434"	"DISEASE: Combined oxidative phosphorylation deficiency 15 (COXPD15) [MIM:614947]: An autosomal recessive, mitochondrial, neurologic disorder characterized by features of Leigh syndrome and combined oxidative phosphorylation deficiency. Clinical features include mild global developmental delay, white matter abnormalities, ataxia, incoordination, speech and reading difficulties, T2-weighted hyperintensities in the basal ganglia, corpus callosum, and brainstem. {ECO:0000269|PubMed:21907147}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:22499348}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3554182;C3714756	611766	614947-618248	2306.035892	187.6521353	Class 1	-3.158773384	4.23187E-06	24727.68142	12366.43333	Peripheral	17.17864265	78.58852834
P49914	MTHFS	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Gastrointestinal system;Hematologic system;Others"	Cofactor metabolism	1				1	"Romero JA, Abdelmoumen I, Hasbani D, Khurana DS, Schneider MC. A case of 5,10-methenyltetrahydrofolate synthetase deficiency due to biallelic null mutations with novel findings of elevated neopterin and macrocytic anemia. Mol Genet Metab Rep. 2019 Nov 21;21:100545. Rodan LH, Qi W, Ducker GS, Demirbas D, Laine R, Yang E, Walker MA, Eichler F, Rabinowitz JD, Anselm I, Berry GT; Undiagnosed Diseases Network (UDN). 5,10-methenyltetrahydrofolate synthetase deficiency causes a neurometabolic disorder associated with microcephaly, epilepsy, and cerebral hypomyelination. Mol Genet Metab. 2018 Sep;125(1-2):118-126."			604197	618367	Infinite	NaN	Class 2	-1.83236332	0.009000223	38474.5147	185180.6667	Peripheral	8.817974387	91.33637418
D6RJI2;D6RA73;P38646	mt-HSP70	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Skeletal system;Hematologic system;Kidney and urinary tract;Integumentary system"	Fe-S protein biogenesis	1				1		"DISEASE: Anemia, sideroblastic, 4 (SIDBA4) [MIM:182170]: A form of sideroblastic anemia, a bone marrow disorder defined by the presence of pathologic iron deposits in erythroblast mitochondria. Sideroblastic anemia is characterized by anemia of varying severity, hypochromic peripheral erythrocytes, systemic iron overload secondary to chronic ineffective erythropoiesis, and the presence of bone marrow ringed sideroblasts. Sideroblasts are characterized by iron-loaded mitochondria clustered around the nucleus. SIDBA4 has been reported to be inherited as an autosomal recessive disease, with a pseudodominant pattern of inheritance in some families. {ECO:0000269|PubMed:26491070}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Even-plus syndrome (EVPLS) [MIM:616854]: An autosomal recessive syndrome characterized by epiphyseal and vertebral dysplasia, prenatal-onset short stature, a distinct craniofacial phenotype with microtia, a flat facial profile with flat nose and triangular nares, cardiac malformations, and additional findings such as anal atresia, hypodontia, aplasia cutis, and others. {ECO:0000269|PubMed:26598328}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002896;C0004364;C0007134;C0019693;C0030567;C0036341;C0042164;C0151744;C0221765;C0279702;C0376618;C0520459;C0751651;C1266042;C1266043;C1266044;C1306837;C2239176;C4225180;C4225428;C4274077;C4505456	600548	182170-616854	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P03886	MT-ND1	Central nervous system;Metabolism;Ophthalmic system;Muscular system	OXPHOS complex subunits	1				1	"Huoponen, K., Vilkki, J., Aula, P., Nikoskelainen, E. K., and Savontaus, M. L. (1991) A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy. Am. J. Hum. Genet. 48, 1147-1153"	"DISEASE: Alzheimer disease mitochondrial (AD-MT) [MIM:502500]: Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. {ECO:0000269|PubMed:8104867}. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry.;DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:15265369, ECO:0000269|PubMed:7733935}. Note=The gene represented in this entry may be involved in disease pathogenesis.;DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes. {ECO:0000269|PubMed:1417830, ECO:0000269|PubMed:1674640, ECO:0000269|PubMed:1900003, ECO:0000269|PubMed:1928099, ECO:0000269|PubMed:1959619, ECO:0000269|PubMed:2018041}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:24105702}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome (MELAS) [MIM:540000]: Genetically heterogeneous disorder, characterized by episodic vomiting, seizures, and recurrent cerebral insults resembling strokes and causing hemiparesis, hemianopsia, or cortical blindness. {ECO:0000269|PubMed:8723687}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002152;C0005586;C0011853;C0038433;C0162671;C0917796;C1838979;C1838990;C2931092;C2936907	516000	mitomap	253.2274762	302.3975288	Class 1	-2.269631603	0.000489275	178686.2874	140786.6667	0	NaN	96.06199431
P03891	MT-ND2	Central nervous system;Metabolism;Ophthalmic system	OXPHOS complex subunits	1				1	"Ugalde, C., Hinttala, R., Timal, S., Smeets, R., Rodenburg, R. J., Uusimaa, J., van Heuvel, L. P., Nijtmans, L. G., Majamaa, K., and Smeitink, J. A. (2007) Mutated ND2 impairs mitochondrial complex I assembly and leads to Leigh syndrome. Mol Genet Metab 90, 10-14"	"DISEASE: Alzheimer disease mitochondrial (AD-MT) [MIM:502500]: Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. {ECO:0000269|PubMed:1370613}. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry.;DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes. {ECO:0000269|PubMed:1732158, ECO:0000269|PubMed:1900003}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0917796;C1838990;C2931092;C2936907	516001	mitomap	Infinite	NaN	Class 1	-2.31894897	0.000163328	4966.522525	32776.4	0	NaN	NaN
P03897	MT-ND3	Central nervous system;Metabolism;Ophthalmic system	OXPHOS complex subunits	1				1	"McFarland, R., Kirby, D. M., Fowler, K. J., Ohtake, A., Ryan, M. T., Amor, D. J., Fletcher, J. M., Dixon, J. W., Collins, F. A., Turnbull, D. M., Taylor, R. W., and Thorburn, D. R. (2004) De novo mutations in the mitochondrial ND3 gene as a cause of infantile mitochondrial encephalopathy and complex I deficiency. Ann Neurol 55, 58-64"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:17152068}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:11456298, ECO:0000269|PubMed:14705112, ECO:0000269|PubMed:20818383}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C1838951;C1838979;C1850597;C1850598;C1850599;C1850600;C2931092;C2931891;C2936907;C4304725	516002	mitomap	51.51116428	127.561579	Class 1	-2.364010102	7.22892E-05	7683.626686	35441.2	0	NaN	96.85105495
P03905	MT-ND4	Central nervous system;Metabolism;Ophthalmic system;Muscular system;Endocrine system	OXPHOS complex subunits	1				1	"Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., and Nikoskelainen, E. K. (1988) Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242, 1427-1430"	"DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes. {ECO:0000269|PubMed:1959619, ECO:0000269|PubMed:1959931, ECO:0000269|PubMed:3201231, ECO:0000269|PubMed:9452107}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leber hereditary optic neuropathy with dystonia (LDYT) [MIM:500001]: Part of a spectrum of Leber hereditary optic neuropathy. It is characterized by the association of optic atrophy and central vision loss with dystonia. {ECO:0000269|PubMed:8644732}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome (MELAS) [MIM:540000]: Genetically heterogeneous disorder, characterized by episodic vomiting, seizures, and recurrent cerebral insults resembling strokes and causing hemiparesis, hemianopsia, or cortical blindness. {ECO:0000269|PubMed:1323207}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0029125;C0036341;C0162671;C0917796;C1838854;C1839040;C2931092;C4304725	516003	mitomap	184.907721	293.7855201	Class 1	-2.195368476	7.55953E-05	93558.72602	175271.1	0	NaN	96.46535154
P03901	MT-ND4L	Metabolism;Ophthalmic system	OXPHOS complex subunits	1				1	"Brown, M. D., Starikovskaya, E., Derbeneva, O., Hosseini, S., Allen, J. C., Mikhailovskaya, I. E., Sukernik, R. I., and Wallace, D. C. (2002) The role of mtDNA background in disease expression: a new primary LHON mutation associated with Western Eurasian haplogroup J. Hum Genet 110, 130-138"	"DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes. {ECO:0000269|PubMed:8680405}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0917796;C1527249	516004	mitomap	NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
P03915	MT-ND5	Central nervous system;Metabolism;Ophthalmic system	OXPHOS complex subunits	1				1	"Santorelli, F. M., Tanji, K., Kulikova, R., Shanske, S., Vilarinho, L., Hays, A. P., and DiMauro, S. (1997) Identification of a novel mutation in the mtDNA ND5 gene associated with MELAS. Biochem Biophys Res Commun 238, 326-328"	"DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes. {ECO:0000269|PubMed:16240359, ECO:0000269|PubMed:1732158, ECO:0000269|PubMed:1900003, ECO:0000269|PubMed:8213825}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:11938446, ECO:0000269|PubMed:12796552, ECO:0000269|PubMed:17400793}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:12509858, ECO:0000269|PubMed:15767514, ECO:0000269|PubMed:17400793, ECO:0000269|PubMed:20818383}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome (MELAS) [MIM:540000]: Genetically heterogeneous disorder, characterized by episodic vomiting, seizures, and recurrent cerebral insults resembling strokes and causing hemiparesis, hemianopsia, or cortical blindness. {ECO:0000269|PubMed:12509858, ECO:0000269|PubMed:15767514, ECO:0000269|PubMed:17400793, ECO:0000269|PubMed:9299505}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0162671;C0162672;C0917796;C1838951;C1838979;C1850597;C1850598;C1850599;C1850600;C2931092;C2931891;C2936907	516005	mitomap	121.3568203	233.6885739	Class 1	-2.043956496	0.000248801	74069.74306	65337.16667	Integral	92.69980816	96.62965862
P03923	MT-ND6	Central nervous system;Metabolism;Ophthalmic system;Ears	OXPHOS complex subunits	1				1	"Jun, A. S., Brown, M. D., and Wallace, D. C. (1994) A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. Proc Natl Acad Sci U S A 91, 6206-6210"	"DISEASE: Leber hereditary optic neuropathy (LHON) [MIM:535000]: A maternally inherited disease resulting in acute or subacute loss of central vision, due to optic nerve dysfunction. Cardiac conduction defects and neurological defects have also been described in some patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes. {ECO:0000269|PubMed:10447650, ECO:0000269|PubMed:11133798, ECO:0000269|PubMed:1417830, ECO:0000269|PubMed:8854108, ECO:0000269|PubMed:9452107}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leber hereditary optic neuropathy with dystonia (LDYT) [MIM:500001]: Part of a spectrum of Leber hereditary optic neuropathy. It is characterized by the association of optic atrophy and central vision loss with dystonia. {ECO:0000269|PubMed:8016139, ECO:0000269|PubMed:8644732}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:14595656, ECO:0000269|PubMed:20818383}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome (MELAS) [MIM:540000]: Genetically heterogeneous disorder, characterized by episodic vomiting, seizures, and recurrent cerebral insults resembling strokes and causing hemiparesis, hemianopsia, or cortical blindness. {ECO:0000269|PubMed:11781695}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0029125;C0162671;C0917796;C1838979;C1839040;C2931092;C2936907;C4304725	516006	mitomap	NaN	142.7123366	Class 1	-2.557167656	0.000755954	8645.03551	57818.33333	Integral	90.82430547	97.5463416
Q9Y2Z2	MTO1	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Liver	tRNA related processes	1				1	"Ghezzi, D., Baruffini, E., Haack, T. B., Invernizzi, F., Melchionda, L., Dallabona, C., Strom, T. M., Parini, R., Burlina, A. B., Meitinger, T., Prokisch, H., Ferrero, I., and Zeviani, M. (2012) Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis. Am. J. Hum. Genet. 90, 1079-1087"	"DISEASE: Combined oxidative phosphorylation deficiency 10 (COXPD10) [MIM:614702]: An autosomal recessive disorder resulting in variable defects of mitochondrial oxidative respiration. Affected individuals present in infancy with hypertrophic cardiomyopathy and lactic acidosis. The severity is variable, but can be fatal in the most severe cases. {ECO:0000269|PubMed:22608499}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3553529;C3714756	614667	614702	11.29126822	21.68899624	Class 1	-2.829898133	0.00036261	44019.94707	58989.46667	Ambiguous	32.32643608	78.38919976
Q9NVV4	MTPAP	Central nervous system;Ophthalmic system	RNA-related processes	1				1	"Crosby, A. H., Patel, H., Chioza, B. A., Proukakis, C., Gurtz, K., Patton, M. A., Sharifi, R., Harlalka, G., Simpson, M. A., Dick, K., Reed, J. A., Al-Memar, A., Chrzanowska-Lightowlers, Z. M., Cross, H. E., and Lightowlers, R. N. (2010) Defective mitochondrial mRNA maturation is associated with spastic ataxia. Am. J. Hum. Genet. 87, 655-660"	"DISEASE: Spastic ataxia 4, autosomal recessive (SPAX4) [MIM:613672]: A slowly progressive neurodegenerative disease characterized by cerebellar ataxia, spastic paraparesis, dysarthria, and optic atrophy. {ECO:0000269|PubMed:20970105}. Note=The disease is caused by mutations affecting the gene represented in this entry. MTPAP mutations result in a defect of mitochondrial mRNA maturation. Affected individuals exhibit a drastic decrease in poly(A) tail length of mitochondrial mRNA transcripts, including COX1 and RNA14 (PubMed:20970105). {ECO:0000269|PubMed:20970105}."	C0004138;C0025202;C0037773;C0751651;C3150925;C3714756	613669	613672	90.12134288	87.36216672	Class 1	-1.609989278	0.000248143	140276.6737	99176.86667	Peripheral	17.10829424	93.81805766
O75431	MTX2	Central nervous system;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Liver;Skeletal system;Kidney and urinary tract;Reproductive system;Integumentary system	Protein import & biogenesis	1				1	"Elouej S, Harhouri K, Le Mao M, Baujat G, Nampoothiri S, Kayserili H, Menabawy NA, Selim L, Paneque AL, Kubisch C, Lessel D, Rubinsztajn R, Charar C, Bartoli C, Airault C, Deleuze JF, Rötig A, Bauer P, Pereira C, Loh A, Escande-Beillard N, Muchir A, Martino L, Gruenbaum Y, Lee SH, Manivet P, Lenaers G, Reversade B, Lévy N, De Sandre-Giovannoli A. Loss of MTX2 causes mandibuloacral dysplasia and links mitochondrial dysfunction to altered nuclear morphology. Nat Commun. 2020 Sep 11;11(1):4589."			608555	619127	284.70973	NaN	Class 1	-1.641841265	7.93457E-05	605818.626	340408.3333	Peripheral	14.82286227	95.70363902
P22033	MUT	Central nervous system;Metabolism;Failure to thrive;Gastrointestinal system	Lipid metabolism	1				1		"DISEASE: Methylmalonic aciduria type mut (MMAM) [MIM:251000]: An often fatal disorder of organic acid metabolism. Common clinical features include lethargy, vomiting, failure to thrive, hypotonia, neurological deficit and early death. Two forms of the disease are distinguished by the presence (mut-) or absence (mut0) of residual enzyme activity. Mut0 patients have more severe neurological manifestations of the disease than do MUT- patients. MMAM is unresponsive to vitamin B12 therapy. {ECO:0000269|PubMed:10923046, ECO:0000269|PubMed:11350191, ECO:0000269|PubMed:1346616, ECO:0000269|PubMed:1351030, ECO:0000269|PubMed:15643616, ECO:0000269|PubMed:15781192, ECO:0000269|PubMed:16281286, ECO:0000269|PubMed:1670635, ECO:0000269|PubMed:17113806, ECO:0000269|PubMed:17957493, ECO:0000269|PubMed:19588269, ECO:0000269|PubMed:1977311, ECO:0000269|PubMed:1980486, ECO:0000269|PubMed:22727635, ECO:0000269|PubMed:25125334, ECO:0000269|PubMed:26615597, ECO:0000269|PubMed:27167370, ECO:0000269|PubMed:28101778, ECO:0000269|PubMed:7909321, ECO:0000269|PubMed:7912889, ECO:0000269|PubMed:9285782, ECO:0000269|PubMed:9452100, ECO:0000269|PubMed:9554742}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0025521;C0028754;C0268583;C1855114;C1855115;C1855116;C1855119	609058	251000	26.07237735	75.96136894	Class 3	-0.791884067	0.001491247	209819.5702	160457.6667	Soluble	10.66577797	42.57885987
Q9UIF7	MUTYH	Tumors	DNA-related processes	1				1		"DISEASE: Familial adenomatous polyposis 2 (FAP2) [MIM:608456]: A condition characterized by the development of multiple colorectal adenomatous polyps, benign neoplasms derived from glandular epithelium. Some affected individuals may develop colorectal carcinoma. {ECO:0000269|PubMed:11818965, ECO:0000269|PubMed:12606733, ECO:0000269|PubMed:12853198, ECO:0000269|PubMed:15366000, ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:18091433, ECO:0000269|PubMed:18515411, ECO:0000269|PubMed:19953527, ECO:0000269|PubMed:20418187, ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570, ECO:0000269|PubMed:26694661}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. {ECO:0000269|PubMed:15273732, ECO:0000269|PubMed:25820570}. Note=The gene represented in this entry may be involved in disease pathogenesis. Somatic mutations contribute to the development of a sub-set of sporadic gastric cancers in carriers of Helicobacter pylori (PubMed:15273732). {ECO:0000269|PubMed:15273732}."	C0006826;C0007102;C0009375;C0017185;C0024623;C0032580;C0038356;C0153943;C0154060;C0206711;C0346153;C0496905;C0699790;C0699791;C1140680;C1319315;C1527249;C1708349;C1837991;C2713442;C2713443;C3150911	604933	608456-613659	NaN	NaN	NaN	NaN	NaN	NaN	238.383	0	NaN	NaN
Q5U5X0	MZM1L	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Muscular system;Hematologic system;Others	OXPHOS assembly & stability	1				1	"Invernizzi, F., Tigano, M., Dallabona, C., Donnini, C., Ferrero, I., Cremonte, M., Ghezzi, D., Lamperti, C., and Zeviani, M. (2013) A homozygous mutation in LYRM7/MZM1L associated with early onset encephalopathy, lactic acidosis, and severe reduction of mitochondrial complex III activity. Hum Mutat 34, 1619-1622"	"DISEASE: Mitochondrial complex III deficiency, nuclear 8 (MC3DN8) [MIM:615838]: A form of mitochondrial complex III deficiency, a disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. Clinical features include mitochondrial encephalopathy, psychomotor retardation, ataxia, severe failure to thrive, liver dysfunction, renal tubulopathy, muscle weakness and exercise intolerance. {ECO:0000269|PubMed:24014394}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0342778;C0751651;C1852372;C4014440	615831	615838	110.1266951	149.6530801	Class 1	-1.683735369	0.000246306	742791.9225	676680	Peripheral	4.094167051	72.2410062
B7Z8V7;Q4G0N4	NADK2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Gastrointestinal system;Kidney and urinary tract"	Cofactor metabolism	1				1	"Houten, S. M., Denis, S., Te Brinke, H., Jongejan, A., van Kampen, A. H., Bradley, E. J., Baas, F., Hennekam, R. C., Millington, D. S., Young, S. P., Frazier, D. M., Gucsavas-Calikoglu, M., and Wanders, R. J. (2014) Mitochondrial NADP(H) deficiency due to a mutation in NADK2 causes dienoyl-CoA reductase deficiency with hyperlysinemia. Hum Mol Genet 23, 5009-5016"	"DISEASE: 2,4-dienoyl-CoA reductase deficiency (DECRD) [MIM:616034]: A rare, autosomal recessive, inborn error of polyunsaturated fatty acids and lysine metabolism, resulting in mitochondrial dysfunction. Affected individuals have a severe encephalopathy with neurologic and metabolic abnormalities beginning in early infancy. Laboratory studies show increased C10:2 carnitine levels and hyperlysinemia. {ECO:0000269|PubMed:24847004}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C1857252;C3714756	615787	616034	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q8N159	NAGS	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Gastrointestinal system	Other known processes	1				1		"DISEASE: N-acetylglutamate synthase deficiency (NAGSD) [MIM:237310]: Rare autosomal recessively inherited metabolic disorder leading to severe neonatal or late-onset hyperammonemia without increased excretion of orotic acid. Clinical symptoms are somnolence, tachypnea, feeding difficulties, a severe neurologic presentation characterized by uncontrollable movements, developmental delay, visual impairment, failure to thrive and hyperammonemia precipitated by the introduction of high-protein diet or febrile illness. {ECO:0000269|PubMed:12754705, ECO:0000269|PubMed:15878741, ECO:0000269|PubMed:27037498}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0268543;C3714756	608300	237310	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q96I59	NARS2	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Muscular system;Gastrointestinal system;Skeletal system"	tRNA related processes	1				1	"Simon, M., Richard, E. M., Wang, X., Shahzad, M., Huang, V. H., Qaiser, T. A., Potluri, P., Mahl, S. E., Davila, A., Nazli, S., Hancock, S., Yu, M., Gargus, J., Chang, R., Al-Sheqaih, N., Newman, W. G., Abdenur, J., Starr, A., Hegde, R., Dorn, T., Busch, A., Park, E., Wu, J., Schwenzer, H., Flierl, A., Florentz, C., Sissler, M., Khan, S. N., Li, R., Guan, M. X., Friedman, T. B., Wu, D. K., Procaccio, V., Riazuddin, S., Wallace, D. C., Ahmed, Z. M., Huang, T., and Riazuddin, S. (2015) Mutations of human NARS2, encoding the mitochondrial asparaginyl-tRNA synthetase, cause nonsyndromic deafness and Leigh syndrome. PLoS Genet 11, e1005097;Sofou, K., Kollberg, G., Holmstrom, M., Davila, M., Darin, N., Gustafsson, C. M., Holme, E., Oldfors, A., Tulinius, M., and Asin-Cayuela, J. (2015) Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome. Mol Genet Genomic Med 3, 59-68;Vanlander, A. V., Menten, B., Smet, J., De Meirleir, L., Sante, T., De Paepe, B., Seneca, S., Pearce, S. F., Powell, C. A., Vergult, S., Michotte, A., De Latter, E., Vantomme, L., Minczuk, M., and Van Coster, R. (2015) Two siblings with homozygous pathogenic splice-site variant in mitochondrial asparaginyl-tRNA synthetase (NARS2). Hum Mutat 36, 222-231"	"DISEASE: Combined oxidative phosphorylation deficiency 24 (COXPD24) [MIM:616239]: An autosomal recessive mitochondrial disorder with wide phenotypic variability. Some patients have a milder form affecting only skeletal muscle, whereas others may have a more severe disorder, reminiscent of Alpers syndrome. Alpers syndrome is a progressive neurodegenerative disorder that presents in infancy or early childhood and is characterized by diffuse degeneration of cerebral gray matter. {ECO:0000269|PubMed:25385316, ECO:0000269|PubMed:25629079}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:25807530}. Note=The disease may be caused by mutations affecting the gene represented in this entry."	C0023264;C0543888;C0751651;C1838951;C1850597;C1850598;C1850599;C1850600;C2931891;C4015643	612803	616239	205.1460927	151.095628	Class 1	-1.366632984	0.000613343	92634.83592	80552.06667	Soluble	10.04692056	29.61977554
Q8IW45;Q8IW45	NAXD	Central nervous system;Cardiovascular system;Others;Integumentary system	Cofactor metabolism	1				1	"Van Bergen NJ, Guo Y, Rankin J, Paczia N, Becker-Kettern J, Kremer LS, Pyle A, Conrotte JF, Ellaway C, Procopis P, Prelog K, Homfray T, Baptista J, Baple E, Wakeling M, Massey S, Kay DP, Shukla A, Girisha KM, Lewis LES, Santra S, Power R, Daubeney P, Montoya J, Ruiz-Pesini E, Kovacs-Nagy R, Pritsch M, Ahting U, Thorburn DR, Prokisch H, Taylor RW, Christodoulou J, Linster CL, Ellard S, Hakonarson H. NAD(P)HX dehydratase (NAXD) deficiency: a novel neurodegenerative disorder exacerbated by febrile illnesses. Brain. 2019 Jan 1;142(1):50-58."			615910	618321	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q8NCW5	NAXE	Central nervous system;Metabolism;Pulmonary system ;Others;Reproductive system;Integumentary system	Cofactor metabolism	1				1	"Kremer, L. S., Danhauser, K., Herebian, D., Petkovic Ramadza, D., Piekutowska-Abramczuk, D., Seibt, A., Muller-Felber, W., Haack, T. B., Ploski, R., Lohmeier, K., Schneider, D., Klee, D., Rokicki, D., Mayatepek, E., Strom, T. M., Meitinger, T., Klopstock, T., Pronicka, E., Mayr, J. A., Baric, I., Distelmaier, F., and Prokisch, H. (2016) NAXE Mutations Disrupt the Cellular NAD(P)HX Repair System and Cause a Lethal Neurometabolic Disorder of Early Childhood. Am. J. Hum. Genet. 99, 894-902"	"DISEASE: Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy (PEBEL) [MIM:617186]: An autosomal recessive severe neurometabolic disorder characterized by severe leukoencephalopathy usually associated with a trivial febrile illness. Affected infants tend to show normal early development followed by acute psychomotor regression with ataxia, hypotonia, respiratory insufficiency, and seizures. Disease course is rapidly progressive, leading to coma, global brain atrophy, and death in the first years of life. Brain imaging shows multiple abnormalities, including brain edema and signal abnormalities in the cortical and subcortical regions. {ECO:0000269|PubMed:27122014, ECO:0000269|PubMed:27616477}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C0751651;C4310675	608862	617186	204.4030546	NaN	Class 1	-1.737967166	0.000246827	163884.4311	1073999.667	Soluble	8.434067828	7.149341956
O15239	NDUFA1	Central nervous system;Metabolism	OXPHOS complex subunits	1				1	"Fernandez-Moreira, D., Ugalde, C., Smeets, R., Rodenburg, R. J., Lopez-Laso, E., Ruiz-Falco, M. L., Briones, P., Martin, M. A., Smeitink, J. A., and Arenas, J. (2007) X-linked NDUFA1 gene mutations associated with mitochondrial encephalomyopathy. Ann Neurol 61, 73-83"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:17262856}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C1527249;C1838979;C2936907	300078	301020	Infinite	NaN	Class 1	-1.862208124	0.005509816	85479.66417	162108.5	Integral	85.92124272	96.49960656
O95299;C9J6X0	NDUFA10	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system "	OXPHOS complex subunits	1				1	"Hoefs, S. J., van Spronsen, F. J., Lenssen, E. W., Nijtmans, L. G., Rodenburg, R. J., Smeitink, J. A., and van den Heuvel, L. P. (2011) NDUFA10 mutations cause complex I deficiency in a patient with Leigh disease. Eur J Hum Genet 19, 270-274"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:21150889}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0543888;C0751267;C0751268;C0751651;C1838951;C1850597;C1850598;C1850599;C1850600;C2931891;C3714756	603835	618243	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q86Y39	NDUFA11	Central nervous system;Metabolism;Cardiovascular system	OXPHOS complex subunits	1				1	"Berger, I., Hershkovitz, E., Shaag, A., Edvardson, S., Saada, A., and Elpeleg, O. (2008) Mitochondrial complex I deficiency caused by a deleterious NDUFA11 mutation. Ann Neurol 63, 405-408"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:18306244}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C1838979;C2936907;C3714756	612638	618236	77.92006505	NaN	Class 1	-1.438633046	0.001179134	576775.3338	626849.3333	Integral	98.9705479	94.16539689
Q9UI09	NDUFA12	Central nervous system;Skeletal system;Integumentary system	OXPHOS complex subunits	1				1	"Ostergaard, E., Rodenburg, R. J., van den Brand, M., Thomsen, L. L., Duno, M., Batbayli, M., Wibrand, F., and Nijtmans, L. (2011) Respiratory chain complex I deficiency due to NDUFA12 mutations as a new cause of Leigh syndrome. J Med Genet 48, 737-740"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:21617257}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0751267;C0751268;C0751651;C3714756	614530	618244	22.78767912	NaN	Class 1	-1.870702426	7.11632E-05	1065655.614	539275.6667	Integral	86.16915393	97.42010313
Q9P0J0	NDUFA13	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Ears;Tumors	OXPHOS complex subunits	1				1	"Angebault, C., Charif, M., Guegen, N., Piro-Megy, C., Mousson de Camaret, B., Procaccio, V., Guichet, P. O., Hebrard, M., Manes, G., Leboucq, N., Rivier, F., Hamel, C. P., Lenaers, G., and Roubertie, A. (2015) Mutation in NDUFA13/GRIM19 leads to early onset hypotonia, dyskinesia and sensorial deficiencies, and mitochondrial complex I instability. Hum Mol Genet 24, 3948-3955"	"DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type. {ECO:0000269|PubMed:15841082}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;DISEASE: Note=Defects in NDUFA13 are a cause of a mitochondrial complex I deficiency characterized by early onset hypotonia, dyskinesia and sensorial deficiencies, as well as a severe optic neuropathy. {ECO:0000269|PubMed:25901006}."	C0238463;C0749424;C0751651	609435	618249-607464	65.71282425	63.03756454	Class 1	-2.49124886	0.000148567	1013008.385	1160714.333	Integral	83.70070886	95.67796016
O43678	NDUFA2	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system	OXPHOS complex subunits	1				1	"Hoefs, S. J., Dieteren, C. E., Distelmaier, F., Janssen, R. J., Epplen, A., Swarts, H. G., Forkink, M., Rodenburg, R. J., Nijtmans, L. G., Willems, P. H., Smeitink, J. A., and van den Heuvel, L. P. (2008) NDUFA2 complex I mutation leads to Leigh disease. Am. J. Hum. Genet. 82, 1306-1315"		C0006142;C0023264;C0023520;C0024623;C0038356;C0235874;C0543888;C0751267;C0751268;C0751651;C1708349;C2751843	602137	618235	25.34255282	49.44190025	Class 1	-2.292069999	2.65369E-06	787183.7418	758193.6667	Ambiguous	62.26124392	85.92723316
O00483	NDUFA4	Central nervous system;Metabolism;Failure to thrive;Peripheral nervous system;Others	OXPHOS assembly & stability	1				1	"Pitceathly, Robert D. S., Rahman, S., Wedatilake, Y., Polke, James M., Cirak, S., Foley, A. R., Sailer, A., Hurles, Matthew E., Stalker, J., Hargreaves, I., Woodward, Cathy E., Sweeney, Mary G., Muntoni, F., Houlden, H., Taanman, J.-W., and Hanna, Michael G. (2013) NDUFA4 Mutations Underlie Dysfunction of a Cytochrome c Oxidase Subunit Linked to Human Neurological Disease. Cell Reports 3, 1795-1805"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:23746447}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651	603833		7.547889393	11.31425347	Class 1	-2.350429724	7.99639E-05	1466869.635	1439981.667	Integral	97.08718606	97.62370042
P56556	NDUFA6	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Gastrointestinal system;Hematologic system"	OXPHOS complex subunits	1				1	"Alston, C. L., Heidler, J., Dibley, M. G., Kremer, L. S., Taylor, L. S., Fratter, C., French, C. E., Glasgow, R. I. C., Feichtinger, R. G., Delon, I., Pagnamenta, A. T., Dolling, H., and 19 others. Bi-allelic mutations in NDUFA6 establish its role in early-onset isolated mitochondrial complex I deficiency. Am. J. Hum. Genet. 103: 592-601, 2018."			602138	618253	13.36362725	NaN	Class 1	-1.541980185	3.96836E-05	584019.4294	335007.3333	Peripheral	50.65706783	94.98024597
P51970	NDUFA8	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Others"	OXPHOS complex subunits	1				1	"Yatsuka Y, Kishita Y, Formosa LE, Shimura M, Nozaki F, Fujii T, Nitta KR, Ohtake A, Murayama K, Ryan MT, Okazaki Y. A homozygous variant in NDUFA8 is associated with developmental delay, microcephaly, and epilepsy due to mitochondrial complex I deficiency. Clin Genet. 2020 Aug;98(2):155-165. Tort F, Barredo E, Parthasarathy R, Ugarteburu O, Ferrer-Cortès X, García-Villoria J, Gort L, González-Quintana A, Martín MA, Fernández-Vizarra E, Zeviani M, Ribes A. Biallelic mutations in NDUFA8 cause complex I deficiency in two siblings with favorable clinical evolution. Mol Genet Metab. 2020 Nov;131(3):349-357. "			603359	619272	44.98746324	81.19944561	Class 1	-2.861536923	3.21013E-05	713262.0052	812775.3333	Integral	68.9696161	90.89001857
Q16795	NDUFA9	Central nervous system;Metabolism;Ophthalmic system;Pulmonary system ;Ears	OXPHOS complex subunits	1				1	"van den Bosch, B. J., Gerards, M., Sluiter, W., Stegmann, A. P., Jongen, E. L., Hellebrekers, D. M., Oegema, R., Lambrichs, E. H., Prokisch, H., Danhauser, K., Schoonderwoerd, K., de Coo, I. F., and Smeets, H. J. (2012) Defective NDUFA9 as a novel cause of neonatally fatal complex I disease. J Med Genet 49, 10-15"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:22114105}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0751267;C0751268;C0751651;C1838951;C1850597;C1850598;C1850599;C1850600;C2931891;C3714756	603834	618247	20.96238182	42.66516599	Class 4	-0.267487979	0.020047307	583238.6508	627558.6667	Integral	89.07818204	96.92794405
Q9Y375	NDUFAF1	Metabolism;Ophthalmic system;Failure to thrive;Cardiovascular system;Muscular system	OXPHOS assembly & stability	1				1	"Dunning, C. J., McKenzie, M., Sugiana, C., Lazarou, M., Silke, J., Connelly, A., Fletcher, J. M., Kirby, D. M., Thorburn, D. R., and Ryan, M. T. (2007) Human CIA30 is involved in the early assembly of mitochondrial complex I and mutations in its gene cause disease. EMBO J 26, 3227-3237"		C0023520;C0751651;C1838979;C2936907	606934	618234	27.87373272	NaN	Class 1	-1.816200762	0.000186088	162768.7877	180703.6333	Peripheral	46.20495883	94.72584714
Q8N183	NDUFAF2	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Gastrointestinal system;Kidney and urinary tract	OXPHOS assembly & stability	1				1	"Ogilvie, I., Kennaway, N. G., and Shoubridge, E. A. (2005) A molecular chaperone for mitochondrial complex I assembly is mutated in a progressive encephalopathy. J Clin Invest 115, 2784-2792"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:20571988}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:16200211}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0543888;C0751267;C0751268;C0751651;C0752107;C0752109;C0752110;C1838979;C2936907;C3714756	609653	618233	91.14387688	130.7814185	Class 1	-2.472018445	3.41489E-05	735647.0711	655200.6667	Ambiguous	61.3519522	76.31910345
Q9BU61	NDUFAF3	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities"	OXPHOS assembly & stability	1				1	"Saada, A., Vogel, R. O., Hoefs, S. J., van den Brand, M. A., Wessels, H. J., Willems, P. H., Venselaar, H., Shaag, A., Barghuti, F., Reish, O., Shohat, M., Huynen, M. A., Smeitink, J. A., van den Heuvel, L. P., and Nijtmans, L. G. (2009) Mutations in NDUFAF3 (C3ORF60), encoding an NDUFAF4 (C6ORF66)-interacting complex I assembly protein, cause fatal neonatal mitochondrial disease. Am. J. Hum. Genet. 84, 718-727"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:19463981}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C1838979;C2936907;C3714756	612911	618240	47.83452615	36.08464734	Class 1	-2.204808555	0.000434446	344218.5121	333367	Integral	84.8206809	92.18257939
Q9P032	NDUFAF4	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Muscular system;Skeletal system	OXPHOS assembly & stability	1				1	"Saada, A., Edvardson, S., Rapoport, M., Shaag, A., Amry, K., Miller, C., Lorberboum-Galski, H., and Elpeleg, O. (2008) C6ORF66 is an assembly factor of mitochondrial complex I. Am. J. Hum. Genet. 82, 32-38"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:18179882}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C1838979;C2936907	611776	618237	207.6392105	69.92985499	Class 1	-2.234471045	2.18339E-05	586984.4851	504013	Integral	76.06099562	97.16333272
Q5TEU4	NDUFAF5	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Endocrine system"	OXPHOS assembly & stability	1				1	"Sugiana, C., Pagliarini, D. J., McKenzie, M., Kirby, D. M., Salemi, R., Abu-Amero, K. K., Dahl, H. H., Hutchison, W. M., Vascotto, K. A., Smith, S. M., Newbold, R. F., Christodoulou, J., Calvo, S., Mootha, V. K., Ryan, M. T., and Thorburn, D. R. (2008) Mutation of C20orf7 disrupts complex I assembly and causes lethal neonatal mitochondrial disease. Am. J. Hum. Genet.  83, 468-478"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:19542079, ECO:0000269|PubMed:21607760}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:18940309}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0543888;C0751651;C1838951;C1838979;C1850597;C1850598;C1850599;C1850600;C2931891;C2936907;C3714756	612360	618238	207.0009555	NaN	Class 1	-1.278576845	0.004498116	25640.58062	25269.83333	Peripheral	5.912490699	86.06035433
Q330K2	NDUFAF6	Central nervous system;Metabolism	OXPHOS assembly & stability	1				1	"Pagliarini, D. J., Calvo, S. E., Chang, B., Sheth, S. A., Vafai, S. B., Ong, S. E., Walford, G. A., Sugiana, C., Boneh, A., Chen, W. K., Hill, D. E., Vidal, M., Evans, J. G., Thorburn, D. R., Carr, S. A., and Mootha, V. K. (2008) A mitochondrial protein compendium elucidates complex I disease biology. Cell 134, 112-123"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:18614015, ECO:0000269|PubMed:22019594, ECO:0000269|PubMed:26741492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0751267;C0751268;C0751651;C1838979;C2936907	612392	618239	Infinite	NaN	Class 1	-1.528093411	0.000387841	26866.86184	15609.96667	Peripheral	19.24779807	95.59905634
Q7L592	NDUFAF7	Ophthalmic system	OXPHOS assembly & stability	1				1	"Wang B, Liu Y, Chen S, Wu Y, Lin S, Duan Y, Zheng K, Zhang L, Gu X, Hong W, Shao H, Zeng X, Sun B, Duan S. Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4182-4192."	"DISEASE: Note=Defects in NDUFAF7 may be a cause of susceptibility to pathologic myopia, a genetically heterogeneous disorder characterized by extreme, familial, early-onset vision loss and described as myopia accompanied by severe deformation of the eye besides excessive elongation of the eye. {ECO:0000269|PubMed:28837730}."		615898		64.39985382	NaN	Class 1	-1.807799068	0.00028713	111707.3628	146459.0667	Peripheral	15.29393474	96.52209443
A1L188	NDUFAF8	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system ;Gastrointestinal system"	OXPHOS assembly & stability	1				1	"Alston, C. L., Veling, M. T., Heidler, J., Taylor, L. S., Alaimo, J. T., Sung, A. Y., He, L., Hopton, S., Broomfield, A., Pavaine, J., Diaz, J., Leon, E., Wolf, P., McFarland, R., Prokisch, H., Wortmann, S. B., Bonnen, P. E., Wittig, I., Pagliarini, D. J., Taylor, R. W. Pathogenic bi-allelic mutations in NDUFAF8 cause Leigh syndrome with an isolated complex I deficiency. Am. J. Hum. Genet. 106: 92-101, 2020."			618461	618776	127.445285	140.3654972	Class 1	-0.953705946	0.001985696	23313.37306	16729.47	Ambiguous	15.88973141	47.17988048
O96000	NDUFB10	"Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system "	OXPHOS complex subunits	1				1	"Friederich, M. W., Erdogan, A. J., Coughlin, C. R., 2nd, Elos, M. T., Jiang, H., O'Rourke, C. P., Lovell, M. A., Wartchow, E., Gowan, K., Chatfield, K. C., Chick, W. S., Spector, E. B., Van Hove, J. L. K., and Riemer, J. (2017) Mutations in the accessory subunit NDUFB10 result in isolated complex I deficiency and illustrate the critical role of intermembrane space import for complex I holoenzyme assembly. Hum Mol Genet 26, 702-716"		C0751651;C2936907	603843		36.08056901	NaN	Class 1	-1.892019874	9.00879E-05	821782.994	931173	Integral	96.40940204	91.61036832
Q9NX14	NDUFB11	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system "	OXPHOS complex subunits	1				1	"van Rahden, V. A., Fernandez-Vizarra, E., Alawi, M., Brand, K., Fellmann, F., Horn, D., Zeviani, M., and Kutsche, K. (2015) Mutations in NDUFB11, encoding a complex I component of the mitochondrial respiratory chain, cause microphthalmia with linear skin defects syndrome. Am. J. Hum. Genet.  96, 640-650"	"DISEASE: Linear skin defects with multiple congenital anomalies 3 (LSDMCA3) [MIM:300952]: A disorder characterized by dermal, ocular, neurological and cardiac abnormalities. LSDMCA3 clinical features include linear skin defects on face and neck at birth, lacrimal duct atresia, myopia, nystagmus, strabismus, cardiomyopathy, axial hypotonia, seizures, corpus callosum agenesis, and dilation of lateral ventricles. {ECO:0000269|PubMed:25772934}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:26741492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C0796070;C1838979;C2936907;C4225421	300403	301021-300952	NaN	96.47487626	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
O43676	NDUFB3	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system ;Muscular system"	OXPHOS complex subunits	1				1	"Calvo, S. E., Compton, A. G., Hershman, S. G., Lim, S. C., Lieber, D. S., Tucker, E. J., Laskowski, A., Garone, C., Liu, S., Jaffe, D. B., Christodoulou, J., Fletcher, J. M., Bruno, D. L., Goldblatt, J., Dimauro, S., Thorburn, D. R., and Mootha, V. K. (2012) Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med 4, 118ra110"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:22499348, ECO:0000269|PubMed:27091925}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C1838979;C2936907	603839	618246	30.56203733	NaN	Class 1	-1.571679849	0.000290795	860758.9828	782333	0	NaN	90.32687676
P17568	NDUFB7	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system "	OXPHOS complex subunits	1				1	"Correia SP, Moedas MF, Naess K, Bruhn H, Maffezzini C, Calvo-Garrido J, Lesko N, Wibom R, Schober FA, Jemt A, Stranneheim H, Freyer C, Wedell A, Wredenberg A. Severe congenital lactic acidosis and hypertrophic cardiomyopathy caused by an intronic variant in NDUFB7. Hum Mutat. 2021 Apr;42(4):378-384."			603842		56.36569857	122.5172017	Class 1	-2.049614945	5.18593E-05	599473.4755	514345	Integral	92.01085887	94.35596819
O95169	NDUFB8	Central nervous system;Metabolism;Failure to thrive;Pulmonary system ;Muscular system;Gastrointestinal system	OXPHOS complex subunits	1				1	"Piekutowska-Abramczuk D, Assouline Z, Matakovi_ L, Feichtinger RG, Ko_a_iková E, Jurkiewicz E, Stawi_ski P, Gusic M, Koller A, Pollak A, Gasperowicz P, Trubicka J, Ciara E, Iwanicka-Pronicka K, Rokicki D, Hanein S, Wortmann SB, Sperl W, Rötig A, Prokisch H, Pronicka E, P_oski R, Barcia G, Mayr JA. NDUFB8 Mutations Cause Mitochondrial Complex I Deficiency in Individuals with Leigh-like Encephalomyopathy. Am J Hum Genet. 2018 Mar 1;102(3):460-467."			602140	618252	59.91593111	NaN	Class 1	-1.974120509	0.000111349	284063.9867	416152.3333	Integral	98.51592802	93.65939417
Q9Y6M9	NDUFB9	Central nervous system;Metabolism	OXPHOS complex subunits	1				1	"Haack, T. B., Madignier, F., Herzer, M., Lamantea, E., Danhauser, K., Invernizzi, F., Koch, J., Freitag, M., Drost, R., Hillier, I., Haberberger, B., Mayr, J. A., Ahting, U., Tiranti, V., Rotig, A., Iuso, A., Horvath, R., Tesarova, M., Baric, I., Uziel, G., Rolinski, B., Sperl, W., Meitinger, T., Zeviani, M., Freisinger, P., and Prokisch, H. (2012) Mutation screening of 75 candidate genes in 152 complex I deficiency cases identifies pathogenic variants in 16 genes including NDUFB9. J Med Genet 49, 83-89"		C0043094;C0751651;C1838979;C2936907	601445	618245	30.34990386	NaN	Class 1	-2.171065306	5.59252E-05	547905.1729	536514.6667	Integral	96.39653952	92.96210592
O95298;E9PQ53	NDUFC2;NDUFC2-KCTD14	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system"	OXPHOS complex subunits	1				1	"Alahmad A, Nasca A, Heidler J, Thompson K, Oláhová M, Legati A, Lamantea E, Meisterknecht J, Spagnolo M, He L, Alameer S, Hakami F, Almehdar A, Ardissone A, Alston CL, McFarland R, Wittig I, Ghezzi D, Taylor RW. Bi-allelic pathogenic variants in NDUFC2 cause early-onset Leigh syndrome and stalled biogenesis of complex I. EMBO Mol Med. 2020 Nov 6;12(11):e12619."			603845	619170	47.75085458	NaN	Class 1	-2.20375135	4.27843E-05	428400.2667	330256.3333	0	NaN	95.27031076
P28331;P28331	NDUFS1	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Liver;Hematologic system	OXPHOS complex subunits	1				1	"Benit, P., Chretien, D., Kadhom, N., de Lonlay-Debeney, P., Cormier-Daire, V., Cabral, A., Peudenier, S., Rustin, P., Munnich, A., and Rotig, A. (2001) Large-scale deletion and point mutations of the nuclear NDUFV1 and NDUFS1 genes in mitochondrial complex I deficiency. Am. J. Hum. Genet. 68, 1344-1352"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:11349233}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007194;C0023520;C0024623;C0036341;C0038356;C0235874;C0543888;C0751651;C1656427;C1708349;C1838979;C2936907;C3714756	157655	618226	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O75306	NDUFS2	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Cardiovascular system	OXPHOS complex subunits	1				1	"Loeffen, J., Elpeleg, O., Smeitink, J., Smeets, R., Stockler-Ipsiroglu, S., Mandel, H., Sengers, R., Trijbels, F., and van den Heuvel, L. (2001) Mutations in the complex I NDUFS2 gene of patients with cardiomyopathy and encephalomyopathy. Ann Neurol 49, 195-201"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:11220739}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C0033141;C0036529;C0162666;C0543888;C0751651;C0878544;C0917796;C1838979;C2936907;C3714756;C4302111	602985	618228	25.20382633	85.26087506	Class 1	-2.140288393	7.78241E-05	581172.0678	767464	Integral	60.06766402	94.39224221
O75489	NDUFS3	Central nervous system;Metabolism;Muscular system;Gastrointestinal system;Skeletal system	OXPHOS complex subunits	1				1	"Benit, P., Slama, A., Cartault, F., Giurgea, I., Chretien, D., Lebon, S., Marsac, C., Munnich, A., Rotig, A., and Rustin, P. (2004) Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome. J Med Genet 41, 14-17"		C0006142;C0023264;C0029124;C0678222;C0751267;C0751268;C0751651;C1257931;C1458155;C1838979;C2936907;C3714756	603846	618230	26.54022694	91.45297909	Class 1	-2.186121463	6.51395E-05	692656.0687	812901.3333	Peripheral	50.05407639	95.00411152
O43181	NDUFS4	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Gastrointestinal system"	OXPHOS complex subunits	1				1	"van den Heuvel, L., Ruitenbeek, W., Smeets, R., Gelman-Kohan, Z., Elpeleg, O., Loeffen, J., Trijbels, F., Mariman, E., de Bruijn, D., and Smeitink, J. (1998) Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit. Am. J. Hum. Genet.  62, 262-268"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:10944442, ECO:0000269|PubMed:12616398, ECO:0000269|PubMed:19107570, ECO:0000269|PubMed:19364667}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:10944442, ECO:0000269|PubMed:11181577, ECO:0000269|PubMed:9463323}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0023520;C0543888;C0751267;C0751268;C0751651;C1838951;C1838979;C1850597;C1850598;C1850599;C1850600;C2931891;C2936907;C3714756	602694	252010	24.12779863	131.363609	Class 1	-2.368149373	0.000296654	268990.1535	271594.3333	Integral	65.85385002	90.31162963
O75380	NDUFS6	Central nervous system;Metabolism	OXPHOS complex subunits	1				1	"Kirby, D. M., Salemi, R., Sugiana, C., Ohtake, A., Parry, L., Bell, K. M., Kirk, E. P., Boneh, A., Taylor, R. W., Dahl, H. H., Ryan, M. T., and Thorburn, D. R. (2004) NDUFS6 mutations are a novel cause of lethal neonatal mitochondrial complex I deficiency. J Clin Invest 114, 837-845"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:15372108, ECO:0000269|PubMed:19259137}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C1838979;C2936907	603848	618232	11.24486374	NaN	Class 1	-1.297125198	0.000469791	826876.9851	765043.6667	Ambiguous	55.25974378	89.54097993
O75251	NDUFS7	Central nervous system;Metabolism;Failure to thrive;Pulmonary system ;Muscular system;Liver;Gastrointestinal system;Others	OXPHOS complex subunits	1				1	"Triepels, R. H., van den Heuvel, L. P., Loeffen, J. L., Buskens, C. A., Smeets, R. J., Rubio Gozalbo, M. E., Budde, S. M., Mariman, E. C., Wijburg, F. A., Barth, P. G., Trijbels, J. M., and Smeitink, J. A. (1999) Leigh syndrome associated with a mutation in the NDUFS7 (PSST) nuclear encoded subunit of complex I. Ann Neurol 45, 787-790"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:10360771}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:10330338}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0023520;C0036341;C0543888;C0751267;C0751268;C0751651;C1838979;C2936907;C3714756	601825	618224	NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
E9PN51;O00217	NDUFS8	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Pulmonary system ;Gastrointestinal system	OXPHOS complex subunits	1				1	"Loeffen, J., Smeitink, J., Triepels, R., Smeets, R., Schuelke, M., Sengers, R., Trijbels, F., Hamel, B., Mullaart, R., and van den Heuvel, L. (1998) The first nuclear-encoded complex I mutation in a patient with Leigh syndrome. Am. J. Hum. Genet. 63, 1598-1608"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:9837812}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0023520;C0029408;C0086743;C0543888;C0751267;C0751268;C0751651;C1838951;C1850597;C1850598;C1850599;C1850600;C2931891;C2936907;C3714756	602141	618222	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
E9PMX3;H0YE81;P49821	NDUFV1	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Gastrointestinal system"	OXPHOS complex subunits	1				1	"Schuelke, M., Smeitink, J., Mariman, E., Loeffen, J., Plecko, B., Trijbels, F., Stockler-Ipsiroglu, S., and van den Heuvel, L. (1999) Mutant NDUFV1 subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy. Nat Genet 21, 260-261"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:10080174}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:10080174, ECO:0000269|PubMed:11349233}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0005586;C0023264;C0023520;C0024623;C0029408;C0036341;C0038356;C0041696;C0086743;C0235874;C0543888;C0751651;C1269683;C1708349;C1838951;C1838979;C1850597;C1850598;C1850599;C1850600;C2931891;C2936907;C3714756	161015	618225	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P19404	NDUFV2	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system"	OXPHOS complex subunits	1				1	"Benit, P., Beugnot, R., Chretien, D., Giurgea, I., De Lonlay-Debeney, P., Issartel, J. P., Corral-Debrinski, M., Kerscher, S., Rustin, P., Rotig, A., and Munnich, A. (2003) Mutant NDUFV2 subunit of mitochondrial complex I causes early onset hypertrophic cardiomyopathy and encephalopathy. Hum Mutat 21, 582-586"		C0005586;C0005587;C0024713;C0033141;C0036341;C0036529;C0041696;C0162666;C0338831;C0751651;C0878544;C1269683;C1838979;C2936907	600532	618229	63.41475437	NaN	Class 1	-1.339128361	0.000154058	578144.8588	586849.3333	Ambiguous	66.58956584	81.76860945
Q9Y697	NFS1	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Liver;Gastrointestinal system;Kidney and urinary tract	Fe-S protein biogenesis	1				1	"Farhan, S. M., Wang, J., Robinson, J. F., Lahiry, P., Siu, V. M., Prasad, C., Kronick, J. B., Ramsay, D. A., Rupar, C. A., and Hegele, R. A. (2014) Exome sequencing identifies NFS1 deficiency in a novel Fe-S cluster disease, infantile mitochondrial complex II/III deficiency. Mol Genet Genomic Med 2, 73-80"		C0751651	603485		NaN	136.3808037	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q9UMS0	NFU1	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Pulmonary system 	Fe-S protein biogenesis	1				1	"Cameron, J. M., Janer, A., Levandovskiy, V., Mackay, N., Rouault, T. A., Tong, W. H., Ogilvie, I., Shoubridge, E. A., and Robinson, B. H. (2011) Mutations in iron-sulfur cluster scaffold genes NFU1 and BOLA3 cause a fatal deficiency of multiple respiratory chain and 2-oxoacid dehydrogenase enzymes. Am. J. Hum. Genet. 89, 486-495"	"DISEASE: Multiple mitochondrial dysfunctions syndrome 1 (MMDS1) [MIM:605711]: A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death. Some patients show failure to thrive, pulmonary hypertension, hypotonia and irritability. Biochemical features include severe combined deficiency of the 2-oxoacid dehydrogenases, defective lipoic acid synthesis and reduction in activity of mitochondrial respiratory chain complexes. {ECO:0000269|PubMed:21944046, ECO:0000269|PubMed:22077971, ECO:0000269|PubMed:25918518, ECO:0000269|PubMed:28161430, ECO:0000269|PubMed:28906594}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3276432;C3502075;C3714756	608100	605711	59.18783968	NaN	Class 1	-3.405805801	2.95837E-05	382716.0611	423114	Peripheral	2.300671407	72.70602631
Q13232	NME3	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system "	Nucleotide/ nucleoside metabolism	1				1	"Chen CW, Wang HL, Huang CW, Huang CY, Lim WK, Tu IC, Koorapati A, Hsieh ST, Kan HW, Tzeng SR, Liao JC, Chong WM, Naroditzky I, Kidron D, Eran A, Nijim Y, Sela E, Feldman HB, Kalfon L, Raveh-Barak H, Falik-Zaccai TC, Elpeleg O, Mandel H, Chang ZF. Two separate functions of NME3 critical for cell survival underlie a neurodegenerative disorder. Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):566-574."			601817		671.2653662	NaN	Class 4	0.153574691	0.267269843	40740.14728	340515	Peripheral	50.3785263	90.71387371
E9PCX7;H0Y8P5;Q13423	NNT	Central nervous system;Metabolism;Cardiovascular system;Others;Endocrine system;Reproductive system;Integumentary system	Other known processes	1				1		"DISEASE: Glucocorticoid deficiency 4 with or without mineralocorticoid deficiency (GCCD4) [MIM:614736]: A form of glucocorticoid deficiency, a rare autosomal recessive disorder characterized by resistance to ACTH action on the adrenal cortex, adrenal insufficiency and an inability of the adrenal cortex to produce cortisol. It usually presents in the neonatal period or in early childhood with episodes of hypoglycemia and other symptoms related to cortisol deficiency, including failure to thrive, recurrent illnesses or infections, convulsions, and shock. In a small number of patients hypoglycemia can be sufficiently severe and persistent that it leads to serious long-term neurological damage or death. The diagnosis is readily confirmed with a low plasma cortisol measurement in the presence of an elevated ACTH level, and normal aldosterone and plasma renin measurements. {ECO:0000269|PubMed:22634753}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0342482;C0751651;C3553587;C4049650	607878	614736	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9H649	NSUN3	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive"	tRNA related processes	1				1	"Van Haute, L., Dietmann, S., Kremer, L., Hussain, S., Pearce, S. F., Powell, C. A., Rorbach, J., Lantaff, R., Blanco, S., Sauer, S., Kotzaeridou, U., Hoffmann, G. F., Memari, Y., Kolb-Kokocinski, A., Durbin, R., Mayr, J. A., Frye, M., Prokisch, H., and Minczuk, M. (2016) Deficient methylation and formylation of mt-tRNA(Met) wobble cytosine in a patient carrying mutations in NSUN3. Nat Commun 7, 12039"	"DISEASE: Note=Mitochondrial complex deficiency (PubMed:27356879). A disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected (PubMed:27356879). Clinical features include combined developmental disability, microcephaly, failure to thrive, recurrent increased lactate levels in plasma, muscular weakness, proximal accentuated, external ophthalmoplegia and convergence nystagmus (PubMed:27356879). Defects are probably caused by deficient methylation and formylation of mt-tRNA(Met) wobble cytosine (PubMed:27356879). The disease may be caused by mutations affecting the gene represented in this entry. {ECO:0000269|PubMed:27356879}."		617491		14.35411668	23.31098358	Class 1	-3.670512807	0.000153435	6608.950704	3533.206667	Peripheral	19.76580771	78.68416725
P78549	NTHL1	Tumors	DNA-related processes	1				1		"DISEASE: Familial adenomatous polyposis 3 (FAP3) [MIM:616415]: A form of familial adenomatous polyposis, a condition characterized by the development of multiple colorectal adenomatous polyps, benign neoplasms derived from glandular epithelium. Some affected individuals may develop colorectal carcinoma. {ECO:0000269|PubMed:25938944}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0017185;C0032580;C1527249;C2713442;C2713443;C4225157	602656	616415	57.08611954	NaN	Class 4	-2.365305573	0.163199877	328.0759592	73846.83333	0	NaN	NaN
Q8TB37	NUBPL	Central nervous system;Metabolism;Muscular system	Fe-S protein biogenesis	1				1	"Calvo, S. E., Tucker, E. J., Compton, A. G., Kirby, D. M., Crawford, G., Burtt, N. P., Rivas, M., Guiducci, C., Bruno, D. L., Goldberger, O. A., Redman, M. C., Wiltshire, E., Wilson, C. J., Altshuler, D., Gabriel, S. B., Daly, M. J., Thorburn, D. R., and Mootha, V. K. (2010) High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency. Nat Genet 42, 851-858"	"DISEASE: Mitochondrial complex I deficiency (MT-C1D) [MIM:252010]: A disorder of the mitochondrial respiratory chain that causes a wide range of clinical manifestations from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. {ECO:0000269|PubMed:20818383, ECO:0000269|PubMed:23553477}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C0949855;C0949856;C0949857;C1838979;C2936907;C3714756	613621	618242	235.9181334	144.4060385	Class 1	-1.314091407	0.000352551	44717.56571	20968.29	Peripheral	19.2519119	95.68751208
P04181;P04181	OAT	Metabolism;Ophthalmic system	Amino acid metabolism	1				1		"DISEASE: Hyperornithinemia with gyrate atrophy of choroid and retina (HOGA) [MIM:258870]: A disorder clinically characterized by a triad of progressive chorioretinal degeneration, early cataract formation, and type II muscle fiber atrophy. Characteristic chorioretinal atrophy with progressive constriction of the visual fields leads to blindness at the latest during the sixth decade of life. Patients generally have normal intelligence. {ECO:0000269|PubMed:1612597, ECO:0000269|PubMed:1737786, ECO:0000269|PubMed:23076989, ECO:0000269|PubMed:2793865, ECO:0000269|PubMed:3375240, ECO:0000269|PubMed:7668253, ECO:0000269|PubMed:7887415}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0018425;C0023893;C0023903;C0220994;C0345904;C0520459;C0599035	613349	258870	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O15527	OGG1	Tumors	DNA-related processes	1				1		"DISEASE: Renal cell carcinoma (RCC) [MIM:144700]: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype. Note=The disease may be caused by mutations affecting the gene represented in this entry."	C0001418;C0004403;C0006111;C0007134;C0008625;C0011757;C0011860;C0018781;C0018799;C0020179;C0020507;C0021364;C0024121;C0024299;C0026613;C0027746;C0033054;C0033578;C0037274;C0042076;C0085584;C0086468;C0152013;C0205641;C0205642;C0205643;C0205644;C0205645;C0242379;C0279702;C0376358;C0393574;C0751207;C0751208;C0751571;C0848676;C0917731;C1148522;C1266042;C1266043;C1266044;C1306837;C1333985	601982	144700	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
O60313;O60313	OPA1	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Cardiovascular system;Muscular system;Ears;Gastrointestinal system;Peripheral nervous system;Skeletal system	"Morphology, dynamics & organization"	1				1	"Alexander, C., Votruba, M., Pesch, U. E., Thiselton, D. L., Mayer, S., Moore, A., Rodriguez, M., Kellner, U., Leo-Kottler, B., Auburger, G., Bhattacharya, S. S., and Wissinger, B. (2000) OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 26, 211-215;Delettre, C., Lenaers, G., Griffoin, J. M., Gigarel, N., Lorenzo, C., Belenguer, P., Pelloquin, L., Grosgeorge, J., Turc-Carel, C., Perret, E., Astarie-Dequeker, C., Lasquellec, L., Arnaud, B., Ducommun, B., Kaplan, J., and Hamel, C. P. (2000) Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 26, 207-210;Hudson, G., Amati-Bonneau, P., Blakely, E. L., Stewart, J. D., He, L., Schaefer, A. M., Griffiths, P. G., Ahlqvist, K., Suomalainen, A., Reynier, P., McFarland, R., Turnbull, D. M., Chinnery, P. F., and Taylor, R. W. (2008) Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 131, 329-337"	"DISEASE: Behr syndrome (BEHRS) [MIM:210000]: An autosomal recessive syndrome characterized by optic atrophy beginning in early childhood associated with ataxia, pyramidal signs, spasticity, mental retardation, and posterior column sensory loss. The ataxia, spasticity, and muscle contractures, mainly of the hip adductors, hamstrings, and soleus, are progressive and become more prominent in the second decade. {ECO:0000269|PubMed:21636302, ECO:0000269|PubMed:25012220, ECO:0000269|PubMed:25146916}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Dominant optic atrophy plus syndrome (DOA+) [MIM:125250]: A neurologic disorder characterized most commonly by an insidious onset of visual loss and sensorineural hearing loss in childhood with variable presentation of other clinical manifestations including progressive external ophthalmoplegia, muscle cramps, hyperreflexia, and ataxia. There appears to be a wide range of intermediate phenotypes. {ECO:0000269|PubMed:15531309, ECO:0000269|PubMed:16240368, ECO:0000269|PubMed:18065439, ECO:0000269|PubMed:18158317, ECO:0000269|PubMed:18195150, ECO:0000269|PubMed:20185555, ECO:0000269|PubMed:21112924, ECO:0000269|PubMed:23387428}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial DNA depletion syndrome 14, cardioencephalomyopathic type (MTDPS14) [MIM:616896]: An autosomal recessive mitochondrial disorder characterized by lethal infantile encephalopathy, hypertrophic cardiomyopathy and optic atrophy. Skeletal muscle biopsies show significant mtDNA depletion and abnormal mitochondria. {ECO:0000269|PubMed:26561570}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Optic atrophy 1 (OPA1) [MIM:165500]: A condition that features progressive visual loss in association with optic atrophy. Atrophy of the optic disk indicates a deficiency in the number of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts. OPA1 is characterized by an insidious onset of visual impairment in early childhood with moderate to severe loss of visual acuity, temporal optic disk pallor, color vision deficits, and centrocecal scotoma of variable density. {ECO:0000269|PubMed:11017079, ECO:0000269|PubMed:11017080, ECO:0000269|PubMed:11440988, ECO:0000269|PubMed:11440989, ECO:0000269|PubMed:11810270, ECO:0000269|PubMed:12036970, ECO:0000269|PubMed:12566046, ECO:0000269|PubMed:14961560, ECO:0000269|PubMed:15948788, ECO:0000269|PubMed:16513463, ECO:0000269|PubMed:16617242, ECO:0000269|PubMed:18204809, ECO:0000269|PubMed:18360822, ECO:0000269|PubMed:19319978, ECO:0000269|PubMed:19325939, ECO:0000269|PubMed:19969356, ECO:0000269|PubMed:20185555, ECO:0000269|PubMed:22382025, ECO:0000269|PubMed:22857269, ECO:0000269|PubMed:23401657}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0029408;C0036341;C0086743;C0221061;C0338508;C0751651;C1832466;C1847730;C1852267;C3276549;C4225163	605290	616896-210000-165500-125250	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9H6K4;Q9H6K4	OPA3	Metabolism;Ophthalmic system;Peripheral nervous system	Unknown	1				1	"Anikster, Y., Kleta, R., Shaag, A., Gahl, W. A., and Elpeleg, O. (2001) Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am. J. Hum. Genet. 69, 1218-1224"	"DISEASE: 3-methylglutaconic aciduria 3 (MGA3) [MIM:258501]: An autosomal recessive metabolic disorder that causes a neuro-ophthalmologic syndrome consisting of early-onset bilateral optic atrophy, spasticity, extrapyramidal dysfunction and cognitive deficit. Urinary excretion of 3-methylglutaconic acid and 3-methylglutaric acid is increased. MGA3 can be distinguished from MGA1 by the absence of increase of 3-hydroxyisovaleric acid levels. {ECO:0000269|PubMed:11668429}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Optic atrophy 3 (OPA3) [MIM:165300]: A condition that features progressive visual loss in association with optic atrophy. Atrophy of the optic disk indicates a deficiency in the number of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts. OPA3 is associated with cataract and a neurologic disorder characterized by extrapyramidal signs and ataxia. {ECO:0000269|PubMed:15342707}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0030567;C0037773;C0086543;C0220994;C0574084;C0751651;C1833809;C3714756	606580	258501-165300	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P00480	OTC	Central nervous system;Metabolism;Pulmonary system 	Other known processes	1				1		"DISEASE: Ornithine carbamoyltransferase deficiency (OTCD) [MIM:311250]: An X-linked disorder of the urea cycle which causes a form of hyperammonemia. Mutations with no residual enzyme activity are always expressed in hemizygote males by a very severe neonatal hyperammonemic coma that generally proves to be fatal. Heterozygous females are either asymptomatic or express orotic aciduria spontaneously or after protein intake. The disorder is treatable with supplemental dietary arginine and low protein diet. The arbitrary classification of patients into the 'neonatal' group (clinical hyperammonemia in the first few days of life) and 'late' onset (clinical presentation after the neonatal period) has been used to differentiate severe from mild forms. {ECO:0000269|PubMed:10070627, ECO:0000269|PubMed:10502831, ECO:0000269|PubMed:10737985, ECO:0000269|PubMed:11793483, ECO:0000269|PubMed:1480464, ECO:0000269|PubMed:1671317, ECO:0000269|PubMed:1721894, ECO:0000269|PubMed:2347583, ECO:0000269|PubMed:2474822, ECO:0000269|PubMed:2556444, ECO:0000269|PubMed:3170748, ECO:0000269|PubMed:7474905, ECO:0000269|PubMed:7951259, ECO:0000269|PubMed:8019569, ECO:0000269|PubMed:8081373, ECO:0000269|PubMed:8081398, ECO:0000269|PubMed:8099056, ECO:0000269|PubMed:8112735, ECO:0000269|PubMed:8530002, ECO:0000269|PubMed:8807340, ECO:0000269|PubMed:8830175, ECO:0000269|PubMed:8956038, ECO:0000269|PubMed:8956045, ECO:0000269|PubMed:9065786, ECO:0000269|PubMed:9143919, ECO:0000269|PubMed:9266388, ECO:0000269|PubMed:9286441, ECO:0000269|PubMed:9452024, ECO:0000269|PubMed:9452049, ECO:0000269|PubMed:9452065, ECO:0000269|Ref.32, ECO:0000269|Ref.43}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006111;C0009241;C0023893;C0027746;C0085584;C0220994;C0268542;C0376618;C1839530;C3714756	300461	311250	NaN	200450.9211	NaN	NaN	NaN	0	0	0	0	0
Q15070	OXA1L	Central nervous system;Metabolism;Pulmonary system ;Peripheral nervous system;Hematologic system;Others	Protein import & biogenesis	1				1	"Thompson K, Mai N, Oláhová M, Scialó F, Formosa LE, Stroud DA, Garrett M, Lax NZ, Robertson FM, Jou C, Nascimento A, Ortez C, Jimenez-Mallebrera C, Hardy SA, He L, Brown GK, Marttinen P, McFarland R, Sanz A, Battersby BJ, Bonnen PE, Ryan MT, Chrzanowska-Lightowlers ZM, Lightowlers RN, Taylor RW. OXA1L mutations cause mitochondrial encephalopathy and a combined oxidative phosphorylation defect. EMBO Mol Med. 2018 Nov;10(11):e9060."			601066		35.26447248	NaN	Class 3	-0.641150408	0.001573694	300013.5511	204721	0	NaN	94.62609013
P55809	OXCT1	Metabolism;Pulmonary system 	Carbohydrate & energy metabolism	1				1		"DISEASE: Succinyl-CoA:3-oxoacid CoA transferase deficiency (SCOTD) [MIM:245050]: A disorder of ketone body metabolism, characterized by episodic ketoacidosis. Patients are usually asymptomatic between episodes. {ECO:0000269|PubMed:10964512, ECO:0000269|PubMed:21296660, ECO:0000269|PubMed:9671268}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0001787;C0029456;C0029459;C0271713;C0342792;C0751406;C1291422;C3714756	601424	245050	141.1844778	160.2388691	Class 3	-0.78858103	0.002354323	524788.4102	523075	Soluble	7.022558837	12.11499558
Q9Y3D7	PAM16	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Pulmonary system ;Skeletal system"	Protein import & biogenesis	1				1		"DISEASE: Spondylometaphyseal dysplasia, Megarbane-Dagher-Melike type (SMDMDM) [MIM:613320]: An autosomal recessive disease characterized by pre- and postnatal short stature, developmental delay, dysmorphic facial appearance, narrow chest, prominent abdomen, platyspondyly, and short limbs. {ECO:0000269|PubMed:24786642}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C1531773;C2750075	614336	613320	NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q9BZ23	PANK2	Central nervous system;Metabolism;Ophthalmic system;Hematologic system	Cofactor metabolism	1				1	"Zhou, B., Westaway, S. K., Levinson, B., Johnson, M. A., Gitschier, J., and Hayflick, S. J. (2001) A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 28, 345-349"	"DISEASE: Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP) [MIM:607236]: Rare syndrome with many clinical similarities to PKAN. {ECO:0000269|PubMed:12058097}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Neurodegeneration with brain iron accumulation 1 (NBIA1) [MIM:234200]: Autosomal recessive neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. Clinical manifestations include progressive muscle spasticity, hyperreflexia, muscle rigidity, dystonia, dysarthria, and intellectual deterioration which progresses to severe dementia over several years. It is clinically classified into classic, atypical, and intermediate phenotypes. Classic forms present with onset in first decade, rapid progression, loss of independent ambulation within 15 years. Atypical forms have onset in second decade, slow progression, maintenance of independent ambulation up to 40 years later. Intermediate forms manifest onset in first decade with slow progression or onset in second decade with rapid progression. Patients with early onset tend to also develop pigmentary retinopathy, whereas those with later onset tend to also have speech disorders and psychiatric features. All patients have the 'eye of the tiger' sign on brain MRI. {ECO:0000269|PubMed:11479594, ECO:0000269|PubMed:12510040, ECO:0000269|PubMed:15834858, ECO:0000269|PubMed:22930366, ECO:0000269|PubMed:24075960, ECO:0000269|PubMed:24655737, ECO:0000269|PubMed:27185474}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0018523;C0027746;C0030567;C0036341;C0270715;C0524851;C0751651;C0751733;C1846582;C2931845;C3714756	606157	607236-234200	NaN	NaN	Class 4	-0.664770652	0.052615763	908.7800447	40865.56667	0	22.33974484	NaN
Q99497	PARK7	Central nervous system	Cell death/ apoptosis	1				1		"DISEASE: Parkinson disease 7 (PARK7) [MIM:606324]: A neurodegenerative disorder characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7 has onset before 40 years, slow progression and initial good response to levodopa. Some patients may show traits reminiscent of amyotrophic lateral sclerosis-parkinsonism/dementia complex (Guam disease). {ECO:0000269|PubMed:12446870, ECO:0000269|PubMed:12851414, ECO:0000269|PubMed:12953260, ECO:0000269|PubMed:14607841, ECO:0000269|PubMed:14713311, ECO:0000269|PubMed:15254937, ECO:0000269|PubMed:15365989, ECO:0000269|PubMed:17846173, ECO:0000269|PubMed:19229105, ECO:0000269|PubMed:22523093, ECO:0000269|PubMed:23792957, ECO:0000269|PubMed:23847046}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0001787;C0029456;C0029459;C0030567;C0206160;C0242422;C0242423;C0520459;C0543859;C0751406;C0752097;C0752098;C0752100;C0752101;C0752104;C0752105;C1853445;C1868675;C2239176;C3714756;C4275179	602533	606324	155.4859291	NaN	Class 1	-1.422706435	0.001416376	351159.0834	6324243.333	Soluble	4.792568956	32.60830213
Q7L3T8	PARS2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Gastrointestinal system;Others"	tRNA related processes	1				1	"Sofou, K., Kollberg, G., Holmstrom, M., Davila, M., Darin, N., Gustafsson, C. M., Holme, E., Oldfors, A., Tulinius, M., and Asin-Cayuela, J. (2015) Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome. Mol Genet Genomic Med 3, 59-68"		C0751651	612036	618437	Infinite	228.5872439	Class 1	-1.477685395	0.000938821	18605.71303	11322.48667	Peripheral	13.83208512	85.29714109
P11498	PC	Central nervous system;Metabolism	Carbohydrate & energy metabolism	1				1		"DISEASE: Pyruvate carboxylase deficiency (PC deficiency) [MIM:266150]: Leads to lactic acidosis, mental retardation and death. It occurs in three forms: mild or type A, severe neonatal or type B, and a very mild lacticacidemia. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006413;C0023893;C0034341;C0343640;C2931141	608786	266150	53.34483909	739.5334994	Class 3	-0.658300278	0.002305245	68554.33958	58727.73333	Peripheral	31.26833807	88.4038135
P05165;Q5JTW6	PCCA	Central nervous system;Metabolism;Gastrointestinal system;Hematologic system	Lipid metabolism	1				1		"DISEASE: Propionic acidemia type I (PA-1) [MIM:606054]: Life-threatening disease characterized by episodic vomiting, lethargy and ketosis, neutropenia, periodic thrombocytopenia, hypogammaglobulinemia, developmental retardation, and intolerance to protein. {ECO:0000269|PubMed:10101253, ECO:0000269|PubMed:10329019, ECO:0000269|PubMed:12559849, ECO:0000269|PubMed:15059621}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0268579;C0271713;C0311298;C0543888;C2717876;C3714756	232000	606054	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P05166	PCCB	Central nervous system;Metabolism;Gastrointestinal system;Hematologic system	Lipid metabolism	1				1		"DISEASE: Propionic acidemia type II (PA-2) [MIM:606054]: Life-threatening disease characterized by episodic vomiting, lethargy and ketosis, neutropenia, periodic thrombocytopenia, hypogammaglobulinemia, developmental retardation, and intolerance to protein. {ECO:0000269|PubMed:10447268, ECO:0000269|PubMed:11749052, ECO:0000269|PubMed:12189489, ECO:0000269|PubMed:12559849, ECO:0000269|PubMed:15059621, ECO:0000269|PubMed:2154743, ECO:0000269|PubMed:8411997, ECO:0000269|PubMed:9683601}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0268579;C0271713;C0311298;C0543888;C2717876;C3714756	232050	606054	231.7121856	NaN	Class 1	-1.288049524	0.000232414	94196.84521	71585.2	Soluble	7.976436398	40.88172712
P08559;Q5JPU3	PDHA1	Central nervous system;Metabolism;Muscular system	PDH complex & PDH regulation	1				1	"Endo, H., Hasegawa, K., Narisawa, K., Tada, K., Kagawa, Y., and Ohta, S. (1989) Defective gene in lactic acidosis: abnormal pyruvate dehydrogenase E1 alpha-subunit caused by a frame shift. Am. J. Hum. Genet. 44, 358-364"	"DISEASE: Pyruvate dehydrogenase E1-alpha deficiency (PDHAD) [MIM:312170]: An enzymatic defect causing primary lactic acidosis in children. It is associated with a broad clinical spectrum ranging from fatal lactic acidosis in the newborn to chronic neurologic dysfunction with structural abnormalities in the central nervous system without systemic acidosis. {ECO:0000269|PubMed:1293379, ECO:0000269|PubMed:1338114, ECO:0000269|PubMed:1551669, ECO:0000269|PubMed:1909401, ECO:0000269|PubMed:27864847, ECO:0000269|PubMed:7545958, ECO:0000269|PubMed:7573035, ECO:0000269|PubMed:7757088, ECO:0000269|PubMed:7887409, ECO:0000269|PubMed:7967473, ECO:0000269|PubMed:8032855, ECO:0000269|PubMed:8199595, ECO:0000269|PubMed:8498846, ECO:0000269|PubMed:8504306, ECO:0000269|PubMed:8664900, ECO:0000269|PubMed:8844217, ECO:0000269|PubMed:9266390, ECO:0000269|PubMed:9671272}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0001125;C0007959;C0024623;C0029408;C0033578;C0034345;C0034350;C0038356;C0086743;C0151744;C0235874;C0376358;C0431350;C0543888;C0751595;C0751596;C0751597;C0751651;C1708349;C1839413;C3714756	300502	312170	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P11177	PDHB	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system "	PDH complex & PDH regulation	1				1	"Brown, R. M., Head, R. A., Boubriak, II, Leonard, J. V., Thomas, N. H., and Brown, G. K. (2004) Mutations in the gene for the E1beta subunit: a novel cause of pyruvate dehydrogenase deficiency. Hum Genet 115, 123-127"	DISEASE: Pyruvate dehydrogenase E1-beta deficiency (PDHBD) [MIM:614111]: An enzymatic defect causing primary lactic acidosis in children. It is associated with a broad clinical spectrum ranging from fatal lactic acidosis in the newborn to chronic neurologic dysfunction with structural abnormalities in the central nervous system without systemic acidosis. {ECO:0000269|PubMed:15138885}. Note=The disease is caused by mutations affecting the gene represented in this entry.	C0007134;C0034345;C0279702;C0751595;C0751596;C0751597;C0751651;C1266042;C1266043;C1266044;C1306837;C3279841	179060	614111	134.5604378	NaN	Class 1	-1.22065547	0.000281612	1019593.201	1199101.333	Soluble	6.227676222	46.21737965
O00330	PDHX	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities"	PDH complex & PDH regulation	1				1	"Aral, B., Benelli, C., Ait-Ghezala, G., Amessou, M., Fouque, F., Maunoury, C., Creau, N., Kamoun, P., and Marsac, C. (1997) Mutations in PDX1, the human lipoyl-containing component X of the pyruvate dehydrogenase-complex gene on chromosome 11p1, in congenital lactic acidosis. Am. J. Hum. Genet. 61, 1318-1326"	"DISEASE: Pyruvate dehydrogenase E3-binding protein deficiency (PDHXD) [MIM:245349]: A metabolic disorder characterized by decreased activity of the pyruvate dehydrogenase complex without observable reduction in the activities of enzymes E1, E2, or E3. Clinical features include hypotonia and psychomotor retardation. {ECO:0000269|PubMed:9399911}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0020796;C0025363;C0543888;C0751651;C0917816;C1855553;C3714756	608769	245349	58.89101926	110.5124586	Class 1	-2.167434226	5.43399E-05	161581.4752	177184.6667	Peripheral	32.31974687	92.03701176
Q15120	PDK3	Metabolism;Ears;Peripheral nervous system;Skeletal system	PDH complex & PDH regulation	1				1	"Kennerson, M. L., Yiu, E. M., Chuang, D. T., Kidambi, A., Tso, S. C., Ly, C., Chaudhry, R., Drew, A. P., Rance, G., Delatycki, M. B., Zuchner, S., Ryan, M. M., and Nicholson, G. A. (2013) A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene. Hum Mol Genet 22, 1404-1416"	"DISEASE: Charcot-Marie-Tooth disease, X-linked dominant, 6 (CMTX6) [MIM:300905]: A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies characterized by severely reduced motor nerve conduction velocities (NCVs) (less than 38m/s) and segmental demyelination and remyelination, and primary peripheral axonal neuropathies characterized by normal or mildly reduced NCVs and chronic axonal degeneration and regeneration on nerve biopsy. {ECO:0000269|PubMed:23297365}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007959;C0751651;C3806702	300906	300905	Infinite	94.05434718	Class 4	-1.177062574	0.267917442	187789.0817	142726.6667	Peripheral	13.91849164	83.77620248
Q9P0J1	PDP1	Central nervous system;Metabolism;Pulmonary system 	PDH complex & PDH regulation	1				1	"Cameron, J. M., Maj, M., Levandovskiy, V., Barnett, C. P., Blaser, S., Mackay, N., Raiman, J., Feigenbaum, A., Schulze, A., and Robinson, B. H. (2009) Pyruvate dehydrogenase phosphatase 1 (PDP1) null mutation produces a lethal infantile phenotype. Hum Genet 125, 319-326"	DISEASE: Pyruvate dehydrogenase phosphatase deficiency (PDP deficiency) [MIM:608782]: Results in lactic acidosis leading to neurological dysfunction. {ECO:0000269|PubMed:15855260}. Note=The disease is caused by mutations affecting the gene represented in this entry.	C0033578;C0376358;C0751651;C1837429	605993	608782	Infinite	91.10654489	Class 1	-1.741892145	0.0001344	19194.78878	31777.48333	Peripheral	8.851355885	91.24816105
Q8NCN5	PDPR	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Kidney and urinary tract"	Carbohydrate & energy metabolism	1				1	"Alazami AM, Patel N, Shamseldin HE, Anazi S, Al-Dosari MS, Alzahrani F, Hijazi H, Alshammari M, Aldahmesh MA, Salih MA, Faqeih E, Alhashem A, Bashiri FA, Al-Owain M, Kentab AY, Sogaty S, Al Tala S, Temsah MH, Tulbah M, Aljelaify RF, Alshahwan SA, Seidahmed MZ, Alhadid AA, Aldhalaan H, AlQallaf F, Kurdi W, Alfadhel M, Babay Z, Alsogheer M, Kaya N, Al-Hassnan ZN, Abdel-Salam GM, Al-Sannaa N, Al Mutairi F, El Khashab HY, Bohlega S, Jia X, Nguyen HC, Hammami R, Adly N, Mohamed JY, Abdulwahab F, Ibrahim N, Naim EA, Al-Younes B, Meyer BF, Hashem M, Shaheen R, Xiong Y, Abouelhoda M, Aldeeri AA, Monies DM, Alkuraya FS. Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiplex consanguineous families. Cell Rep. 2015 Jan 13;10(2):148-61."			617835		80.66341378	NaN	Class 1	-1.197478498	0.000595738	29669.70903	21940.04333	Soluble	9.900753287	44.22607497
Q5T2R2	PDSS1	Central nervous system;Ophthalmic system;Cardiovascular system;Ears;Peripheral nervous system;Integumentary system	Cofactor metabolism	1				1	"Mollet, J., Giurgea, I., Schlemmer, D., Dallner, G., Chretien, D., Delahodde, A., Bacq, D., de Lonlay, P., Munnich, A., and Rotig, A. (2007) Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest  117, 765-772"	"DISEASE: Coenzyme Q10 deficiency, primary, 2 (COQ10D2) [MIM:614651]: An autosomal recessive multisystem disorder characterized by early-onset deafness, optic atrophy, mild mental retardation, peripheral neuropathy, obesity, livedo reticularis, and cardiac valvulopathy. {ECO:0000269|PubMed:17332895}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3553354;C3714756	607429	614651	18.07139543	9.692840692	Class 1	-2.486222519	1.70574E-05	33672.81922	27747.06667	Peripheral	15.53517294	92.55731523
Q86YH6	PDSS2	Central nervous system;Pulmonary system ;Gastrointestinal system	Cofactor metabolism	1				1	"Lopez, L. C., Schuelke, M., Quinzii, C. M., Kanki, T., Rodenburg, R. J., Naini, A., Dimauro, S., and Hirano, M. (2006) Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am. J. Hum. Genet.  79, 1125-1129"	"a multisystem infantile form with encephalopathy, cardiomyopathy and renal failure;a predominantly cerebellar form with ataxia and cerebellar atrophy;and an isolated myopathic form. {ECO:0000269|PubMed:17186472}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Coenzyme Q10 deficiency, primary, 3 (COQ10D3) [MIM:614652]: A fatal encephalomyopathic form of coenzyme Q10 deficiency with nephrotic syndrome. Coenzyme Q10 deficiency is an autosomal recessive disorder with variable manifestations consistent with 5 major phenotypes. The phenotypes include an encephalomyopathic form with seizures and ataxia;Leigh syndrome with growth retardation"	C0543888;C0751651;C3553358;C3714756	610564	614652	49.11770198	61.29122913	Class 1	-1.837598328	0.000105421	36085.85151	30799.96667	Peripheral	14.28776555	89.21554192
P0DJ07	PET100	Central nervous system;Metabolism;Ophthalmic system;Pulmonary system ;Skeletal system	OXPHOS assembly & stability	1				1	"Lim, S. C., Smith, K. R., Stroud, D. A., Compton, A. G., Tucker, E. J., Dasvarma, A., Gandolfo, L. C., Marum, J. E., McKenzie, M., Peters, H. L., Mowat, D., Procopis, P. G., Wilcken, B., Christodoulou, J., Brown, G. K., Ryan, M. T., Bahlo, M., and Thorburn, D. R. (2014) A founder mutation in PET100 causes isolated complex IV deficiency in Lebanese individuals with Leigh syndrome. Am. J. Hum. Genet. 94, 209-222"		C0268237;C0543888;C0751651;C3714756	614770	220110	6.362445011	NaN	Class 1	-3.322211464	1.08935E-05	93332.3598	127252.1667	0	21.54659186	NaN
Q6UWS5	PET117	Central nervous system;Metabolism;Gastrointestinal system;Hematologic system;Others	OXPHOS assembly & stability	1				1	"Renkema, G. H., Visser, G., Baertling, F., Wintjes, L. T., Wolters, V. M., van Montfrans, J., de Kort, G. A., Nikkels, P. G., van Hasselt, P. M., van der Crabben, S. N., and Rodenburg, R. J. (2017) Mutated PET117 causes complex IV deficiency and is associated with neurodevelopmental regression and medulla oblongata lesions. Hum Genet 136, 759-769"		C0268237	614771		26.22110996	35.51808529	Class 1	-2.532914649	0.000246241	24766.2738	14628.8	0	NaN	NaN
Q9BXM7	PINK1	Central nervous system	Autophagy/ mitophagy	1				1		"DISEASE: Parkinson disease 6 (PARK6) [MIM:605909]: An early-onset form of Parkinson disease, a neurodegenerative disorder characterized by parkinsonian signs such as rigidity, resting tremor and bradykinesia. A subset of patients manifest additional symptoms including hyperreflexia, autonomic instability, dementia and psychiatric disturbances. Symptoms show diurnal fluctuation and can improve after sleep. PARK6 pathogenesis involves respiratory complex I deficiency causing mitochondrial depolarization and dysfunction. Inheritance is autosomal recessive. {ECO:0000269|PubMed:15087508, ECO:0000269|PubMed:15349860, ECO:0000269|PubMed:15349870, ECO:0000269|PubMed:15505171, ECO:0000269|PubMed:15596610, ECO:0000269|PubMed:15955953, ECO:0000269|PubMed:15970950, ECO:0000269|PubMed:16009891, ECO:0000269|PubMed:16207217, ECO:0000269|PubMed:16207731, ECO:0000269|PubMed:16257123, ECO:0000269|PubMed:16401616, ECO:0000269|PubMed:16482571, ECO:0000269|PubMed:16632486, ECO:0000269|PubMed:16966503, ECO:0000269|PubMed:17030667, ECO:0000269|PubMed:18286320, ECO:0000269|PubMed:19229105, ECO:0000269|PubMed:20798600, ECO:0000269|PubMed:22043288, ECO:0000269|PubMed:22956510, ECO:0000269|PubMed:24652937, ECO:0000269|PubMed:24784582}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0027746;C0027819;C0030567;C0036341;C0041696;C0242422;C0242423;C0752097;C0752098;C0752100;C0752101;C0752104;C0752105;C1269683;C1621958;C1853833;C1868675;C1970035;C3714756;C4275179	608309	605909	NaN	NaN	Class 4	0.973516726	0.037894358	NaN	NaN	0	NaN	NaN
Q9UG56	PISD	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Ears;Skeletal system;Others"	Lipid metabolism	1				1	"Girisha KM, von Elsner L, Neethukrishna K, Muranjan M, Shukla A, Bhavani GS, Nishimura G, Kutsche K, Mortier G. The homozygous variant c.797G>A/p.(Cys266Tyr) in PISD is associated with a Spondyloepimetaphyseal dysplasia with large epiphyses and disturbed mitochondrial function. Hum Mutat. 2019 Mar;40(3):299-309. Zhao T, Goedhart CM, Sam PN, Sabouny R, Lingrell S, Cornish AJ, Lamont RE, Bernier FP, Sinasac D, Parboosingh JS; Care4Rare Canada Consortium, Vance JE, Claypool SM, Innes AM, Shutt TE. PISD is a mitochondrial disease gene causing skeletal dysplasia, cataracts, and white matter changes. Life Sci Alliance. 2019 Mar 11;2(2):e201900353. "			612770	618889	72.65648862	NaN	Class 3	-0.889608014	0.000397337	48353.5044	63107.63333	Ambiguous	57.25679721	95.92208283
O94903	PLPBP	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Gastrointestinal system"	Unknown	1				1		"DISEASE: Epilepsy, early-onset, vitamin B6-dependent (EPVB6D) [MIM:617290]: An autosomal recessive neurologic disorder characterized by seizures responsive to treatment with activated vitamin B6 and/or pyridoxine. Most patients show delayed psychomotor development, mental retardation and learning disability. Seizures onset is in the first days or months of life. {ECO:0000269|PubMed:27912044}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C1291560;C1849508;C3714756;C4310632	604436	617290	NaN	NaN	Class 1	-2.605395159	0.000397165	79798.64802	457106	Soluble	5.527658716	16.41564161
Q8N490;Q8N490	PNKD	Central nervous system	Regulation & signaling	1				1		"DISEASE: Dystonia 8 (DYT8) [MIM:118800]: A paroxysmal non-kinesigenic dystonia/dyskinesia. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. Dystonia type 8 is characterized by attacks of involuntary movements brought on by stress, alcohol, fatigue or caffeine. The attacks generally last between a few seconds and four hours or longer. The attacks may begin in one limb and spread throughout the body, including the face. {ECO:0000269|PubMed:15262732, ECO:0000269|PubMed:15824259, ECO:0000269|PubMed:16632198, ECO:0000269|PubMed:16717228, ECO:0000269|PubMed:16972263}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007134;C0279702;C1266042;C1266043;C1266044;C1306837;C1869117;C3714756	609023	118800	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9NP80	PNPLA8	Central nervous system;Metabolism;Muscular system	Lipid metabolism	1				1	"Saunders, C. J., Moon, S. H., Liu, X., Thiffault, I., Coffman, K., LePichon, J. B., Taboada, E., Smith, L. D., Farrow, E. G., Miller, N., Gibson, M., Patterson, M., Kingsmore, S. F., and Gross, R. W. (2015) Loss of function variants in human PNPLA8 encoding calcium-independent phospholipase A2 gamma recapitulate the mitochondriopathy of the homologous null mouse. Hum Mutat 36, 301-306"	"DISEASE: Mitochondrial myopathy with lactic acidosis (MMLA) [MIM:251950]: An autosomal recessive disorder characterized by progressive muscle weakness, hypotonia, seizures, poor weight gain, lactic acidosis, and elevated serum pyruvate concentration. Some patients manifest growth failure and moderate neural deafness. {ECO:0000269|PubMed:25512002}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C1855033	612123	251950	173.3947955	NaN	Class 4	-0.531396991	0.031547374	11300.36222	21438.25	Peripheral	30.3832727	93.6047854
Q9NVS9	PNPO	Central nervous system;Metabolism;Hematologic system	Cofactor metabolism	1				1		"DISEASE: Pyridoxine-5'-phosphate oxidase deficiency (PNPOD) [MIM:610090]: The main feature of neonatal epileptic encephalopathy is the onset within hours of birth of a severe seizure disorder that does not respond to anticonvulsant drugs and can be fatal. Seizures can cease with the administration of PLP, being resistant to treatment with pyridoxine,. {ECO:0000269|PubMed:15772097, ECO:0000269|PubMed:23708187, ECO:0000269|PubMed:27864847}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0036341;C0038220;C0270823;C0311335;C0393734;C0543888;C0751522;C0751523;C0751524;C1864723;C3714756	603287	610090	Infinite	NaN	Class 1	-1.719086546	0.000249555	17946.35681	230753.6667	Soluble	7.721223418	37.01046704
Q8TCS8	PNPT1	Central nervous system;Metabolism;Failure to thrive;Muscular system;Ears;Peripheral nervous system	RNA-related processes	1				1	"Vedrenne, V., Gowher, A., De Lonlay, P., Nitschke, P., Serre, V., Boddaert, N., Altuzarra, C., Mager-Heckel, A. M., Chretien, F., Entelis, N., Munnich, A., Tarassov, I., and Rotig, A. (2012) Mutation in PNPT1, which Encodes a Polyribonucleotide Nucleotidyltransferase, Impairs RNA Import into Mitochondria and Causes Respiratory-Chain Deficiency. Am. J. Hum. Genet.  91, 912-918;von Ameln, S., Wang, G., Boulouiz, R., Rutherford, M. A., Smith, G. M., Li, Y., Pogoda, H. M., Nurnberg, G., Stiller, B., Volk, A. E., Borck, G., Hong, J. S., Goodyear, R. J., Abidi, O., Nurnberg, P., Hofmann, K., Richardson, G. P., Hammerschmidt, M., Moser, T., Wollnik, B., Koehler, C. M., Teitell, M. A., Barakat, A., and Kubisch, C. (2012) A Mutation in PNPT1, Encoding Mitochondrial-RNA-Import Protein PNPase, Causes Hereditary Hearing Loss. Am. J. Hum. Genet. 91, 919-927"	"DISEASE: Combined oxidative phosphorylation deficiency 13 (COXPD13) [MIM:614932]: A mitochondrial disorder characterized by early onset severe encephalomyopathy, dystonia, choreoathetosis, bucofacial dyskinesias and combined mitochondrial respiratory chain deficiency. Nerve conductions velocities are decreased. Levels of plasma and cerebrospinal fluid lactate are increased. {ECO:0000269|PubMed:23084291}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Deafness, autosomal recessive, 70 (DFNB70) [MIM:614934]: A form of non-syndromic deafness characterized by severe, bilateral hearing impairment with prelingual onset, resulting in inability to acquire normal speech. {ECO:0000269|PubMed:23084290}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C1824925;C2239176;C3554129;C3714756	610316	614932-614934	120.3374963	57.93479832	Class 1	-1.875206418	0.000127767	387195.334	491503	Peripheral	3.620914196	80.41091111
P54098	POLG	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Muscular system;Ears;Liver;Gastrointestinal system;Peripheral nervous system;Others;Reproductive system"	DNA-related processes	1				1	"Van Goethem, G., Dermaut, B., Lofgren, A., Martin, J. J., and Van Broeckhoven, C. (2001) Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 28, 211-212"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:18828154}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial DNA depletion syndrome 4A (MTDPS4A) [MIM:203700]: An autosomal recessive hepatocerebral syndrome due to mitochondrial dysfunction. The typical course of the disease includes severe developmental delay, intractable seizures, liver failure, and death in childhood. Refractory seizures, cortical blindness, progressive liver dysfunction, and acute liver failure after exposure to valproic acid are considered diagnostic features. The neuropathological hallmarks are neuronal loss, spongiform degeneration, and astrocytosis of the visual cortex. Liver biopsy results show steatosis, often progressing to cirrhosis. {ECO:0000269|PubMed:15122711, ECO:0000269|PubMed:15689359, ECO:0000269|PubMed:15929042, ECO:0000269|PubMed:16621917, ECO:0000269|PubMed:16639411, ECO:0000269|PubMed:18828154}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial DNA depletion syndrome 4B (MTDPS4B) [MIM:613662]: An autosomal recessive progressive multisystem disorder due to mitochondrial dysfunction. It is clinically characterized by chronic gastrointestinal dysmotility and pseudo-obstruction, cachexia, progressive external ophthalmoplegia, axonal sensory ataxic neuropathy, and muscle weakness. {ECO:0000269|PubMed:12825077, ECO:0000269|PubMed:19307547}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1 (PEOA1) [MIM:157640]: A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism. {ECO:0000269|PubMed:11897778, ECO:0000269|PubMed:12210792, ECO:0000269|PubMed:15351195, ECO:0000269|PubMed:15534189, ECO:0000269|PubMed:17420318, ECO:0000269|PubMed:17846414, ECO:0000269|PubMed:18575922}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive, 1 (PEOB1) [MIM:258450]: A severe form of progressive external ophthalmoplegia, a disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. It is clinically more heterogeneous than the autosomal dominant forms. {ECO:0000269|PubMed:11431686, ECO:0000269|PubMed:12565911, ECO:0000269|PubMed:12707443, ECO:0000269|PubMed:12872260, ECO:0000269|PubMed:12975295, ECO:0000269|PubMed:14635118, ECO:0000269|PubMed:15349879, ECO:0000269|PubMed:15351195, ECO:0000269|PubMed:15477547, ECO:0000269|PubMed:15917273, ECO:0000269|PubMed:16401742, ECO:0000269|PubMed:16621917, ECO:0000269|PubMed:16634032, ECO:0000269|PubMed:16639411}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) [MIM:607459]: A systemic disorder resulting from mitochondrial dysfunction associated with mitochondrial depletion in skeletal muscle and peripheral nerve tissue. The clinical triad of symptoms consists of sensory ataxic neuropathy, dysarthria, and ophthalmoparesis. However, the phenotype varies widely, even within the same family, and can also include myopathy, seizures, and hearing loss. {ECO:0000269|PubMed:12565911, ECO:0000269|PubMed:14745080, ECO:0000269|PubMed:15477547, ECO:0000269|PubMed:15824347, ECO:0000269|PubMed:15917273, ECO:0000269|PubMed:16080118, ECO:0000269|PubMed:16621917, ECO:0000269|PubMed:16639411, ECO:0000269|PubMed:16919951}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Spinocerebellar ataxia with epilepsy (SCAE) [MIM:607459]: An autosomal recessive syndrome characterized by headaches and/or seizures manifesting in childhood or adolescence, cerebellar and sensory ataxia, dysarthria, and myoclonus manifesting in early adulthood. Neuropathological findings include spinocerebellar degeneration associated with cortical neuronal degeneration in advanced cases. {ECO:0000269|PubMed:26942291}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0004138;C0004712;C0005586;C0007795;C0007959;C0008370;C0014544;C0019193;C0021364;C0022333;C0023264;C0023520;C0035410;C0036572;C0086237;C0149958;C0162674;C0205710;C0220994;C0234533;C0234535;C0236018;C0242422;C0242423;C0270824;C0270844;C0270846;C0422850;C0422852;C0422853;C0422854;C0422855;C0494475;C0525045;C0543888;C0751056;C0751110;C0751111;C0751123;C0751494;C0751495;C0751496;C0751651;C0752097;C0752098;C0752100;C0752101;C0752104;C0752105;C0848676;C0860207;C0872218;C0917731;C0949855;C0949856;C0949857;C1112213;C1262760;C1834846;C1838951;C1843851;C1843852;C1850303;C1850597;C1850598;C1850599;C1850600;C1868675;C2931891;C3150914;C3495874;C3658290;C3714756;C4048158;C4225153;C4225409;C4225440;C4277682;C4279912;C4316903;C4317109;C4317123;C4505436	174763	203700-613662-607459-157640-258450	88.04069471	NaN	Class 1	-2.547282826	5.81674E-07	29414.39999	18302.43333	Peripheral	17.40465559	81.47249384
Q9UHN1	POLG2	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Liver;Gastrointestinal system	DNA-related processes	1				1	"Longley, M. J., Clark, S., Yu Wai Man, C., Hudson, G., Durham, S. E., Taylor, R. W., Nightingale, S., Turnbull, D. M., Copeland, W. C., and Chinnery, P. F. (2006) Mutant POLG2 disrupts DNA polymerase gamma subunits and causes progressive external ophthalmoplegia. Am. J. Hum. Genet.  78, 1026-1034"	"DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 4 (PEOA4) [MIM:610131]: A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism. {ECO:0000269|PubMed:16685652}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C0035410;C0751651;C1834846;C1864668	604983	610131	Infinite	872.7646125	Class 1	-1.422931109	0.000174745	25045.98856	12665.56667	Peripheral	14.46914735	84.51785432
O00411	POLRMT	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Muscular system;Ears;Gastrointestinal system;Skeletal system;Hematologic system;Kidney and urinary tract;Others"	RNA-related processes	1				1	"Oláhová M, Peter B, Szilagyi Z, Diaz-Maldonado H, Singh M, Sommerville EW, Blakely EL, Collier JJ, Hoberg E, Stráneck_ V, Hartmannová H, Bleyer AJ, McBride KL, Bowden SA, Korandová Z, Pecinová A, Ropers HH, Kahrizi K, Najmabadi H, Tarnopolsky MA, Brady LI, Weaver KN, Prada CE, Õunap K, Wojcik MH, Pajusalu S, Syeda SB, Pais L, Estrella EA, Bruels CC, Kunkel LM, Kang PB, Bonnen PE, Mrá_ek T, Kmoch S, Gorman GS, Falkenberg M, Gustafsson CM, Taylor RW. POLRMT mutations impair mitochondrial transcription causing neurological disease. Nat Commun. 2021 Feb 18;12(1):1135."			601778		108.0803432	35.72617403	Class 1	-1.849688973	5.92722E-05	143936.7551	96938.8	Peripheral	38.99159042	90.37229188
A0A0C4DGB9;Q9H2U2	PPA2	Metabolism;Failure to thrive;Cardiovascular system;Muscular system	Other known processes	1				1	"Guimier, A., Gordon, C. T., Godard, F., Ravenscroft, G., Oufadem, M., Vasnier, C., Rambaud, C., Nitschke, P., Bole-Feysot, C., Masson, C., Dauger, S., Longman, C., Laing, N. G., Kugener, B., Bonnet, D., Bouvagnet, P., Di Filippo, S., Probst, V., Redon, R., Charron, P., Rotig, A., Lyonnet, S., Dautant, A., de Pontual, L., di Rago, J. P., Delahodde, A., and Amiel, J. (2016) Biallelic PPA2 Mutations Cause Sudden Unexpected Cardiac Arrest in Infancy. Am. J. Hum. Genet.  99, 666-673;Kennedy, H., Haack, T. B., Hartill, V., Matakovic, L., Baumgartner, E. R., Potter, H., Mackay, R., Alston, C. L., O'Sullivan, S., McFarland, R., Connolly, G., Gannon, C., King, R., Mead, S., Crozier, I., Chan, W., Florkowski, C. M., Sage, M., Hofken, T., Alhaddad, B., Kremer, L. S., Kopajtich, R., Feichtinger, R. G., Sperl, W., Rodenburg, R. J., Minet, J. C., Dobbie, A., Strom, T. M., Meitinger, T., George, P. M., Johnson, C. A., Taylor, R. W., Prokisch, H., Doudney, K., and Mayr, J. A. (2016) Sudden Cardiac Death Due to Deficiency of the Mitochondrial Inorganic Pyrophosphatase PPA2. Am. J. Hum. Genet.  99, 674-682"	"DISEASE: Sudden cardiac failure, alcohol-induced (SCFAI) [MIM:617223]: An autosomal recessive disease characterized by sudden death due to unexpected cardiac arrest following ingestion of small amounts of alcohol. {ECO:0000269|PubMed:27523597}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Sudden cardiac failure, infantile (SCFI) [MIM:617222]: A disease characterized by sudden death within the first 2 years of life due to unexpected cardiac arrest. Some patients manifest hypertrophic cardiomyopathy, lipid accumulation in myocardium, degeneration of mitochondrial cristae, metabolic acidosis, and elevated plasma lactate levels. SCFI transmission pattern is consistent with autosomal recessive inheritance. {ECO:0000269|PubMed:27523597, ECO:0000269|PubMed:27523598}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3714756;C4310663;C4310664	609988	617223-617222	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q8N3J5	PPM1K	Metabolism	Regulation & signaling	1				1		"DISEASE: Maple syrup urine disease, mild variant (MSUDMV) [MIM:615135]: A mild form of maple syrup urine disease, a metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated. MSUDMV is characterized by increased plasma levels of branched-chain amino acids (BCAA) apparent at birth. Treatment with a low-protein diet free of BCAA can result in normal psychomotor development and lack of metabolic episodes. {ECO:0000269|PubMed:23086801}. Note=The gene represented in this entry is involved in disease pathogenesis."	C0024776;C0268568;C0268569;C0751285;C1621920	611065	615135	NaN	NaN	NaN	NaN	NaN	854.1828824	NaN	0	NaN	72.74032146
P50336	PPOX	Central nervous system;Metabolism;Liver;Gastrointestinal system;Peripheral nervous system;Integumentary system	Cofactor metabolism	1				1		"DISEASE: Variegate porphyria (VP) [MIM:176200]: A form of porphyria. Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. Variegate porphyria is the most common form of porphyria in South Africa. It is characterized by skin hyperpigmentation and hypertrichosis, abdominal pain, tachycardia, hypertension and neuromuscular disturbances. High fecal levels of protoporphyrin and coproporphyrin, increased urine uroporphyrins and iron overload are typical markers of the disease. {ECO:0000269|PubMed:10486317, ECO:0000269|PubMed:10870850, ECO:0000269|PubMed:11074242, ECO:0000269|PubMed:11102990, ECO:0000269|PubMed:11286631, ECO:0000269|PubMed:11348478, ECO:0000269|PubMed:11350188, ECO:0000269|PubMed:11474578, ECO:0000269|PubMed:12380696, ECO:0000269|PubMed:12655566, ECO:0000269|PubMed:12859407, ECO:0000269|PubMed:12922165, ECO:0000269|PubMed:14669009, ECO:0000269|PubMed:16433813, ECO:0000269|PubMed:16621625, ECO:0000269|PubMed:16922948, ECO:0000269|PubMed:16947091, ECO:0000269|PubMed:18350656, ECO:0000269|PubMed:18570668, ECO:0000269|PubMed:19320019, ECO:0000269|PubMed:21048046, ECO:0000269|PubMed:23430901, ECO:0000269|PubMed:23467411, ECO:0000269|PubMed:24073655, ECO:0000269|PubMed:8673113, ECO:0000269|PubMed:8817334, ECO:0000269|PubMed:8852667, ECO:0000269|PubMed:9541112, ECO:0000269|PubMed:9763307, ECO:0000269|PubMed:9811936}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations leading to severe PPOX deficiency cause the rare homozygous variant form of VP. Missense mutations that preserve 10%-25% of wild-type activity may not cause clinically overt VP in heterozygotes (PubMed:9811936). Mutations with intermediate effect on catalytic activity may cause VP, but with a low clinical penetrance (PubMed:10486317). {ECO:0000269|PubMed:10486317, ECO:0000269|PubMed:9811936}."	C0009402;C0009404;C0162532;C1527249;C2936913;C3149848;C3714756	600923	176200	120.2099848	71.86784497	Class 1	-1.269151137	0.000171573	98222.48802	62441.26667	Peripheral	44.19193804	94.89528061
Q5JRX3	PREP	Central nervous system;Muscular system	Protein degradation & quality control	1				1	"Langer Y, Aran A, Gulsuner S, Abu Libdeh B, Renbaum P, Brunetti D, Teixeira PF, Walsh T, Zeligson S, Ruotolo R, Beeri R, Dweikat I, Shahrour M, Weinberg-Shukron A, Zahdeh F, Baruffini E, Glaser E, King MC, Levy-Lahad E, Zeviani M, Segel R. Mitochondrial PITRM1 peptidase loss-of-function in childhood cerebellar atrophy. J Med Genet. 2018 Sep;55(9):599-606."			618211		583.4688387	NaN	Class 1	-1.184103627	0.000706379	425842.182	382615	Peripheral	23.10134627	70.82034445
Q4J6C6	PREPL	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Muscular system;Endocrine system"	Unknown	1				1		"DISEASE: Hypotonia-cystinuria syndrome (HCS) [MIM:606407]: Characterized generalized hypotonia at birth, nephrolithiasis, growth hormone deficiency, minor facial dysmorphism, failure to thrive, followed by hyperphagia and rapid weight gain in late childhood. {ECO:0000269|PubMed:16385448}. Note=The gene represented in this entry is involved in disease pathogenesis. Hypotonia-cystinuria syndrome is a contiguous gene syndrome caused by a homozygous deletion on chromosome 2p21 that disrupts the gene represented in this entry and SLC3A1.;DISEASE: Myasthenic syndrome, congenital, 22 (CMS22) [MIM:616224]: A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features include easy fatigability and muscle weakness. CMS22 is an autosomal recessive form characterized by neonatal hypotonia. {ECO:0000269|PubMed:24610330}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751882;C0751883;C0751884;C0751885;C1848030;C3714756;C4304537	609557	616224	31.61786318	57.37360489	Class 1	-2.56558401	8.1728E-05	19354.10566	63431.7	Peripheral	16.35644898	85.94751172
Q96LW4	PRIMPOL	Ophthalmic system	DNA-related processes	1				1		"DISEASE: Myopia 22, autosomal dominant (MYP22) [MIM:615420]: A refractive error of the eye, in which parallel rays from a distant object come to focus in front of the retina, vision being better for near objects than for far. {ECO:0000269|PubMed:23579484}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C3809464	615421	615420	Infinite	NaN	NaN	NaN	NaN	31.43653388	2017.173333	0	NaN	NaN
O43272	PRODH	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities"	Amino acid metabolism	1				1		"DISEASE: Hyperprolinemia 1 (HYRPRO1) [MIM:239500]: An inborn error of proline metabolism resulting in elevated levels of proline in the plasma and urine. The disorder is generally benign and most affected individuals are clinically asymptomatic. Some patients, however, have neurologic manifestations, including epilepsy and mental retardation. Association with certain forms of schizophrenia have been reported. {ECO:0000269|PubMed:12217952, ECO:0000269|PubMed:15662599, ECO:0000269|PubMed:17135275}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Schizophrenia 4 (SCZD4) [MIM:600850]: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder. {ECO:0000269|PubMed:11891283, ECO:0000269|PubMed:15662599}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry."	C0002514;C0005586;C0006142;C0023893;C0027765;C0036341;C0268529;C0543888;C0750905;C1833247;C3714756	606810	239500-600850	NaN	NaN	NaN	NaN	NaN	1809.924092	NaN	Peripheral	33.95035514	83.12880463
Q06124	PTPN11	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Ears;Skeletal system;Others;Reproductive system;Integumentary system"	Regulation & signaling	1				1		"DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. {ECO:0000269|PubMed:12058348, ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796, ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399, ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933, ECO:0000269|PubMed:16733669, ECO:0000269|PubMed:24891296, ECO:0000269|PubMed:26742426}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:26742426}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest. {ECO:0000269|PubMed:20577567}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. {ECO:0000269|PubMed:11704759, ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469, ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711, ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436, ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218, ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15889278, ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799, ECO:0000269|PubMed:24891296, ECO:0000269|PubMed:28074573}. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases."	C0001418;C0004114;C0007137;C0007194;C0007959;C0010828;C0014084;C0015306;C0020305;C0023418;C0023467;C0023480;C0024454;C0026998;C0027019;C0027819;C0027831;C0028326;C0029423;C0029434;C0041409;C0158995;C0175704;C0205641;C0205642;C0205643;C0205644;C0205645;C0205768;C0265261;C0280783;C0280785;C0334579;C0334580;C0334581;C0334582;C0334583;C0338070;C0349639;C0376545;C0410530;C0547065;C0587248;C0750935;C0750936;C1275081;C1527404;C1535926;C1704230;C1879321;C3463824;C3714756	176876	151100-156250	93.58164006	123.6157109	NaN	NaN	NaN	NaN	666342.6667	0	NaN	NaN
Q9Y3E5	PTRH2	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Ears;Liver;Gastrointestinal system;Peripheral nervous system;Skeletal system;Hematologic system;Endocrine system"	Cell death/ apoptosis	1				1		"DISEASE: Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset (IMNEPD) [MIM:616263]: A progressive multisystem disease characterized by a variety of neurologic, endocrine, and, in some patients, pancreatic features. Variable clinical symptoms include global developmental delay, hypotonia, hearing loss, ataxia, hyporeflexia, facial dysmorphism, hypothyroidism, and pancreatic insufficiency. {ECO:0000269|PubMed:25558065, ECO:0000269|PubMed:25574476}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0033578;C0376358;C4015728	608625	616263	68.74122804	NaN	Class 3	-0.764298052	0.002696478	314500.7898	701551.3333	Peripheral	49.49431421	94.2777757
Q9Y606	PUS1	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Muscular system;Hematologic system"	tRNA related processes	1				1	"Bykhovskaya, Y., Casas, K., Mengesha, E., Inbal, A., and Fischel-Ghodsian, N. (2004) Missense Mutation in Pseudouridine Synthase 1 (PUS1) Causes Mitochondrial Myopathy and Sideroblastic Anemia (MLASA). Am. J. Hum. Genet. 74, 1303-1308"	"DISEASE: Myopathy with lactic acidosis and sideroblastic anemia 1 (MLASA1) [MIM:600462]: A rare oxidative phosphorylation disorder specific to skeletal muscle and bone marrow. Affected individuals manifest progressive muscle weakness, exercise intolerance, lactic acidosis, sideroblastic anemia and delayed growth. {ECO:0000269|PubMed:15108122, ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:19731322}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0006142;C0010828;C0024623;C0038356;C0158995;C0235874;C0270960;C0751651;C1708349;C1838103;C3714756	608109	600462	161.4140144	NaN	Class 1	-3.376266938	5.35242E-06	260560.8381	366042.3333	Soluble	6.27674327	29.7028661
Q96C36	PYCR2	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Ears;Skeletal system"	Amino acid metabolism	1				1		"DISEASE: Leukodystrophy, hypomyelinating, 10 (HLD10) [MIM:616420]: An autosomal recessive neurologic disorder characterized by postnatal microcephaly, severely delayed psychomotor development, hypomyelination, and reduced cerebral white-matter volume. {ECO:0000269|PubMed:25865492}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C3711387;C3714756;C4225332	616406	616420	57.68353557	NaN	Class 1	-1.76999705	2.96775E-05	1008985.023	1208032	Peripheral	20.52346111	95.56539463
P09417	QDPR	Central nervous system;Metabolism	Cofactor metabolism	1				1		"DISEASE: Hyperphenylalaninemia, BH4-deficient, C (HPABH4C) [MIM:261630]: Rare autosomal recessive disorder characterized by hyperphenylalaninemia and severe neurologic symptoms (malignant hyperphenylalaninemia) including axial hypotonia and truncal hypertonia, abnormal thermogenesis, and microcephaly. These signs are attributable to depletion of the neurotransmitters dopamine and serotonin, whose syntheses are controlled by tryptophan and tyrosine hydroxylases that use BH-4 as cofactor. Patients do not respond to phenylalanine-restricted diet. HPABH4C is lethal if untreated. {ECO:0000269|PubMed:10408783, ECO:0000269|PubMed:11153907, ECO:0000269|PubMed:2116088, ECO:0000269|PubMed:8326489, ECO:0000269|PubMed:9744478}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0031485;C0268465;C0543888;C0751434;C0751435;C0751436;C3714756	612676	261630	Infinite	944.9527773	Class 1	-2.636785616	2.3317E-05	24188.58552	172351.3333	Peripheral	4.725616843	59.32336597
Q9H0R6	QRSL1	Cardiovascular system;Ears;Endocrine system	tRNA related processes	1				1	"Kohda, M., Tokuzawa, Y., Kishita, Y., Nyuzuki, H., Moriyama, Y., Mizuno, Y., Hirata, T., Yatsuka, Y., Yamashita-Sugahara, Y., Nakachi, Y., Kato, H., Okuda, A., Tamaru, S., Borna, N. N., Banshoya, K., Aigaki, T., Sato-Miyata, Y., Ohnuma, K., Suzuki, T., Nagao, A., Maehata, H., Matsuda, F., Higasa, K., Nagasaki, M., Yasuda, J., Yamamoto, M., Fushimi, T., Shimura, M., Kaiho-Ichimoto, K., Harashima, H., Yamazaki, T., Mori, M., Murayama, K., Ohtake, A., and Okazaki, Y. (2016) A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies. PLoS Genet 12, e1005679"	DISEASE: Note=Defects in QRSL1 may play a role in mitochondrial disorders characterized by combined respiratory chain complex deficiencies. {ECO:0000269|PubMed:26741492}.	C0751651	617209	618835	38.87000698	NaN	Class 1	-1.086942219	0.00083887	181985.6625	170015.6667	Peripheral	9.582040585	82.96715982
Q06609	RAD51	"Central nervous system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Skeletal system;Hematologic system;Reproductive system;Tumors"	DNA-related processes	1				1		"DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. {ECO:0000269|PubMed:10807537, ECO:0000269|PubMed:25539919}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;DISEASE: Fanconi anemia, complementation group R (FANCR) [MIM:617244]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. {ECO:0000269|PubMed:26253028, ECO:0000269|PubMed:26681308}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mirror movements 2 (MRMV2) [MIM:614508]: A disorder characterized by contralateral involuntary movements that mirror voluntary ones. While mirror movements are occasionally found in young children, persistence beyond the age of 10 is abnormal. Mirror movements occur more commonly in the upper extremities. {ECO:0000269|PubMed:22305526}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006142;C0015625;C0018671;C0018675;C0027533;C0278996;C0346153;C0677776;C0678222;C0746787;C0751177;C0887900;C1257931;C1458155;C1861906;C3281089;C4284093	179617	617244-614508-114480	Infinite	NaN	Class 4	-0.33368958	0.135316069	52.54723424	27982.7	0	NaN	NaN
Q5T160	RARS2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system "	tRNA related processes	1				1	"Edvardson, S., Shaag, A., Kolesnikova, O., Gomori, J. M., Tarassov, I., Einbinder, T., Saada, A., and Elpeleg, O. (2007) Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. Am. J. Hum. Genet. 81, 857-862"	"DISEASE: Pontocerebellar hypoplasia 6 (PCH6) [MIM:611523]: A disorder characterized by an abnormally small cerebellum and brainstem, infantile encephalopathy, generalized hypotonia, lethargy and poor feeding. Recurrent apnea, intractable seizures occur early in the course of this condition. {ECO:0000269|PubMed:17847012}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0025958;C0266470;C0543888;C0751651;C1843504;C1969084;C3714756	611524	611523	127.1578973	74.07417951	Class 3	-0.82071131	0.001713737	131337.5606	106569.8	Peripheral	25.33418774	83.71203185
Q9NWS8	RMND1	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Ears;Peripheral nervous system;Skeletal system;Kidney and urinary tract	Ribosome assembly & translation	1				1	"Garcia-Diaz, B., Barros, M. H., Sanna-Cherchi, S., Emmanuele, V., Akman, H. O., Ferreiro-Barros, C. C., Horvath, R., Tadesse, S., El Gharaby, N., Dimauro, S., De Vivo, D. C., Shokr, A., Hirano, M., and Quinzii, C. M. (2012) Infantile Encephaloneuromyopathy and Defective Mitochondrial Translation Are Due to a Homozygous RMND1 Mutation. Am. J. Hum. Genet.  91, 729-736;Janer, A., Antonicka, H., Lalonde, E., Nishimura, T., Sasarman, F., Brown, G. K., Brown, R. M., Majewski, J., and Shoubridge, E. A. (2012) An RMND1 Mutation Causes Encephalopathy Associated with Multiple Oxidative Phosphorylation Complex Deficiencies and a Mitochondrial Translation Defect. Am. J. Hum. Genet. 91, 737-743"	"DISEASE: Combined oxidative phosphorylation deficiency 11 (COXPD11) [MIM:614922]: A severe, multisystemic, autosomal recessive, disorder characterized by deficiencies of multiple mitochondrial respiratory enzymes leading to neonatal hypotonia and lactic acidosis. Affected individuals may have respiratory insufficiency, foot deformities, or seizures. {ECO:0000269|PubMed:23022098, ECO:0000269|PubMed:23022099, ECO:0000269|PubMed:25604853, ECO:0000269|PubMed:26238252}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C3554067;C3714756	614917	614922	941.6751603	NaN	Class 1	-1.705060872	0.000123453	75181.70519	78677.53333	Integral	94.08071737	97.40246959
O60930	RNASEH1	Central nervous system;Metabolism;Pulmonary system ;Muscular system;Peripheral nervous system	RNA-related processes	1				1	"Reyes, A., Melchionda, L., Nasca, A., Carrara, F., Lamantea, E., Zanolini, A., Lamperti, C., Fang, M., Zhang, J., Ronchi, D., Bonato, S., Fagiolari, G., Moggio, M., Ghezzi, D., and Zeviani, M. (2015) RNASEH1 Mutations Impair mtDNA Replication and Cause Adult-Onset Mitochondrial Encephalomyopathy. Am. J. Hum. Genet. 97, 186-193"	"DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2 (PEOB2) [MIM:616479]: A form of progressive external ophthalmoplegia, a mitochondrial myopathy characterized by progressive paralysis of the levator palpebrae, orbicularis oculi, and extraocular muscles. PEOB2 patients manifest exercise intolerance, muscle weakness, and signs and symptoms of spinocerebellar ataxia, such as impaired gait and dysarthria. Some patients may have respiratory insufficiency. {ECO:0000269|PubMed:26094573}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C4225312;C4511138	604123	616479	61.91810837	76.34857329	Class 1	-3.177278432	5.20577E-05	2935.009014	4531.255667	Peripheral	25.67533288	86.75445578
P49247	RPIA	Central nervous system;Metabolism;Ophthalmic system;Peripheral nervous system	Carbohydrate & energy metabolism	1				1		"DISEASE: Ribose 5-phosphate isomerase deficiency (RPID) [MIM:608611]: A patient has been described with a deficiency of ribose 5-phosphate isomerase who presented with leukoencephalopathy and peripheral neuropathy. Proton magnetic resonance spectroscopy of the brain revealed a highly elevated level of the polyols ribitol and D-arabitol, which were subsequently also found in high concentrations in body fluids. Deficient activity of RPIA, one of the pentose phosphate pathway enzymes, has been demonstrated in fibroblasts. {ECO:0000269|PubMed:14988808}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C1291609	180430	608611	Infinite	NaN	Class 1	-1.903512635	0.001501536	32178.99145	127405.4667	Soluble	6.469817814	35.49571708
Q8WWV3	RTN4IP1	Central nervous system;Ophthalmic system	Regulation & signaling	1				1	"Angebault, C., Guichet, P. O., Talmat-Amar, Y., Charif, M., Gerber, S., Fares-Taie, L., Gueguen, N., Halloy, F., Moore, D., Amati-Bonneau, P., Manes, G., Hebrard, M., Bocquet, B., Quiles, M., Piro-Megy, C., Teigell, M., Delettre, C., Rossel, M., Meunier, I., Preising, M., Lorenz, B., Carelli, V., Chinnery, P. F., Yu-Wai-Man, P., Kaplan, J., Roubertie, A., Barakat, A., Bonneau, D., Reynier, P., Rozet, J. M., Bomont, P., Hamel, C. P., and Lenaers, G. (2015) Recessive Mutations in RTN4IP1 Cause Isolated and Syndromic Optic Neuropathies. Am. J. Hum. Genet. 97, 754-760"	"DISEASE: Optic atrophy 10 with or without ataxia, mental retardation, and seizures (OPA10) [MIM:616732]: An autosomal recessive disease characterized by progressive visual loss in association with optic atrophy. Atrophy of the optic disk indicates a deficiency in the number of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts. OPA10 patients may also manifest mild ataxia, mild mental retardation and, rarely, generalized seizures. {ECO:0000269|PubMed:26593267}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3714756;C4225227	610502	616732	114.4731552	92.19866765	Class 1	-1.660167442	0.00025673	83765.78669	100203.7333	Peripheral	5.017273078	84.86393161
Q9UL12	SARDH	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Ears	Other known processes	1				1		"DISEASE: Sarcosinemia (SARCOS) [MIM:268900]: A metabolic disorder characterized by an increased concentration of sarcosine in plasma and an increased excretion of sarcosine in urine. Sarcosinemia is most probably a benign condition without significant clinical problems. Some reports have associated sarcosinemia with mental retardation and neurologic problems. {ECO:0000269|PubMed:10444331, ECO:0000269|PubMed:22825317}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003129;C0003130;C0242184;C0268563;C0700292	604455	268900	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9NP81	SARS2	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Pulmonary system ;Hematologic system;Kidney and urinary tract;Endocrine system	tRNA related processes	1				1	"Belostotsky, R., Ben-Shalom, E., Rinat, C., Becker-Cohen, R., Feinstein, S., Zeligson, S., Segel, R., Elpeleg, O., Nassar, S., and Frishberg, Y. (2011) Mutations in the mitochondrial seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis, HUPRA syndrome. Am. J. Hum. Genet. 88, 193-200"	"DISEASE: Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome (HUPRAS) [MIM:613845]: A multisystem disorder characterized by onset in infancy of progressive renal failure leading to electrolyte imbalances, metabolic alkalosis, pulmonary hypertension, hypotonia, and delayed development. Affected individuals are born prematurely. {ECO:0000269|PubMed:21255763}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3151209	612804	613845	204.8059364	NaN	Class 4	-0.715902557	0.008820115	506821.0026	438053	Soluble	5.646166393	18.89249735
O75880	SCO1	Central nervous system;Metabolism;Pulmonary system ;Liver	OXPHOS assembly & stability	1				1	"Valnot, I., Osmond, S., Gigarel, N., Mehaye, B., Amiel, J., Cormier-Daire, V., Munnich, A., Bonnefont, J. P., Rustin, P., and Rotig, A. (2000) Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy. Am. J. Hum. Genet. 67, 1104-1109"	"DISEASE: Mitochondrial complex IV deficiency (MT-C4D) [MIM:220110]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations, ranging from isolated myopathy to severe multisystem disease affecting several tissues and organs. Features include hypertrophic cardiomyopathy, hepatomegaly and liver dysfunction, hypotonia, muscle weakness, exercise intolerance, developmental delay, delayed motor development and mental retardation. Some affected individuals manifest a fatal hypertrophic cardiomyopathy resulting in neonatal death. A subset of patients manifest Leigh syndrome. {ECO:0000269|PubMed:11013136, ECO:0000269|PubMed:17182746, ECO:0000269|PubMed:17189203, ECO:0000269|PubMed:19336478}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006111;C0018799;C0023520;C0023895;C0085584;C0086565;C0162557;C0268237;C0543888;C0751651;C0949855;C0949856;C0949857;C1858424;C3714756	603644	220110	121.2906081	NaN	Class 1	-1.259694979	0.000171024	388043.0482	489911.3333	Integral	75.97934662	95.19107262
O43819	SCO2	Central nervous system;Metabolism;Cardiovascular system;Pulmonary system 	OXPHOS assembly & stability	1				1	"Papadopoulou, L. C., Sue, C. M., Davidson, M. M., Tanji, K., Nishino, I., Sadlock, J. E., Krishna, S., Walker, W., Selby, J., Glerum, D. M., Coster, R. V., Lyon, G., Scalais, E., Lebel, R., Kaplan, P., Shanske, S., De Vivo, D. C., Bonilla, E., Hirano, M., DiMauro, S., and Schon, E. A. (1999) Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nat Genet 23, 333-337"	"DISEASE: Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1 (CEMCOX1) [MIM:604377]: A disorder characterized by hypotonia, developmental delay, hypertrophic cardiomyopathy, lactic acidosis, gliosis, neuronal loss in basal ganglia, brainstem and spinal cord, and cytochrome c oxidase deficiency. {ECO:0000269|PubMed:10545952, ECO:0000269|PubMed:10749987, ECO:0000269|PubMed:11673586, ECO:0000269|PubMed:14994243, ECO:0000269|PubMed:17189203, ECO:0000269|PubMed:19336478, ECO:0000269|PubMed:19353847, ECO:0000269|PubMed:25959673}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:26741492}. Note=The disease may be caused by mutations affecting the gene represented in this entry.;DISEASE: Myopia 6 (MYP6) [MIM:608908]: A refractive error of the eye, in which parallel rays from a distant object come to focus in front of the retina, vision being better for near objects than for far. {ECO:0000269|PubMed:23643385, ECO:0000269|PubMed:25525168, ECO:0000269|PubMed:25959673}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007194;C0021400;C0023264;C0023520;C0027092;C0033141;C0036529;C0162666;C0268237;C0543888;C0751651;C0752107;C0752109;C0752110;C0878544;C1837148;C1838951;C1850597;C1850598;C1850599;C1850600;C1858424;C2931111;C2931891;C3714756	604272	604377-608908	42.51046431	100.9318397	Class 1	-2.021986178	2.42691E-05	298634.6399	239184	Integral	87.45428876	91.07761362
P31040	SDHA	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Cardiovascular system;Muscular system	OXPHOS complex subunits	1				1	"Bourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Pequignot, E., Munnich, A., and Rotig, A. (1995) Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet 11, 144-149"	"DISEASE: Cardiomyopathy, dilated 1GG (CMD1GG) [MIM:613642]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:20551992}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:10746566, ECO:0000269|PubMed:24781757, ECO:0000269|PubMed:7550341}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial complex II deficiency (MT-C2D) [MIM:252011]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry. {ECO:0000269|PubMed:12794685}.;DISEASE: Paragangliomas 5 (PGL5) [MIM:614165]: A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion. Paragangliomas can develop at various body sites, including the head, neck, thorax and abdomen. Most commonly, they are located in the head and neck region, specifically at the carotid bifurcation, the jugular foramen, the vagal nerve, and in the middle ear. {ECO:0000269|PubMed:20484225}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006826;C0007193;C0023264;C0023520;C0029408;C0036341;C0086743;C0154040;C0154045;C0206695;C0238198;C0264886;C0340427;C0344456;C0438413;C0543888;C0751267;C0751268;C0751651;C1449563;C1838951;C1850597;C1850598;C1850599;C1850600;C1855008;C2931891;C3150898;C3179349;C3279992;C3714756;C4021133	600857	613642-256000-252011-614165	37.08341438	NaN	Class 1	-1.197287643	0.001022499	1138608.248	1369843.333	Soluble	7.190350942	37.75928973
A6NFY7	SDHAF1	Central nervous system;Metabolism;Failure to thrive	OXPHOS assembly & stability	1				1	"Ghezzi, D., Goffrini, P., Uziel, G., Horvath, R., Klopstock, T., Lochmuller, H., D'Adamo, P., Gasparini, P., Strom, T. M., Prokisch, H., Invernizzi, F., Ferrero, I., and Zeviani, M. (2009) SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy. Nat Genet 41, 654-656"	"DISEASE: Mitochondrial complex II deficiency (MT-C2D) [MIM:252011]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome. {ECO:0000269|PubMed:19465911, ECO:0000269|PubMed:22995659, ECO:0000269|PubMed:26749241}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0011269;C0023520;C0270786;C0393560;C0393561;C0600359;C0751651;C1855008;C3714756	612848	252011	NaN	NaN	NaN	NaN	NaN	7776.144655	9962.7955	Peripheral	7.455139027	61.90892216
Q9NX18	SDHAF2	Tumors	OXPHOS assembly & stability	1				1		"DISEASE: Paragangliomas 2 (PGL2) [MIM:601650]: A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion. Paragangliomas can develop at various body sites, including the head, neck, thorax and abdomen. Most commonly, they are located in the head and neck region, specifically at the carotid bifurcation, the jugular foramen, the vagal nerve, and in the middle ear. {ECO:0000269|PubMed:19628817}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006826;C0019202;C0030421;C0154040;C0154045;C0206695;C0344456;C0438413;C0751651;C1527352;C1866552	613019	601650	166.222805	NaN	Class 1	-2.657601612	3.63937E-05	19350.11188	9787.04	Soluble	10.82868938	21.74904026
A0A087WWT1;A0A087WXX8;P21912	SDHB	Metabolism;Tumors	OXPHOS complex subunits	1				1	"Alston, C. L., Davison, J. E., Meloni, F., van der Westhuizen, F. H., He, L., Hornig-Do, H. T., Peet, A. C., Gissen, P., Goffrini, P., Ferrero, I., Wassmer, E., McFarland, R., and Taylor, R. W. (2012) Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency. J Med Genet 49, 569-577;Astuti, D., Latif, F., Dallol, A., Dahia, P. L., Douglas, F., George, E., Skoldberg, F., Husebye, E. S., Eng, C., and Maher, E. R. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 69, 49-54"	"DISEASE: Paraganglioma and gastric stromal sarcoma (PGGSS) [MIM:606864]: Gastrointestinal stromal tumors may be sporadic or inherited in an autosomal dominant manner, alone or as a component of a syndrome associated with other tumors, such as in the context of neurofibromatosis type 1 (NF1). Patients have both gastrointestinal stromal tumors and paragangliomas. Susceptibility to the tumors was inherited in an apparently autosomal dominant manner, with incomplete penetrance. {ECO:0000269|PubMed:17804857}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Paragangliomas 4 (PGL4) [MIM:115310]: A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion. Paragangliomas can develop at various body sites, including the head, neck, thorax and abdomen. Most commonly, they are located in the head and neck region, specifically at the carotid bifurcation, the jugular foramen, the vagal nerve, and in the middle ear. {ECO:0000269|PubMed:11404820, ECO:0000269|PubMed:11897817, ECO:0000269|PubMed:14715873, ECO:0000269|PubMed:14974914, ECO:0000269|PubMed:15328326}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent. {ECO:0000269|PubMed:11404820, ECO:0000269|PubMed:12000816, ECO:0000269|PubMed:12618761, ECO:0000269|PubMed:14500403, ECO:0000269|PubMed:14974914, ECO:0000269|PubMed:15328326, ECO:0000269|PubMed:17634472}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry."	C0006826;C0018553;C0023520;C0030421;C0031511;C0154040;C0154045;C0206695;C0238198;C0344456;C0438413;C0740457;C0751651;C1257877;C1847319;C1855008;C1861848;C2676500;C3149711;C3179349;C3552552	185470	606764-606864-115310	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q99643	SDHC	Tumors	OXPHOS complex subunits	1				1		"DISEASE: Paraganglioma and gastric stromal sarcoma (PGGSS) [MIM:606864]: Gastrointestinal stromal tumors may be sporadic or inherited in an autosomal dominant manner, alone or as a component of a syndrome associated with other tumors, such as in the context of neurofibromatosis type 1 (NF1). Patients have both gastrointestinal stromal tumors and paragangliomas. Susceptibility to the tumors was inherited in an apparently autosomal dominant manner, with incomplete penetrance. {ECO:0000269|PubMed:17804857}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Paragangliomas 3 (PGL3) [MIM:605373]: A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion. Paragangliomas can develop at various body sites, including the head, neck, thorax and abdomen. Most commonly, they are located in the head and neck region, specifically at the carotid bifurcation, the jugular foramen, the vagal nerve, and in the middle ear. {ECO:0000269|PubMed:11062460}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006826;C0018553;C0030421;C0031511;C0154040;C0154045;C0206695;C0238198;C0344456;C0438413;C0751651;C1847319;C1854336;C1861848;C3179349	602413	606764-606864-605373	72.15550027	81.3266229	Class 1	-1.575081703	0.000385261	222970.3566	424892.3333	0	NaN	96.93391967
O14521	SDHD	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Muscular system;Tumors"	OXPHOS complex subunits	1				1	"Jackson, C. B., Nuoffer, J. M., Hahn, D., Prokisch, H., Haberberger, B., Gautschi, M., Haberli, A., Gallati, S., and Schaller, A. (2014) Mutations in SDHD lead to autosomal recessive encephalomyopathy and isolated mitochondrial complex II deficiency. J Med Genet 51, 170-175"	"DISEASE: Mitochondrial complex II deficiency (MT-C2D) [MIM:252011]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome. {ECO:0000269|PubMed:24367056, ECO:0000269|PubMed:26008905}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Paraganglioma and gastric stromal sarcoma (PGGSS) [MIM:606864]: Gastrointestinal stromal tumors may be sporadic or inherited in an autosomal dominant manner, alone or as a component of a syndrome associated with other tumors, such as in the context of neurofibromatosis type 1 (NF1). Patients have both gastrointestinal stromal tumors and paragangliomas. Susceptibility to the tumors was inherited in an apparently autosomal dominant manner, with incomplete penetrance. {ECO:0000269|PubMed:17804857}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Paragangliomas 1 (PGL1) [MIM:168000]: A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion. PGL1 is a rare autosomal dominant disorder which is characterized by the development of mostly benign, highly vascular, slowly growing tumors in the head and neck. In the head and neck region, the carotid body is the largest of all paraganglia and is also the most common site of the tumors. {ECO:0000269|PubMed:10657297, ECO:0000269|PubMed:11343322, ECO:0000269|PubMed:11391796, ECO:0000269|PubMed:11391798, ECO:0000269|PubMed:15328326}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent. {ECO:0000269|PubMed:11156372, ECO:0000269|PubMed:12000816, ECO:0000269|PubMed:15328326}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry."	C0006826;C0007129;C0007279;C0017671;C0018553;C0024586;C0025202;C0030421;C0030422;C0031511;C0154040;C0154045;C0206695;C0344456;C0349535;C0438413;C0751651;C1257877;C1847319;C1855008;C1868633;C2676500;C3149711;C3494181	602690	252011-606864	604.0332873	244.4382744	Class 1	-1.841352032	0.000492336	193363.792	546587.5	Integral	92.5359319	94.43569015
Q96JX3	SERAC1	Central nervous system;Metabolism;Failure to thrive;Cardiovascular system;Ears;Liver;Others	Lipid metabolism	1				1	"Sarig, O., Goldsher, D., Nousbeck, J., Fuchs-Telem, D., Cohen-Katsenelson, K., Iancu, T. C., Manov, I., Saada, A., Sprecher, E., and Mandel, H. (2013) Infantile mitochondrial hepatopathy is a cardinal feature of MEGDEL syndrome (3-methylglutaconic aciduria type IV with sensorineural deafness, encephalopathy and Leigh-like syndrome) caused by novel mutations in SERAC1. Am J Med Genet A 161A, 2204-2215;Wortmann, S. B., Vaz, F. M., Gardeitchik, T., Vissers, L. E., Renkema, G. H., Schuurs-Hoeijmakers, J. H., Kulik, W., Lammens, M., Christin, C., Kluijtmans, L. A., Rodenburg, R. J., Nijtmans, L. G., Grunewald, A., Klein, C., Gerhold, J. M., Kozicz, T., van Hasselt, P. M., Harakalova, M., Kloosterman, W., Baric, I., Pronicka, E., Ucar, S. K., Naess, K., Singhal, K. K., Krumina, Z., Gilissen, C., van Bokhoven, H., Veltman, J. A., Smeitink, J. A., Lefeber, D. J., Spelbrink, J. N., Wevers, R. A., Morava, E., and de Brouwer, A. P. (2012) Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness. Nat Genet 44, 797-802"	"DISEASE: 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome (MEGDEL) [MIM:614739]: An autosomal recessive disorder characterized by childhood onset of delayed psychomotor development or psychomotor regression, sensorineural deafness, spasticity or dystonia, and increased excretion of 3-methylglutaconic acid. Brain imaging shows cerebral and cerebellar atrophy as well as lesions in the basal ganglia reminiscent of Leigh syndrome. Laboratory studies show increased serum lactate and alanine, mitochondrial oxidative phosphorylation defects, abnormal mitochondria, abnormal phosphatidylglycerol and cardiolipin profiles in fibroblasts, and abnormal accumulation of unesterified cholesterol within cells. {ECO:0000269|PubMed:22683713, ECO:0000269|PubMed:23707711, ECO:0000269|PubMed:28778788}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0011052;C0011053;C0013421;C0023772;C0037773;C0086395;C0220994;C0393588;C0393610;C0581883;C0751068;C0751093;C0751651;C3553597;C3665473;C3714756;C4082305	614725	614739	NaN	NaN	NaN	NaN	NaN	6902.698281	NaN	0	NaN	NaN
Q6P4A7;Q6P4A7	SFXN4	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Muscular system;Hematologic system"	"Carriers, channels & transporters"	1				1	"Hildick-Smith, G. J., Cooney, J. D., Garone, C., Kremer, L. S., Haack, T. B., Thon, J. N., Miyata, N., Lieber, D. S., Calvo, S. E., Akman, H. O., Yien, Y. Y., Huston, N. C., Branco, D. S., Shah, D. I., Freedman, M. L., Koehler, C. M., Italiano, J. E., Jr., Merkenschlager, A., Beblo, S., Strom, T. M., Meitinger, T., Freisinger, P., Donati, M. A., Prokisch, H., Mootha, V. K., DiMauro, S., and Paw, B. H. (2013) Macrocytic anemia and mitochondriopathy resulting from a defect in sideroflexin 4. Am. J. Hum. Genet.  93, 906-914"	"DISEASE: Combined oxidative phosphorylation deficiency 18 (COXPD18) [MIM:615578]: An autosomal recessive disorder of mitochondrial dysfunction characterized by intrauterine growth retardation, hypotonia, visual impairment, speech delay, and lactic acidosis associated with decreased mitochondrial respiratory chain activity. Affected patients may also show hematologic abnormalities, mainly macrocytic anemia. {ECO:0000269|PubMed:24119684}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3810001	615564	615578	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P49281	SLC11A2	Metabolism;Liver;Hematologic system	"Carriers, channels & transporters"	1				1		"DISEASE: Anemia, hypochromic microcytic, with iron overload 1 (AHMIO1) [MIM:206100]: A hematologic disease characterized by abnormal hemoglobin content in the erythrocytes which are reduced in size. The disorder is due to an error of iron metabolism that results in high serum iron, massive hepatic iron deposition, and absence of sideroblasts and stainable bone marrow iron store. Despite adequate transferrin-iron complex, delivery of iron to the erythroid bone marrow is apparently insufficient for the demands of hemoglobin synthesis. {ECO:0000269|PubMed:15459009, ECO:0000269|PubMed:16160008, ECO:0000269|PubMed:16439678}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0010828;C0018995;C0023903;C0158995;C0162316;C0345904;C0392514;C1527249;C2673913;C3806153	600523	206100	NaN	110.3798864	NaN	NaN	NaN	0	0	0	0	0
Q9H015	SLC22A4	Ears	"Carriers, channels & transporters"	1				1		"DISEASE: Rheumatoid arthritis (RA) [MIM:180300]: An inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. {ECO:0000269|PubMed:14608356}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry."	C0003873;C0010246;C0014378;C0027059;C0869523	604190	180300	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
B4DP62;P53007	SLC25A1	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Muscular system;Skeletal system"	"Carriers, channels & transporters"	1				1	"Nota, B., Struys, E. A., Pop, A., Jansen, E. E., Fernandez Ojeda, M. R., Kanhai, W. A., Kranendijk, M., van Dooren, S. J., Bevova, M. R., Sistermans, E. A., Nieuwint, A. W., Barth, M., Ben-Omran, T., Hoffmann, G. F., de Lonlay, P., McDonald, M. T., Meberg, A., Muntau, A. C., Nuoffer, J. M., Parini, R., Read, M. H., Renneberg, A., Santer, R., Strahleck, T., van Schaftingen, E., van der Knaap, M. S., Jakobs, C., and Salomons, G. S. (2013) Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. Am. J. Hum. Genet.  92, 627-631;Smith, A., McBride, S., Marcadier, J. L., Michaud, J., Al-Dirbashi, O. Y., Schwartzentruber, J., Beaulieu, C. L., Katz, S. L., Consortium, F. C., Majewski, J., Bulman, D. E., Geraghty, M. T., Harper, M. E., Chakraborty, P., and Lines, M. A. (2016) Severe Neonatal Presentation of Mitochondrial Citrate Carrier (SLC25A1) Deficiency. JIMD Rep 30, 73-79"	"DISEASE: Combined D-2- and L-2-hydroxyglutaric aciduria (D2L2AD) [MIM:615182]: An autosomal recessive neurometabolic disorder characterized by neonatal-onset encephalopathy with severe muscular weakness, intractable seizures, respiratory distress, and lack of psychomotor development resulting in early death. Brain imaging shows abnormalities including enlarged ventricles, delayed myelination, and germinal layer cysts. {ECO:0000269|PubMed:23561848, ECO:0000269|PubMed:27306203}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0036341;C0751884;C2746066	190315	618197-615182	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
F6RGN5;Q9UBX3	SLC25A10	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Ears"	"Carriers, channels & transporters"	1				1	"Punzi G, Porcelli V, Ruggiu M, Hossain MF, Menga A, Scarcia P, Castegna A, Gorgoglione R, Pierri CL, Laera L, Lasorsa FM, Paradies E, Pisano I, Marobbio CMT, Lamantea E, Ghezzi D, Tiranti V, Giannattasio S, Donati MA, Guerrini R, Palmieri L, Palmieri F, De Grassi A. SLC25A10 biallelic mutations in intractable epileptic encephalopathy with complex I deficiency. Hum Mol Genet. 2018 Feb 1;27(3):499-504. "			606794	618972	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
I3L1P8;Q02978	SLC25A11	Tumors	"Carriers, channels & transporters"	1				1	"Buffet A, Morin A, Castro-Vega LJ, Habarou F, Lussey-Lepoutre C, Letouzé E, Lefebvre H, Guilhem I, Haissaguerre M, Raingeard I, Padilla-Girola M, Tran T, Tchara L, Bertherat J, Amar L, Ottolenghi C, Burnichon N, Gimenez-Roqueplo AP, Favier J. Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas. Cancer Res. 2018 Apr 15;78(8):1914-1922."			604165	618464	NaN	426.8250827	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O75746	SLC25A12	Central nervous system;Metabolism	"Carriers, channels & transporters"	1				1	"Falk, M. J., Li, D., Gai, X., McCormick, E., Place, E., Lasorsa, F. M., Otieno, F. G., Hou, C., Kim, C. E., Abdel-Magid, N., Vazquez, L., Mentch, F. D., Chiavacci, R., Liang, J., Liu, X., Jiang, H., Giannuzzi, G., Marsh, E. D., Yiran, G., Tian, L., Palmieri, F., and Hakonarson, H. (2014) AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate. JIMD Rep 14, 77-85;Wibom, R., Lasorsa, F. M., Tohonen, V., Barbaro, M., Sterky, F. H., Kucinski, T., Naess, K., Jonsson, M., Pierri, C. L., Palmieri, F., and Wedell, A. (2009) AGC1 deficiency associated with global cerebral hypomyelination. N Engl J Med 361, 489-495"	"DISEASE: Epileptic encephalopathy, early infantile, 39 (EIEE39) [MIM:612949]: A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. EIEE39 is characterized by global hypomyelination of the central nervous system, with the gray matter appearing relatively unaffected. Inheritance is autosomal recessive. {ECO:0000269|PubMed:19641205, ECO:0000269|PubMed:24515575}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003873;C0004352;C0023520;C0036341;C0543888;C0751651;C2751855;C3714756	603667	612949	235.4344559	279.3527031	Class 1	-1.489246617	0.000301763	242890.6963	276552	Integral	91.23523409	97.94622118
Q9UJS0	SLC25A13	Central nervous system;Metabolism;Liver	"Carriers, channels & transporters"	1				1		"DISEASE: Cholestasis, neonatal intrahepatic, caused by citrin deficiency (NICCD) [MIM:605814]: A form of citrullinemia type 2 with neonatal onset, characterized by suppression of the bile flow, hepatic fibrosis, low birth weight, growth retardation, hypoproteinemia, variable liver dysfunction. Neonatal intrahepatic cholestasis due to citrin deficiency is generally not severe and symptoms disappear by one year of age with an appropriate diet. Years or even decades later, however, some individuals develop the characteristic features of citrullinemia type 2 with neuropsychiatric symptoms. {ECO:0000269|PubMed:11793471}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Citrullinemia 2 (CTLN2) [MIM:603471]: A form of citrullinemia, an autosomal recessive disease characterized primarily by elevated serum and urine citrulline levels. Ammonia intoxication is another manifestation. Citrullinemia type 2 is characterized by neuropsychiatric symptoms including abnormal behaviors, loss of memory, seizures and coma. Death can result from brain edema. Onset is sudden and usually between the ages of 20 and 50 years. {ECO:0000269|PubMed:10369257, ECO:0000269|PubMed:10610724}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0008370;C0016658;C0023893;C0220994;C0332712;C0751651;C1112213;C1853942;C1863844;C3714756	603859	603471-605814	NaN	273.8545567	Class 4	-0.300820735	0.609611558	NaN	NaN	0	NaN	NaN
Q9Y619	SLC25A15	Central nervous system;Metabolism;Failure to thrive;Liver	"Carriers, channels & transporters"	1				1		"DISEASE: Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (HHH syndrome) [MIM:238970]: Autosomal recessive disorder resulting in various neurologic symptoms, including mental retardation, spastic paraparesis with pyramidal signs, cerebellar ataxia, and episodic disturbance of consciousness or coma caused by hyperammonemia. It causes a functional impairment of the urea cycle. {ECO:0000269|PubMed:10369256, ECO:0000269|PubMed:10805333, ECO:0000269|PubMed:11552031, ECO:0000269|PubMed:11668643, ECO:0000269|PubMed:11814739, ECO:0000269|PubMed:16601889, ECO:0000269|PubMed:19242930}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0268540;C3714756	603861	238970	301.6666965	546.3122349	Class 1	-2.031491454	0.000247807	188427.5691	210500	Integral	96.54290523	96.56378733
Q9HC21	SLC25A19	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Peripheral nervous system;Skeletal system"	"Carriers, channels & transporters"	1				1	"Spiegel, R., Shaag, A., Edvardson, S., Mandel, H., Stepensky, P., Shalev, S. A., Horovitz, Y., Pines, O., and Elpeleg, O. (2009) SLC25A19 mutation as a cause of neuropathy and bilateral striatal necrosis. Ann Neurol 66, 419-424"	"DISEASE: Microcephaly, Amish type (MCPHA) [MIM:607196]: A disorder characterized by severe congenital microcephaly and severe 2-ketoglutaric aciduria leading to death within the first year. {ECO:0000269|PubMed:12185364}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Thiamine metabolism dysfunction syndrome 4, bilateral striatal degeneration and progressive polyneuropathy type (THMD4) [MIM:613710]: A disease characterized by recurrent episodes of flaccid paralysis and encephalopathy associated with bilateral striatal necrosis and chronic progressive polyneuropathy. {ECO:0000269|PubMed:19798730}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0025958;C0431350;C0751651;C1846648;C3150973;C3714756	606521	607196-613710	199.7904115	NaN	Class 1	-1.585359788	8.84008E-05	145616.1854	118240.6667	Integral	93.91041267	86.65916022
O43772	SLC25A20	Central nervous system;Metabolism;Cardiovascular system;Pulmonary system ;Muscular system;Liver	"Carriers, channels & transporters"	1				1		"DISEASE: Carnitine-acylcarnitine translocase deficiency (CACTD) [MIM:212138]: A rare long-chain fatty acid oxidation disorder. Metabolic consequences include hypoketotic hypoglycemia under fasting conditions, hyperammonemia, elevated creatine kinase and transaminases, dicarboxylic aciduria, very low free carnitine and abnormal acylcarnitine profile with marked elevation of the long-chain acylcarnitines. Clinical features include neurologic abnormalities, cardiomyopathy, arrhythmias, skeletal muscle damage, liver dysfunction and episodes of life-threatening coma, which eventually lead to death. Most patients become symptomatic in the neonatal period with a rapidly progressive deterioration and a high mortality rate. {ECO:0000269|PubMed:12859414, ECO:0000269|PubMed:15057979, ECO:0000269|PubMed:15365988}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0220994;C0342791;C3714756	613698	212138	187.1003377	NaN	Class 1	-1.093718086	0.000754359	81622.56534	57606.56667	Integral	96.05861298	96.10661643
Q9BQT8	SLC25A21	Central nervous system;Metabolism;Failure to thrive;Muscular system;Peripheral nervous system;Skeletal system;Hematologic system	"Carriers, channels & transporters"	1				1	"Boczonadi V, King MS, Smith AC, Olahova M, Bansagi B, Roos A, Eyassu F, Borchers C, Ramesh V, Lochmüller H, Polvikoski T, Whittaker RG, Pyle A, Griffin H, Taylor RW, Chinnery PF, Robinson AJ, Kunji ERS, Horvath R. Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy-like disease. Genet Med. 2018 Oct;20(10):1224-1235. doi: 10.1038/gim.2017.251. Epub 2018 Mar 8. Erratum in: Genet Med. 2019 Sep;21(9):2163-2164."			607571	618811	3794.704283	NaN	Class 1	-2.393218018	0.000167184	59731.67432	63239.76667	Integral	90.50569281	96.5619184
Q9H936	SLC25A22	Central nervous system;Metabolism	"Carriers, channels & transporters"	1				1		"DISEASE: Epileptic encephalopathy, early infantile, 3 (EIEE3) [MIM:609304]: A severe form of epilepsy characterized by frequent tonic seizures or spasms beginning in infancy with a specific EEG finding of suppression-burst patterns, characterized by high-voltage bursts alternating with almost flat suppression phases. Epileptic encephalopathy early infantile type 3 is characterized by a very early onset, erratic and fragmentary myoclonus, massive myoclonus, partial motor seizures and late tonic spasms. The prognosis is poor, with no effective treatment, and children with the condition either die within 1 to 2 years after birth or survive in a persistent vegetative state. {ECO:0000269|PubMed:15592994}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0270855;C0393706;C0543888;C0751651;C3714756	609302	609304	383.461562	NaN	Class 1	-2.420272191	4.41666E-05	280445.7307	182596.6667	Integral	96.31600679	97.5693184
Q6NUK1	SLC25A24	"Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Ears;Skeletal system;Reproductive system"	"Carriers, channels & transporters"	1				1	"Ehmke, N., Graul-Neumann, L., Smorag, L., Koenig, R., Segebrecht, L., Magoulas, P., Scaglia, F., Kilic, E., Hennig, A. F., Adolphs, N., Saha, N., Fauler, B., Kalscheuer, V. M., Hennig, F., Altmuller, J., Netzer, C., Thiele, H., Nurnberg, P., Yigit, G., Jager, M., Hecht, J., Kruger, U., Mielke, T., Krawitz, P. M., Horn, D., Schuelke, M., Mundlos, S., Bacino, C. A., Bonnen, P. E., Wollnik, B., Fischer-Zirnsak, B., and Kornak, U. (2017) De Novo Mutations in SLC25A24 Cause a Craniosynostosis Syndrome with Hypertrichosis, Progeroid Appearance, and Mitochondrial Dysfunction. Am. J. Hum. Genet. 101, 833-843;Writzl, K., Maver, A., Kovacic, L., Martinez-Valero, P., Contreras, L., Satrustegui, J., Castori, M., Faivre, L., Lapunzina, P., van Kuilenburg, A. B. P., Radovic, S., Thauvin-Robinet, C., Peterlin, B., Del Arco, A., and Hennekam, R. C. (2017) De Novo Mutations in SLC25A24 Cause a Disorder Characterized by Early Aging, Bone Dysplasia, Characteristic Face, and Early Demise. Am. J. Hum. Genet. 101, 844-855"	"DISEASE: Fontaine progeroid syndrome (FPS) [MIM:612289]: An autosomal dominant progeroid disorder characterized by prenatal and postnatal growth retardation, decreased subcutaneous fat tissue, wrinkled skin, an aged appearance since birth, an abnormal scalp hair pattern, sparse hair, hypoplastic distal phalanges with hypoplastic nails, a widely open anterior fontanel, facial dysmorphisms, and craniosynostosis. Early death is observed in some patients. {ECO:0000269|PubMed:29100093}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0010278;C0023893;C0345382;C2931653;C3714756	608744	612289	998.0789274	132.8871582	Class 1	-1.246241094	0.000239776	266035.8668	260654.6667	Integral	93.51323797	96.97011145
Q70HW3	SLC25A26	"Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system ;Muscular system"	"Carriers, channels & transporters"	1				1	"Kishita, Y., Pajak, A., Bolar, N. A., Marobbio, C. M., Maffezzini, C., Miniero, D. V., Monne, M., Kohda, M., Stranneheim, H., Murayama, K., Naess, K., Lesko, N., Bruhn, H., Mourier, A., Wibom, R., Nennesmo, I., Jespers, A., Govaert, P., Ohtake, A., Van Laer, L., Loeys, B. L., Freyer, C., Palmieri, F., Wredenberg, A., Okazaki, Y., and Wedell, A. (2015) Intra-mitochondrial Methylation Deficiency Due to Mutations in SLC25A26. Am. J. Hum. Genet. 97, 761-768"	"DISEASE: Combined oxidative phosphorylation deficiency 28 (COXPD28) [MIM:616794]: An autosomal recessive mitochondrial disorder characterized by decreased activities of respiratory chain enzymes, and variable clinical manifestations. Clinical features include episodic metabolic decompensation beginning in infancy, mild muscle weakness, cardiorespiratory insufficiency, developmental delay, or even death. {ECO:0000269|PubMed:26522469}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3714756;C4225206	611037	616794	235.1353065	NaN	Class 1	-2.452048637	0.000154728	13121.46593	12910.58	Integral	77.06483768	93.3938528
Q00325	SLC25A3	Metabolism;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system	"Carriers, channels & transporters"	1				1	"Mayr, J. A., Merkel, O., Kohlwein, S. D., Gebhardt, B. R., Bohles, H., Fotschl, U., Koch, J., Jaksch, M., Lochmuller, H., Horvath, R., Freisinger, P., and Sperl, W. (2007) Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation. Am. J. Hum. Genet. 80, 478-484"	"DISEASE: Mitochondrial phosphate carrier deficiency (MPCD) [MIM:610773]: Fatal disorder of oxidative phosphorylation. Patients have lactic acidosis, hypertrophic cardiomyopathy and muscular hypotonia and die within the first year of life. {ECO:0000269|PubMed:17273968}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C1835845	600370	610773	205.3142103	NaN	Class 1	-1.000622531	0.000485128	2733154.132	3418186.667	Integral	97.61528709	97.28301139
Q9H2D1	SLC25A32	Central nervous system;Metabolism;Muscular system	"Carriers, channels & transporters"	1				1	"Hellebrekers, D., Sallevelt, S., Theunissen, T. E. J., Hendrickx, A. T. M., Gottschalk, R. W., Hoeijmakers, J. G. J., Habets, D. D., Bierau, J., Schoonderwoerd, K. G., and Smeets, H. J. M. (2017) Novel SLC25A32 mutation in a patient with a severe neuromuscular phenotype. Eur J Hum Genet 25, 886-888;Schiff, M., Veauville-Merllie, A., Su, C. H., Tzagoloff, A., Rak, M., Ogier de Baulny, H., Boutron, A., Smedts-Walters, H., Romero, N. B., Rigal, O., Rustin, P., Vianey-Saban, C., and Acquaviva-Bourdain, C. (2016) SLC25A32 Mutations and Riboflavin-Responsive Exercise Intolerance. N Engl J Med 374, 795-797"	"DISEASE: Exercise intolerance, riboflavin-responsive (RREI) [MIM:616839]: A riboflavin-responsive form of exercise intolerance, a condition characterized by failure to maintain an expected level of force during sustained or repeated muscle contraction, resulting in an overwhelming sense of tiredness, lack of energy and feeling of exhaustion. RREI transmission pattern is consistent with autosomal recessive inheritance. {ECO:0000269|PubMed:26933868}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C4225187	610815	616839	37.15609214	33.85420674	Class 1	-1.232370618	0.000446017	26509.06706	31074	0	NaN	96.73578455
Q96DW6	SLC25A38	Hematologic system	"Carriers, channels & transporters"	1				1		"DISEASE: Anemia, sideroblastic, 2, pyridoxine-refractory (SIDBA2) [MIM:205950]: A form of sideroblastic anemia not responsive to pyridoxine. Sideroblastic anemia is characterized by anemia of varying severity, hypochromic peripheral erythrocytes, systemic iron overload secondary to chronic ineffective erythropoiesis, and the presence of bone marrow ringed sideroblasts. Sideroblasts are characterized by iron-loaded mitochondria clustered around the nucleus. {ECO:0000269|PubMed:19412178}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002896;C0010828;C0158995;C0751651;C2673914;C3714756;C4225425;C4274077	610819	205950	19.50196235	NaN	Class 3	-0.629230749	0.002119181	7992.830868	10812.34667	0	NaN	NaN
P12235	SLC25A4	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Muscular system;Ears;Endocrine system	"Carriers, channels & transporters"	1				1	"Kaukonen, J., Juselius, J. K., Tiranti, V., Kyttala, A., Zeviani, M., Comi, G. P., Keranen, S., Peltonen, L., and Suomalainen, A. (2000) Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 289, 782-785"	"DISEASE: Mitochondrial DNA depletion syndrome 12A, cardiomyopathic type (MTDPS12A) [MIM:617184]: An autosomal dominant mitochondrial disorder characterized by severe hypotonia due to mitochondrial dysfunction apparent at birth. Affected infants have respiratory insufficiency requiring mechanical ventilation and have poor or no motor development. Many die in infancy, and those that survive have profound hypotonia with significant muscle weakness and inability to walk independently. Some patients develop hypertrophic cardiomyopathy. Muscle samples show mtDNA depletion and severe combined mitochondrial respiratory chain deficiencies. {ECO:0000269|PubMed:27693233}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Mitochondrial DNA depletion syndrome 12B, cardiomyopathic type (MTDPS12B) [MIM:615418]: An autosomal recessive mitochondrial disorder characterized by childhood onset of slowly progressive hypertrophic cardiomyopathy and generalized skeletal myopathy resulting in exercise intolerance and, in some patients, muscle weakness and atrophy. Skeletal muscle biopsy shows ragged red fibers, mtDNA depletion, and accumulation of abnormal mitochondria. {ECO:0000269|PubMed:16155110, ECO:0000269|PubMed:22187496, ECO:0000269|PubMed:25732997, ECO:0000269|PubMed:27693233}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 2 (PEOA2) [MIM:609283]: A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism. {ECO:0000269|PubMed:10926541, ECO:0000269|PubMed:11756613, ECO:0000269|PubMed:12112115, ECO:0000269|PubMed:12707443, ECO:0000269|PubMed:15792871, ECO:0000269|PubMed:18575922, ECO:0000269|PubMed:27693233}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0005586;C0007194;C0023520;C0023893;C0270960;C0751651;C0853897;C1834846;C1836460;C1859317;C3809443;C4310676	103220	617184-615418-609283	196.5373996	NaN	Class 1	-1.404637221	0.000209228	1046822.745	962901.6667	Integral	77.40650212	97.76136154
Q86VD7	SLC25A42	Central nervous system;Metabolism;Cardiovascular system;Muscular system;Liver;Gastrointestinal system;Kidney and urinary tract	"Carriers, channels & transporters"	1				1	"Shamseldin, H. E., Smith, L. L., Kentab, A., Alkhalidi, H., Summers, B., Alsedairy, H., Xiong, Y., Gupta, V. A., and Alkuraya, F. S. (2016) Mutation of the mitochondrial carrier SLC25A42 causes a novel form of mitochondrial myopathy in humans. Hum Genet 135, 21-30"		C0003886;C0270960;C0751651	610823	618416	NaN	238.0733048	Class 4	0.717504304	0.185585839	673.9094379	766.908	0	NaN	NaN
Q96AG3	SLC25A46	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Ears;Peripheral nervous system;Skeletal system"	"Morphology, dynamics & organization"	1				1	"Abrams, A. J., Hufnagel, R. B., Rebelo, A., Zanna, C., Patel, N., Gonzalez, M. A., Campeanu, I. J., Griffin, L. B., Groenewald, S., Strickland, A. V., Tao, F., Speziani, F., Abreu, L., Schule, R., Caporali, L., La Morgia, C., Maresca, A., Liguori, R., Lodi, R., Ahmed, Z. M., Sund, K. L., Wang, X., Krueger, L. A., Peng, Y., Prada, C. E., Prows, C. A., Schorry, E. K., Antonellis, A., Zimmerman, H. H., Abdul-Rahman, O. A., Yang, Y., Downes, S. M., Prince, J., Fontanesi, F., Barrientos, A., Nemeth, A. H., Carelli, V., Huang, T., Zuchner, S., and Dallman, J. E. (2015) Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder. Nat Genet 47, 926-932;Janer, A., Prudent, J., Paupe, V., Fahiminiya, S., Majewski, J., Sgarioto, N., Des Rosiers, C., Forest, A., Lin, Z. Y., Gingras, A. C., Mitchell, G., McBride, H. M., and Shoubridge, E. A. (2016) SLC25A46 is required for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome. EMBO Mol Med 8, 1019-1038;Wan, J., Steffen, J., Yourshaw, M., Mamsa, H., Andersen, E., Rudnik-Schoneborn, S., Pope, K., Howell, K. B., McLean, C. A., Kornberg, A. J., Joseph, J., Lockhart, P. J., Zerres, K., Ryan, M. M., Nelson, S. F., Koehler, C. M., and Jen, J. C. (2016) Loss of function of SLC25A46 causes lethal congenital pontocerebellar hypoplasia. Brain, pii: aww212"	"DISEASE: Neuropathy, hereditary motor and sensory, 6B (HMSN6B) [MIM:616505]: An autosomal recessive neurologic disorder characterized by early-onset optic atrophy, progressive visual loss, and peripheral sensorimotor neuropathy manifesting as axonal Charcot-Marie-Tooth disease, with variable age at onset and severity. Charcot-Marie-Tooth disease is a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. It is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies and primary peripheral axonal neuropathies. Peripheral axonal neuropathies are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, and normal or slightly reduced nerve conduction velocities. {ECO:0000269|PubMed:26168012}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007959;C0029124;C0037773;C0205713;C0270911;C0270912;C0270914;C0393807;C0751036;C0751651;C4225302	610826	616505	27.8415392	NaN	Class 4	-0.383128649	0.009142057	22859.34716	31871	Integral	65.06543149	97.17072517
Q6PML9	SLC30A9	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Kidney and urinary tract	"Carriers, channels & transporters"	1				1		"DISEASE: Birk-Landau-Perez syndrome (BILAPES) [MIM:617595]: An autosomal recessive syndrome characterized by early-childhood onset of different combinations of intellectual disability, muscle weakness, camptocormia, oculomotor apraxia, and nephropathy. {ECO:0000269|PubMed:28334855}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C3714756;C4539828	604604	617595	104.5425493	205.6941208	Class 4	-0.431443636	0.021039117	58959.88401	44699.73333	Integral	82.58492413	95.70449595
O95721	SNAP29	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Ears;Integumentary system"	Autophagy/ mitophagy	1				1		"DISEASE: Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome (CEDNIK) [MIM:609528]: A neurocutaneous syndrome characterized by cerebral dysgenesis, neuropathy, ichthyosis and palmoplantar keratoderma. {ECO:0000269|PubMed:15968592}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0022596;C0023893;C0036341;C0432330;C1836033;C3714756	604202	609528	20.96969322	NaN	Class 3	-0.76535025	0.000324395	29905.25719	204630.6667	Ambiguous	25.44984854	45.29744147
P00441	SOD1	Central nervous system	Oxidative stress response	1				1		"DISEASE: Amyotrophic lateral sclerosis 1 (ALS1) [MIM:105400]: A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. {ECO:0000269|PubMed:10400992, ECO:0000269|PubMed:10430435, ECO:0000269|PubMed:10732812, ECO:0000269|PubMed:11369193, ECO:0000269|PubMed:11535232, ECO:0000269|PubMed:12145308, ECO:0000269|PubMed:12402272, ECO:0000269|PubMed:12754496, ECO:0000269|PubMed:12963370, ECO:0000269|PubMed:14506936, ECO:0000269|PubMed:15056757, ECO:0000269|PubMed:18301754, ECO:0000269|PubMed:18378676, ECO:0000269|PubMed:18552350, ECO:0000269|PubMed:19741096, ECO:0000269|PubMed:21220647, ECO:0000269|PubMed:21247266, ECO:0000269|PubMed:27604643, ECO:0000269|PubMed:7496169, ECO:0000269|PubMed:7501156, ECO:0000269|PubMed:7647793, ECO:0000269|PubMed:7655468, ECO:0000269|PubMed:7655469, ECO:0000269|PubMed:7655471, ECO:0000269|PubMed:7700376, ECO:0000269|PubMed:7795609, ECO:0000269|PubMed:7836951, ECO:0000269|PubMed:7870076, ECO:0000269|PubMed:7881433, ECO:0000269|PubMed:7887412, ECO:0000269|PubMed:7951252, ECO:0000269|PubMed:7980516, ECO:0000269|PubMed:7997024, ECO:0000269|PubMed:8069312, ECO:0000269|PubMed:8179602, ECO:0000269|PubMed:8351519, ECO:0000269|PubMed:8446170, ECO:0000269|PubMed:8528216, ECO:0000269|PubMed:8682505, ECO:0000269|PubMed:8907321, ECO:0000269|PubMed:8938700, ECO:0000269|PubMed:8990014, ECO:0000269|PubMed:9101297, ECO:0000269|PubMed:9131652, ECO:0000269|PubMed:9455977, ECO:0000269|PubMed:9541385}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002152;C0002736;C0003493;C0004045;C0004096;C0004153;C0005586;C0007621;C0007786;C0007787;C0011156;C0011570;C0011573;C0011581;C0011616;C0011849;C0011853;C0011860;C0011884;C0013080;C0013221;C0015695;C0015696;C0015934;C0017638;C0018801;C0018802;C0019054;C0019189;C0019193;C0020538;C0020550;C0020649;C0020672;C0021368;C0022116;C0022650;C0022660;C0023212;C0023895;C0024796;C0025193;C0025312;C0026846;C0027051;C0027540;C0027720;C0027746;C0027765;C0028754;C0030567;C0033626;C0033687;C0034069;C0034531;C0035126;C0035304;C0036330;C0036341;C0036457;C0037929;C0038433;C0038454;C0041408;C0041696;C0041755;C0085084;C0085786;C0086133;C0086565;C0086664;C0149519;C0154681;C0154682;C0162316;C0162351;C0162671;C0162674;C0231686;C0231687;C0231688;C0231689;C0231693;C0231694;C0231695;C0231696;C0231698;C0231712;C0234996;C0235000;C0235527;C0235574;C0242497;C0242526;C0259783;C0270763;C0270764;C0270948;C0274285;C0282126;C0312854;C0337210;C0393554;C0427128;C0427149;C0427169;C0427177;C0432416;C0432417;C0433895;C0433900;C0433905;C0472381;C0520463;C0521659;C0524611;C0543858;C0543859;C0555198;C0751019;C0751020;C0751021;C0751022;C0751081;C0751316;C0751515;C0751829;C0751830;C0751831;C0751832;C0751956;C0860207;C0917798;C0917805;C0919267;C1140680;C1262477;C1262760;C1384666;C1456865;C1527168;C1527335;C1563937;C1565662;C1862939;C1862941;C1959583;C1961112;C2609414;C2711227;C2718067;C3542025;C3658290;C3714618;C4277682;C4279912	147450	105400	235.1423128	NaN	Class 4	-0.520034581	0.059843741	79830.87293	3698873.333	Soluble	4.584645233	9.848146232
F5H4R2;P04179	SOD2	Metabolism;Cardiovascular system;Pulmonary system 	Oxidative stress response	1				1	"Almomani R, Herkert JC, Posafalvi A, Post JG, Boven LG, van der Zwaag PA, Willems PHGM, van Veen-Hof IH, Verhagen JMA, Wessels MW, Nikkels PGJ, Wintjes LT, van den Berg MP, Sinke RJ, Rodenburg RJ, Niezen-Koning KE, van Tintelen JP, Jongbloed JDH. Homozygous damaging SOD2 variant causes lethal neonatal dilated cardiomyopathy. J Med Genet. 2020 Jan;57(1):23-30."			147460	612634	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9UQ90	SPG7	Central nervous system;Ophthalmic system;Muscular system;Peripheral nervous system;Skeletal system;Kidney and urinary tract	Protein degradation & quality control	1				1	"Casari, G., De Fusco, M., Ciarmatori, S., Zeviani, M., Mora, M., Fernandez, P., De Michele, G., Filla, A., Cocozza, S., Marconi, R., Durr, A., Fontaine, B., and Ballabio, A. (1998) Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 93, 973-983"	"DISEASE: Note=Defects in SPG7 may cause autosomal recessive osteogenesis imperfecta (OI). Osteogenesis imperfecta defines a group of connective tissue disorders characterized by bone fragility and low bone mass. Clinical features of SPG7-related osteogenesis imperfecta include recurrent fractures, mild bone deformities, delayed tooth eruption, normal hearing and white sclera. {ECO:0000269|PubMed:20579626}.;DISEASE: Spastic paraplegia 7, autosomal recessive (SPG7) [MIM:607259]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG7 is a complex form. Additional clinical features are cerebellar syndrome, supranuclear palsy, and cognitive impairment, particularly disturbance of attention and executive functions. {ECO:0000269|PubMed:16534102, ECO:0000269|PubMed:17646629, ECO:0000269|PubMed:20186691, ECO:0000269|PubMed:27217339, ECO:0000269|PubMed:9635427}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0007959;C0023520;C0030486;C0037772;C0037773;C0154682;C0242036;C0278114;C0278115;C0452143;C0751651;C1846564;C1968845;C3711370;C3714756	602783	607259	52.36288728	NaN	Class 1	-2.224792502	0.000121378	48483.09131	34410.83333	Integral	80.5477941	93.00946496
Q9Y6N5	SQOR	Central nervous system;Metabolism;Ophthalmic system;Pulmonary system ;Muscular system;Liver;Gastrointestinal system;Others	Other known processes	1				1	"Friederich MW, Elias AF, Kuster A, Laugwitz L, Larson AA, Landry AP, Ellwood-Digel L, Mirsky DM, Dimmock D, Haven J, Jiang H, MacLean KN, Styren K, Schoof J, Goujon L, Lefrancois T, Friederich M, Coughlin CR 2nd, Banerjee R, Haack TB, Van Hove JLK. Pathogenic variants in SQOR encoding sulfide:quinone oxidoreductase are a potentially treatable cause of Leigh disease. J Inherit Metab Dis. 2020 Sep;43(5):1024-1036."			617658	619221	Infinite	NaN	NaN	NaN	NaN	60152.48354	40883.36667	Ambiguous	77.04736327	87.40770463
Q04837	SSBP1	Central nervous system;Ophthalmic system;Ears;Hematologic system;Kidney and urinary tract;Endocrine system	DNA-related processes	1				1	"Del Dotto V, Ullah F, Di Meo I, Magini P, Gusic M, Maresca A, Caporali L, Palombo F, Tagliavini F, Baugh EH, Macao B, Szilagyi Z, Peron C, Gustafson MA, Khan K, La Morgia C, Barboni P, Carbonelli M, Valentino ML, Liguori R, Shashi V, Sullivan J, Nagaraj S, El-Dairi M, Iannaccone A, Cutcutache I, Bertini E, Carrozzo R, Emma F, Diomedi-Camassei F, Zanna C, Armstrong M, Page M, Stong N, Boesch S, Kopajtich R, Wortmann S, Sperl W, Davis EE, Copeland WC, Seri M, Falkenberg M, Prokisch H, Katsanis N, Tiranti V, Pippucci T, Carelli V. SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder. J Clin Invest. 2020 Jan 2;130(1):108-125. Piro-Mégy C, Sarzi E, Tarrés-Solé A, Péquignot M, Hensen F, Quilès M, Manes G, Chakraborty A, Sénéchal A, Bocquet B, Cazevieille C, Roubertie A, Müller A, Charif M, Goudenège D, Lenaers G, Wilhelm H, Kellner U, Weisschuh N, Wissinger B, Zanlonghi X, Hamel C, Spelbrink JN, Sola M, Delettre C. Dominant mutations in mtDNA maintenance gene SSBP1 cause optic atrophy and foveopathy. J Clin Invest. 2020 Jan 2;130(1):143-156. Jurkute N, Leu C, Pogoda HM, Arno G, Robson AG, Nürnberg G, Altmüller J, Thiele H, Motameny S, Toliat MR, Powell K, Höhne W, Michaelides M, Webster AR, Moore AT, Hammerschmidt M, Nürnberg P, Yu-Wai-Man P, Votruba M. SSBP1 mutations in dominant optic atrophy with variable retinal degeneration. Ann Neurol. 2019 Sep;86(3):368-383. "			600439	165510	216.6642464	NaN	Class 1	-0.944138982	0.000640308	1750401.24	800850.6667	Ambiguous	30.39423801	51.53468914
P49675	STAR	Metabolism;Failure to thrive;Pulmonary system ;Endocrine system;Reproductive system;Integumentary system	Lipid metabolism	1				1		"DISEASE: Adrenal hyperplasia 1 (AH1) [MIM:201710]: The most severe form of adrenal hyperplasia. It is a condition characterized by onset of profound adrenocortical insufficiency shortly after birth, hyperpigmentation reflecting increased production of pro-opiomelanocortin, elevated plasma renin activity as a consequence of reduced aldosterone synthesis, and male pseudohermaphroditism resulting from deficient fetal testicular testosterone synthesis. Affected individuals are phenotypic females irrespective of gonadal sex, and frequently die in infancy if mineralocorticoid and glucocorticoid replacement are not instituted. {ECO:0000269|PubMed:10566637, ECO:0000269|PubMed:8948562, ECO:0000269|PubMed:9097960}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0014170;C0032460;C0036875;C0342474;C0342482;C0476089;C1136382;C3714756;C4049650	600617	201710	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
A0A2R8YDQ9;Q5T9Q5;Q9P2R7	SUCLA2	Central nervous system;Metabolism;Ophthalmic system;Muscular system;Ears;Gastrointestinal system;Peripheral nervous system;Skeletal system;Others	TCA cycle	1				1	"Elpeleg, O., Miller, C., Hershkovitz, E., Bitner-Glindzicz, M., Bondi-Rubinstein, G., Rahman, S., Pagnamenta, A., Eshhar, S., and Saada, A. (2005) Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am. J. Hum. Genet.  76, 1081-1086"	"DISEASE: Mitochondrial DNA depletion syndrome 5 (MTDPS5) [MIM:612073]: A disorder due to mitochondrial dysfunction. It is characterized by infantile onset of hypotonia, neurologic deterioration, a hyperkinetic-dystonic movement disorder, external ophthalmoplegia, deafness, variable renal tubular dysfunction, and mild methylmalonic aciduria in some patients. {ECO:0000269|PubMed:15877282, ECO:0000269|PubMed:17287286, ECO:0000269|PubMed:17301081, ECO:0000269|PubMed:23759946}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023520;C0028754;C0035410;C0543888;C0751651;C2749864	603921	612073	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P53597	SUCLG1	Central nervous system;Metabolism;Failure to thrive;Ears	TCA cycle	1				1	"Ostergaard, E., Christensen, E., Kristensen, E., Mogensen, B., Duno, M., Shoubridge, E. A., and Wibrand, F. (2007) Deficiency of the alpha subunit of succinate-coenzyme A ligase causes fatal infantile lactic acidosis with mitochondrial DNA depletion. Am. J. Hum. Genet. 81, 383-387"	"DISEASE: Mitochondrial DNA depletion syndrome 9 (MTDPS9) [MIM:245400]: A severe disorder due to mitochondrial dysfunction. It is characterized by infantile onset of hypotonia, lactic acidosis, severe psychomotor retardation, progressive neurologic deterioration, and excretion of methylmalonic acid. {ECO:0000269|PubMed:17668387, ECO:0000269|PubMed:19526370, ECO:0000269|PubMed:20453710, ECO:0000269|PubMed:20693550}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0024623;C0038356;C0220994;C0235874;C0543888;C0751651;C1708349;C3151476;C3714756	611224	245400	78.32673887	29.53910701	Class 1	-1.751584506	0.000133322	635011.5212	803461.3333	Peripheral	8.784093277	57.68047502
Q9HAC7	SUGCT	Metabolism	Other known processes	1				1		"DISEASE: Glutaric aciduria 3 (GA3) [MIM:231690]: A metabolic disorder due to peroxisomal glutaryl-CoA oxidase deficiency and characterized by the excretion of abnormal quantities of glutaric acid but low 3-hydroxyglutaric acid. {ECO:0000269|PubMed:18926513, ECO:0000269|PubMed:23893049}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007852;C0018984;C0030297;C0042331;C0149931;C0270858;C0338489;C0342873;C0346647;C0521664;C0700438	609187	231690	NaN	27.21935353	Class 3	-0.595772743	0.004693746	1731.177925	NaN	0	NaN	NaN
P51687	SUOX	Central nervous system;Metabolism;Ophthalmic system	Other known processes	1				1		"DISEASE: Sulfite oxidase deficiency, isolated (ISOD) [MIM:272300]: A life-threatening, autosomal recessive neurometabolic disorder characterized by severe neurological impairment. Classic ISOD manifests in the first few hours to days of life and is characterized by intractable seizures, feeding difficulties, rapidly progressive encephalopathy, microcephaly, and profound intellectual disability. Children usually die during the first few months of life. Mild ISOD manifests in infancy or early childhood and is characterized by ectopia lentis that is variably present, developmental delay and regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and rarely acute hemiplegia due to metabolic stroke. {ECO:0000269|PubMed:10519592, ECO:0000269|PubMed:12112661, ECO:0000269|PubMed:12368985, ECO:0000269|PubMed:9428520, ECO:0000269|PubMed:9600976}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0268624;C0543888;C2931746;C3714756	606887	272300	13.56402375	88.29911396	Class 2	-1.246599052	0.019119496	41467.78504	10293.25667	Soluble	7.933438833	14.8428769
Q15526	SURF1	Central nervous system;Metabolism;Ophthalmic system;Pulmonary system ;Ears;Peripheral nervous system;Skeletal system	OXPHOS assembly & stability	1				1	"Tiranti, V., Hoertnagel, K., Carrozzo, R., Galimberti, C., Munaro, M., Granatiero, M., Zelante, L., Gasparini, P., Marzella, R., Rocchi, M., Bayona-Bafaluy, M. P., Enriquez, J. A., Uziel, G., Bertini, E., Dionisi-Vici, C., Franco, B., Meitinger, T., and Zeviani, M. (1998) Mutations of SURF-1 in Leigh disease associated with cytochrome c oxidase deficiency. Am. J. Hum. Genet.  63, 1609-1621, Zhu, Z., Yao, J., Johns, T., Fu, K., De Bie, I., Macmillan, C., Cuthbert, A. P., Newbold, R. F., Wang, J., Chevrette, M., Brown, G. K., Brown, R. M., and Shoubridge, E. A. (1998) SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet 20, 337-343"	"DISEASE: Charcot-Marie-Tooth disease 4K (CMT4K) [MIM:616684]: An autosomal recessive, demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4. CMT4K patients manifest upper and lower limbs involvement. Some affected individuals have nystagmus and late-onset cerebellar ataxia. {ECO:0000269|PubMed:24027061}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:10647889, ECO:0000269|PubMed:10746561, ECO:0000269|PubMed:14564068, ECO:0000269|PubMed:21937992, ECO:0000269|PubMed:22410471, ECO:0000269|PubMed:22488715, ECO:0000269|PubMed:9843204}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0006142;C0020796;C0023264;C0023520;C0025363;C0376634;C0543888;C0751267;C0751268;C0751651;C0917816;C1838951;C1850597;C1850598;C1850599;C1850600;C1857355;C2931891;C3714756;C4225246	185620	616684-256000	120.6442648	NaN	Class 1	-1.152915073	0.000690182	38480.06887	40970.36667	Integral	94.17527686	96.1417943
Q9BSH4	TACO1	Central nervous system;Metabolism;Ophthalmic system;Others	Ribosome assembly & translation	1				1	"Weraarpachai, W., Antonicka, H., Sasarman, F., Seeger, J., Schrank, B., Kolesar, J. E., Lochmuller, H., Chevrette, M., Kaufman, B. A., Horvath, R., and Shoubridge, E. A. (2009) Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome. Nat Genet 41, 833-837"	"DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0023264;C0023520;C0268237;C0751267;C0751268;C0751651;C3714756	612958	220110	75.83146991	98.11587282	Class 1	-1.509102032	0.000231616	589841.8488	504221.3333	Peripheral	5.589097179	71.81375116
Q9BW92;U3KQG0;F6S7Q7	TARS2	Central nervous system;Metabolism;Muscular system	tRNA related processes	1				1	"Diodato, D., Melchionda, L., Haack, T. B., Dallabona, C., Baruffini, E., Donnini, C., Granata, T., Ragona, F., Balestri, P., Margollicci, M., Lamantea, E., Nasca, A., Powell, C. A., Minczuk, M., Strom, T. M., Meitinger, T., Prokisch, H., Lamperti, C., Zeviani, M., and Ghezzi, D. (2014) VARS2 and TARS2 mutations in patients with mitochondrial encephalomyopathies. Hum Mutat 35, 983-989"	"DISEASE: Combined oxidative phosphorylation deficiency 21 (COXPD21) [MIM:615918]: A mitochondrial disorder characterized by a lethal encephalomyopathy. Shortly after birth, affected individuals manifest axial hypotonia, limb hypertonia, psychomotor delay, and increased serum lactate. Additional features include subsarcolemmal lipofuscin-positive deposits in muscle, cerebral spongiosis, and hepatic steatosis. {ECO:0000269|PubMed:24827421, ECO:0000269|PubMed:26811336}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C4014668	612805	615918	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q16635	TAZ	Central nervous system;Metabolism;Cardiovascular system;Pulmonary system ;Muscular system;Hematologic system	Cardiolipin biosynthesis & remodeling	1				1	"Bione, S., D'Adamo, P., Maestrini, E., Gedeon, A. K., Bolhuis, P. A., and Toniolo, D. (1996) A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet 12, 385-389, McKenzie, M., Lazarou, M., Thorburn, D. R., and Ryan, M. T. (2006) Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients. J. Mol. Biol. 361, 462-469"	"DISEASE: Barth syndrome (BTHS) [MIM:302060]: An X-linked disease characterized by dilated cardiomyopathy with endocardial fibroelastosis, a predominantly proximal skeletal myopathy, growth retardation, neutropenia, and organic aciduria, particularly excess of 3-methylglutaconic acid. Additional features include hypertrophic cardiomyopathy, isolated left ventricular non-compaction, ventricular arrhythmia, motor delay, poor appetite, fatigue and exercise intolerance, hypoglycemia, lactic acidosis, hyperammonemia, and dramatic late catch-up growth after growth delay throughout childhood. {ECO:0000269|PubMed:11238270, ECO:0000269|PubMed:12032589, ECO:0000269|PubMed:9382096, ECO:0000269|PubMed:9382097}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007193;C0007959;C0010828;C0158995;C0220994;C0264886;C0340427;C0574083;C0751651;C3714756;C4021133	300394	302060	59.73085408	NaN	Class 1	-1.089820082	0.001943442	11316.07524	4314.33	Peripheral	27.71969748	90.38164449
Q00059	TFAM	"Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Liver"	DNA-related processes	1				1	"Stiles, A. R., Simon, M. T., Stover, A., Eftekharian, S., Khanlou, N., Wang, H. L., Magaki, S., Lee, H., Partynski, K., Dorrani, N., Chang, R., Martinez-Agosto, J. A., and Abdenur, J. E. (2016) Mutations in TFAM, encoding mitochondrial transcription factor A, cause neonatal liver failure associated with mtDNA depletion. Mol Genet Metab 119, 91-99"	"DISEASE: Mitochondrial DNA depletion syndrome 15, hepatocerebral type (MTDPS15) [MIM:617156]: An autosomal recessive mitochondrial disorder characterized by severe intrauterine growth restriction, neonatal-onset hypoglycemia and liver dysfunction, mitochondrial DNA depletion in liver and skeletal muscle, and abnormal mitochondrial morphology observed in skeletal muscle. Hepatic pathology includes cirrhosis, steatosis and cholestasis. Progression to liver failure and death is rapid with no evidence of neurological impairment or other organ involvement. {ECO:0000269|PubMed:27448789}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0002395;C0006079;C0011265;C0030569;C0276496;C0494463;C0546126;C0750900;C0750901;C0751414;C0751415;C2931673;C4310690	600438	617156	102.2304838	NaN	Class 1	-2.449966647	4.76342E-05	1502918.959	2039553.333	Peripheral	2.804423717	71.70533325
Q9H5Q4	TFB2M	Central nervous system	RNA-related processes	1				1	"Park CB, Choi VN, Jun JB, Kim JH, Lee Y, Lee J, Lim G, Kim J, Jeong SY, Yim SY. Identification of a rare homozygous c.790C>T variation in the TFB2M gene in Korean patients with autism spectrum disorder. Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):148-154."			607055		41.1306351	37.68906329	Class 1	-1.040919351	0.000813919	95361.25612	46688.7	Peripheral	5.335231463	88.19461548
Q9NWX6	THG1L	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Muscular system;Gastrointestinal system;Others"	tRNA related processes	1				1	"Edvardson S, Elbaz-Alon Y, Jalas C, Matlock A, Patel K, Labbé K, Shaag A, Jackman JE, Elpeleg O. A mutation in the THG1L gene in a family with cerebellar ataxia and developmental delay. Neurogenetics. 2016 Oct;17(4):219-225. Walker MA, Lerman-Sagie T, Swoboda K, Lev D, Blumkin L. Refining the phenotype of the THG1L (p.Val55Ala mutation)-related mitochondrial autosomal recessive congenital cerebellar ataxia. Am J Med Genet A. 2019 Aug;179(8):1575-1579.  Rabin R, Hirsch Y, Johansson MM, Ekstein J, Ekstein A, Pappas J. Severe epileptic encephalopathy associated with compound heterozygosity of THG1L variants in the Ashkenazi Jewish population. Am J Med Genet A. 2021 May;185(5):1589-1597."			618802	618800	403.3031947	NaN	Class 1	-3.320390254	1.76234E-05	29915.87043	233699.4	Peripheral	4.522758295	76.9087481
Q96EY1;Q96EY1	TID1	Central nervous system;Ophthalmic system;Peripheral nervous system	Cell death/ apoptosis	1				1	"Patra M, Weiss C, Abu-Libdeh B, Ashhab M, Abuzer S, Elpeleg O, Mahajnah M, Kessel A, Azem A. A novel variant of the human mitochondrial DnaJ protein, Tid1, associates with a human disease exhibiting developmental delay and polyneuropathy. Eur J Hum Genet. 2019 Jul;27(7):1072-1080."			608382		NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q3ZCQ8	TIMM50	Central nervous system;Metabolism;Failure to thrive	Protein import & biogenesis	1				1	"Shahrour, M. A., Staretz-Chacham, O., Dayan, D., Stephen, J., Weech, A., Damseh, N., Pri Chen, H., Edvardson, S., Mazaheri, S., Saada, A., Sequencing, N. I., Hershkovitz, E., Shaag, A., Huizing, M., Abu-Libdeh, B., Gahl, W. A., Azem, A., Anikster, Y., Vilboux, T., Elpeleg, O., and Malicdan, M. C. (2017) Mitochondrial epileptic encephalopathy, 3-methylglutaconic aciduria and variable complex V deficiency associated with TIMM50 mutations. Clin Genet 91, 690-696"	"DISEASE: 3-methylglutaconic aciduria 9 (MGCA9) [MIM:617698]: An autosomal recessive disease characterized by early-onset seizures, severely delayed psychomotor development and intellectual disability. Patients have hypotonia or spasticity, and laboratory investigations show increased serum lactate and 3-methylglutaconic aciduria. {ECO:0000269|PubMed:27573165}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0543888;C0751651;C4540171	607381	617698	134.7332242	NaN	Class 1	-1.509401041	0.000233887	1194127.535	1809500	Integral	87.49096097	98.05535689
O60220	TIMM8A	Central nervous system;Ears	Protein import & biogenesis	1				1	"Blesa, J. R., Solano, A., Briones, P., Prieto-Ruiz, J. A., Hernandez-Yago, J., and Coria, F. (2007) Molecular genetics of a patient with Mohr-Tranebjaerg Syndrome due to a new mutation in the DDP1 gene. Neuromolecular Med 9, 285-291;Jin, H., May, M., Tranebjaerg, L., Kendall, E., Fontan, G., Jackson, J., Subramony, S. H., Arena, F., Lubs, H., Smith, S., Stevenson, R., Schwartz, C., and Vetrie, D. (1996) A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. Nat Genet 14, 177-180"	"DISEASE: Mohr-Tranebjaerg syndrome (MTS) [MIM:304700]: An X-linked recessive disorder characterized by postlingual sensorineural deafness with onset in early childhood, dystonia, spasticity, dysphagia, mental deterioration, paranoia and cortical blindness. {ECO:0000269|PubMed:10878669, ECO:0000269|PubMed:11803487, ECO:0000269|PubMed:11875042, ECO:0000269|PubMed:11956200}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C0796074;C1839564;C3714756	300356	304700	348.1615276	178.5903	Class 4	-0.411645894	0.038192437	948449.1995	1173217	Soluble	6.601779944	11.18833709
Q9NPL8	TIMMDC1	Central nervous system;Failure to thrive;Ears;Peripheral nervous system	OXPHOS assembly & stability	1				1	"Kremer, L. S., Bader, D. M., Mertes, C., Kopajtich, R., Pichler, G., Iuso, A., Haack, T. B., Graf, E., Schwarzmayr, T., Terrile, C., Konarikova, E., Repp, B., Kastenmuller, G., Adamski, J., Lichtner, P., Leonhardt, C., Funalot, B., Donati, A., Tiranti, V., Lombes, A., Jardel, C., Glaser, D., Taylor, R. W., Ghezzi, D., Mayr, J. A., Rotig, A., Freisinger, P., Distelmaier, F., Strom, T. M., Meitinger, T., Gagneur, J., and Prokisch, H. (2017) Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun 8, 15824"		C1838979;C2936907	615534	618251	10.40023483	NaN	Class 1	-1.236077803	0.000167837	236071.7217	235608.6667	Integral	97.32998478	96.22354137
O00142	TK2	Metabolism;Ophthalmic system;Muscular system;Peripheral nervous system	Nucleotide/ nucleoside metabolism	1				1	"Saada, A., Shaag, A., Mandel, H., Nevo, Y., Eriksson, S., and Elpeleg, O. (2001) Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 29, 342-344"	"DISEASE: Mitochondrial DNA depletion syndrome 2 (MTDPS2) [MIM:609560]: A disorder due to mitochondrial dysfunction characterized by childhood onset of muscle weakness associated with depletion of mtDNA in skeletal muscle. There is wide clinical variability;DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3 (PEOB3) [MIM:617069]: A form of progressive external ophthalmoplegia, a mitochondrial myopathy characterized by progressive paralysis of the levator palpebrae, orbicularis oculi, and extraocular muscles. PEOB3 patients manifest adult-onset progressive external ophthalmoplegia and progressive proximal muscle weakness associated with muscle atrophy. {ECO:0000269|PubMed:21937588}. Note=The disease is caused by mutations affecting the gene represented in this entry.;some patients have onset in infancy and show a rapidly progressive course with early death due to respiratory failure, whereas others have later onset of a slowly progressive myopathy. {ECO:0000269|PubMed:11687801, ECO:0000269|PubMed:12391347, ECO:0000269|PubMed:15639197, ECO:0000269|PubMed:15907288, ECO:0000269|PubMed:25446393}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0035410;C0751651;C1850303;C3149750;C3501891;C3714756;C4310734	188250	617069-609560	Infinite	NaN	Class 1	-0.943706168	0.000794351	4391.165796	2811.283333	Peripheral	6.9679982	51.59230475
Q9H061	TMEM126A	Ophthalmic system;Cardiovascular system;Ears;Peripheral nervous system	Other known processes	1				1		"DISEASE: Optic atrophy 7 with or without auditory neuropathy (OPA7) [MIM:612989]: A hereditary condition that features progressive visual loss in association with optic atrophy. Atrophy of the optic disk indicates a deficiency in the number of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts. OPA7 is an autosomal recessive juvenile-onset optic atrophy characterized by severe bilateral deficiency in visual acuity, optic disk pallor, and central scotoma. Some patients manifest hearing loss. {ECO:0000269|PubMed:19327736}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C2751812	612988	612989	374.1958562	NaN	Class 1	-1.954994481	0.000114855	190797.3322	168606.3333	Integral	98.38312906	95.73970348
Q8IUX1;Q8IUX1	TMEM126B	"Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Muscular system;Hematologic system;Kidney and urinary tract"	OXPHOS assembly & stability	1				1	"Alston, C. L., Compton, A. G., Formosa, L. E., Strecker, V., Olahova, M., Haack, T. B., Smet, J., Stouffs, K., Diakumis, P., Ciara, E., Cassiman, D., Romain, N., Yarham, J. W., He, L., De Paepe, B., Vanlander, A. V., Seneca, S., Feichtinger, R. G., Ploski, R., Rokicki, D., Pronicka, E., Haller, R. G., Van Hove, J. L., Bahlo, M., Mayr, J. A., Van Coster, R., Prokisch, H., Wittig, I., Ryan, M. T., Thorburn, D. R., and Taylor, R. W. (2016) Biallelic Mutations in TMEM126B Cause Severe Complex I Deficiency with a Variable Clinical Phenotype. Am. J. Hum. Genet. 99, 217-227;Sanchez-Caballero, L., Ruzzenente, B., Bianchi, L., Assouline, Z., Barcia, G., Metodiev, M. D., Rio, M., Funalot, B., van den Brand, M. A., Guerrero-Castillo, S., Molenaar, J. P., Koolen, D., Brandt, U., Rodenburg, R. J., Nijtmans, L. G., and Rotig, A. (2016) Mutations in Complex I Assembly Factor TMEM126B Result in Muscle Weakness and Isolated Complex I Deficiency. Am. J. Hum. Genet. 99, 208-216"		C0751651;C1838979;C2936907;C3714756	615533	618250	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q6PI78	TMEM65	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Muscular system;Skeletal system"	Unknown	1				1	"Nazli, A., Safdar, A., Saleem, A., Akhtar, M., Brady, L. I., Schwartzentruber, J., and Tarnopolsky, M. A. (2017) A mutation in the TMEM65 gene results in mitochondrial myopathy with severe neurological manifestations. Eur J Hum Genet 25, 744-751"	"DISEASE: Note=Defects in TMEM65 may cause a mitochondrial disorder characterized by a complex encephalomyopathic phenotype. Clinical features includ microcephaly, dysmorphic features, psychomotor regression, hypotonia, growth retardation, lactic acidosis, intractable seizures, dyskenetics movements, without cardiomyopathy (PubMed:28295037). {ECO:0000269|PubMed:28295037}."	C0023893	616609		316.7837902	219.3932664	Class 1	-1.194661656	0.000368939	130541.9574	154552.0667	Integral	87.56368465	95.93976532
Q9BUB7	TMEM70	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Pulmonary system ;Gastrointestinal system"	OXPHOS assembly & stability	1				1	"Cizkova, A., Stranecky, V., Mayr, J. A., Tesarova, M., Havlickova, V., Paul, J., Ivanek, R., Kuss, A. W., Hansikova, H., Kaplanova, V., Vrbacky, M., Hartmannova, H., Noskova, L., Honzik, T., Drahota, Z., Magner, M., Hejzlarova, K., Sperl, W., Zeman, J., Houstek, J., and Kmoch, S. (2008) TMEM70 mutations cause isolated ATP synthase deficiency and neonatal mitochondrial encephalocardiomyopathy. Nat Genet 40, 1288-1290"	"DISEASE: Mitochondrial complex V deficiency, nuclear type 2 (MC5DN2) [MIM:614052]: A mitochondrial disorder with heterogeneous clinical manifestations including dysmorphic features, psychomotor retardation, hypotonia, growth retardation, cardiomyopathy, enlarged liver, hypoplastic kidneys and elevated lactate levels in urine, plasma and cerebrospinal fluid. {ECO:0000269|PubMed:18953340, ECO:0000269|PubMed:22986587}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007194;C0033141;C0036529;C0086543;C0162666;C0206669;C0220994;C0543888;C0751651;C0878544;C2239176;C3279699;C3714756	612418	614052	202.4447064	193.3702332	Class 1	-2.067808683	1.29459E-05	274288.3125	230187.3333	Integral	92.63793717	98.29205009
Q9NVH6	TMLHE	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities"	Other known processes	1				1		"DISEASE: Autism, X-linked 6 (AUTSX6) [MIM:300872]: A form of autism, a complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate mental retardation. AUTSX6 patients may respond favorably to carnitine supplementation. {ECO:0000269|PubMed:21865298, ECO:0000269|PubMed:23092983}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004352;C3550875;C3714756	300777	300872	NaN	42.93200504	Class 2	-1.842855884	0.008521931	61298.5772	40969.26667	Peripheral	9.105728263	76.58258392
O94826	TOMM70	Metabolism;Failure to thrive;Hematologic system	Protein import & biogenesis	1				1	"J, Chen D, Xu P, Jia M, Zhou H, Fang H, Lyu J, Yang Y. Mutations in TOMM70 lead to multi-OXPHOS deficiencies and cause severe anemia, lactic acidosis, and developmental delay. J Hum Genet. 2020 Mar;65(3):231-240."			606081		86.73926192	136.4632508	Class 3	-0.597566565	0.001354479	457080.0691	485606	Ambiguous	50.34076703	71.83022101
Q13472	TOP3A	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Muscular system;Ears;Gastrointestinal system;Peripheral nervous system;Others;Integumentary system"	DNA-related processes	1				1		"DISEASE: Microcephaly, growth restriction, and increased sister chromatid exchange 2 (MGRISCE2) [MIM:618097]: An autosomal recessive disorder characterized by intrauterine growth restriction, poor postnatal growth with short stature and microcephaly, and increased sister chromatid exchange on cell studies. {ECO:0000269|PubMed:30057030}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 5 (PEOB5) [MIM:618098]: A form of progressive external ophthalmoplegia, a mitochondrial myopathy characterized by progressive paralysis of the levator palpebrae, orbicularis oculi, and extraocular muscles. PEOB5 features include slowly progressive ptosis, intermittent double vision, cardiac arrhythmias, exercise intolerance, proximal limb and neck muscle weakness, and cerebellar ataxia. Patients skeletal muscle biopsy show numerous COX-deficient ragged-red fibers, increased mtDNA deletions, and extensive variable mtDNA rearrangements. {ECO:0000269|PubMed:29290614}. Note=The disease is caused by mutations affecting the gene represented in this entry."		601243	618098-618097	16.38606353	54.90441766	Class 1	-3.075587927	0.000201104	25988.17764	28562.26667	Peripheral	25.89474175	88.2896494
Q9H3H1	TRIT1	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Endocrine system"	tRNA related processes	1				1	"Yarham, J. W., Lamichhane, T. N., Pyle, A., Mattijssen, S., Baruffini, E., Bruni, F., Donnini, C., Vassilev, A., He, L., Blakely, E. L., Griffin, H., Santibanez-Koref, M., Bindoff, L. A., Ferrero, I., Chinnery, P. F., McFarland, R., Maraia, R. J., and Taylor, R. W. (2014) Defective i6A37 modification of mitochondrial and cytosolic tRNAs results from pathogenic mutations in TRIT1 and its substrate tRNA. PLoS Genet 10, e1004424"	"DISEASE: Combined oxidative phosphorylation deficiency 35 (COXPD35) [MIM:617873]: An autosomal recessive disorder caused by defective mitochondrial metabolism and deficiencies of mitochondrial respiratory enzyme complexes. Clinical manifestations include global developmental delay, intellectual disability, microcephaly, and early-onset seizures. {ECO:0000269|PubMed:24901367, ECO:0000269|PubMed:28185376}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0025958;C0032927;C0282313;C0751651;C3714756	617840	617873	37.27027249	NaN	Class 1	-3.399058224	3.54886E-06	12839.40864	27521.8	Peripheral	8.67784686	91.05713203
Q7L0Y3	TRMT10C	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Muscular system;Ears;Liver"	tRNA related processes	1				1	"Metodiev, M. D., Thompson, K., Alston, C. L., Morris, A. A., He, L., Assouline, Z., Rio, M., Bahi-Buisson, N., Pyle, A., Griffin, H., Siira, S., Filipovska, A., Munnich, A., Chinnery, P. F., McFarland, R., Rotig, A., and Taylor, R. W. (2016) Recessive Mutations in TRMT10C Cause Defects in Mitochondrial RNA Processing and Multiple Respiratory Chain Deficiencies. Am. J. Hum. Genet. 98, 993-1000"	"DISEASE: Combined oxidative phosphorylation deficiency 30 (COXPD30) [MIM:616974]: An autosomal recessive, severe mitochondrial disease characterized by lactic acidosis, hypotonia, feeding difficulties, deafness, and respiratory failure with fatal issue. Patient skeletal muscle cells show decreased activities of mitochondrial complexes I, III and IV. {ECO:0000269|PubMed:27132592}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C4310773	615423	616974	100.5339916	NaN	Class 1	-1.855602817	3.67575E-05	603482.0141	685262.6667	Peripheral	3.935943396	94.29417455
Q32P41	TRMT5	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Muscular system;Gastrointestinal system;Kidney and urinary tract"	tRNA related processes	1				1	"Powell, C. A., Kopajtich, R., D'Souza, A. R., Rorbach, J., Kremer, L. S., Husain, R. A., Dallabona, C., Donnini, C., Alston, C. L., Griffin, H., Pyle, A., Chinnery, P. F., Strom, T. M., Meitinger, T., Rodenburg, R. J., Schottmann, G., Schuelke, M., Romain, N., Haller, R. G., Ferrero, I., Haack, T. B., Taylor, R. W., Prokisch, H., and Minczuk, M. (2015) TRMT5 Mutations Cause a Defect in Post-transcriptional Modification of Mitochondrial tRNA Associated with Multiple Respiratory-Chain Deficiencies. Am. J. Hum. Genet.  97, 319-328"	"DISEASE: Combined oxidative phosphorylation deficiency 26 (COXPD26) [MIM:616539]: A mitochondrial disorder characterized by lactic acidosis, multiple mitochondrial respiratory-chain-complex deficiencies in skeletal muscle, and additional variable features including hypertrophic cardiomyopathy, exercise intolerance, and failure to thrive. {ECO:0000269|PubMed:26189817}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C4225290	611023	616539	85.68691013	NaN	Class 1	-3.189704252	2.201E-06	14795.84602	79571.2	Ambiguous	21.73741225	33.59399709
O75648	TRMU	Metabolism;Liver;Gastrointestinal system;Hematologic system	tRNA related processes	1				1	"Zeharia, A., Shaag, A., Pappo, O., Mager-Heckel, A. M., Saada, A., Beinat, M., Karicheva, O., Mandel, H., Ofek, N., Segel, R., Marom, D., Rotig, A., Tarassov, I., and Elpeleg, O. (2009) Acute infantile liver failure due to mutations in the TRMU gene. Am. J. Hum. Genet. 85, 401-407"	"DISEASE: Deafness, aminoglycoside-induced (DFNI) [MIM:580000]: A form of sensorineural deafness characterized by moderate-to-profound hearing loss and mitochondrial inheritance. It is induced by exposure to aminoglycosides. {ECO:0000269|PubMed:16826519}. Note=The gene represented in this entry acts as a disease modifier. DFNI is caused by mutations in mitochondrial rRNA genes, including homoplasmic A1555G and C1494T mutations in the highly conserved decoding site of the mitochondrial 12S rRNA. Mutated TRMU modulates the phenotypic manifestation of these mutations. {ECO:0000269|PubMed:16826519}.;DISEASE: Liver failure, infantile, transient (LFIT) [MIM:613070]: A transient disorder of hepatic function characterized by elevated liver enzymes, jaundice, vomiting, coagulopathy, hyperbilirubinemia, increased serum lactate. Patients who survive the initial acute episode can recover, show normal development and have no recurrence. {ECO:0000269|PubMed:19732863}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0008370;C0751651;C1112213;C1838854;C1857332;C3151898;C3278664	610230	613070	413.7318887	NaN	Class 1	-1.635977902	0.000720783	87892.63145	74901.66667	Peripheral	14.27905883	88.08019901
Q96Q11	TRNT1	Central nervous system;Ophthalmic system;Cardiovascular system;Ears;Hematologic system;Others	tRNA related processes	1				1	"Chakraborty, P. K., Schmitz-Abe, K., Kennedy, E. K., Mamady, H., Naas, T., Durie, D., Campagna, D. R., Lau, A., Sendamarai, A. K., Wiseman, D. H., May, A., Jolles, S., Connor, P., Powell, C., Heeney, M. M., Giardina, P. J., Klaassen, R. J., Kannengiesser, C., Thuret, I., Thompson, A. A., Marques, L., Hughes, S., Bonney, D. K., Bottomley, S. S., Wynn, R. F., Laxer, R. M., Minniti, C. P., Moppett, J., Bordon, V., Geraghty, M., Joyce, P. B., Markianos, K., Rudner, A. D., Holcik, M., and Fleming, M. D. (2014) Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood 124, 2867-2871;DeLuca, A. P., Whitmore, S. S., Barnes, J., Sharma, T. P., Westfall, T. A., Scott, C. A., Weed, M. C., Wiley, J. S., Wiley, L. A., Johnston, R. M., Schnieders, M. J., Lentz, S. R., Tucker, B. A., Mullins, R. F., Scheetz, T. E., Stone, E. M., and Slusarski, D. C. (2016) Hypomorphic mutations in TRNT1 cause retinitis pigmentosa with erythrocytic microcytosis. Hum Mol Genet 25, 44-56"	"DISEASE: Retinitis pigmentosa and erythrocytic microcytosis (RPEM) [MIM:616959]: An autosomal recessive disease characterized by retinitis pigmentosa, red blood cell microcytosis and anisocytosis with mild anemia. {ECO:0000269|PubMed:26494905}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD) [MIM:616084]: An autosomal recessive disease characterized by severe sideroblastic anemia with onset in the neonatal period or infancy, recurrent periodic fevers without an infectious etiology, B-cell lymphopenia and hypogammaglobulinemia. Affected individuals show delayed psychomotor development with variable neurodegeneration. Additional variable features include sensorineural hearing loss, retinitis pigmentosa, nephrocalcinosis, and cardiomyopathy. {ECO:0000269|PubMed:25193871}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C3889979;C4015172;C4310776	612907	616959-616084	177.2754895	161.1092003	Class 1	-2.517660145	1.58999E-05	61349.43953	151626.6667	Peripheral	6.059633594	77.37672331
C9JT21;P43897	TSFM	Central nervous system;Metabolism;Ophthalmic system;Cardiovascular system;Pulmonary system ;Muscular system;Liver;Peripheral nervous system	tRNA related processes	1				1	"Smeitink, J. A., Elpeleg, O., Antonicka, H., Diepstra, H., Saada, A., Smits, P., Sasarman, F., Vriend, G., Jacob-Hirsch, J., Shaag, A., Rechavi, G., Welling, B., Horst, J., Rodenburg, R. J., van den Heuvel, B., and Shoubridge, E. A. (2006) Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. Am. J. Hum. Genet. 79, 869-877"	"DISEASE: Combined oxidative phosphorylation deficiency 3 (COXPD3) [MIM:610505]: A mitochondrial disease resulting in severe metabolic acidosis with encephalomyopathy or with hypertrophic cardiomyopathy. Patients show a severe defect in mitochondrial translation leading to a failure to assemble adequate amounts of three of the oxidative phosphorylation complexes. {ECO:0000269|PubMed:17033963, ECO:0000269|PubMed:22499341, ECO:0000269|PubMed:27677415}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0007194;C0035410;C0543888;C0751651;C1864840;C3714756	604723	610505	NaN	144.6492728	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q6DKK2	TTC19	Central nervous system;Metabolism;Ophthalmic system;Ears;Peripheral nervous system	OXPHOS assembly & stability	1				1	"Ghezzi, D., Arzuffi, P., Zordan, M., Da Re, C., Lamperti, C., Benna, C., D'Adamo, P., Diodato, D., Costa, R., Mariotti, C., Uziel, G., Smiderle, C., and Zeviani, M. (2011) Mutations in TTC19 cause mitochondrial complex III deficiency and neurological impairment in humans and flies. Nat Genet 43, 259-263"	"DISEASE: Mitochondrial complex III deficiency, nuclear 2 (MC3DN2) [MIM:615157]: A disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. Clinical features include mitochondrial encephalopathy, psychomotor retardation, ataxia, severe failure to thrive, liver dysfunction, renal tubulopathy, muscle weakness and exercise intolerance. {ECO:0000269|PubMed:21278747}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0021359;C0027765;C0231686;C0231687;C0231688;C0231689;C0231693;C0231694;C0231695;C0231696;C0231698;C0231712;C0234996;C0235000;C0270715;C0337210;C0342778;C0427128;C0427149;C0427169;C0427177;C0524851;C0729353;C0751651;C0751733;C0751829;C0751830;C0751831;C0751832;C1852372;C3714756;C4074771	613814	615157	110.3824195	1074.495682	Class 1	-1.007129112	0.003277298	117657.9282	157680	Peripheral	5.611504277	89.2142429
P49411	TUFM	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Liver"	Autophagy/ mitophagy	1				1	"Valente, L., Tiranti, V., Marsano, R. M., Malfatti, E., Fernandez-Vizarra, E., Donnini, C., Mereghetti, P., De Gioia, L., Burlina, A., Castellan, C., Comi, G. P., Savasta, S., Ferrero, I., and Zeviani, M. (2007) Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu. Am. J. Hum. Genet. 80, 44-58"	"DISEASE: Combined oxidative phosphorylation deficiency 4 (COXPD4) [MIM:610678]: A mitochondrial disease resulting in neonatal lactic acidosis, rapidly progressive encephalopathy, severely decreased mitochondrial protein synthesis, and combined deficiency of mtDNA-related mitochondrial respiratory chain complexes. {ECO:0000269|PubMed:17160893}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0014859;C0023520;C0546837;C0751651;C1857682;C3714756	602389	610678	118.1996859	260.0283354	Class 1	-1.920238673	6.75384E-05	2476826.007	4053740	Peripheral	14.38100335	95.9168875
Q96RR1	TWNK	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Muscular system;Ears;Liver;Gastrointestinal system;Peripheral nervous system;Skeletal system;Endocrine system;Reproductive system"	DNA-related processes	1				1	"Spelbrink, J. N., Li, F. Y., Tiranti, V., Nikali, K., Yuan, Q. P., Tariq, M., Wanrooij, S., Garrido, N., Comi, G., Morandi, L., Santoro, L., Toscano, A., Fabrizi, G. M., Somer, H., Croxen, R., Beeson, D., Poulton, J., Suomalainen, A., Jacobs, H. T., Zeviani, M., and Larsson, C. (2001) Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 28, 223-231"	"DISEASE: Mitochondrial DNA depletion syndrome 7 (MTDPS7) [MIM:271245]: A severe disease associated with mitochondrial dysfunction. Some patients are affected by progressive atrophy of the cerebellum, brain stem, the spinal cord, and sensory axonal neuropathy. Clinical features include hypotonia, athetosis, ataxia, ophthalmoplegia, sensorineural hearing deficit, sensory axonal neuropathy, epileptic encephalopathy and female hypogonadism. In some individuals liver dysfunction and multi-organ failure is present. {ECO:0000269|PubMed:16135556, ECO:0000269|PubMed:17722119, ECO:0000269|PubMed:17921179, ECO:0000269|PubMed:19853444, ECO:0000269|PubMed:22353293}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Perrault syndrome 5 (PRLTS5) [MIM:616138]: A form of Perrault syndrome, a sex-influenced disorder characterized by sensorineural deafness in both males and females, and ovarian dysgenesis in females. Affected females have primary amenorrhea, streak gonads, and infertility, whereas affected males show normal pubertal development and are fertile. {ECO:0000269|PubMed:25355836}. Note=The disease is caused by mutations affecting the gene represented in this entry.;DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 3 (PEOA3) [MIM:609286]: A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism. {ECO:0000269|PubMed:11431692, ECO:0000269|PubMed:12163192, ECO:0000269|PubMed:12921794, ECO:0000269|PubMed:15668446, ECO:0000269|PubMed:16639411, ECO:0000269|PubMed:17614277, ECO:0000269|PubMed:18396044, ECO:0000269|PubMed:18575922, ECO:0000269|PubMed:19353676, ECO:0000269|PubMed:19428252, ECO:0000269|PubMed:20479361, ECO:0000269|PubMed:20880070}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0004138;C0007959;C0023520;C0685838;C0751651;C1834846;C1836439;C1843851;C1849096;C4015307	606075	271245-616138-609286	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q99757	TXN2	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Peripheral nervous system	Oxidative stress response	1				1	"Holzerova, E., Danhauser, K., Haack, T. B., Kremer, L. S., Melcher, M., Ingold, I., Kobayashi, S., Terrile, C., Wolf, P., Schaper, J., Mayatepek, E., Baertling, F., Friedmann Angeli, J. P., Conrad, M., Strom, T. M., Meitinger, T., Prokisch, H., and Distelmaier, F. (2016) Human thioredoxin 2 deficiency impairs mitochondrial redox homeostasis and causes early-onset neurodegeneration. Brain 139, 346-354"	"DISEASE: Combined oxidative phosphorylation deficiency 29 (COXPD29) [MIM:616811]: An autosomal recessive, infantile-onset, neurodegenerative disorder characterized by decreased activities of mitochondrial respiratory complexes I and III, severe cerebellar atrophy, epilepsy, dystonia, optic atrophy, and peripheral neuropathy. {ECO:0000269|PubMed:26626369}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0038219;C0080178;C0266508;C0751651;C4225200	609063	616811	86.99511393	NaN	Class 1	-1.406295061	0.000205442	578337.3665	518335.3333	Soluble	2.097630655	21.78241613
Q9NNW7	TXNRD2	Metabolism;Cardiovascular system;Endocrine system;Integumentary system	Oxidative stress response	1				1		"DISEASE: Glucocorticoid deficiency 5 (GCCD5) [MIM:617825]: A form of glucocorticoid deficiency, a rare autosomal recessive disorder characterized by resistance to ACTH action on the adrenal cortex, adrenal insufficiency and an inability of the adrenal cortex to produce cortisol. It usually presents in the neonatal period or in early childhood with episodes of hypoglycemia and other symptoms related to cortisol deficiency, including failure to thrive, recurrent illnesses or infections, convulsions, and shock. In a small number of patients hypoglycemia can be sufficiently severe and persistent that it leads to serious long-term neurological damage or death. The diagnosis is readily confirmed with a low plasma cortisol measurement in the presence of an elevated ACTH level, and normal aldosterone and plasma renin measurements. {ECO:0000269|PubMed:24601690}. Note=The disease may be caused by mutations affecting the gene represented in this entry."	C0007193;C0017612;C0033578;C0086132;C0264886;C0271148;C0339573;C0340427;C0342482;C0376358;C4049650	606448	617825	149.2437918	NaN	Class 3	-0.893598627	0.001485942	199943.0401	275257	Soluble	5.362005972	16.16426964
P55916	UCP3	Metabolism;Cardiovascular system;Endocrine system	"Carriers, channels & transporters"	1				1		"DISEASE: Obesity (OBESITY) [MIM:601665]: A condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat. {ECO:0000269|PubMed:9769326, ECO:0000269|Ref.9}. Note=The gene represented in this entry may be involved in disease pathogenesis."	C0028754;C0033578;C0039870;C0376358	602044	601665	NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P13051;P13051	UNG	Hematologic system	DNA-related processes	1				1		"DISEASE: Immunodeficiency with hyper-IgM 5 (HIGM5) [MIM:608106]: A rare immunodeficiency syndrome characterized by normal or elevated serum IgM levels with absence of IgG, IgA, and IgE. It results in a profound susceptibility to bacterial infections. {ECO:0000269|PubMed:12958596, ECO:0000269|PubMed:15967827}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0005859;C0009402;C0009404;C0272236;C1527249;C1720956;C1720957;C1720958	191525	608106	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9BRT2	UQCC2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Pulmonary system ;Ears;Kidney and urinary tract;Reproductive system"	OXPHOS assembly & stability	1				1	"Tucker, E. J., Wanschers, B. F., Szklarczyk, R., Mountford, H. S., Wijeyeratne, X. W., van den Brand, M. A., Leenders, A. M., Rodenburg, R. J., Reljic, B., Compton, A. G., Frazier, A. E., Bruno, D. L., Christodoulou, J., Endo, H., Ryan, M. T., Nijtmans, L. G., Huynen, M. A., and Thorburn, D. R. (2013) Mutations in the UQCC1-interacting protein, UQCC2, cause human complex III deficiency associated with perturbed cytochrome b protein expression. PLoS Genet 9, e1004034"	"DISEASE: Mitochondrial complex III deficiency, nuclear 7 (MC3DN7) [MIM:615824]: A form of mitochondrial complex III deficiency, a disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. MC3DN7 is characterized by severe intrauterine growth retardation, neonatal lactic acidosis and renal tubular dysfunction. Additional clinical features include a dysmorphic facial appearance, delayed psychomotor development, autistic features, aggressive behavior, and mild sensorineural hearing loss. {ECO:0000269|PubMed:24385928}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0342778;C0751651;C1852372	614461	615824	39.40830202	NaN	Class 1	-1.509035263	0.00028607	360976.6455	367347	Ambiguous	34.80409543	53.23237245
Q6UW78	UQCC3	Central nervous system;Metabolism;Failure to thrive	OXPHOS assembly & stability	1				1	"Wanschers, B. F., Szklarczyk, R., van den Brand, M. A., Jonckheere, A., Suijskens, J., Smeets, R., Rodenburg, R. J., Stephan, K., Helland, I. B., Elkamil, A., Rootwelt, T., Ott, M., van den Heuvel, L., Nijtmans, L. G., and Huynen, M. A. (2014) A mutation in the human CBP4 ortholog UQCC3 impairs complex III assembly, activity and cytochrome b stability. Hum Mol Genet 23, 6356-6365"	"DISEASE: Mitochondrial complex III deficiency, nuclear 9 (MC3DN9) [MIM:616111]: A form of mitochondrial complex III deficiency, a disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. MC3DN9 clinical features include feeding difficulties, hypoglycemia, severe lactic acidosis, and delayed psychomotor development. {ECO:0000269|PubMed:25008109}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0342778;C0751651;C1852372;C4015253	616097	616111	34.01315196	NaN	Class 1	-1.787449691	0.000592563	149885.8593	109318.8	Ambiguous	87.24441067	77.34587426
E5RHG9;P14927	UQCRB	Metabolism;Liver	OXPHOS complex subunits	1				1	"Haut, S., Brivet, M., Touati, G., Rustin, P., Lebon, S., Garcia-Cazorla, A., Saudubray, J. M., Boutron, A., Legrand, A., and Slama, A. (2003) A deletion in the human QP-C gene causes a complex III deficiency resulting in hypoglycaemia and lactic acidosis. Hum Genet 113, 118-122"	"DISEASE: Mitochondrial complex III deficiency, nuclear 3 (MC3DN3) [MIM:615158]: A disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. Clinical features include mitochondrial encephalopathy, psychomotor retardation, ataxia, severe failure to thrive, liver dysfunction, renal tubulopathy, muscle weakness and exercise intolerance. {ECO:0000269|PubMed:12709789}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0342778;C0751651;C1852372;C3714756	191330	615158	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P31930	UQCRC1	Central nervous system;Peripheral nervous system	OXPHOS complex subunits	1				1	"Lin CH, Tsai PI, Lin HY, Hattori N, Funayama M, Jeon B, Sato K, Abe K, Mukai Y, Takahashi Y, Li Y, Nishioka K, Yoshino H, Daida K, Chen ML, Cheng J, Huang CY, Tzeng SR, Wu YS, Lai HJ, Tsai HH, Yen RF, Lee NC, Lo WC, Hung YC, Chan CC, Ke YC, Chao CC, Hsieh ST, Farrer M, Wu RM. Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy. Brain. 2020 Dec 5;143(11):3352-3373."			191328	619279	111.1380266	79.14519657	Class 1	-1.308094403	0.000345922	1145015.761	1376350	Integral	95.19996894	91.85022366
P22695	UQCRC2	"Central nervous system;Metabolism;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Pulmonary system ;Liver"	OXPHOS complex subunits	1				1	"Miyake, N., Yano, S., Sakai, C., Hatakeyama, H., Matsushima, Y., Shiina, M., Watanabe, Y., Bartley, J., Abdenur, J. E., Wang, R. Y., Chang, R., Tsurusaki, Y., Doi, H., Nakashima, M., Saitsu, H., Ogata, K., Goto, Y. I., and Matsumoto, N. (2012) Mitochondrial Complex III Deficiency Caused by a Homozygous UQCRC2 Mutation Presenting with Neonatal-Onset Recurrent Metabolic Decompensation. Hum Mutat 34, 446-52"	"DISEASE: Mitochondrial complex III deficiency, nuclear 5 (MC3DN5) [MIM:615160]: A disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. Clinical features include mitochondrial encephalopathy, psychomotor retardation, ataxia, severe failure to thrive, liver dysfunction, renal tubulopathy, muscle weakness and exercise intolerance. {ECO:0000269|PubMed:23281071}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0028754;C0342778;C0751651;C1527249;C1852372;C3554608	191329	615160	93.38402738	NaN	Class 1	-1.804023876	0.000173363	1044768.341	1370580	Integral	97.72258184	92.49447591
P47985;P0C7P4	UQCRFS1;UQCRFS1P1	"Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Failure to thrive;Cardiovascular system;Muscular system;Ears;Gastrointestinal system;Hematologic system;Others;Integumentary system"	OXPHOS complex subunits	1				1	"Gusic M, Schottmann G, Feichtinger RG, Du C, Scholz C, Wagner M, Mayr JA, Lee CY, Yépez VA, Lorenz N, Morales-Gonzalez S, Panneman DM, Rötig A, Rodenburg RJT, Wortmann SB, Prokisch H, Schuelke M. Bi-Allelic UQCRFS1 Variants Are Associated with Mitochondrial Complex III Deficiency, Cardiomyopathy, and Alopecia Totalis. Am J Hum Genet. 2020 Jan 2;106(1):102-111. "			191327	618775	82.98085272	NaN	Class 1	-1.88813766	7.28205E-05	924415.3798	976729.6667	Integral	71.12076385	92.45410734
O14949	UQCRQ	Central nervous system;Metabolism	OXPHOS complex subunits	1				1	"Barel, O., Shorer, Z., Flusser, H., Ofir, R., Narkis, G., Finer, G., Shalev, H., Nasasra, A., Saada, A., and Birk, O. S. (2008) Mitochondrial complex III deficiency associated with a homozygous mutation in UQCRQ. Am. J. Hum. Genet.  82, 1211-1216"	"DISEASE: Mitochondrial complex III deficiency, nuclear 4 (MC3DN4) [MIM:615159]: A disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. Clinical features include mitochondrial encephalopathy, psychomotor retardation, ataxia, severe failure to thrive, liver dysfunction, renal tubulopathy, muscle weakness and exercise intolerance. {ECO:0000269|PubMed:18439546}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0342778;C0751651;C1852372;C3554607;C3714756	612080	615159	89.33680868	142.0768333	Class 1	-2.029337273	0.000187029	566607.4957	1218634.667	Integral	95.99269528	97.70297527
Q5ST30	VARS2	"Central nervous system;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities"	tRNA related processes	1				1	"Diodato, D., Melchionda, L., Haack, T. B., Dallabona, C., Baruffini, E., Donnini, C., Granata, T., Ragona, F., Balestri, P., Margollicci, M., Lamantea, E., Nasca, A., Powell, C. A., Minczuk, M., Strom, T. M., Meitinger, T., Prokisch, H., Lamperti, C., Zeviani, M., and Ghezzi, D. (2014) VARS2 and TARS2 mutations in patients with mitochondrial encephalomyopathies. Hum Mutat 35, 983-989"	"DISEASE: Combined oxidative phosphorylation deficiency 20 (COXPD20) [MIM:615917]: A disorder due to mitochondrial respiratory chain complex defects. Clinical features are variable and include muscle weakness with hypotonia, central neurological disease with progressive external ophthalmoplegia, ptosis and ataxia, delayed psychomotor development, cardiomyopathy, abnormal liver function, facial dysmorphism, microcephaly and epilepsy. {ECO:0000269|PubMed:24827421, ECO:0000269|PubMed:25058219}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C4014660	612802	615917	NaN	NaN	Class 1	-1.344293644	0.001042169	69343.15114	53259.3	Peripheral	20.65507972	74.56694372
Q96RL7;Q96RL7	VPS13A	Central nervous system;Ophthalmic system;Hematologic system	Autophagy/ mitophagy	1				1		"DISEASE: Choreoacanthocytosis (CHAC) [MIM:200150]: An autosomal recessive neurodegenerative disorder characterized by the gradual onset of hyperkinetic movements and abnormal erythrocyte morphology. Basal ganglia atrophy in the brain is a pathological feature of the disease. Other clinical symptoms include psychiatric features, epilepsy, peripheral neuropathy, myopathy and oral self-mutilation. {ECO:0000269|PubMed:11381253, ECO:0000269|PubMed:12404112}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0030567;C0393576;C0525045;C1527249	605978	200150	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q5THJ4	VPS13D	Central nervous system;Ophthalmic system;Peripheral nervous system	Autophagy/ mitophagy	1				1		"DISEASE: Note=Variants in VPS13D may be the cause of childhood onset movement disorders, characterized in most cases by developmental delay, axial hypotonia and hyperkinetic movement disorders associated with spastic paraparesis, as well as truncal and appendicular ataxia. {ECO:0000269|PubMed:29518281}."	C0004138;C0043094	608877	607317	NaN	NaN	Class 4	-0.31770557	0.01132917	2874.694932	5348.34	Peripheral	25.27655249	90.97326376
Q9UGM6	WARS2	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities;Cardiovascular system;Hematologic system"	tRNA related processes	1				1	"Theisen, B. E., Rumyantseva, A., Cohen, J. S., Alcaraz, W. A., Shinde, D. N., Tang, S., Srivastava, S., Pevsner, J., Trifunovic, A., and Fatemi, A. (2017) Deficiency of WARS2, encoding mitochondrial tryptophanyl tRNA synthetase, causes severe infantile onset leukoencephalopathy. Am J Med Genet A 173, 2505-2510"	"DISEASE: Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures (NEMMLAS) [MIM:617710]: An autosomal recessive, mitochondrial disorder with a broad phenotypic spectrum ranging from severe neonatal lactic acidosis, encephalomyopathy and early death to an attenuated course with milder manifestations. Clinical features include delayed psychomotor development, intellectual disability, hypotonia, dystonia, ataxia, and spasticity. Severe combined respiratory chain deficiency may be found in severely affected individuals. {ECO:0000269|PubMed:28236339, ECO:0000269|PubMed:28650581, ECO:0000269|PubMed:28905505}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C4540192	604733	617710	161.0411831	320.9495799	Class 1	-1.6622215	0.000180975	185107.5572	130485.6667	Peripheral	7.809752085	91.26161104
Q9NQH7	XPNPEP3	Central nervous system;Cardiovascular system;Ears;Gastrointestinal system;Kidney and urinary tract	Protein maturation & folding	1				1		"DISEASE: Nephronophthisis-like nephropathy 1 (NPHPL1) [MIM:613159]: A disorder with features of nephronophthisis, a cystic kidney disease leading to end-stage renal failure. Nephronophthisis is histologically characterized by modifications of the tubules with thickening of the basement membrane, interstitial fibrosis and, in the advanced stages, medullary cysts. Typical clinical manifestation are chronic renal failure, anemia, polyuria, polydipsia, isosthenuria, and growth retardation. Associations with extrarenal symptoms are frequent. In NPHPL1 patients, extrarenal symptoms include hypertension, essential tremor, sensorineural hearing loss and gout. Severely affected individuals can manifest a mitochondrial disorder with isolated complex I deficiency activity in muscle, seizures, mental retardation and hypertrophic dilated cardiomyopathy. {ECO:0000269|PubMed:20179356}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0751651;C1691228;C3150419;C3714756;C4277690	613553	613159	68.9161364	128.4024063	Class 1	-1.458228405	8.04215E-05	38028.77271	46095.83333	Peripheral	12.29111678	75.38903288
Q9Y2Z4	YARS2	Central nervous system;Metabolism;Ophthalmic system;Failure to thrive;Cardiovascular system;Pulmonary system ;Muscular system;Liver;Gastrointestinal system;Hematologic system;Kidney and urinary tract	tRNA related processes	1				1	"Riley, L. G., Cooper, S., Hickey, P., Rudinger-Thirion, J., McKenzie, M., Compton, A., Lim, S. C., Thorburn, D., Ryan, M. T., Giege, R., Bahlo, M., and Christodoulou, J. (2010) Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome. Am. J. Hum. Genet. 87, 52-59"	"DISEASE: Myopathy with lactic acidosis and sideroblastic anemia 2 (MLASA2) [MIM:613561]: A rare oxidative phosphorylation disorder specific to skeletal muscle and bone marrow. Affected individuals manifest sideroblastic anemia, progressive lethargy, muscle weakness, and exercise intolerance associated with persistent lactic acidemia. {ECO:0000269|PubMed:20598274, ECO:0000269|PubMed:22504945}. Note=The disease is caused by mutations affecting the gene represented in this entry."	C0003886;C0010828;C0158995;C0270960;C0751651;C1838103;C3150802	610957	613561	160.5825719	NaN	Class 1	-1.328803402	0.00022042	545284.8895	446592.6667	Peripheral	14.48704831	87.56189087
Q96TA2	YME1L1	"Central nervous system;Metabolism;Ophthalmic system;Congenital anomalies and dysmorphisms, intrauterine abnormalities"	Protein degradation & quality control	1				1	"Hartmann, B., Wai, T., Hu, H., MacVicar, T., Musante, L., Fischer-Zirnsak, B., Stenzel, W., Graf, R., van den Heuvel, L., Ropers, H. H., Wienker, T. F., Hubner, C., Langer, T., and Kaindl, A. M. (2016) Homozygous YME1L1 mutation causes mitochondriopathy with optic atrophy and mitochondrial network fragmentation. Elife 5, pii: e16078"	"DISEASE: Optic atrophy 11 (OPA11) [MIM:617302]: An autosomal recessive disease characterized by progressive visual loss in association with optic atrophy. Atrophy of the optic disk indicates a deficiency in the number of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts. OPA11 patients also manifest delayed psychomotor development, intellectual disability, ataxia, and leukoencephalopathy on brain imaging. {ECO:0000269|PubMed:27495975}. Note=The disease may be caused by mutations affecting the gene represented in this entry."	C4310628	607472	617302	43.84415546	NaN	Class 1	-2.387189405	2.53418E-05	150925.9218	124719.6667	Integral	79.36845898	96.68016821
Q9NPJ3	ACOT13	-	Lipid metabolism	1	1		1							123.047489	387.6838489	Class 1	-2.156289712	8.51792E-05	876713.1869	1003345.667	Peripheral	7.493033267	80.33329848
Q86TW2	ADCK1	-	Unknown	1	1		1							259.0868264	64.12734372	Class 1	-1.843909033	8.26135E-05	1518.804408	NaN	Integral	73.46166308	91.99621492
Q3MIX3	ADCK5	-	Unknown	1	1		1							Infinite	224.2691558	Class 3	-0.392767846	0.005839036	211.4109982	NaN	0	NaN	92.08287601
Q96SZ5	ADO	-	Amino acid metabolism	1	1		1							NaN	NaN	Class 2	-1.246605474	0.017540525	8266.669791	137601.6667	Peripheral	17.37895463	76.02035202
P15121	AKR1B1	-	Carbohydrate & energy metabolism	1	1		1							263.9370033	NaN	Class 2	-1.002009062	0.009343944	88475.46771	4003470	Soluble	6.631747121	19.18116435
Q9Y6H3	ATP23	-	OXPHOS assembly & stability	1	1		1							NaN	NaN	Class 1	-1.273545078	0.003208511	13916.74102	9650.776667	Peripheral	12.87451702	85.81495032
O43521	BCL2L11	-	Cell death/ apoptosis	1	1		1							38.01134881	NaN	NaN	NaN	NaN	7929.836063	NaN	0	NaN	NaN
A6NF51;O95861	BPNT1	-	Nucleotide/ nucleoside metabolism	1	1		1							NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q8WUR7	C15orf40	-	Unknown	1	1		1							41.92802739	NaN	Class 1	-1.850376914	0.000154167	15366.3405	140217.8	0	NaN	NaN
U3KQB8	C5orf63	-	Unknown	1	1		1							NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q9BUK0	CHCHD7	-	OXPHOS assembly & stability	1	1		1							17.60712959	NaN	Class 2	-2.011429533	0.017373814	37124.18185	52290.2	Peripheral	4.242868841	63.85220901
Q9NRF8	CTPS2	-	Nucleotide/ nucleoside metabolism	1	1		1							102.5620142	1527.086698	Class 1	-2.184818107	0.001726704	8558.79831	116384.1667	Peripheral	20.24253547	80.12942093
O60888	CUTA	-	Unknown	1	1		1							75.37451182	NaN	Class 1	-2.571194322	0.002945456	66292.14222	594909	Peripheral	5.813799812	65.98131138
Q9BTZ2	DHRS4	-	Lipid metabolism	1	1		1							NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q9BQD7	FAM173A	-	Unknown	1	1		1							14.78447993	NaN	Class 1	-3.485320645	1.54706E-05	9786.856421	2626.763333	0	NaN	NaN
P49789	FHIT	-	Nucleotide/ nucleoside metabolism	1	1		1							NaN	NaN	Class 1	-1.334053588	0.002540158	20668.13782	72494.6	Peripheral	11.31979422	81.16496016
Q96MZ0	GDAP1L1	-	Unknown	1	1		1							NaN	NaN	NaN	NaN	NaN	436.7947795	3206.953333	0	31.11952625	NaN
Q6ZS86	GK5	-	Other known processes	1	1		1							NaN	NaN	Class 1	-1.575855723	0.001420883	1071.238138	2962.464	0	NaN	NaN
Q9BUP3	HTATIP2	-	Cell death/ apoptosis	1	1		1							33.06004521	68.43670135	Class 3	-0.773634938	0.000340277	25262.18691	138686.5	0	NaN	NaN
Q96A73	KIAA1191	-	Unknown	1	1		1							NaN	NaN	Class 1	-2.083175915	0.000756787	NaN	NaN	0	NaN	NaN
Q16773	KYAT1	-	Amino acid metabolism	1	1		1							NaN	NaN	Class 1	-2.098796433	0.000478587	9808.244988	51376.43333	0	NaN	30.62035284
O75608	LYPLA1	-	Lipid metabolism	1	1		1							Infinite	NaN	Class 4	-1.450041364	0.204470333	155394.0468	498196.5	0	NaN	79.48647622
Q5VWZ2	LYPLAL1	-	Other known processes	1	1		1							225.4011585	107.152905	Class 1	-1.832446843	0.003171298	82350.29399	341982.3333	Peripheral	23.89020535	88.72731743
A8MSI8	LYRM9	-	Unknown	1	1		1							NaN	NaN	NaN	NaN	NaN	4371.563428	6237.343333	Peripheral	7.579549105	72.07657357
Q9H1A3	METTL9	-	Unknown	1	1		1							NaN	NaN	Class 1	-1.21076765	0.002866457	4384.266002	25610.06333	0	NaN	NaN
Q7L4E1	MIGA2	-	"Morphology, dynamics & organization"	1	1		1							NaN	47.32068056	Class 4	0.148507712	0.01796818	2358.199602	1396.383333	Peripheral	48.23868107	88.49394609
Q9NQR4	NIT2	-	Amino acid metabolism	1	1		1							5144.304173	NaN	Class 1	-2.603475039	0.000764918	27061.03969	274162.6667	Peripheral	6.340968602	65.15756323
Q5BKU9	OXLD1	-	Unknown	1	1		1							31.89599562	NaN	Class 1	-1.560240861	0.001113676	39881.76482	28168.36667	Peripheral	3.890761424	69.82651301
Q9H0N5	PCBD2	-	Other known processes	1	1		1							353.6879332	NaN	Class 1	-1.553880193	0.000644747	39725.3881	35022.76667	Peripheral	11.67250623	59.27602143
Q96N28	PRELID3A	-	"Carriers, channels & transporters"	1	1		1							NaN	NaN	NaN	NaN	NaN	454.9181273	NaN	0	NaN	NaN
Q969G6	RFK	-	Cofactor metabolism	1	1		1							70.97213593	NaN	Class 4	-1.349920845	0.061708969	19134.57162	211942	0	NaN	53.93826706
Q9NRG7	SDR39U1	-	Unknown	1	1		1							110.3777239	NaN	Class 1	-1.8384419	0.000220827	143090.6324	90779.05	Ambiguous	56.32599956	97.28750531
Q8IXJ6	SIRT2	-	Regulation & signaling	1	1		1							NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q9NX00	TMEM160	-	Unknown	1	1		1							68.34666067	92.93709062	Class 1	-2.641590057	0.003227373	35057.44568	46400.7	Integral	68.84646881	95.16977801
Q9NWH2	TMEM242	-	Unknown	1	1		1							205.3194812	NaN	Class 1	-1.995117456	0.000962739	41732.73839	29550.03333	0	NaN	72.63586762
Q8N2U0	TMEM256	-	Unknown	1	1		1							NaN	NaN	Class 1	-1.542144079	0.004729247	284330.1562	295801	0	NaN	94.99828154
Q5SWH9	TMEM69	-	Unknown	1	1		1							NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q8WWH5	TRUB1	-	RNA-related processes	1	1		1							23.32288291	24.14179747	Class 1	-1.124527657	0.000326562	47817.0734	186230.3333	Peripheral	8.8124563	85.37768507
Q8N4Q0	ZADH2	-	Lipid metabolism	1	1		1							56.15888986	88.68854378	Class 1	-2.085309042	0.000179427	59055.30817	59116.2	Peripheral	13.48804626	91.12266224
Q0P651	ABHD18	-	Unknown	1	1	1								NaN	NaN	Class 1	-2.008583045	0.000175848	4773.114491	2817.445	Peripheral	31.58113911	71.34562173
Q8N8L6	ARL10	-	Unknown	1	1	1								NaN	NaN	NaN	NaN	NaN	7668.913592	3366.683333	0	NaN	NaN
P56559	ARL4C	-	Regulation & signaling	1	1	1								NaN	NaN	Class 1	-1.611585599	0.000845067	1263.668562	8055.42	0	NaN	NaN
Q9BSJ5	C17orf80	-	Unknown	1	1	1								NaN	NaN	Class 4	-1.279945282	0.295725706	12876.34609	NaN	0	NaN	NaN
Q5VUE5	C1orf53	-	Unknown	1	1	1								NaN	NaN	Class 4	-0.325516563	0.218607857	8348.965369	5660.42	0	NaN	NaN
Q6P5X5	C22orf39	-	Unknown	1	1	1								NaN	NaN	NaN	NaN	NaN	4492.570441	NaN	Peripheral	13.06278575	72.81580463
Q07002	CDK18	-	Regulation & signaling	1	1	1								NaN	57.6451223	Class 4	-0.538395719	0.025288213	629.4478402	375.8315	0	NaN	NaN
Q8TB03	CXorf38	-	Unknown	1	1	1								75.14505336	NaN	Class 2	-1.129714775	0.016028919	2868.598802	52357.86667	0	NaN	NaN
Q8TE69;Q96DE9	CXorf40A;CXorf40B	-	Unknown	1	1	1								NaN	NaN	NaN	NaN	NaN	6643.328275	6443.533333	Peripheral	5.930797755	54.71664817
Q4G0S4	CYP27C1	-	Lipid metabolism	1	1	1								NaN	NaN	Class 1	-0.972081986	0.00174214	NaN	NaN	0	NaN	NaN
Q6PKH6	DHRS4L2	-	Unknown	1	1	1								NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q8TEA8	DTD1	-	tRNA related processes	1	1	1								Infinite	NaN	Class 1	-2.418387902	0.007696409	4182.557804	63041.1	Soluble	6.540566269	16.64030779
O75319	DUSP11	-	RNA-related processes	1	1	1								NaN	NaN	Class 1	-1.541240503	0.002171077	1411.956222	25672.73333	0	NaN	NaN
Q8TBF2	FAM213B	-	Lipid metabolism	1	1	1								NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q8WU58	FAM222B	-	Unknown	1	1	1								NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q9UK73	FEM1B	-	Protein degradation & quality control	1	1	1								NaN	NaN	Class 4	-0.745027653	0.028767885	4723.938936	22738.83333	0	NaN	NaN
P56937	HSD17B7	-	Lipid metabolism	1	1	1								61.19450453	79.85509154	Class 1	-1.038350083	0.001764124	13120.52938	42729.93333	Integral	78.38178628	91.92528844
Q9BVG8	KIFC3	-	Other known processes	1	1	1								8.216424733	NaN	Class 1	-1.379649727	0.000174918	NaN	NaN	0	NaN	NaN
Q8WWI1	LMO7	-	Other known processes	1	1	1								NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q68D91	MBLAC2	-	Unknown	1	1	1								25.87660221	50.49984823	Class 1	-1.088098285	0.003925874	30451.61215	81289.66667	Integral	83.45600462	89.85285913
Q9BRT3	MIEN1	-	Cell death/ apoptosis	1	1	1								NaN	NaN	Class 4	0.108044412	0.743651937	11033.19752	144619.7	Peripheral	12.64420146	90.76937916
Q69YL0	NCBP2-AS2	-	Unknown	1	1	1								43.03937169	25.99438463	Class 1	-2.58016918	2.39261E-05	181569.6171	118831.3333	Integral	96.40207092	94.10882901
Q9UK39	NOCT	-	RNA-related processes	1	1	1								11.80029068	22.92569259	Class 1	-1.047677794	0.0009339	3872.847655	13250.58667	Peripheral	17.50910573	86.43479198
P10588	NR2F6	-	DNA-related processes	1	1	1								NaN	30.69696765	Class 1	-1.870683592	0.001329257	4444.313623	35238.63333	Ambiguous	36.32673129	77.00917295
Q9BSD7	NTPCR	-	Nucleotide/ nucleoside metabolism	1	1	1								241.4946197	NaN	Class 1	-1.836088319	0.000214901	115177.645	708315.3333	Peripheral	17.03520778	77.35804938
Q8WZ82	OVCA2	-	Unknown	1	1	1								Infinite	NaN	Class 1	-3.132501059	0.000116149	38275.64658	283145.3333	Peripheral	17.66716369	64.85064493
A0A0B4J2F0	PIGBOS1	-	Unknown	1	1	1								188.2870611	NaN	Class 1	-2.319438565	0.004006911	64732.2463	60682.56667	0	NaN	97.20646068
Q9H3Y8	PPDPF	-	Unknown	1	1	1								1.639365573	NaN	Class 4	-0.782984432	0.019910818	7181.320533	3271.723333	0	6.813567023	NaN
Q7Z6K3	PTAR1	-	Unknown	1	1	1								265.1233101	NaN	Class 1	-1.57846546	0.001012403	9034.690853	40672.53333	0	NaN	NaN
Q9H0H5	RACGAP1	-	Regulation & signaling	1	1	1								NaN	15.06282388	Class 4	-0.543478473	0.410693072	101508.9169	243393	Integral	66.01661736	95.1269736
Q96LZ7	RMDN2	-	Unknown	1	1	1								Infinite	NaN	Class 4	-0.279229482	0.018877692	3811.5453	4725.193333	0	NaN	93.29841333
Q6IQ49	SDE2	-	DNA-related processes	1	1	1								Infinite	36.85834984	Class 1	-2.213243488	0.000806669	3337.341053	88049.36667	Peripheral	10.43795952	60.35700997
L0R6Q1	SLC35A4	-	Unknown	1	1	1								52.32757586	87.15958998	Class 1	-1.992515834	0.000176498	507461.7326	623468	Ambiguous	66.78045936	84.56981408
P0DMW3	SMIM10L1	-	Unknown	1	1	1								9.101979936	22.65569339	Class 2	-2.808763581	0.024509825	25384.46729	14520.3	0	NaN	NaN
A0A096LPB2	SMIM26	-	Unknown	1	1	1								NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q6P1N9	TATDN1	-	Unknown	1	1	1								Infinite	NaN	Class 1	-3.232943157	0.000243746	17172.34662	148834.6667	Ambiguous	15.20320771	11.62247987
Q17R31	TATDN3	-	Unknown	1	1	1								Infinite	NaN	Class 1	-1.899854337	0.001496457	1398.622262	30745.35	0	NaN	NaN
Q86YL5	TDRP	-	Other known processes	1	1	1								NaN	NaN	NaN	NaN	NaN	6274.617446	37554.2	Peripheral	20.15245613	63.44399614
Q9H7S9	ZNF703	-	Regulation & signaling	1	1	1								NaN	NaN	NaN	NaN	NaN	7222.277266	116869.5	Peripheral	9.424688168	74.70296494
Q8N5Z0	AADAT	-	Amino acid metabolism	1										NaN	NaN	Class 2	-1.64413084	0.03377656	2884.948296	4756.493333	Peripheral	20.34546892	78.02976069
Q9NRK6	ABCB10	-	Unknown	1										556.2386748	220.0100868	Class 1	-0.920471473	0.000916439	183945.8575	172721	Integral	95.36750739	91.19689451
Q9NUT2	ABCB8	-	"Carriers, channels & transporters"	1										585.0157165	117.9085827	Class 1	-1.644548276	0.000197564	19428.63973	8901.223333	Integral	90.9879147	95.13350084
Q9NUJ1	ABHD10	-	Other known processes	1										365.235153	349.5573531	Class 1	-1.579339397	0.000117944	282744.5359	379546	Peripheral	5.32594146	92.06202733
Q8NFV4	ABHD11	-	Unknown	1										245.0056564	156.6959915	Class 1	-1.884965404	7.51452E-05	142693.5022	148027	Peripheral	20.20015988	93.4992058
K7ER88;P42765	ACAA2	-	Fatty acid _-oxidation 	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q6JQN1	ACAD10	-	Fatty acid _-oxidation 	1										NaN	47.81621759	Class 4	-2.49070372	0.166472233	NaN	NaN	0	NaN	NaN
P28330	ACADL	-	Fatty acid _-oxidation 	1										NaN	NaN	NaN	NaN	NaN	6763.567091	7620.772333	Peripheral	8.995256225	58.54836498
Q86TX2	ACOT1	-	Fatty acid _-oxidation 	1										NaN	NaN	Class 1	-1.298924312	0.000252525	266119.6365	203585.3333	Peripheral	16.80987013	95.82487298
P49753	ACOT2	-	Lipid metabolism	1										224.1286777	NaN	Class 1	-1.186483747	0.000961073	89789.10435	234644.5	Peripheral	10.18937687	95.66949669
Q9Y305;Q9Y305;Q9Y305	ACOT9	-	Lipid metabolism	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9NPH0	ACP6	-	Lipid metabolism	1										NaN	233.1204734	Class 3	-0.855284083	0.004501155	33063.1595	37644.26667	Ambiguous	14.87464583	33.1119847
Q96CM8	ACSF2	-	Lipid metabolism	1										93.2508193	NaN	Class 4	-0.502045045	0.015864556	83144.42572	55833.16667	Peripheral	12.62343307	87.38577584
P33121	ACSL1	-	Fatty acid _-oxidation 	1										NaN	NaN	NaN	NaN	NaN	67646.06064	137141	0	NaN	NaN
Q08AH1	ACSM1	-	Lipid metabolism	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q08AH3	ACSM2A	-	Lipid metabolism	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q68CK6	ACSM2B	-	Lipid metabolism	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q53FZ2	ACSM3	-	Lipid metabolism	1										NaN	NaN	Class 3	-0.688398784	0.001880305	2502.294266	659.936	0	NaN	89.99204936
P0C7M7	ACSM4	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q6NUN0	ACSM5	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q6P461	ACSM6	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9NUB1	ACSS1	-	Carbohydrate & energy metabolism	1										NaN	NaN	Class 4	-0.827243255	0.030472934	154875.3058	127939.3333	Peripheral	7.551392967	76.81125338
Q9H6R3	ACSS3	-	Carbohydrate & energy metabolism	1										NaN	NaN	Class 4	-0.506245548	0.378018551	19904.79875	15631.72333	Peripheral	9.950858101	81.18752053
P14621	ACYP2	-	Unknown	1										Infinite	NaN	NaN	NaN	NaN	3026.655034	40412.26667	0	6.538270999	NaN
Q7Z695	ADCK2	-	Unknown	1										NaN	NaN	Class 2	-1.711773536	0.00852539	5406.125433	9768.88	Ambiguous	84.24311328	71.10263152
Q8IWW8	ADHFE1	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q8WV93	AFG1L	-	Protein degradation & quality control	1										176.6503887	NaN	Class 1	-3.208246622	0.000252366	13224.14309	12257.76667	Peripheral	17.21505898	88.24594063
Q9BSE5	AGMAT	-	Other known processes	1										55.41438431	322.9296626	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q9NUQ2	AGPAT5	-	Cardiolipin biosynthesis & remodeling	1										35.1456811	127.5569248	Class 3	-0.397091977	0.004495796	52726.71839	74874	Integral	94.96265731	93.80802288
Q9BYV1	AGXT2	-	Amino acid metabolism	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q96NN9	AIFM3	-	Cell death/ apoptosis	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9UIJ7	AK3	-	Nucleotide/ nucleoside metabolism	1										120.1305983	210.0657264	Class 1	-1.389483645	0.000302906	689649.7852	560678.3333	Peripheral	2.574915088	87.15310771
P27144	AK4	-	Nucleotide/ nucleoside metabolism	1										149.1504833	NaN	Class 1	-1.09243499	0.000124662	729397.6534	701943.6667	Peripheral	5.817667822	95.11168713
Q92667	AKAP1	-	Regulation & signaling	1										20.10305736	27.08103485	Class 3	-0.589954676	0.005916218	88427.61032	100766.7333	Peripheral	26.27476656	74.3312677
O43572	AKAP10	-	Regulation & signaling	1										320.9174256	NaN	Class 4	0.393016686	0.05343511	440.0507409	21910.26667	0	NaN	NaN
O43488	AKR7A2	-	Carbohydrate & energy metabolism	1										415.5221496	NaN	Class 3	-0.85829185	0.000342692	101179.8881	528934.6667	Peripheral	4.020523061	66.90929563
P13196	ALAS1	-	Cofactor metabolism	1										2.617874293	7.38585484	Class 1	-0.950479674	0.001762471	15380.98862	7716.493333	Peripheral	18.77086491	91.66698058
A0A0U1RQK9;P30837	ALDH1B1	-	Carbohydrate & energy metabolism	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O75891	ALDH1L1	-	Cofactor metabolism	1										149.0935373	NaN	NaN	NaN	NaN	2496.644606	871.5676667	Peripheral	15.9287193	92.6065864
P05091	ALDH2	-	Carbohydrate & energy metabolism	1										NaN	83.773396	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
P49189	ALDH9A1	-	Other known processes	1										138.7399152	142.0453885	Class 1	-1.085112534	0.000287173	338243.6884	1493493.333	Soluble	5.390989325	10.07825443
Q13686	ALKBH1	-	tRNA related processes	1										75.85132162	30.93923379	Class 1	-3.412132703	8.00836E-06	17188.89927	24508.7	Peripheral	11.7882339	88.81052665
Q9BT30	ALKBH7	-	Cell death/ apoptosis	1										3.927546607	NaN	Class 1	-3.158696987	4.45735E-05	22827.37401	8927.306667	Peripheral	12.18770126	83.34711768
Q5VTE6	ANGEL2	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	11091.72912	29023.9	0	NaN	NaN
P27695	APEX1	-	Oxidative stress response	1										234.5332149	NaN	Class 2	-0.93116422	0.015870952	24166.2011	3267723.333	Soluble	10.66110683	30.79975562
Q9UBZ4	APEX2	-	DNA-related processes	1										NaN	NaN	NaN	NaN	NaN	17.36610922	4169.45	0	NaN	NaN
P78540	ARG2	-	Amino acid metabolism	1										NaN	36.95432475	Class 4	-0.247649704	0.153398815	155319.3073	86050.5	Peripheral	5.915817178	86.10298837
Q9NVT9	ARMC1	-	Unknown	1										35.25145547	NaN	Class 3	-0.47423771	0.002818329	94393.81084	220530.4667	Peripheral	27.97184338	90.79241203
C9J5N7;Q8N2F6	ARMC10	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q7L311	ARMCX2	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	12698.67787	5670.615667	Peripheral	24.87254353	79.01572372
Q9UH62	ARMCX3	-	"Morphology, dynamics & organization"	1										NaN	57.5750821	Class 3	-0.795542263	0.000372538	39039.68478	68858.03333	Integral	87.77959476	95.33545321
Q5T9A4	ATAD3B	-	"Morphology, dynamics & organization"	1										Infinite	544.1140539	Class 1	-2.408092255	8.64666E-06	577391.7715	694838	Integral	97.25966889	97.15156306
P24539	ATP5F1	-	OXPHOS complex subunits	1										111.9802768	NaN	Class 1	-1.646593316	0.000185049	1470151.848	1768106.667	Integral	98.34177922	94.9525983
F8W0P7;P06576	ATP5F1B	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P36542	ATP5F1C	-	OXPHOS complex subunits	1										NaN	202.3245266	Class 1	-1.630738816	0.001692669	1813045.837	NaN	Peripheral	18.52416035	70.01816805
O75947	ATP5H	-	OXPHOS complex subunits	1										92.99453825	341.3655048	Class 1	-1.668206374	0.000204173	2429205.559	2661850	Ambiguous	94.18390778	57.09331164
Q9UII2	ATP5IF1	-	Regulation & signaling	1										82.09760858	151.3660795	Class 1	-1.074509236	0.00113983	391948.4047	790373.6667	Soluble	0.212638991	39.15721332
P18859	ATP5J	-	OXPHOS complex subunits	1										113.7020574	NaN	Class 1	-1.642178113	0.00018855	1129992.087	1768573.333	Ambiguous	57.41803801	47.02433921
O75964	ATP5L	-	OXPHOS complex subunits	1										101.444648	NaN	Class 1	-1.869017499	0.000162442	1819696.471	1850446.667	Integral	76.22076221	95.39870701
P05496	ATP5MC1	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q06055	ATP5MC2	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	338.7023871	NaN	0	NaN	NaN
P48201	ATP5MC3	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P56385	ATP5ME	-	OXPHOS complex subunits	1										101.0573606	236.0907176	Class 1	-1.866683843	9.98874E-05	3126741.913	3373636.667	Ambiguous	94.9008654	78.30380279
P56134	ATP5MF	-	OXPHOS complex subunits	1										NaN	NaN	Class 1	-2.003869531	0.000102492	114184.5181	174841	0	NaN	NaN
Q7Z4Y8	ATP5MGL	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
G3V556;A0A0A0MTQ5;P56378	ATP5MPL	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P48047	ATP5PO	-	OXPHOS complex subunits	1										138.3599602	230.7149124	Class 1	-1.594082298	0.000393103	3114395.689	3497433.333	Peripheral	6.385331205	92.58545393
Q99766	ATP5S	-	Unknown	1										491.692492	NaN	Class 1	-2.846894906	1.9222E-05	66732.61045	38840.73333	Peripheral	16.28253713	98.77519815
Q5TC12	ATPAF1	-	OXPHOS assembly & stability	1										83.32025829	NaN	Class 1	-3.113917094	1.02797E-05	347661.3107	431103.6667	Peripheral	6.490229514	89.76666456
Q92934	BAD	-	Cell death/ apoptosis	1										Infinite	35.19344854	NaN	NaN	NaN	875.2159497	47659.3	0	NaN	NaN
Q16611	BAK1	-	Cell death/ apoptosis	1										396.3556039	NaN	Class 4	-0.46736144	0.040686582	88360.38017	90412.76667	Integral	96.0813222	92.0097572
Q07812	BAX	-	Cell death/ apoptosis	1										172.0493079	NaN	Class 4	-0.446926603	0.087850777	109188.7325	367480.6667	Peripheral	47.86420831	92.4871407
Q9BXH1	BBC3	-	Cell death/ apoptosis	1										NaN	NaN	Class 4	0.406501907	0.226382488	15851.86343	11563.91	Ambiguous	72.63839286	85.3632137
P10415	BCL2	-	Cell death/ apoptosis	1										43.03867551	NaN	Class 4	0.023447237	0.849241279	27809.75344	28152.68667	0	NaN	NaN
Q07817	BCL2L1	-	Cell death/ apoptosis	1										NaN	NaN	NaN	NaN	NaN	NaN	23462.55	0	NaN	NaN
Q9BXK5	BCL2L13	-	Cell death/ apoptosis	1										136.708096	NaN	Class 3	-0.670789691	0.000291568	95457.85793	89145.36667	Integral	79.73057969	93.58503611
Q92843	BCL2L2	-	Cell death/ apoptosis	1										NaN	54.90803619	NaN	NaN	NaN	7701.579346	NaN	0	NaN	NaN
Q02338	BDH1	-	Carbohydrate & energy metabolism	1										NaN	NaN	Class 1	-1.029220808	0.001486563	NaN	NaN	0	NaN	NaN
Q12983	BNIP3	-	Cell death/ apoptosis	1										NaN	NaN	Class 1	-2.029623991	0.000867753	4946.046179	3059.6	0	NaN	NaN
O60238	BNIP3L	-	Cell death/ apoptosis	1										NaN	NaN	Class 4	-0.639695575	0.345229256	2491.651247	2888.175	Ambiguous	71.43363287	76.78057809
Q9Y3E2	BOLA1	-	Fe-S protein biogenesis	1										132.1776997	64.06229113	Class 4	-1.293360395	0.088402496	9672.903484	26877.21333	Ambiguous	36.75745845	55.52005538
H7C0M3;Q86WA6	BPHL	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q8WY22	BRI3BP	-	Unknown	1										141.0277514	270.3525061	Class 4	-0.182709711	0.323007627	10906.37786	108582	0	NaN	NaN
Q9HB07	C12orf10	-	Unknown	1										422.6521575	NaN	Class 1	-1.887765867	0.000140721	14650.46358	568732.6667	Soluble	12.43326748	22.30426702
Q69YU5	C12orf73	-	Unknown	1										46.46798985	31.65190332	Class 1	-2.338552814	7.66146E-05	374410.0453	167938	0	NaN	76.76789556
A6NNL5	C15orf61	-	Unknown	1										45.85825153	NaN	Class 3	-0.900403485	0.000368001	54047.75716	17090.50667	Integral	91.61927067	88.29611451
A8K5M9	C15orf62	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q6P1S2	C3orf33	-	Regulation & signaling	1										NaN	NaN	Class 4	-0.780770457	0.010117158	7208.484493	9027.95	0	NaN	88.25919682
Q6P1X6	C8orf82	-	Unknown	1										245.8628197	102.9027463	Class 1	-1.494317156	0.000143619	62249.86683	NaN	Peripheral	22.332667	80.82160844
Q9Y2D0	CA5B	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	14450.93102	46751.47333	Peripheral	5.149099464	51.33059693
Q96LW7	CARD19	-	Regulation & signaling	1										150.4102008	51.90016446	Class 1	-2.301434439	2.58905E-05	47093.37092	36646.16667	Integral	97.35765292	89.51342816
Q8N4T8	CBR4	-	Lipid metabolism	1										233.1885787	NaN	Class 1	-1.540468572	0.000240526	57921.78657	42213.16667	Peripheral	9.005335808	75.38267558
Q96BQ5	CCDC127	-	Unknown	1										137.2947694	422.1425011	Class 1	-2.838598311	5.2414E-05	30983.59653	10294.37333	Integral	98.20957699	96.27959266
C9JSW8;Q96ER9	CCDC51	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q4VC31	CCDC58	-	Unknown	1										384.3170529	NaN	Class 1	-0.989454657	0.000240088	908134.2013	1382836.667	Soluble	3.482229145	40.80580347
Q9GZT6	CCDC90B	-	Unknown	1										1300.017308	NaN	Class 3	-0.75721431	0.000692065	42808.50072	22861.6	0	NaN	NaN
O14618	CCS	-	Protein maturation & folding	1										NaN	NaN	Class 4	0.132201214	0.216846804	1300.889239	92332.56667	Peripheral	12.54086921	63.1979419
Q4G0I0	CCSMST1	-	Unknown	1										49.28232552	754.8680301	Class 1	-3.620485469	0.000408957	9205.333392	13537.38	Integral	92.7214578	90.53725203
Q96SZ6	CDK5RAP1	-	Regulation & signaling	1										8.033274046	10.79414501	Class 1	-2.499819012	1.22807E-05	86650.93605	59241.86667	Peripheral	20.48142052	87.58931623
A8MTT3	CEBPZOS	-	Unknown	1										26.66894379	31.69383889	Class 1	-3.138924373	1.35053E-05	99627.08837	48180.83333	0	NaN	91.48978563
Q9BSY4	CHCHD5	-	Unknown	1										20.7872478	30.23553176	Class 2	-1.149085724	0.014425889	97464.74532	99022.16667	Soluble	5.262727695	13.62183639
Q8NE62	CHDH	-	Other known processes	1										193.0580593	160.8700808	Class 1	-0.946028541	0.001729472	47635.81732	28412.16667	Peripheral	13.50889078	84.14449916
Q9NZ45	CISD1	-	Unknown	1										111.3781189	25.03835932	Class 3	-0.677733861	0.001612847	1748742.267	2234203.333	Integral	89.97485974	94.35273986
P0C7P0	CISD3	-	Regulation & signaling	1										82.79591857	577.5574507	Class 1	-3.691847878	2.98845E-06	107020.9288	55664.86667	Integral	62.90777274	88.96285178
C9JFS8;P12532	CKMT1A	-	Carbohydrate & energy metabolism	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P17540	CKMT2	-	Carbohydrate & energy metabolism	1										NaN	33.0056085	NaN	NaN	NaN	NaN	330542.3333	0	NaN	NaN
O75153	CLUH	-	"Morphology, dynamics & organization"	1										NaN	94.81187857	NaN	NaN	NaN	4013.266793	NaN	0	NaN	NaN
Q8N0X4	CLYBL	-	Cofactor metabolism	1										NaN	70.85879034	Class 1	-0.923555252	0.001572002	60433.11819	42545.3	Peripheral	4.797038725	73.86668521
Q7Z7K0	CMC1	-	OXPHOS assembly & stability	1										93.28728505	NaN	Class 1	-1.736250836	0.000139996	528357.021	351363.6667	Peripheral	10.13331697	65.17438888
H3BNN8;H3BTB6;H3BQQ1;Q9NRP2	CMC2	-	OXPHOS assembly & stability	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P56277	CMC4	-	Unknown	1										94.21247883	93.93830512	Class 4	-0.356987456	0.116673539	19924.57201	71192.86667	Soluble	3.775465638	31.46064236
Q5EBM0	CMPK2	-	Nucleotide/ nucleoside metabolism	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9GZY4	COA1	-	OXPHOS assembly & stability	1										108.8999212	NaN	Class 1	-3.096872299	5.41068E-05	170509.0616	131389	Integral	96.3702438	95.20963094
Q9NYJ1	COA4	-	OXPHOS assembly & stability	1										12.97932027	22.22274392	Class 3	-0.624472998	0.004385365	279156.0344	366732.6667	Ambiguous	4.399447399	3.535039742
Q86VU5	COMTD1	-	Unknown	1										185.8299797	NaN	Class 1	-0.970962988	0.003724767	49432.99151	36735	Integral	93.63076335	95.7612107
Q96MF6	COQ10A	-	Cofactor metabolism	1										NaN	NaN	Class 4	-0.137413066	0.179491261	2759.708643	NaN	0	NaN	NaN
Q9H8M1	COQ10B	-	Cofactor metabolism	1										NaN	NaN	Class 4	-0.288525969	0.032041781	5584.467817	1939.8405	0	NaN	NaN
Q9NZJ6	COQ3	-	Cofactor metabolism	1										31.04860627	44.1121799	Class 1	-1.161922231	0.000200791	78522.19004	57540.16667	Peripheral	8.326166702	95.58835569
Q9Y6N1	COX11	-	OXPHOS assembly & stability	1										72.95531003	NaN	Class 1	-1.998402022	5.72547E-05	54773.16905	40916.56667	Ambiguous	56.59335018	93.76594231
Q14061	COX17	-	OXPHOS assembly & stability	1										29.62949478	NaN	Class 3	-0.814793746	0.006799075	632376.2802	1098376	Peripheral	3.295936706	59.83605734
Q8N8Q8	COX18	-	OXPHOS assembly & stability	1										1510.621585	NaN	Class 1	-1.617761946	0.000130382	29264.26577	25630	0	NaN	93.16622593
Q49B96	COX19	-	OXPHOS assembly & stability	1										34.67878793	NaN	Class 1	-1.163979962	0.001000991	134936.4167	123392.6667	Peripheral	3.778745631	82.14769684
P10606	COX5B	-	OXPHOS complex subunits	1										59.33436166	62.94019014	Class 1	-2.290801201	7.04796E-05	1529295.019	1707253.333	Integral	83.66004563	88.2422382
Q6YFQ2	COX6B2	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P09669	COX6C	-	OXPHOS complex subunits	1										94.84104461	99.29197316	Class 1	-2.42255191	3.05075E-05	1846880.671	2572940	0	NaN	94.81967406
P24310	COX7A1	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P14406	COX7A2	-	OXPHOS complex subunits	1										89.63980129	NaN	Class 1	-2.271340138	0.000496017	1363171.632	1660908	Integral	91.56996382	91.61497813
O14548	COX7A2L	-	OXPHOS assembly & stability	1										29.08362843	NaN	Class 1	-2.223592413	0.000109013	305508.8099	369592.3333	0	NaN	90.68926127
Q8TF08	COX7B2	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P15954	COX7C	-	OXPHOS complex subunits	1										120.8985124	NaN	Class 1	-2.240037928	0.000334233	726368.7526	867534	Integral	96.57685375	94.22435963
Q7Z4L0	COX8C	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9UJA2	CRLS1	-	Cardiolipin biosynthesis & remodeling	1										NaN	NaN	Class 1	-1.058775471	0.001825307	3770.04582	11704.71333	0	NaN	NaN
Q08257	CRYZ	-	Other known processes	1										140.1521791	NaN	Class 1	-2.553643694	9.80839E-05	590394.4448	848163	Soluble	3.5554207	32.08585336
O75390;F8VRI6;F8VX07	CS	-	TCA cycle	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
A8MUP2	CSKMT	-	Other known processes	1										NaN	26.69860686	Class 2	-3.092185566	0.028658281	912.2463228	21093.55	0	NaN	NaN
J3KNF8	CYB5B	-	Unknown	1										378.8106686	140.6296703	Class 4	-0.682001713	0.012355894	87963.40643	651285.5	0	NaN	NaN
Q9UHQ9	CYB5R1	-	Lipid metabolism	1										193.3368668	NaN	Class 4	-0.549654048	0.020783266	202491.445	274687	Integral	96.47313347	97.72312633
P04798	CYP1A1	-	Lipid metabolism	1										NaN	NaN	Class 4	0.822227288	0.025474454	NaN	NaN	0	NaN	NaN
Q9NUL7	DDX28	-	Ribosome assembly & translation	1										25.06367682	11.68066741	Class 1	-2.380459861	4.43461E-05	79384.32964	52226.3	Peripheral	44.46055807	92.23843962
Q16698	DECR1	-	Lipid metabolism	1										112.3954251	NaN	Class 3	-0.629780372	0.002382551	NaN	NaN	0	NaN	NaN
Q14154	DELE1	-	Cell death/ apoptosis	1										NaN	NaN	Class 4	1.269754562	0.00648873	61.88305532	1794.76	0	NaN	NaN
Q7Z3D6	DGLUCY	-	Amino acid metabolism	1										NaN	NaN	Class 3	-0.626395612	0.004548427	44458.87316	25116.23333	Peripheral	11.7720745	96.06501359
Q86XF0	DHFR2	-	Cofactor metabolism	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q13268	DHRS2	-	Lipid metabolism	1										53.28073782	NaN	NaN	NaN	NaN	14799.56965	52100.85	Peripheral	14.48447858	73.18286482
Q7L7V1	DHX32	-	Unknown	1										18.13611131	NaN	Class 4	0.06187109	0.82603594	146.7461976	12439.72333	0	NaN	NaN
Q96GE9	DMAC1	-	OXPHOS assembly & stability	1										31.71450973	60.36963186	Class 1	-1.306653115	0.001680568	8431.078509	26043.6	0	NaN	90.89205604
M0QZC4;B4DFT4;K7EIV4;Q9NW81;Q9NW81	DMAC2	-	OXPHOS assembly & stability	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9NVH1	DNAJC11	-	"Morphology, dynamics & organization"	1										189.6378646	97.66301103	Class 3	-0.737253351	0.000948566	266897.1009	242636.6667	Integral	88.17050059	94.1723937
Q9Y5T4	DNAJC15	-	Protein import & biogenesis	1										15.69371066	8.894957205	Class 1	-1.528183816	0.00037041	NaN	NaN	0	NaN	NaN
Q5SXM8	DNLZ	-	Protein maturation & folding	1										932.5340079	76.80876183	Class 1	-1.514377877	0.000763625	71447.2642	63410.96667	Peripheral	8.265545939	67.00910254
P23919	DTYMK	-	Nucleotide/ nucleoside metabolism	1										Infinite	NaN	Class 1	-2.061441298	0.000954102	188912.4303	1308825.667	Peripheral	6.75041365	79.93268438
Q9NX74	DUS2	-	tRNA related processes	1										28.33872597	NaN	Class 1	-3.779724554	3.15982E-05	8472.747923	48462.6	Peripheral	11.78793508	81.81207422
Q13011	ECH1	-	Fatty acid _-oxidation 	1										94.55689529	NaN	Class 1	-1.368021022	0.000465162	860191.7267	1198030	Peripheral	10.49511015	60.60837002
Q86YB7	ECHDC2	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q96DC8	ECHDC3	-	Unknown	1										NaN	162.4939296	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
P42126	ECI1	-	Fatty acid _-oxidation 	1										206.6134629	NaN	Class 1	-1.153785784	0.000911684	1024996.887	1283603.333	Peripheral	2.904105556	73.59260571
O75521	ECI2	-	Lipid metabolism	1										NaN	134.4479359	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q9BQ95	ECSIT	-	OXPHOS assembly & stability	1										38.49581466	NaN	Class 1	-1.734348429	7.49889E-05	129645.0273	63802.46667	Peripheral	50.67486132	92.65606901
Q9H4I9	EMRE	-	"Carriers, channels & transporters"	1										74.07273607	38.96349297	Class 1	-2.246550127	0.00350579	28339.32243	18101.1	0	NaN	99.32578184
Q14249	ENDOG	-	DNA-related processes	1										4.529941262	43.18796753	Class 1	-1.543108597	0.000102871	92480.6461	56198.2	Peripheral	8.149600021	81.61002696
Q7L5Y1	ENOSF1	-	Carbohydrate & energy metabolism	1										NaN	NaN	Class 4	0.117585298	0.665733678	NaN	55618.5	0	NaN	NaN
Q8IXQ9	ETFBKMT	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	562.0872851	NaN	0	NaN	NaN
Q6IPR1	ETFRF1	-	Regulation & signaling	1										81.79863047	NaN	Class 1	-3.906049602	0.000677815	66018.94884	29292.16667	Peripheral	2.784162253	83.26014053
Q9NVH0	EXD2	-	DNA-related processes	1										14.13839039	17.63069138	Class 3	-0.604518941	0.001146677	91003.07261	66422.33333	Peripheral	47.70836299	90.36788462
Q9Y2C4	EXOG	-	DNA-related processes	1										241.0241824	148.7281736	Class 1	-1.435582352	0.00036412	59153.02346	29519.63333	Integral	94.58694321	90.3606862
Q6P587	FAHD1	-	Carbohydrate & energy metabolism	1										Infinite	201.4150674	Class 1	-2.32350575	0.000146725	153879.106	174905	Peripheral	18.82314962	92.77687109
Q96GK7	FAHD2A	-	Unknown	1										187.8949104	326.7635114	Class 2	-0.929874235	0.008567969	126824.479	259646	Peripheral	4.404587934	59.88755895
Q6P2I3	FAHD2B	-	Unknown	1										NaN	336.2711615	NaN	NaN	NaN	3000.38988	NaN	0	NaN	NaN
Q96A26	FAM162A	-	Cell death/ apoptosis	1										93.77797805	NaN	Class 1	-2.589778652	4.66544E-05	428989.5722	486711.6667	Integral	91.56463875	94.28689008
Q6P4H8	FAM173B	-	Other known processes	1										67.07799904	NaN	Class 1	-1.289596611	0.000577401	9313.490944	9139.376667	0	NaN	90.01298313
Q8N0U4	FAM185A	-	Unknown	1										Infinite	210.6831907	Class 1	-1.852885612	0.000286618	9976.933751	8867.146667	Peripheral	8.440159097	88.13281643
Q96ND0	FAM210A	-	Unknown	1										333.8630084	NaN	Class 1	-1.209163025	0.000224899	34828.17765	34111.9	Integral	91.63832397	97.26832602
Q96KR6	FAM210B	-	Other known processes	1										NaN	NaN	Class 4	-0.417047358	0.147388337	14502.7469	7999.95	0	NaN	90.39504315
Q14296	FASTK	-	Regulation & signaling	1										NaN	NaN	NaN	NaN	NaN	248.8177455	2606.66	0	36.28981109	NaN
Q53R41	FASTKD1	-	RNA-related processes	1										130.3667205	37.11392659	Class 1	-2.174999367	8.29948E-05	19256.89555	12070.78667	Peripheral	28.00129911	87.18876516
Q14CZ7	FASTKD3	-	RNA-related processes	1										23.11834039	NaN	Class 1	-3.637603883	2.89427E-05	21432.72205	11207.4	Peripheral	25.08222999	89.42881378
Q7L8L6	FASTKD5	-	RNA-related processes	1										49.90394054	62.84844787	Class 1	-2.081440303	3.38233E-05	117726.6928	102830.6667	Peripheral	33.35908815	91.19484907
P10109	FDX1	-	Lipid metabolism	1										26.1193505	40.2115566	Class 1	-1.036728077	0.001139869	227991.0052	206678.3333	Soluble	1.864950522	17.41353376
Q9Y3D6	FIS1	-	"Morphology, dynamics & organization"	1										49.69947706	44.6978758	Class 3	-0.43101626	0.005491474	201470.8222	256010.3333	Peripheral	16.83303279	91.40893703
Q14318;Q14318	FKBP8	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q96HJ9	FMC1	-	OXPHOS assembly & stability	1										38.86237448	69.32603946	Class 1	-2.740412415	0.000555921	150643.5808	379042	Peripheral	5.929567524	85.40010681
Q05932	FPGS	-	Cofactor metabolism	1										13.35856981	6.395134804	Class 3	-0.56097174	0.001159487	21891.04951	49245.66667	Peripheral	24.8188831	88.78695949
Q8N4E7	FTMT	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q8IVP5	FUNDC1	-	Autophagy/ mitophagy	1										7.393217874	16.33676732	Class 3	-0.762180314	0.006067821	14017.06723	18198.00333	0	NaN	91.47399204
Q9BWH2	FUNDC2	-	Unknown	1										17.57988275	29.04159703	Class 4	-0.39804142	0.052673843	261683.4473	204354	Integral	91.35610218	91.8418947
A0A096LNH5;H7C2G3;H7C1F6;P0DPI2;A0A0B4J2D5	GATD3A;GATD3B	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O75600	GCAT	-	Amino acid metabolism	1										79.81608208	72.74412681	Class 1	-1.88076396	0.000222026	74224.1507	59891.56667	Ambiguous	22.93408402	48.71572773
P23434	GCSH	-	Amino acid metabolism	1										200.0210748	NaN	Class 1	-1.400494154	0.000829355	179750.1406	325233	Ambiguous	1.774196145	2.435885089
Q5U4N7	GDF5OS	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9H3K2	GHITM	-	"Morphology, dynamics & organization"	1										6.767083162	71.30439215	Class 3	-0.65400201	0.003079123	165321.9192	169042.7667	Integral	85.79671603	95.90806519
Q14410	GK2	-	Other known processes	1										Infinite	194.6564858	Class 4	-0.750362872	0.140165206	175391.5388	199236	Integral	98.59473665	97.60892507
Q9HC38	GLOD4	-	Unknown	1										175.6543689	NaN	Class 1	-1.451548532	0.001413387	52030.41177	1973656.667	Soluble	8.536034662	29.49188831
Q9NS18	GLRX2	-	Oxidative stress response	1										5.714442005	12.35511399	Class 3	-0.886564274	0.004846083	39146.84524	47103.23333	Peripheral	5.823021989	72.9263338
O94925	GLS	-	Amino acid metabolism	1										81.7977536	112.1679464	Class 3	-0.43616827	0.003598922	191426.432	165028.6667	Peripheral	17.16366749	96.15544881
Q9UI32	GLS2	-	Amino acid metabolism	1										NaN	NaN	NaN	NaN	NaN	10143.37764	3760.286667	Peripheral	15.60424865	91.14754116
P49448	GLUD2	-	Amino acid metabolism	1										NaN	546.6566062	NaN	NaN	NaN	0	0	0	0	0
Q6IB77	GLYAT	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9H4A6	GOLPH3	-	Other known processes	1										27.74622773	291.6568857	Class 4	-0.242120709	0.119855107	10046.95174	168760.6667	Peripheral	31.38986141	88.02235679
Q9HCL2	GPAM	-	Cardiolipin biosynthesis & remodeling	1										31.1812049	NaN	Class 1	-1.016960456	0.000462764	9217.873986	10024.63333	Ambiguous	75.192493	85.51334749
Q6NUI2	GPAT2	-	Cardiolipin biosynthesis & remodeling	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P43304	GPD2	-	Carbohydrate & energy metabolism	1										155.4330141	209.5226672	Class 1	-0.946024834	0.000684377	267300.0219	246273.6667	Integral	88.547423	94.44511726
P07203	GPX1	-	Oxidative stress response	1										Infinite	NaN	Class 1	-2.306761219	5.84216E-05	166465.8006	216226	Ambiguous	29.14156035	60.58697439
Q9HAV7	GRPEL1	-	Protein import & biogenesis	1										97.51536461	230.769616	Class 1	-1.369191469	0.000735578	812296.1701	825134.3333	Peripheral	2.830720807	70.64398405
Q8TAA5	GRPEL2	-	Protein import & biogenesis	1										12.41231759	19.59562961	Class 4	-0.472037964	0.008532832	159482.9757	153177.5667	Peripheral	9.979944247	87.31027667
Q12849;Q12849	GRSF1	-	Ribosome assembly & translation	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P00390;P00390	GSR	-	Oxidative stress response	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9Y2Q3	GSTK1	-	Oxidative stress response	1										283.81168	NaN	Class 2	-0.990132347	0.010399342	277755.3437	377830	Peripheral	5.950880189	92.29669572
A4D1E9	GTPBP10	-	Unknown	1										41.21140091	NaN	Class 1	-2.23903847	6.93937E-05	259656.9374	239791.3333	Peripheral	15.87247099	91.40295871
O43824	GTPBP6	-	Unknown	1										41.4980665	21.51715512	Class 1	-2.329043603	3.10345E-05	25376.13043	32827.86667	Peripheral	31.49787608	93.70458204
Q8N3Z3	GTPBP8	-	Unknown	1										9.560955605	NaN	Class 1	-1.303450964	0.001464668	39656.77453	24481.53333	Peripheral	35.49541105	90.5279628
Q16774	GUK1	-	Nucleotide/ nucleoside metabolism	1										NaN	NaN	Class 2	-1.7812418	0.031100818	75693.57224	146540.4333	Peripheral	10.79087647	89.7842063
Q16775;Q16775	HAGH	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9BSH5	HDHD3	-	Unknown	1										104.0123223	206.4332482	Class 1	-2.670428927	4.85329E-05	128460.5026	109064.9667	Peripheral	5.889573093	95.09629508
Q9BXW7	HDHD5	-	Unknown	1										134.1651862	202.2081296	Class 1	-1.144122313	0.000294268	555285.9903	1356059.333	Peripheral	26.40164594	91.91231394
Q9NRV9	HEBP1	-	Other known processes	1										365.1570491	NaN	Class 4	-0.661224875	0.072812433	75028.66361	401159.6667	Soluble	7.410581357	45.25243159
Q9Y5R4	HEMK1	-	Ribosome assembly & translation	1										NaN	NaN	Class 1	-1.947226463	0.0020835	2447.964037	NaN	Peripheral	27.22436477	72.5314407
P31937	HIBADH	-	Amino acid metabolism	1										139.0893866	NaN	Class 3	-0.615949895	0.005205697	508210.9689	405439.6667	Soluble	9.965413911	14.31373801
Q9Y241	HIGD1A	-	Cell death/ apoptosis	1										51.79781833	NaN	Class 1	-2.430294457	1.07464E-05	675393.3189	522406.6667	Integral	98.13737703	92.02006574
Q9BW72	HIGD2A	-	Cell death/ apoptosis	1										21.88280191	34.55920114	Class 1	-2.332602859	0.00017991	166842.6303	95419.43333	Integral	98.12467737	93.69109929
Q9BX68	HINT2	-	Lipid metabolism	1										169.2414543	127.3104147	Class 1	-1.405477514	0.000807089	466822.6813	611625	Peripheral	3.771893173	77.62777418
Q9NQE9	HINT3	-	Other known processes	1										65.90472221	48.30236677	Class 3	-0.406867332	0.006641792	42159.70926	168268.0333	Peripheral	17.18759258	87.89469448
Q92506	HSD17B8	-	Lipid metabolism	1										1683.494514	63.11057947	Class 1	-1.542993248	0.000142439	106864.7123	73861.56667	Peripheral	6.607968629	59.40604247
Q3SXM5	HSDL1	-	Unknown	1										83.52865155	98.65318612	Class 3	-0.652137014	0.003259335	70776.16949	53065.2	Integral	91.79942216	96.80461879
Q6YN16	HSDL2	-	Unknown	1										111.3074791	338.0358469	Class 1	-1.764417069	0.000397441	211783.8297	343577.6667	Peripheral	7.096377403	92.4138255
P86397	HTD2	-	Lipid metabolism	1										138.4883486	NaN	Class 1	-2.658051861	0.000158465	8568.54673	NaN	0	11.87041525	NaN
P14735	IDE	-	Regulation & signaling	1										117.5816109	174.3526782	Class 1	-1.963135455	0.000120222	23907.86866	521011	Peripheral	15.34555438	66.64816906
P51553	IDH3G	-	TCA cycle	1										61.78629172	NaN	Class 1	-1.311772551	0.000712297	431288.7977	297350	Peripheral	10.18249283	49.92109195
P40305	IFI27	-	Cell death/ apoptosis	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9H2X8	IFI27L2	-	Cell death/ apoptosis	1										NaN	NaN	NaN	NaN	NaN	1188.632418	NaN	0	NaN	NaN
Q96LU5	IMMP1L	-	Protein maturation & folding	1										Infinite	NaN	Class 4	-0.965796961	0.056848983	3045.654186	19801.79667	0	NaN	NaN
K7EKW4;K7ENV7;Q96AB3	ISOC2	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O15229	KMO	-	Amino acid metabolism	1										NaN	NaN	Class 4	0.749698666	0.311258838	NaN	NaN	0	NaN	NaN
Q6YP21	KYAT3	-	Amino acid metabolism	1										NaN	125.8776215	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
P83111	LACTB	-	Protein degradation & quality control	1										538.7666208	334.5882457	Class 4	-0.420245101	0.016492901	43589.23547	56343.06667	Peripheral	27.43539424	75.57692193
Q53H82	LACTB2	-	RNA-related processes	1										Infinite	582.434515	Class 1	-1.796102322	0.00074214	66130.40782	251842.3333	Soluble	4.672813153	39.78238369
P28838	LAP3	-	Protein maturation & folding	1										NaN	277.9829203	NaN	NaN	NaN	379428.3093	NaN	0	NaN	NaN
Q86WU2	LDHD	-	Unknown	1										NaN	NaN	Class 1	-1.971901747	3.38248E-05	335.7853804	NaN	Peripheral	20.27473356	73.25865327
O95202	LETM1	-	"Carriers, channels & transporters"	1										166.4431861	286.9354442	Class 1	-1.512852957	0.000163353	419399.2798	464403	Integral	94.82128974	96.52962496
Q2VYF4	LETM2	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	3088.126046	11551.97667	0	89.75177207	NaN
Q6P1Q0	LETMD1	-	Regulation & signaling	1										99.59063711	NaN	Class 1	-2.221170715	8.73659E-05	82035.46113	52895.5	Integral	93.01170393	92.13324325
O43325	LYRM1	-	Cell death/ apoptosis	1										NaN	NaN	Class 4	-2.378262051	0.084214301	29915.52281	31878.75333	Peripheral	8.979154778	79.74252774
Q9NU23	LYRM2	-	Unknown	1										80.32250307	56.26162465	Class 2	-1.528230116	0.020446573	174822.4885	112154.1	Peripheral	7.261376788	83.66622813
Q9BQ69	MACROD1	-	Regulation & signaling	1										75.40842808	84.58461008	Class 3	-0.835407159	0.001636346	128135.3621	133910.8333	Peripheral	10.99806149	93.50275713
Q8WWC4	MAIP1	-	Protein maturation & folding	1										109.8028329	NaN	Class 1	-0.951852781	0.001414858	103546.2579	71635.7	Peripheral	38.70381997	96.31175953
Q96EH3	MALSU1	-	Ribosome assembly & translation	1										20.52637336	23.70403773	Class 1	-2.163149387	3.91132E-06	20566.89884	21578.78333	Peripheral	7.703890775	80.63407342
P27338	MAOB	-	Other known processes	1										NaN	390.030266	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q5VT66	MARC1	-	Other known processes	1										14.971625	NaN	Class 1	-1.257277641	0.001417687	100383.5922	130479.0667	Integral	96.63887243	92.4095185
Q969Z3	MARC2	-	Other known processes	1										30.37629384	84.99806888	Class 1	-0.934751816	0.000279321	154001.2692	95889.03333	0	NaN	91.39091198
Q9NX47	MARCH5	-	"Morphology, dynamics & organization"	1										35.95611936	23.35699963	Class 3	-0.706420782	0.002091777	122338.6043	145504	Integral	93.85116713	96.62147388
Q7Z434	MAVS	-	Regulation & signaling	1										56.21168047	182.8615775	Class 4	-0.529013699	0.008408659	56395.69898	104994.5	Peripheral	17.92758784	60.14116514
P59942	MCCD1	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q07820	MCL1	-	Cell death/ apoptosis	1										NaN	NaN	Class 4	-0.190745562	0.393524092	14331.13533	16618.33333	0	NaN	NaN
Q8NE86	MCU	-	"Carriers, channels & transporters"	1										250.1866213	195.2241814	Class 1	-0.948133076	0.001706446	290538.8784	241047	Integral	77.27714442	97.23901491
Q9NWR8	MCUB	-	Regulation & signaling	1										NaN	NaN	Class 1	-1.259123489	0.000622667	39662.47277	28350.83333	Integral	76.06769785	95.86166961
Q96AQ8	MCUR1	-	"Carriers, channels & transporters"	1										103.7514981	NaN	Class 1	-0.965718582	0.00030531	57321.6744	125953.8	Integral	91.38129944	95.93940621
P23368	ME2	-	TCA cycle	1										111.9863902	NaN	Class 1	-1.670741309	0.000113665	723195.49	672905.6667	Soluble	4.345481336	37.52074522
Q16798	ME3	-	Carbohydrate & energy metabolism	1										496.2910291	NaN	Class 1	-2.485934161	8.63225E-05	NaN	NaN	0	NaN	NaN
Q6UB28	METAP1D	-	Protein maturation & folding	1										Infinite	86.47871039	Class 1	-2.002274982	0.000833829	10421.74392	8229.156667	Peripheral	7.488360388	88.97681154
A6NJ78	METTL15	-	Unknown	1										19.37619059	NaN	Class 1	-2.399050271	5.99372E-05	51251.47494	38045.16667	Peripheral	14.68723107	85.60589835
Q9H7H0;Q9H7H0	METTL17	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
B3KW44;E7ETE0	METTL8	-	Unknown	1										NaN	NaN	Class 1	-2.142833727	0.000124245	4342.328701	5433.795	Peripheral	13.52760782	90.00620401
Q8IWA4	MFN1	-	"Morphology, dynamics & organization"	1										8.249331395	NaN	Class 4	-0.4202376	0.018670349	39395.79593	36159.5	Integral	89.69692313	97.10143198
Q8TDB4	MGARP	-	"Morphology, dynamics & organization"	1										NaN	NaN	NaN	NaN	NaN	7811.416547	8709.85	Ambiguous	57.32960462	59.16302061
O14880	MGST3	-	Oxidative stress response	1										108.0606538	NaN	Class 4	-0.398694595	0.012985184	173561.0487	167789.7333	Integral	92.77198181	95.70776502
Q8N4Q1	MIA40	-	Protein import & biogenesis	1										NaN	2372.351421	Class 4	-0.290148634	0.071473165	192140.0767	397676	Soluble	4.228721117	24.50252716
Q5TGZ0	MIC10	-	"Morphology, dynamics & organization"	1										87.4472033	NaN	Class 1	-1.578238043	0.001607824	147309.9271	514029.8	0	NaN	NaN
C9JRZ6;Q9NX63	MIC19	-	"Morphology, dynamics & organization"	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9BRQ6	MIC25	-	"Morphology, dynamics & organization"	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q6UXV4	MIC27	-	"Morphology, dynamics & organization"	1										143.6193476	NaN	Class 1	-1.791184892	0.000211722	86868.40021	57788.3	Integral	86.76693984	91.6130234
B9A067;C9J406;Q16891	MIC60	-	"Morphology, dynamics & organization"	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q86XE3	MICU3	-	"Carriers, channels & transporters"	1										NaN	NaN	Class 4	0.439987984	0.78016562	1140.707167	2048.285	Ambiguous	44.56886373	80.99965865
A0A2R8YF99;A0A2R8YE40;A0A2R8YFQ8;Q8NAN2	MIGA1	-	"Morphology, dynamics & organization"	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q8N5G0	MITRAC7	-	OXPHOS assembly & stability	1										237.7604353	121.5166836	Class 2	-1.903604422	0.040190364	62238.42775	80319.15	0	NaN	84.62141471
O95563	MPC2	-	"Carriers, channels & transporters"	1										45.88330501	NaN	Class 1	-1.397952905	0.000190402	447865.7661	380147	Integral	97.04993562	95.38148804
P29372	MPG	-	DNA-related processes	1										21.04090532	NaN	Class 4	-0.60321791	0.036934486	764.8864327	190816.6667	0	26.62896444	NaN
P25325	MPST	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	NaN	510050	0	NaN	NaN
Q567V2	MPV17L2	-	Ribosome assembly & translation	1										32.67371761	20.50214515	Class 1	-1.09001433	0.000736938	17091.12173	19507.66667	Ambiguous	82.64893283	76.1674454
Q6IN84	MRM1	-	RNA-related processes	1										154.7822024	133.0734812	Class 1	-1.998021199	0.000107424	29091.20439	23271.53333	Peripheral	16.69471698	90.11638955
Q9HC36	MRM3	-	RNA-related processes	1										38.48231339	NaN	Class 1	-2.057358857	6.85719E-05	275105.0663	193438.6667	Peripheral	4.821610696	83.40554241
Q9BYD6	MRPL1	-	Mitochondrial ribosomes	1										1023.637312	NaN	Class 1	-2.49033477	6.26038E-05	329152.433	324320.3333	Peripheral	3.471384905	77.98114576
Q7Z7H8	MRPL10	-	Mitochondrial ribosomes	1										72.74955827	261.1763404	Class 1	-1.722315157	0.000132723	279917.9533	231975	Peripheral	30.40977354	88.66175388
Q9Y3B7	MRPL11	-	Mitochondrial ribosomes	1										57.49421199	21.22581268	Class 1	-2.495993194	9.93213E-05	1044220.505	701378.3333	Peripheral	22.92965631	81.94932872
Q9BYD1	MRPL13	-	Mitochondrial ribosomes	1										74.51568809	NaN	Class 1	-2.570915281	4.00509E-05	490513.8791	608466.3333	Peripheral	13.0795172	78.93704702
Q6P1L8	MRPL14	-	Mitochondrial ribosomes	1										35.89918378	70.93566138	Class 1	-2.422611876	0.000151675	357822.5368	257395.6667	Peripheral	8.425162501	73.8990095
Q9P015	MRPL15	-	Mitochondrial ribosomes	1										73.22720536	NaN	Class 1	-2.061417195	0.000118374	511105.0029	429557.6667	Ambiguous	61.20413916	79.45600263
Q9NX20	MRPL16	-	Mitochondrial ribosomes	1										69.59289536	81.53177681	Class 1	-2.34477962	0.000101489	339549.6034	275075.6667	Peripheral	12.25850678	84.51922818
E9PKV2;Q9NRX2	MRPL17	-	Mitochondrial ribosomes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9H0U6	MRPL18	-	Mitochondrial ribosomes	1										98.37899501	88.0125236	Class 1	-2.103274898	1.29007E-05	269374.1424	335115.6667	Peripheral	27.51907775	73.76414867
P49406	MRPL19	-	Mitochondrial ribosomes	1										46.0984211	NaN	Class 1	-2.522887482	5.67934E-05	464170.3205	464280	Peripheral	3.85376551	83.7911276
Q5T653	MRPL2	-	Mitochondrial ribosomes	1										75.20597028	NaN	Class 1	-2.44565498	0.000195659	267867.8623	228455.3333	Ambiguous	63.11879936	69.17797244
Q9BYC9	MRPL20	-	Mitochondrial ribosomes	1										147.1473818	100.8999669	Class 1	-1.768547999	9.65054E-05	359017.7825	416562	Ambiguous	49.07102531	82.91226394
Q7Z2W9	MRPL21	-	Mitochondrial ribosomes	1										217.947042	NaN	Class 1	-2.127180875	0.000104582	308278.5136	417911.3333	Ambiguous	59.15904731	75.8412555
Q9NWU5	MRPL22	-	Mitochondrial ribosomes	1										44.64731916	NaN	Class 1	-2.380237784	8.89029E-05	310780.4033	262186	Peripheral	7.998713705	76.58597371
Q16540	MRPL23	-	Mitochondrial ribosomes	1										69.29848376	NaN	Class 1	-2.717627948	0.000245146	198330.9044	228326	Ambiguous	58.01996091	79.80868041
Q9P0M9	MRPL27	-	Mitochondrial ribosomes	1										119.329361	NaN	Class 1	-2.396042042	5.73523E-05	370770.7799	486145.3333	Peripheral	5.773888099	76.39153529
Q13084;Q4TT37	MRPL28	-	Mitochondrial ribosomes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q8TCC3	MRPL30	-	Mitochondrial ribosomes	1										62.78543497	NaN	Class 1	-2.518814749	9.10277E-06	75544.71316	70765.1	Peripheral	6.67797953	92.89103489
Q9BYC8	MRPL32	-	Mitochondrial ribosomes	1										69.63138269	57.45979619	Class 1	-2.326257484	8.01897E-06	223759.7816	187241	Peripheral	2.606934968	81.72162398
O75394	MRPL33	-	Mitochondrial ribosomes	1										23.57215451	61.07273743	Class 1	-2.458477391	0.000187243	394879.4561	385890.6667	Peripheral	7.065805712	84.69044222
Q9BQ48	MRPL34	-	Mitochondrial ribosomes	1										35.93398199	NaN	Class 1	-2.307573314	0.000146723	141127.9037	57564.1	Ambiguous	69.00713197	77.14492643
Q9NZE8	MRPL35	-	Mitochondrial ribosomes	1										214.9924407	29.34651318	Class 1	-2.392740218	7.51636E-05	125013.0258	78010.36667	0	NaN	75.14255632
Q9P0J6	MRPL36	-	Mitochondrial ribosomes	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
A6NHR2;H0Y4J2;S4R369;Q9BZE1	MRPL37	-	Mitochondrial ribosomes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q96DV4	MRPL38	-	Mitochondrial ribosomes	1										131.6631099	82.65406712	Class 1	-2.121355615	5.15848E-05	256531.2212	300633	Peripheral	12.07680764	69.93843306
Q9NYK5	MRPL39	-	Mitochondrial ribosomes	1										61.16279076	NaN	Class 1	-1.379661198	0.000220287	506173.9102	477730.3333	Peripheral	5.09152578	77.52644886
Q9BYD3	MRPL4	-	Mitochondrial ribosomes	1										78.62885324	NaN	Class 1	-2.170699567	8.7324E-05	417990.9382	356238.6667	Ambiguous	64.30473281	79.50801062
Q9NQ50	MRPL40	-	Mitochondrial ribosomes	1										51.73105352	61.40752413	Class 1	-2.040016186	4.41513E-05	367373.7554	222498.3333	Peripheral	4.185756158	72.36113853
Q8IXM3	MRPL41	-	Mitochondrial ribosomes	1										60.66965414	47.07428116	Class 1	-2.858424252	4.80593E-05	787974.6293	801695	Ambiguous	41.90103787	81.96440561
Q9Y6G3	MRPL42	-	Mitochondrial ribosomes	1										184.2367783	NaN	Class 1	-1.966915304	0.000129952	108636.1357	81165.7	Ambiguous	44.63226616	84.44228985
Q8N983;Q8N983;Q8N983	MRPL43	-	Mitochondrial ribosomes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9BRJ2	MRPL45	-	Mitochondrial ribosomes	1										51.5536672	NaN	Class 1	-2.298603195	5.85217E-05	229616.4629	213636.3333	Peripheral	11.2931641	77.06291138
Q9H2W6	MRPL46	-	Mitochondrial ribosomes	1										134.0580965	176.140357	Class 1	-1.825373153	9.62209E-05	284008.6378	269514.3333	Peripheral	3.798975528	80.80083687
Q9HD33	MRPL47	-	Mitochondrial ribosomes	1										65.69111322	59.05627004	Class 1	-2.423149796	5.03375E-05	469291.7827	381939	Ambiguous	47.14947582	77.71960036
Q96GC5	MRPL48	-	Mitochondrial ribosomes	1										72.45745974	NaN	Class 1	-2.281200818	9.47631E-05	409927.6156	321809.3333	Peripheral	3.815221528	82.0876555
Q13405	MRPL49	-	Mitochondrial ribosomes	1										171.2195785	NaN	Class 1	-2.25951901	5.90875E-05	221086.157	238353	Ambiguous	45.81327176	74.80158546
Q8N5N7	MRPL50	-	Mitochondrial ribosomes	1										85.99902004	118.3155384	Class 1	-1.589932917	0.000168475	510647.0286	381714.3333	Ambiguous	63.36930385	77.89098413
A0A087WU28;A0A0B4J2C1;Q4U2R6	MRPL51	-	Mitochondrial ribosomes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q86TS9	MRPL52	-	Mitochondrial ribosomes	1										79.15414707	NaN	Class 1	-2.072657285	0.00033242	9480.314842	34626.6	Peripheral	10.06332722	75.27674018
Q96EL3	MRPL53	-	Mitochondrial ribosomes	1										44.88224666	153.5860331	Class 1	-2.120462343	1.21704E-05	775318.3716	435666.3333	Peripheral	19.39745332	80.83048686
Q6P161	MRPL54	-	Mitochondrial ribosomes	1										49.05885446	54.6328621	Class 1	-2.662297964	0.000237407	235181.9319	256064.9333	Peripheral	3.090788641	62.94192488
Q7Z7F7	MRPL55	-	Mitochondrial ribosomes	1										82.24208458	NaN	Class 1	-2.313780681	0.007246488	219497.2134	193222.3333	Soluble	7.206420761	42.48681145
Q9BQC6	MRPL57	-	Mitochondrial ribosomes	1										85.89339847	NaN	Class 1	-2.502922806	0.000253344	145121.12	79479.6	Ambiguous	37.64259031	78.40425992
Q14197	MRPL58	-	Mitochondrial ribosomes	1										74.15508638	NaN	Class 1	-2.290317027	8.07994E-05	211478.145	164580.3333	Peripheral	4.356455319	77.249078
Q8TAE8	MRPL59	-	Mitochondrial ribosomes	1										60.92248986	57.2411692	Class 1	-2.313278323	3.24602E-05	351183.8345	255673	Peripheral	6.168987468	72.27162619
Q9BYD2	MRPL9	-	Mitochondrial ribosomes	1										86.19462886	NaN	Class 1	-2.570132643	0.000115765	320981.6246	424559.6667	Peripheral	12.75074136	80.5031862
O15091	MRPP3	-	tRNA related processes	1										16.93743995	30.88298737	Class 1	-1.481461114	6.29077E-05	51275.64128	45140.13333	Peripheral	16.16247829	88.67540161
P82664	MRPS10	-	Mitochondrial ribosomes	1										36.66255817	80.27005494	Class 1	-2.072385035	6.42086E-05	208733.5062	221951.3333	Peripheral	31.76646398	87.13887915
P82912	MRPS11	-	Mitochondrial ribosomes	1										67.23276833	NaN	Class 1	-2.908252148	9.19069E-05	195505.9736	206869.6667	Peripheral	5.531358622	86.44804707
O15235	MRPS12	-	Mitochondrial ribosomes	1										43.13874295	133.9797585	Class 1	-3.083493623	2.49158E-05	267876.9147	126421.8667	Peripheral	8.055180955	72.6097652
P82914	MRPS15	-	Mitochondrial ribosomes	1										42.2504645	120.4662418	Class 1	-2.978295796	6.33908E-05	296447.8035	428803.6667	Peripheral	12.2634226	86.42817456
Q9Y2R5	MRPS17	-	Mitochondrial ribosomes	1										135.082614	NaN	Class 1	-3.065421693	1.96168E-05	556689.0797	733370	Peripheral	26.07090226	82.36501799
Q9NVS2	MRPS18A	-	Mitochondrial ribosomes	1										82.41495537	NaN	Class 1	-2.389002968	6.53657E-05	279534.3995	171536	Peripheral	17.64364819	79.74391907
Q9Y676	MRPS18B	-	Mitochondrial ribosomes	1										45.78149452	NaN	Class 1	-2.748952777	2.06077E-05	281169.2799	307380.6667	Peripheral	30.28393774	83.99488956
Q9Y3D5	MRPS18C	-	Mitochondrial ribosomes	1										102.7722565	NaN	Class 1	-3.006691862	6.62391E-06	96768.88099	86620.1	Peripheral	11.89548905	96.99317177
P82921	MRPS21	-	Mitochondrial ribosomes	1										85.55843492	262.2540407	Class 1	-3.147050641	0.000527999	304218.12	425009.6667	Peripheral	38.28309713	84.35950755
Q96EL2	MRPS24	-	Mitochondrial ribosomes	1										92.38323911	78.5453847	Class 1	-2.447949184	6.41721E-05	274693.1801	432533.3333	Peripheral	38.3920597	89.71806396
Q9BYN8	MRPS26	-	Mitochondrial ribosomes	1										91.87550651	80.7386681	Class 1	-2.680934324	2.39552E-05	334844.9853	303842.6667	Peripheral	25.81137617	85.79673941
Q92552	MRPS27	-	Mitochondrial ribosomes	1										28.04708415	NaN	Class 1	-1.624931883	0.000124492	484562.2663	392336	Peripheral	9.858778116	88.65753346
P51398	MRPS29	-	Mitochondrial ribosomes	1										64.42377817	NaN	Class 1	-1.953490379	6.66675E-05	795741.6267	662859.6667	Peripheral	15.9061524	88.71864207
Q9NP92	MRPS30	-	Mitochondrial ribosomes	1										64.40155269	84.08093989	Class 1	-1.677197734	5.13861E-05	130194.9955	114827.0333	Peripheral	16.2095865	73.24908519
Q92665	MRPS31	-	Mitochondrial ribosomes	1										238.3746943	117.4852088	Class 1	-2.399702347	5.84311E-05	344633.4478	304612.3333	Peripheral	33.34037087	80.83816823
Q9Y291	MRPS33	-	Mitochondrial ribosomes	1										88.04168803	NaN	Class 1	-3.166338947	8.93073E-06	407708.5378	506476.6667	Peripheral	39.99435884	85.94279473
P82673	MRPS35	-	Mitochondrial ribosomes	1										31.11000291	43.49106728	Class 1	-2.122966121	7.65409E-05	270416.3168	258752.6667	Peripheral	30.96831713	88.62368594
P82909	MRPS36	-	Mitochondrial ribosomes	1										36.67159963	48.58804489	Class 3	-0.868198003	0.000349787	485151.6274	497881.6667	Peripheral	16.25140438	72.61618164
Q96BP2	MRPS37	-	Mitochondrial ribosomes	1										11.51348556	NaN	Class 1	-2.484207121	5.02665E-05	193281.9768	252746.6667	Ambiguous	13.58407046	51.86503349
Q9NWT8	MRPS38	-	Mitochondrial ribosomes	1										17.40035985	46.70177436	Class 1	-2.561682232	0.000129676	33636.19748	39352.41	0	NaN	70.04412812
P82675	MRPS5	-	Mitochondrial ribosomes	1										78.12538245	122.5728924	Class 1	-2.661997912	1.76948E-05	314522.6724	271639.6667	Peripheral	41.23172169	87.6631861
P82932	MRPS6	-	Mitochondrial ribosomes	1										72.7999373	257.628263	Class 1	-2.872348477	1.17794E-05	693096.1707	670814.3333	Peripheral	25.94663322	87.00149554
P82933	MRPS9	-	Mitochondrial ribosomes	1										95.54112298	128.4495694	Class 1	-2.083342216	0.000111115	350501.4416	273768	Peripheral	35.27272637	89.08169678
Q96E11	MRRF	-	Ribosome assembly & translation	1										96.79504292	161.8416842	Class 1	-2.687496495	0.000105872	194085.5984	273783.6667	Peripheral	6.55956287	72.76144331
Q9HD23	MRS2	-	"Carriers, channels & transporters"	1										566.2844055	NaN	Class 1	-1.210271587	0.000535697	43890.02909	28152.56667	0	NaN	97.48111125
Q9UJ68	MSRA	-	Oxidative stress response	1										NaN	NaN	Class 2	-1.615016787	0.044279163	NaN	NaN	0	NaN	NaN
Q9Y3D2	MSRB2	-	Oxidative stress response	1										26.4633627	32.94778812	Class 4	-0.337841402	0.123626873	98870.23212	29389.2	Peripheral	8.374811369	78.30747602
Q9NZJ7	MTCH1	-	"Carriers, channels & transporters"	1										194.3167176	147.9301508	Class 4	-0.140152172	0.114980776	227410.2839	159565.6333	Integral	95.6765089	94.53115324
E9PIE4;Q9Y6C9	MTCH2	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q99551	MTERF1	-	DNA-related processes	1										NaN	NaN	Class 1	-2.398000528	0.000262493	13016.96861	16665.58667	Peripheral	9.597816682	85.35689637
Q49AM1	MTERF2	-	DNA-related processes	1										NaN	NaN	Class 4	-1.06394123	0.49438298	9505.560158	5975.41	Peripheral	12.7858286	90.35415965
Q96E29	MTERF3	-	DNA-related processes	1										16.80575211	NaN	Class 1	-1.920506727	3.29383E-05	96515.58304	60835.43333	Peripheral	11.10678009	94.2576928
Q7Z6M4	MTERF4	-	Ribosome assembly & translation	1										40.93513977	NaN	Class 1	-2.051966039	0.00029098	50446.04662	29146.7	Peripheral	13.40875533	87.6378426
B5MC22;Q9UDX5	MTFP1	-	"Morphology, dynamics & organization"	1										NaN	153.512617	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q15390	MTFR1	-	"Morphology, dynamics & organization"	1										12.76566981	NaN	Class 3	-0.84742872	0.004721488	20504.30556	25866.7	Peripheral	23.2372882	71.03291594
Q9H019	MTFR1L	-	Unknown	1										22.62415106	NaN	Class 4	-0.367146259	0.025428117	45633.38567	82343.33333	Peripheral	14.80805064	79.63718701
Q6P444	MTFR2	-	"Morphology, dynamics & organization"	1										5.927745208	NaN	Class 1	-1.52380435	0.000685303	14784.46775	21016.73333	Peripheral	11.11052864	81.61338492
Q9BT17	MTG1	-	Ribosome assembly & translation	1										22.01883716	NaN	Class 1	-2.470061573	0.000172027	91824.83587	73741.73333	Peripheral	23.42747032	85.97079481
Q9H4K7	MTG2	-	Ribosome assembly & translation	1										6.846152667	20.82381911	Class 1	-2.784882667	2.01332E-05	25909.1463	22693.9	Peripheral	22.19993278	93.21095658
B7ZM99;A0A087WVM4;Q6UB35	MTHFD1L	-	Cofactor metabolism	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P13995;P13995	MTHFD2	-	Cofactor metabolism	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9H903	MTHFD2L	-	Cofactor metabolism	1										32.27487065	NaN	Class 1	-1.614251487	0.000829344	3023.832052	627.685	0	5.480637193	NaN
P46199	MTIF2	-	tRNA related processes	1										164.0687442	94.462083	Class 1	-1.919095047	9.70392E-05	62991.39336	54345.33333	Peripheral	15.59790228	90.60892356
Q9H2K0	MTIF3	-	Ribosome assembly & translation	1										34.14735893	36.04492928	Class 1	-2.016102878	5.46365E-05	36122.82208	20976.23333	Peripheral	3.700889501	66.29603167
O75570	MTRF1	-	Ribosome assembly & translation	1										NaN	NaN	Class 1	-2.870740435	0.000130601	22417.77929	11720.98333	Peripheral	4.766604537	80.25846619
Q9UGC7;Q9UGC7	MTRF1L	-	Ribosome assembly & translation	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q13505	MTX1	-	Protein import & biogenesis	1										19.04498987	NaN	Class 1	-1.678920426	0.000123741	158332.3162	209042	Integral	96.04502356	97.22473599
Q5HYI7;Q5HYI7	MTX3	-	Protein import & biogenesis	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q969V5	MUL1	-	Cell death/ apoptosis	1										11.66145077	12.97733896	Class 1	-0.910410001	0.000553293	40644.78765	24665.46667	Integral	95.44150868	91.07148235
Q96H55	MYO19	-	"Morphology, dynamics & organization"	1										20.69667292	26.32245156	Class 3	-0.86639935	0.000800008	45517.3262	35610.56667	Integral	65.75413932	96.62688995
O95167	NDUFA3	-	OXPHOS complex subunits	1										54.37741547	NaN	Class 1	-2.439434485	1.81521E-06	330623.2942	235500	Integral	96.36849228	87.04603529
Q9NRX3	NDUFA4L2	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q16718	NDUFA5	-	OXPHOS complex subunits	1										46.5918786	NaN	Class 1	-2.176427826	0.000147294	2038066.776	1777856.667	Ambiguous	48.49466426	74.72824017
O95182	NDUFA7	-	OXPHOS complex subunits	1										18.62945561	40.72634384	Class 1	-1.774978008	0.002241838	437111.8417	375376.6667	Integral	62.44008956	89.8064277
I3L505;O14561	NDUFAB1	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O75438	NDUFB1	-	OXPHOS complex subunits	1										113.3051834	90.99517961	Class 1	-2.165589774	2.63891E-05	709955.4561	830843.3333	Integral	99.60429956	96.47672687
O95178	NDUFB2	-	OXPHOS complex subunits	1										NaN	NaN	Class 4	-0.798935719	0.544064184	71587.29183	22186.155	0	NaN	75.3145958
O95168	NDUFB4	-	OXPHOS complex subunits	1										77.47140686	NaN	Class 1	-2.042967347	0.00036245	900519.1673	1077826	Integral	81.65202514	95.21860635
O43674	NDUFB5	-	OXPHOS complex subunits	1										50.72916529	NaN	Class 1	-2.025766922	2.25795E-05	428919.6276	349220.3333	0	NaN	90.14841969
O95139	NDUFB6	-	OXPHOS complex subunits	1										25.31599595	NaN	Class 1	-2.594374586	1.27962E-05	169000.7532	88605.1	Integral	94.49540563	93.73548254
O43677	NDUFC1	-	OXPHOS complex subunits	1										Infinite	73.97017912	Class 1	-2.147168503	0.000357096	52337.44471	103433.6333	0	NaN	94.77150036
O43920	NDUFS5	-	OXPHOS complex subunits	1										72.23364742	77.22080913	Class 1	-2.377925482	4.21727E-05	1123291.62	852483.3333	Integral	68.70388756	89.66024984
P56181;P56181	NDUFV3	-	OXPHOS complex subunits	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9NPE2	NGRN	-	Ribosome assembly & translation	1										24.45113538	NaN	Class 1	-1.866019557	0.000245394	17500.41694	14867.93	Peripheral	6.065030497	74.77362875
Q9BPW8	NIPSNAP1	-	Unknown	1										108.531919	NaN	Class 1	-1.13527955	0.000219072	433229.6486	341411.3333	Peripheral	9.891215271	88.83081036
O75323	NIPSNAP2	-	Unknown	1										190.6931322	223.9899576	Class 3	-0.735537085	0.001490878	394390.2222	506606.6667	Peripheral	8.498119557	92.25306392
Q9UFN0	NIPSNAP3A	-	Unknown	1										113.8323155	203.7833777	Class 1	-1.473132126	0.000460525	439565.3129	381562.3333	Soluble	8.908869779	46.04630272
Q9BS92	NIPSNAP3B	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	1749.59606	11390.897	0	NaN	NaN
Q86X76	NIT1	-	Cell death/ apoptosis	1										NaN	318.0100878	NaN	NaN	NaN	9864.249515	67968.96667	0	NaN	NaN
Q9BYT8	NLN	-	Protein degradation & quality control	1										302.6277481	NaN	Class 1	-1.700793108	7.36889E-05	130329.4499	291916.6667	Soluble	5.146449386	11.43284099
Q86UT6	NLRX1	-	Autophagy/ mitophagy	1										NaN	38.53810381	Class 3	-0.823366943	0.002292425	26394.09664	16466.45	Integral	70.25570784	97.33285273
O00746	NME4	-	Nucleotide/ nucleoside metabolism	1										409.5111966	NaN	Class 2	-1.202385966	0.02297336	213732.2662	281519.6667	Peripheral	6.623056607	64.97981711
O75414	NME6	-	Nucleotide/ nucleoside metabolism	1										55.91986454	NaN	Class 1	-2.873810049	1.28095E-05	52535.45706	64734.63333	Peripheral	20.51931283	84.66074162
Q9C002	NMES1	-	Unknown	1										NaN	NaN	Class 4	1.371987432	0.587830656	5058.690881	4170.335	0	NaN	94.52585481
Q96T66	NMNAT3	-	Cofactor metabolism	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q8NC60	NOA1	-	Cell death/ apoptosis	1										68.44295757	47.17134766	Class 1	-3.622222147	2.12365E-05	56532.26667	37560.96667	Peripheral	11.26925402	87.09247739
Q96CB9	NSUN4	-	Ribosome assembly & translation	1										47.14507433	45.51704965	Class 1	-2.004134342	5.80276E-05	129253.2334	78033.46667	Peripheral	16.4747121	71.34566525
Q8TCD5	NT5C	-	Nucleotide/ nucleoside metabolism	1										Infinite	NaN	Class 2	-2.666585404	0.047566223	20221.63241	166844.9667	Ambiguous	15.55248465	31.20094679
Q9H857	NT5DC2	-	Unknown	1										20.14247425	NaN	Class 1	-1.34409703	0.00057854	253691.2302	205444.5	Peripheral	16.43980294	88.75532112
Q86UY8	NT5DC3	-	Unknown	1										2028.010511	224.4341261	Class 1	-1.724678021	0.000154594	102306.87	78841.53333	Peripheral	8.238673834	68.60508285
Q9NPB1	NT5M	-	Nucleotide/ nucleoside metabolism	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
P36639	NUDT1	-	Oxidative stress response	1										Infinite	NaN	Class 2	-1.723328589	0.04923348	8131.420592	141657.6667	0	12.04319424	NaN
Q86X67	NUDT13	-	Unknown	1										NaN	NaN	Class 4	-1.074172051	0.336110248	3340.968859	600530.9	0	NaN	NaN
A8MXV4	NUDT19	-	Lipid metabolism	1										94.38588579	138.5113978	Class 1	-1.513388978	0.001098265	520148.9492	839068.3333	Peripheral	10.26255459	89.58790399
P53370	NUDT6	-	Regulation & signaling	1										NaN	NaN	Class 1	-3.232078431	0.000135495	3464.026631	2510.766667	Peripheral	9.135701326	90.35214177
Q8WV74	NUDT8	-	Unknown	1										298.3302115	57.78153624	Class 1	-2.48186974	0.000656181	40396.83305	12407.75333	Peripheral	24.9422454	93.71463314
Q9BW91	NUDT9	-	Nucleotide/ nucleoside metabolism	1										42.59762461	NaN	Class 1	-1.341477783	9.6701E-05	34041.80588	140045.6667	Peripheral	3.338640369	74.41877566
Q9NX40;Q9NX40	OCIAD1	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q56VL3	OCIAD2	-	Unknown	1										33.81825724	NaN	Class 3	-0.541473396	0.00713264	315723.8195	236178	Integral	87.82693528	96.33411554
A0A0D9SFS3;Q02218	OGDH	-	TCA cycle	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9ULD0	OGDHL	-	TCA cycle	1										NaN	71.84447149	Class 4	-1.379332595	0.215354353	58578.46786	68131.86667	Peripheral	19.40076141	83.40157116
Q96E52	OMA1	-	Protein degradation & quality control	1										39.52206503	NaN	Class 1	-1.071475222	0.000445783	16123.08029	15734.53333	0	NaN	93.76280712
Q9H4B0	OSGEPL1	-	tRNA related processes	1										269.737696	127.4398605	Class 1	-2.559079868	6.78017E-05	41838.90469	30204.66667	Peripheral	20.60499092	87.5090893
Q9BYC2	OXCT2	-	Carbohydrate & energy metabolism	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q96HP4	OXNAD1	-	Unknown	1										61.99602534	NaN	Class 1	-1.915729612	9.83688E-05	47456.78041	39870.03333	Peripheral	11.02259197	68.06737069
Q8N573;Q8N573	OXR1	-	Oxidative stress response	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9NWU1	OXSM	-	Lipid metabolism	1										302.388485	NaN	Class 1	-1.349884821	0.000681774	35065.57915	12620.39667	Soluble	6.913164963	19.21720309
Q9H300	PARL	-	Protein maturation & folding	1										456.1594142	NaN	Class 3	-0.819048477	0.00259651	20514.66894	25237.75	Integral	98.08251284	93.40768058
Q16822	PCK2	-	Carbohydrate & energy metabolism	1										Infinite	NaN	Class 4	0.015349971	0.861411112	178608.5835	172075	Peripheral	14.16905238	82.34217177
Q6L8Q7	PDE12	-	RNA-related processes	1										41.25275981	NaN	Class 1	-1.506259249	0.000276785	106065.7376	297125	Peripheral	25.90046402	74.19542037
Q9HBH1	PDF	-	Ribosome assembly & translation	1										Infinite	180.328822	Class 1	-0.984015413	0.000878791	86341.50036	57572.8	Integral	88.25854543	88.23578251
P29803	PDHA2	-	PDH complex & PDH regulation	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q15118	PDK1	-	PDH complex & PDH regulation	1										21.19987505	39.59427573	Class 3	-0.842605318	0.001099315	87006.53442	74209.23333	Peripheral	13.83542832	86.64941991
Q15119	PDK2	-	PDH complex & PDH regulation	1										8.700923834	NaN	Class 1	-1.315794356	3.2406E-05	41898.93843	58070.33333	Peripheral	9.751055356	85.14013513
Q16654	PDK4	-	PDH complex & PDH regulation	1										NaN	NaN	Class 4	-0.03883424	0.795003907	279.2457354	NaN	0	NaN	NaN
Q9P2J9	PDP2	-	PDH complex & PDH regulation	1										7.834976214	NaN	Class 1	-2.143984362	1.21918E-05	8936.141895	15963.80333	Peripheral	12.3396442	89.5434841
Q96HS1	PGAM5	-	Regulation & signaling	1										222.0674549	688.2565854	Class 1	-1.879360285	6.60517E-05	1012179.59	1470526.667	Peripheral	23.54944125	93.75562963
Q32NB8	PGS1	-	Cardiolipin biosynthesis & remodeling	1										110.0783443	NaN	Class 1	-1.280045633	0.000163996	27769.78209	28626.1	Peripheral	45.6812899	92.90730545
P35232	PHB	-	DNA-related processes	1										275.0433749	NaN	Class 1	-1.591048693	5.31829E-05	5404177.05	6679030	Integral	95.84119697	97.36101515
Q99623	PHB2	-	Regulation & signaling	1										259.9509706	NaN	Class 1	-1.63261682	6.21983E-05	3536380.703	5215400	Integral	97.74022361	94.1141868
Q8N2A8	PLD6	-	"Morphology, dynamics & organization"	1										NaN	NaN	Class 1	-3.104412811	0.000204324	13552.17865	9987.863333	Integral	63.8208667	95.42130225
Q9HBL7	PLGRKT	-	Regulation & signaling	1										Infinite	91.17068842	Class 1	-1.717382674	5.13789E-05	126969.6968	137439	Integral	95.4102687	96.0266856
Q9NRY6	PLSCR3	-	Cell death/ apoptosis	1										Infinite	NaN	Class 4	0.101237506	0.647680638	532.0086461	NaN	0	NaN	NaN
Q13794	PMAIP1	-	Cell death/ apoptosis	1										NaN	NaN	NaN	NaN	NaN	18462.82849	64502.56667	0	NaN	NaN
P41247	PNPLA4	-	Lipid metabolism	1										56.03859258	NaN	Class 3	-0.413526176	0.004356408	NaN	NaN	0	NaN	NaN
Q9Y2S7	POLDIP2	-	Unknown	1										23.2900382	NaN	Class 1	-2.104244189	7.91557E-05	397087.9044	388405.6667	Peripheral	11.33891572	91.81946501
P30405	PPIF	-	Protein maturation & folding	1										213.6088465	NaN	Class 1	-0.982184436	0.000773032	1314424.705	1005833.333	Peripheral	6.486902734	68.76714009
Q8NI37	PPTC7	-	Unknown	1										89.8594946	131.7869626	Class 1	-4.09935169	0.001593472	23147.13865	22020.06667	Peripheral	10.66872121	91.58304833
P30048	PRDX3	-	Oxidative stress response	1										127.5710406	230.4136741	Class 1	-2.062887943	5.83738E-05	3819599.507	6962306.667	Peripheral	3.084933961	78.82197429
P30044	PRDX5	-	Oxidative stress response	1										NaN	236.9842415	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q9Y255	PRELID1	-	Cell death/ apoptosis	1										NaN	NaN	Class 3	-0.754185514	0.006680379	25873.1758	15382.33	0	NaN	NaN
Q9Y3B1	PRELID3B	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	25440.44582	34628.15	0	NaN	NaN
O75127	PTCD1	-	tRNA related processes	1										27.21818491	NaN	Class 1	-1.663208562	0.000187285	190060.9513	254863	Peripheral	18.96584231	91.19556417
Q8WV60	PTCD2	-	RNA-related processes	1										26.31318538	48.39441882	Class 1	-2.325978708	0.000185592	21721.06314	15844.19	Peripheral	19.47776287	88.09587471
Q9H7Z7	PTGES2	-	Lipid metabolism	1										153.7244092	NaN	Class 1	-1.711877856	9.60099E-05	253357.9242	178686.3333	Peripheral	9.85972226	94.88532871
Q8WUK0	PTPMT1	-	Cardiolipin biosynthesis & remodeling	1										48.10440521	51.28975634	Class 1	-1.424344107	0.000372234	98738.61094	48010.76667	Peripheral	44.78047291	96.2171277
Q86Y79	PTRH1	-	Unknown	1										123.2124459	NaN	Class 1	-2.475809257	4.87617E-05	23976.22848	21174.13333	Peripheral	20.08399343	71.50331686
Q8N0Z8	PUSL1	-	Unknown	1										NaN	NaN	Class 1	-2.112480387	0.000944115	56729.94906	52902.66667	Peripheral	24.82015954	79.83592313
J3QKT3	PYCR1	-	Unknown	1										NaN	95.9792128	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q8N2H3	PYROXD2	-	Unknown	1										NaN	NaN	Class 3	-0.507341902	0.005993758	NaN	NaN	0	NaN	NaN
Q96I23	PYURF	-	Unknown	1										126.4145996	NaN	Class 1	-1.639047292	0.000323873	42095.49057	5341.115	Soluble	6.523999411	37.27433745
Q9BXR0	QTRT1	-	tRNA related processes	1										238.0437036	143.994705	Class 1	-3.704161904	4.58896E-05	41763.94576	222572.3333	Peripheral	5.381908337	52.47923031
Q9H974	QTRT2	-	tRNA related processes	1										233.2384604	45.92755376	Class 1	-3.280040453	0.007801281	46317.65604	168736.3333	Peripheral	13.4236522	56.48644368
Q969Q5	RAB24	-	Autophagy/ mitophagy	1										Infinite	NaN	Class 3	-0.489824926	0.002215958	18421.72805	50784.76667	Integral	81.57750999	85.28618132
O60518	RANBP6	-	Unknown	1										43.60812933	NaN	Class 3	-0.71426235	0.000764636	18679.86968	104399.8333	0	33.24349335	NaN
Q8N0V3	RBFA	-	Unknown	1										96.10420174	36.06641716	Class 1	-3.409063419	1.78883E-05	30110.27928	15530.7	Peripheral	11.24646651	90.28736018
Q96I51	RCC1L	-	Regulation & signaling	1										23.60183669	33.15974718	Class 1	-1.224708695	0.000484937	97003.76035	63638.03333	Peripheral	12.21748166	73.62459015
Q8NBN7	RDH13	-	Other known processes	1										172.1038907	NaN	Class 1	-1.5649897	0.000289068	204173.9596	161027.2667	Peripheral	27.86631677	91.18654274
Q9Y3B8	REXO2	-	RNA-related processes	1										Infinite	NaN	Class 1	-2.69813565	8.05742E-05	15842.5335	168726.3333	0	NaN	NaN
Q8IXI2;Q8IXI2;Q8IXI2	RHOT1	-	Regulation & signaling	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q8IXI1	RHOT2	-	"Morphology, dynamics & organization"	1										106.809162	69.99666843	Class 3	-0.667479103	0.004266291	179374.6478	229988.6667	Integral	93.94862957	97.79845262
P52758	RIDA	-	Other known processes	1										Infinite	NaN	Class 1	-2.67184158	0.002888636	138126.7352	241623.3333	Peripheral	3.039430345	87.0247082
Q96DB5	RMDN1	-	Unknown	1										101.8466242	NaN	Class 4	0.314526467	0.012546858	168263.9961	177542.3333	0	NaN	NaN
Q96TC7	RMDN3	-	Regulation & signaling	1										74.34918927	NaN	Class 3	-0.526631361	0.004044607	196924.6097	442246.3333	Peripheral	46.67455064	86.938328
P60602	ROMO1	-	Protein import & biogenesis	1										19.59130672	36.91828479	Class 1	-1.788794118	0.000219086	295504.1276	307305	0	NaN	63.37735589
Q6DKI1	RPL7L1	-	Other known processes	1										24.09349747	NaN	Class 3	-0.734210339	0.005326232	1965.883546	1227740	0	50.61131732	NaN
Q6P087	RPUSD3	-	RNA-related processes	1										50.94494254	NaN	Class 4	-0.56397011	0.009862582	92610.44284	99334	Peripheral	14.58091358	93.09280182
Q96CM3	RPUSD4	-	Ribosome assembly & translation	1										33.86280151	17.54943882	Class 1	-1.078950261	0.00046796	29853.69099	19925.23333	Peripheral	8.533775681	85.48218015
Q9HA92	RSAD1	-	Unknown	1										6.424843113	9.357639644	Class 1	-3.721585772	0.000214075	25208.07882	17708.23333	Peripheral	32.50107128	86.45085868
Q9Y512	SAMM50	-	Protein import & biogenesis	1										179.9864013	237.0029174	Class 1	-1.940426067	0.000139222	295247.5476	267442.3333	Integral	97.82439197	97.71107905
Q6SZW1	SARM1	-	Regulation & signaling	1										NaN	NaN	NaN	NaN	NaN	64159.79043	165224	Peripheral	50.12364553	96.53768317
Q8NBX0	SCCPDH	-	Unknown	1										Infinite	147.4666427	Class 3	-0.78140967	0.002747986	67277.88329	105510.3	Integral	94.04814843	93.77044162
Q9NRP4	SDHAF3	-	OXPHOS assembly & stability	1										26.55855681	51.34640644	Class 1	-2.985737819	5.13131E-05	64166.34117	29153.36667	Peripheral	10.18387434	59.86342602
Q5VUM1	SDHAF4	-	OXPHOS assembly & stability	1										519.6868124	178.5346175	Class 1	-1.67398815	0.000240258	17302.25287	10763.88	0	NaN	NaN
Q9BVL4	SELENOO	-	Oxidative stress response	1										41.80995348	NaN	Class 1	-1.426409614	0.000316436	7251.017331	31396.26667	Peripheral	20.72954982	93.37143965
Q8NE22	SETD9	-	Regulation & signaling	1										NaN	NaN	Class 1	-2.199146095	7.52641E-06	5418.622004	99500.09667	0	NaN	NaN
Q9H9B4	SFXN1	-	"Carriers, channels & transporters"	1										184.8073919	NaN	Class 1	-1.227705986	0.00013318	2421972.836	3082293.333	Integral	97.30099685	97.5477306
Q96NB2	SFXN2	-	"Carriers, channels & transporters"	1										Infinite	NaN	Class 1	-1.996651184	8.55903E-05	195955.1862	83500.96667	Integral	97.09921543	95.59943564
Q9BWM7	SFXN3	-	"Carriers, channels & transporters"	1										135.4404143	NaN	Class 1	-1.11548789	0.000425386	136934.2363	101454.8	Integral	97.21671013	90.55940781
Q8TD22	SFXN5	-	"Carriers, channels & transporters"	1										NaN	NaN	Class 1	-0.963199411	0.002996023	9853.756605	4794.456667	0	NaN	81.09185176
G3V2Y4;G3V4W5;P34897	SHMT2	-	Amino acid metabolism	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
E9PN58;Q9NTG7	SIRT3	-	Regulation & signaling	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9Y6E7	SIRT4	-	Regulation & signaling	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9NXA8	SIRT5	-	Regulation & signaling	1										195.6613891	131.761848	Class 1	-1.794926982	0.001449605	22128.95977	43605.6	Peripheral	8.692644229	92.61065349
O95258	SLC25A14	-	"Carriers, channels & transporters"	1										153.0220389	NaN	Class 2	-1.158149612	0.031827343	16550.82536	19626.36667	0	NaN	87.27647029
P16260	SLC25A16	-	"Carriers, channels & transporters"	1										167.8319738	56.13410956	Class 4	-0.186227059	0.024765446	13783.08109	15492.14	0	NaN	94.54704087
Q9H1K4	SLC25A18	-	"Carriers, channels & transporters"	1										NaN	145.8834475	Class 4	-0.580696234	0.104199697	NaN	NaN	0	NaN	NaN
Q9BXI2	SLC25A2	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9BV35	SLC25A23	-	"Carriers, channels & transporters"	1										NaN	NaN	Class 1	-1.880963221	3.69473E-05	6128.509451	3468.746667	0	NaN	93.8660339
Q6KCM7	SLC25A25	-	"Carriers, channels & transporters"	1										NaN	41.0259805	Class 2	-2.349604605	0.03599697	14941.04088	20992.5	Integral	74.38169758	92.20918289
O95847	SLC25A27	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q96A46	SLC25A28	-	Fe-S protein biogenesis	1										23.19806789	11.12600102	Class 3	-0.485941425	0.001995737	6740.225945	1896.370667	0	NaN	42.71465837
Q8N8R3	SLC25A29	-	"Carriers, channels & transporters"	1										38.9811606	NaN	Class 1	-1.586165499	0.001072771	22172.47314	18888.20667	0	NaN	79.60869196
Q5SVS4	SLC25A30	-	Unknown	1										NaN	36.15681407	Class 1	-1.5149077	0.000132645	23244.02985	10475.21333	0	NaN	94.80890256
Q9H0C2	SLC25A31	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9BSK2	SLC25A33	-	"Carriers, channels & transporters"	1										28.61549634	16.72112338	Class 3	-0.649769293	0.003647271	29698.73435	15467.40667	0	NaN	90.47071158
Q3KQZ1;Q3KQZ1	SLC25A35	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q96CQ1	SLC25A36	-	"Carriers, channels & transporters"	1										31.90927635	NaN	Class 3	-0.856287996	0.001838204	19569.86223	8984.236667	Integral	90.35252215	84.94091327
Q9NYZ2	SLC25A37	-	Fe-S protein biogenesis	1										NaN	NaN	Class 1	-0.918475607	0.001863884	4483.970422	1465.035	0	NaN	80.43567736
Q9BZJ4	SLC25A39	-	Unknown	1										NaN	NaN	Class 4	0.544857462	0.045755681	3726.943893	NaN	0	NaN	NaN
Q8TBP6	SLC25A40	-	"Carriers, channels & transporters"	1										796.426153	106.6132697	Class 1	-1.818145619	0.000275157	15021.99348	22947.92	Integral	82.34545999	85.77101242
Q96H78	SLC25A44	-	"Carriers, channels & transporters"	1										Infinite	NaN	Class 1	-1.899843536	0.000218791	3861.452082	4816.526667	Ambiguous	77.99113253	74.32612182
Q6Q0C1	SLC25A47	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P05141	SLC25A5	-	"Carriers, channels & transporters"	1										152.0379108	251.3085583	Class 1	-1.164970429	0.000574081	3431892.283	7550373.333	Integral	97.32197717	97.27327483
Q9H1U9	SLC25A51	-	"Carriers, channels & transporters"	1										NaN	NaN	Class 1	-1.067949972	0.003275936	4907.017261	NaN	0	NaN	87.26970775
Q3SY17	SLC25A52	-	Unknown	1										NaN	NaN	Class 4	-0.554151413	0.337723515	3688.308858	4462.33	0	NaN	NaN
Q5H9E4	SLC25A53	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
P12236	SLC25A6	-	"Carriers, channels & transporters"	1										284.5038376	339.7919467	Class 1	-0.985439082	0.002527376	918038.5846	1679855	Integral	89.39355996	92.16142634
P55851	SLC25A8	-	"Carriers, channels & transporters"	1										NaN	NaN	Class 1	-1.284287329	0.001984238	702.1149904	NaN	0	NaN	NaN
Q6J4K2	SLC8B1	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q86UD5	SLC9B2	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
Q9GZT3	SLIRP	-	RNA-related processes	1										63.23481035	NaN	Class 1	-1.15597429	0.000290194	1213945.481	2753590	Ambiguous	29.04217136	39.61905254
P49901	SMCP	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q96EX1	SMIM12	-	Unknown	1										57.23997249	NaN	Class 1	-2.087327794	0.000290784	377794.4537	179474.3667	Peripheral	47.43954993	94.38539295
Q8WVI0	SMIM4	-	Unknown	1										10.99858971	25.58921907	Class 1	-2.116629082	6.7298E-05	163874.134	145535.3333	Integral	95.88566965	92.94607232
Q96KF7	SMIM8	-	Unknown	1										5068.441744	34.76924744	Class 1	-2.909292665	8.58615E-05	51292.40651	24387.05	Ambiguous	90.9006532	82.55301173
O15079	SNPH	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	870.4657004	NaN	0	NaN	NaN
Q8TC71	SPATA18	-	Protein degradation & quality control	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q7Z5L4	SPATA19	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q8TB22	SPATA20	-	Other known processes	1										319.3835229	NaN	Class 1	-1.008608395	0.000887661	4927.561338	4072.183333	Peripheral	10.17019856	88.03761867
Q8WW59	SPRYD4	-	Unknown	1										120.4704512	165.0417168	Class 1	-1.792043737	0.000158369	223785.6776	269641.6667	Peripheral	2.08790298	91.29356442
Q9NQZ5	STARD7	-	Unknown	1										21.00315571	22.94366174	Class 1	-1.019495008	0.000398452	9087.86662	15713.36667	Peripheral	18.03431718	86.99187415
E0CX11	STMP1	-	Unknown	1										NaN	NaN	Class 4	-1.697340413	0.087632625	NaN	NaN	0	NaN	NaN
Q9UJZ1	STOML2	-	Regulation & signaling	1										210.2581303	NaN	Class 1	-1.342457787	0.000106603	1132828.923	1056200.667	Integral	77.16268715	95.23019952
P56962	STX17	-	Autophagy/ mitophagy	1										34.03912502	NaN	Class 4	-0.502043139	0.029316422	21394.90463	59319.73333	Ambiguous	60.45475616	73.28354108
Q96I99	SUCLG2	-	TCA cycle	1										97.37257966	NaN	Class 4	-0.330414143	0.027471755	318523.1882	291702.3333	Soluble	5.464371319	20.28688962
Q8IYB8	SUPV3L1	-	RNA-related processes	1										98.50346808	151.6350949	Class 1	-2.095983129	3.51398E-05	166728.4583	135897.3333	Peripheral	14.94976786	92.97547563
Q9NX95	SYBU	-	Other known processes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	0	NaN	NaN
P57105	SYNJ2BP	-	Regulation & signaling	1										48.84741368	NaN	Class 1	-0.915582026	0.000677969	326554.4716	299321	0	NaN	95.77058436
Q96BW9	TAMM41	-	Cardiolipin biosynthesis & remodeling	1										971.9977769	463.1504173	Class 1	-1.517084168	0.000253472	124942.6918	111234.5667	Ambiguous	35.29866279	97.76131205
C9J7P5;Q969Z0	TBRG4	-	RNA-related processes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q8N3R3	TCAIM	-	Regulation & signaling	1										203.4028018	NaN	Class 1	-2.091126752	0.001136937	3272.313339	2690.766667	Peripheral	22.41556705	78.75847875
Q9BT92	TCHP	-	"Morphology, dynamics & organization"	1										NaN	NaN	NaN	NaN	NaN	237.1533713	9296.066667	0	NaN	NaN
Q9Y2W6	TDRKH	-	Other known processes	1										NaN	NaN	Class 1	-0.90971532	0.003479397	43002.12616	38832	Integral	80.42134594	95.22336947
Q96QE5	TEFM	-	DNA-related processes	1										117.0941178	NaN	Class 1	-2.700645266	1.07973E-05	77573.92685	59737.6	Peripheral	5.724033437	90.40327144
Q8WVM0	TFB1M	-	RNA-related processes	1										122.2558194	75.55354914	Class 1	-1.085148008	0.000282644	117199.2346	259803.2	Peripheral	12.00243788	85.15823017
Q5T1C6	THEM4	-	Lipid metabolism	1										1956.574567	289.2760399	Class 1	-1.13202751	0.000178632	75068.66942	55366.56667	Peripheral	11.9165514	91.25266653
Q8N1Q8	THEM5	-	Lipid metabolism	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q8IYQ7	THNSL1	-	Unknown	1										284.1636232	563.8271419	Class 1	-2.080147527	6.11229E-05	65668.46834	52911.16667	Peripheral	11.53863864	94.59890197
P62072	TIMM10	-	Protein import & biogenesis	1										67.70483069	367.6250641	Class 1	-1.422838789	0.000188756	465204.6312	543594	Ambiguous	41.20218366	23.24983465
Q9Y5J6	TIMM10B	-	Protein import & biogenesis	1										120.7346598	540.1814327	Class 1	-1.715692165	0.000387547	88080.40543	72776.03333	Ambiguous	70.11725262	61.70066162
Q9Y5L4	TIMM13	-	Protein import & biogenesis	1										17.54780931	NaN	Class 3	-0.79016632	0.001344098	2286787.042	2918513.333	Peripheral	9.384389483	58.43304691
Q99595	TIMM17A	-	Protein import & biogenesis	1										8.234965647	15.0913892	Class 1	-1.632578644	5.82083E-05	108124.4883	71932.8	0	NaN	92.62629787
O60830	TIMM17B	-	Protein import & biogenesis	1										113.5596286	NaN	Class 1	-2.018804441	0.000414738	94987.01099	107592.8	Integral	82.01370435	88.21872028
Q9BVV7	TIMM21	-	Protein import & biogenesis	1										146.7631987	NaN	Class 1	-2.29106852	5.49891E-07	130891.9144	134257	Integral	90.58478611	96.6375412
Q9Y584	TIMM22	-	Protein import & biogenesis	1										17.84375999	25.69438836	Class 1	-1.621622548	0.000420432	58694.70202	93079.86667	Integral	94.0730771	95.26704912
O14925	TIMM23	-	Protein import & biogenesis	1										93.67505058	NaN	Class 2	-1.826409367	0.02056117	267057.6737	NaN	0	NaN	95.06456717
Q5SRD1	TIMM23B	-	Protein import & biogenesis	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9BSF4	TIMM29	-	Protein import & biogenesis	1										70.12596004	355.802413	Class 1	-1.461203259	9.45068E-05	123902.2695	95629.83333	Integral	96.37453769	93.11932133
M0R301;O43615	TIMM44	-	Protein import & biogenesis	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9Y5J9	TIMM8B	-	Protein import & biogenesis	1										32.02759065	32.55775295	Class 1	-1.069397857	0.000855598	1126057.619	1438443.333	0	NaN	NaN
Q9Y5J7	TIMM9	-	Protein import & biogenesis	1										389.0573209	NaN	Class 1	-1.272053514	0.000218539	806389.705	502761.3333	Ambiguous	31.22684692	41.57686191
P17152	TMEM11	-	"Morphology, dynamics & organization"	1										121.5955859	151.5666482	Class 3	-0.760360064	0.00116415	411550.5903	328548.3333	Peripheral	48.11555244	97.93677784
Q96I45	TMEM141	-	Unknown	1										28.30140041	24.79215955	Class 1	-2.117418127	0.000233524	35404.53057	NaN	0	NaN	NaN
Q96AN5	TMEM143	-	Unknown	1										Infinite	NaN	Class 2	-2.011184978	0.010210136	3712.606224	2171.604	0	NaN	80.12045257
Q9P0S9	TMEM14C	-	Cofactor metabolism	1										141.9948685	164.7167188	Class 3	-0.520487974	0.003400501	78300.28868	88246.93333	Integral	83.7588639	90.05483421
Q53S58	TMEM177	-	OXPHOS assembly & stability	1										Infinite	156.5907886	Class 3	-0.861749543	0.002113094	33964.20166	41394.50333	0	NaN	96.63435806
Q96B77	TMEM186	-	Unknown	1										Infinite	NaN	Class 1	-1.347838524	3.00489E-05	19903.78846	11304.325	0	NaN	94.99483062
A0PJW6	TMEM223	-	Unknown	1										140.0820938	79.42810596	Class 1	-1.26569678	0.000640286	59430.56535	28362.66667	Ambiguous	98.55293431	75.07208269
Q15388	TOMM20	-	Protein import & biogenesis	1										21.90103308	62.86476636	Class 1	-2.67449058	0.000248738	439978.9108	1013591.333	Integral	73.74908532	93.12015843
Q9NS69	TOMM22	-	Protein import & biogenesis	1										404.0173549	379.9438028	Class 1	-3.102631088	4.55578E-05	1050556.349	825971.3333	Integral	97.24417234	94.96264803
Q15785	TOMM34	-	Protein import & biogenesis	1										78.25820673	75.72290822	Class 4	0.095777019	0.253025529	17352.68803	562337.3333	Peripheral	10.22652943	80.97926796
O96008	TOMM40	-	Protein import & biogenesis	1										443.3252673	NaN	Class 1	-4.215032048	3.54589E-05	1441522.834	1720623.333	Integral	97.50322183	96.45680051
Q969M1	TOMM40L	-	Protein import & biogenesis	1										NaN	196.5518207	Class 1	-2.061634592	0.000744746	15865.23411	10121.66667	0	NaN	84.36943177
Q8N4H5	TOMM5	-	Protein import & biogenesis	1										67.794136	NaN	Class 4	-3.243478346	0.05927265	NaN	NaN	0	NaN	NaN
Q96B49	TOMM6	-	Protein import & biogenesis	1										15.38326485	95.21617921	Class 4	-2.346868675	0.223739244	148911.1321	370006	0	NaN	NaN
Q9P0U1	TOMM7	-	Protein import & biogenesis	1										62.81030606	NaN	Class 1	-4.16266414	2.384E-05	917868.9468	1428515.667	0	NaN	99.39076967
Q969P6	TOP1MT	-	DNA-related processes	1										NaN	NaN	Class 1	-1.887707284	0.000259387	4145.466571	3240.9	Peripheral	18.92263679	74.22419571
Q9H4I3	TRABD	-	Unknown	1										24.63624965	NaN	Class 1	-1.008325497	0.000364103	83058.92108	76469.83333	Integral	89.38324292	96.67966853
I3L0K7;I3L0P6;Q12931	TRAP1	-	Protein maturation & folding	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O43715	TRIAP1	-	Cell death/ apoptosis	1										37.01708898	57.1210878	Class 4	-0.812744054	0.010160385	618850.2909	576057.3333	Soluble	3.014660247	18.1185063
Q7Z4G4	TRMT11	-	tRNA related processes	1										Infinite	NaN	Class 1	-3.666632597	1.8625E-06	19247.12656	66030.2	Peripheral	8.615774625	61.66221365
Q96GJ1	TRMT2B	-	Unknown	1										37.0386879	NaN	Class 1	-1.478869118	4.94333E-05	6840.602092	3508.866667	Peripheral	18.0673609	75.24221534
H7C2E8;Q9BVS5	TRMT61B	-	tRNA related processes	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
O95900	TRUB2	-	RNA-related processes	1										5.050557313	2.587041656	Class 1	-1.31697208	0.001085941	43278.70927	30963.53333	Peripheral	10.60698293	93.1544885
P30536;B1AH88	TSPO	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q16762	TST	-	Other known processes	1										44.55103612	75.02649148	Class 1	-1.627443332	0.000301376	374352.4487	324270.6667	Peripheral	16.26832237	68.18934899
P25874	UCP1	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	0	0	0	0	0
Q9NVA1	UQCC1	-	OXPHOS assembly & stability	1										47.05374352	NaN	Class 1	-1.577233844	0.000287239	133111.2261	152012.6333	Peripheral	33.35692086	97.17491406
Q9UDW1	UQCR10	-	OXPHOS complex subunits	1										68.38627911	179.8348905	Class 1	-2.728346454	3.05487E-05	532638.4274	620575.6667	0	NaN	90.28070048
O14957	UQCR11	-	OXPHOS complex subunits	1										12.43854521	NaN	Class 1	-1.991315392	0.000503073	286710.6971	124889.9333	0	NaN	NaN
P07919;A0A096LP55	UQCRH;UQCRHL	-	OXPHOS complex subunits	1										68.98547516	NaN	Class 1	-1.887430835	8.89529E-05	1367038.319	1284266.333	Ambiguous	92.70495413	59.88832213
F5H8D3;Q70CQ3	USP30	-	Autophagy/ mitophagy	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
C9JI87;P21796	VDAC1	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
P45880;Q5JSD2	VDAC2	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Q9Y277;Q9Y277	VDAC3	-	"Carriers, channels & transporters"	1										NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
A3KMH1	VWA8	-	Unknown	1										116.4568125	120.2694336	Class 1	-1.889126282	6.14288E-05	67883.88024	60782.2	Peripheral	36.71305028	95.16509429
P58557	YBEY	-	Ribosome assembly & translation	1										79.84058933	NaN	Class 1	-1.773395358	0.000112444	112782.6493	119251	Peripheral	29.03727834	94.27459313
Q86U90	YRDC	-	Unknown	1										19.69466505	21.2046201	Class 4	-0.523537839	0.037593557	36272.19	485457.3333	Peripheral	15.82785469	80.73299302
M0QXZ5	ZNF428	-	Unknown	1										NaN	NaN	NaN	NaN	NaN	3984.514011	291340	0	NaN	NaN